<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Bisphosphonates and other bone agents for breast cancer - O'Carrigan, B - 2017 | Cochrane Library</title> <meta content="Bisphosphonates and other bone agents for breast cancer - O'Carrigan, B - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003474.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Bisphosphonates and other bone agents for breast cancer - O'Carrigan, B - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003474.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003474.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Bisphosphonates and other bone agents for breast cancer" name="citation_title"/> <meta content="Brent O'Carrigan" name="citation_author"/> <meta content="Matthew HF Wong" name="citation_author"/> <meta content="Gosford Hospital" name="citation_author_institution"/> <meta content="Melina L Willson" name="citation_author"/> <meta content="NHMRC Clinical Trials Centre, The University of Sydney" name="citation_author_institution"/> <meta content="Martin R Stockler" name="citation_author"/> <meta content="The University of Sydney" name="citation_author_institution"/> <meta content="Nick Pavlakis" name="citation_author"/> <meta content="Royal North Shore Hospital" name="citation_author_institution"/> <meta content="Annabel Goodwin" name="citation_author"/> <meta content="Annabel.Goodwin@sswahs.nsw.gov.au" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD003474.pub4" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/10/30" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003474.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003474.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003474.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Bone Density Conservation Agents [*therapeutic use]; Bone Neoplasms [mortality, *prevention &amp; control, *secondary]; Breast Neoplasms [mortality, *pathology]; Clodronic Acid [therapeutic use]; Denosumab [therapeutic use]; Diphosphonates [*therapeutic use]; Imidazoles [therapeutic use]; Injections, Intravenous; Randomized Controlled Trials as Topic; Zoledronic Acid" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003474.pub4&amp;doi=10.1002/14651858.CD003474.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003474.pub4&amp;doi=10.1002/14651858.CD003474.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003474.pub4&amp;doi=10.1002/14651858.CD003474.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003474.pub4&amp;doi=10.1002/14651858.CD003474.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003474.pub4&amp;doi=10.1002/14651858.CD003474.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003474.pub4&amp;doi=10.1002/14651858.CD003474.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003474.pub4&amp;doi=10.1002/14651858.CD003474.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003474.pub4&amp;doi=10.1002/14651858.CD003474.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003474.pub4&amp;doi=10.1002/14651858.CD003474.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003474.pub4&amp;doi=10.1002/14651858.CD003474.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003474.pub4&amp;doi=10.1002/14651858.CD003474.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003474.pub4&amp;doi=10.1002/14651858.CD003474.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003474.pub4&amp;doi=10.1002/14651858.CD003474.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003474.pub4&amp;doi=10.1002/14651858.CD003474.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003474.pub4&amp;doi=10.1002/14651858.CD003474.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003474.pub4&amp;doi=10.1002/14651858.CD003474.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003474.pub4&amp;doi=10.1002/14651858.CD003474.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003474.pub4&amp;doi=10.1002/14651858.CD003474.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003474.pub4&amp;doi=10.1002/14651858.CD003474.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003474.pub4&amp;doi=10.1002/14651858.CD003474.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003474.pub4&amp;doi=10.1002/14651858.CD003474.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003474.pub4&amp;doi=10.1002/14651858.CD003474.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003474.pub4&amp;doi=10.1002/14651858.CD003474.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="eLIOL3Be";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003474\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003474\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003474\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003474\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ms","ja","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003474.pub4",title:"Bisphosphonates and other bone agents for breast cancer",firstPublishedDate:"Oct 30, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Breast Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003474.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003474.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003474.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003474.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003474.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003474.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;アブストラクト&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003474.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003474.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003474.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003474.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10383 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003474.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-sec-0193"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-sec-0063"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-sec-0180"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/appendices#CD003474-sec-0201"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/table_n/CD003474StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/table_n/CD003474StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Bisphosphonates and other bone agents for breast cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/information#CD003474-cr-0002">Brent O'Carrigan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/information#CD003474-cr-0003">Matthew HF Wong</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/information#CD003474-cr-0004">Melina L Willson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/information#CD003474-cr-0005">Martin R Stockler</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/information#CD003474-cr-0006">Nick Pavlakis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003474.pub4/information#CD003474-cr-0007"><i class="icon corresponding-author fa fa-envelope"></i>Annabel Goodwin</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/information/en#CD003474-sec-0214">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 30 October 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003474.pub4">https://doi.org/10.1002/14651858.CD003474.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003474-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003474-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003474-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003474-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003474-abs-0003">日本語</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003474-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003474-abs-0001" lang="en"> <section id="CD003474-sec-0001"> <h3 class="title" id="CD003474-sec-0001">Background</h3> <p>Bone is the most common site of metastatic disease associated with breast cancer (BC). Bisphosphonates inhibit osteoclast‐mediated bone resorption, and novel targeted therapies such as denosumab inhibit other key bone metabolism pathways. We have studied these agents in both early breast cancer and advanced breast cancer settings. This is an update of the review originally published in 2002 and subsequently updated in 2005 and 2012. </p> </section> <section id="CD003474-sec-0002"> <h3 class="title" id="CD003474-sec-0002">Objectives</h3> <p>To assess the effects of bisphosphonates and other bone agents in addition to anti‐cancer treatment: (i) in women with early breast cancer (EBC); (ii) in women with advanced breast cancer without bone metastases (ABC); and (iii) in women with metastatic breast cancer and bone metastases (BCBM). </p> </section> <section id="CD003474-sec-0003"> <h3 class="title" id="CD003474-sec-0003">Search methods</h3> <p>In this review update, we searched Cochrane Breast Cancer's Specialised Register, CENTRAL, MEDLINE, Embase, the World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP) and ClinicalTrials.gov on 19 September 2016. </p> </section> <section id="CD003474-sec-0004"> <h3 class="title" id="CD003474-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) comparing: (a) one treatment with a bisphosphonate/bone‐acting agent with the same treatment without a bisphosphonate/bone‐acting agent; (b) treatment with one bisphosphonate versus treatment with a different bisphosphonate; (c) treatment with a bisphosphonate versus another bone‐acting agent of a different mechanism of action (e.g. denosumab); and (d) immediate treatment with a bisphosphonate/bone‐acting agent versus delayed treatment of the same bisphosphonate/bone‐acting agent. </p> </section> <section id="CD003474-sec-0005"> <h3 class="title" id="CD003474-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data, and assessed risk of bias and quality of the evidence. The primary outcome measure was bone metastases for EBC and ABC, and a skeletal‐related event (SRE) for BCBM. We derived risk ratios (RRs) for dichotomous outcomes and the meta‐analyses used random‐effects models. Secondary outcomes included overall survival and disease‐free survival for EBC; we derived hazard ratios (HRs) for these time‐to‐event outcomes where possible. We collected toxicity and quality‐of‐life information. GRADE was used to assess the quality of evidence for the most important outcomes in each treatment setting. </p> </section> <section id="CD003474-sec-0006"> <h3 class="title" id="CD003474-sec-0006">Main results</h3> <p>We included 44 RCTs involving 37,302 women.</p> <p>In women with EBC, bisphosphonates were associated with a reduced risk of bone metastases compared to placebo/no bisphosphonate (RR 0.86, 95% confidence interval (CI) 0.75 to 0.99; P = 0.03, 11 studies; 15,005 women; moderate‐quality evidence with no significant heterogeneity). Bisphosphonates provided an overall survival benefit with time‐to‐event data (HR 0.91, 95% CI 0.83 to 0.99; P = 0.04; 9 studies; 13,949 women; high‐quality evidence with evidence of heterogeneity). Subgroup analysis by menopausal status showed a survival benefit from bisphosphonates in postmenopausal women (HR 0.77, 95% CI 0.66 to 0.90; P = 0.001; 4 studies; 6048 women; high‐quality evidence with no evidence of heterogeneity) but no survival benefit for premenopausal women (HR 1.03, 95% CI 0.86 to 1.22; P = 0.78; 2 studies; 3501 women; high‐quality evidence with no heterogeneity). There was evidence of no effect of bisphosphonates on disease‐free survival (HR 0.94, 95% 0.87 to 1.02; P = 0.13; 7 studies; 12,578 women; high‐quality evidence with significant heterogeneity present) however subgroup analyses showed a disease‐free survival benefit from bisphosphonates in postmenopausal women only (HR 0.82, 95% CI 0.74 to 0.91; P &lt; 0.001; 7 studies; 8314 women; high‐quality evidence with no heterogeneity). Bisphosphonates did not significantly reduce the incidence of fractures when compared to placebo/no bisphosphonates (RR 0.77, 95% CI 0.54 to 1.08, P = 0.13, 6 studies, 7602 women; moderate‐quality evidence due to wide confidence intervals). We await mature overall survival and disease‐free survival results for denosumab trials. </p> <p>In women with ABC without clinically evident bone metastases, there was no evidence of an effect of bisphosphonates on bone metastases (RR 0.96, 95% CI 0.65 to 1.43; P = 0.86; 3 studies; 330 women; moderate‐quality evidence with no heterogeneity) or overall survival (RR 0.89, 95% CI 0.73 to 1.09; P = 0.28; 3 studies; 330 women; high‐quality evidence with no heterogeneity) compared to placebo/no bisphosphonates however the confidence intervals were wide. One study reported a trend towards an extended period of time without a SRE with bisphosphonate compared to placebo (low‐quality evidence). One study reported quality of life and there was no apparent difference in scores between bisphosphonate and placebo (moderate‐quality evidence). </p> <p>In women with BCBM, bisphosphonates reduced the SRE risk by 14% (RR 0.86, 95% CI 0.78 to 0.95; P = 0.003; 9 studies; 2810 women; high‐quality evidence with evidence of heterogeneity) compared with placebo/no bisphosphonates. This benefit persisted when administering either intravenous or oral bisphosphonates versus placebo. Bisphosphonates delayed the median time to a SRE with a median ratio of 1.43 (95% CI 1.29 to 1.58; P &lt; 0.00001; 9 studies; 2891 women; high‐quality evidence with no heterogeneity) and reduced bone pain (in 6 out of 11 studies; moderate‐quality evidence) compared to placebo/no bisphosphonate. Treatment with bisphosphonates did not appear to affect overall survival (RR 1.01, 95% CI 0.91 to 1.11; P = 0.85; 7 studies; 1935 women; moderate‐quality evidence with significant heterogeneity). Quality‐of‐life scores were slightly better with bisphosphonates than placebo at comparable time points (in three out of five studies; moderate‐quality evidence) however scores decreased during the course of the studies. Denosumab reduced the risk of developing a SRE compared with bisphosphonates by 22% (RR 0.78, 0.72 to 0.85; P &lt; 0.001; 3 studies, 2345 women). One study reported data on overall survival and observed no difference in survival between denosumab and bisphosphonate. </p> <p>Reported toxicities across all settings were generally mild. Osteonecrosis of the jaw was rare, occurring less than 0.5% in the adjuvant setting (high‐quality evidence). </p> </section> <section id="CD003474-sec-0007"> <h3 class="title" id="CD003474-sec-0007">Authors' conclusions</h3> <p>For women with EBC, bisphosphonates reduce the risk of bone metastases and provide an overall survival benefit compared to placebo or no bisphosphonates. There is preliminary evidence suggestive that bisphosphonates provide an overall survival and disease‐free survival benefit in postmenopausal women only when compared to placebo or no bisphosphonate. This was not a planned subgroup for these early trials, and we await the completion of new large clinical trials assessing benefit for postmenopausal women. For women with BCBM, bisphosphonates reduce the risk of developing SREs, delay the median time to an SRE, and appear to reduce bone pain compared to placebo or no bisphosphonate. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003474-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003474-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD003474-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD003474-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003474-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003474-abs-0010">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003474-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD003474-abs-0011">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003474-abs-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003474-abs-0008">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003474-abs-0005" lang="en"> <h3>Bisphosphonates and denosumab for breast cancer</h3> <p><b>What is the issue?</b> </p> <p>Breast cancer may spread and recur in the bones. This may cause fractures, pain and high calcium in the bloodstream (known as complications). </p> <p>Medicines for osteoporosis may prevent these complications and may help cure cancer by reducing cancer growth in the bone. These medicines are called 'bisphosphonates'. A newer type is called ‘denosumab’. Bisphosphonates or denosumab are given in addition to other cancer treatment medications. These may be given along with chemotherapy, endocrine therapy, or radiotherapy. </p> <p><b>Study questions</b> </p> <p>The goal of bisphosphonates and denosumab differs based on the women's breast cancer status. </p> <p>We asked three main questions:</p> <p>1. For <b>women with early breast cancer (EBC)</b>, can bisphosphonates or denosumab reduce the risk of the cancer spreading to the bone? Will adding this medicine to anticancer treatments allow women to live longer (improve survival)? </p> <p>2. For <b>women with advanced breast cancer which does not appear to involve the bone (ABC)</b>, can bisphosphonates reduce the risk of the cancer spreading to the bone and improve survival? Will bisphosphonates reduce complications and improve quality of life? </p> <p>3. For <b>women with metastatic breast cancer that has spread to the bone (BCBM),</b> can bisphosphonates or denosumab reduce the risk of complication, and improve quality of life and survival? </p> <p><b>Study Results</b> </p> <p>We found 44 studies involving 37,302 participants. We included studies published by September 2016. </p> <p><b>Study results for women with early breast cancer (EBC)</b> </p> <p>For women with EBC, we included 17 studies with 26,129 participants. The women’s health was monitored for at least 12 months from the start of the study. Some studies monitored women for 10 years. </p> <p>The studies tested different types of bisphosphonate drugs and denosumab, and different doses of these drugs. Some studies compared the drugs to no treatment. Some studies used oral medications. Other studies gave the medicine as an injection into a vein or under the skin. </p> <p>Bisphosphonates probably lowered the risk of cancer spreading to the bone.</p> <p>Bisphosphonates were found to improve survival, but the benefit in the whole group of women was small. Postmenopausal women had a benefit from bisphosphonates with improved survival and reduced risk of cancer returning. Premenopausal women did not have improved survival or reduced risk of the cancer returning. New studies that test bisphosphonates by the women's menopausal status are awaited. </p> <p>We await the reporting of data on survival and other important outcomes from denosumab trials. </p> <p><b>Study results for women with advanced breast cancer (ABC)</b> </p> <p>For women with ABC that had not spread to the bone, we included three studies enrolling 330 participants. All three studies compared oral bisphosphonates to no treatment. </p> <p>Bisphosphonates did not reduce the risk of cancer spreading to the bone or improve survival. Very little information was available on complications and quality of life from only one study. </p> <p><b>Study results for women with metastatic breast cancer that has spread to the bone (BCBM)</b> </p> <p>For women with BCBM, we included 24 studies enrolling 10,853 participants. Their health was monitored for at least 12 months. Some women were followed for 24 months. Most studies compared bisphosphonates to receiving no medication. </p> <p>Bisphosphonates reduced complications (fractures and bone pain). Bisphosphonates did not appear to increase the length of time women survived. Quality of life scores were slightly better for women receiving bisphosphonates compared to similar women having no bisphosphonates. </p> <p>Denosumab reduced the risk of complications compared to bisphosphonates in the three studies that collected these data. There was no benefit in survival from denosumab in the one study that collected data. </p> <p><b>Side effects for women with all types of breast cancer</b> </p> <p>Side effects were uncommon and mild. There was a rare risk of damage to the jaw bone (“osteonecrosis of the jaw”). </p> <p><b>Quality of the evidence</b> </p> <p>Overall, most of the evidence was moderate to high‐quality. This means that we are fairly confident in the findings. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003474-sec-0193" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003474-sec-0193"></div> <h3 class="title" id="CD003474-sec-0194">Implications for practice</h3> <section id="CD003474-sec-0194"> <section id="CD003474-sec-0195"> <h5 class="title">Early breast cancer</h5> <p>Adjuvant bisphosphonates reduce bone metastases and most of the studies used either intravenous zoledronate or oral clodronate. On the basis of published and unpublished aggregate data available for this meta‐analysis, there is evidence to suggest that adjuvant bisphosphonates improve overall survival and there is preliminary evidence indicating an overall survival and disease‐free survival benefit is in those women who were postmenopausal when treatment began. Of the studies included in the stratified analysis by menopausal status, studies used either intravenous zoledronate (4 mg), oral clodronate (1600 mg a day) or oral ibandronate (50 mg a day). The results are limited by the fact that these are subgroup analyses of trials rather than trials planned to test whether the effect differs between postmenopausal and premenopausal or perimenopausal women. </p> </section> <section id="CD003474-sec-0196"> <h5 class="title">Advanced breast cancer without bone metastases</h5> <p>The use of bisphosphonates outside of clinical research is currently not supported by evidence. </p> </section> <section id="CD003474-sec-0197"> <h5 class="title">Breast cancer with bone metastases</h5> <p>In general, bisphosphonates are effective in reducing the risk of skeletal‐related events (SRE), delaying time to SRE, reducing bone pain and improving quality of life. Most of the included studies with data involved intravenous zoledronate or oral clodronate. When comparing different bisphosphonates, one bisphosphonate compared to another did not show any superior benefit, except for one study where ibandronate was inferior to zoledronate in terms of the number of SREs. Denosumab is effective in reducing bone pain and delaying the time to SREs compared to placebo. </p> <p>In general, when considering all settings, toxicity is generally mild, with rates of osteonecrosis of the jaw (ONJ) across studies in mature data sets approximately less than 0.5%. </p> <p>The ideal choice of bisphosphonates and other bone agents may be different from woman to woman. It is likely to depend on the bisphosphonate efficacy versus its toxicity, ease of administration, patient's prior treatment, patient preference, drug availability and local guidelines and legislation. </p> </section> </section> <h3 class="title" id="CD003474-sec-0198">Implications for research</h3> <section id="CD003474-sec-0198"> <p>This meta‐analysis suggests that adjuvant bisphosphonates provide a survival benefit for postmenopausal women with early breast cancer however further trials are awaited before a firm conclusion can be made. Trials should be stratified and reported by menopausal status at study entry. Multi‐variate analysis reporting rates of recurrence within different risk groups (or stage of the breast cancer), menopausal status, high or low oestrogen level and endocrine receptor status will be useful in finding a subgroup that will benefit from bisphosphonates. In addition, a uniform definition of recurrence or invasive recurrence would help when combining data for meta‐analysis. The benefit of bisphosphonates in women receiving aromatase inhibitors in early breast cancer or targeted non‐cytotoxic therapy, such as treatment with monoclonal antibody to HER2‐neu, or both, requires further study. </p> <p>The following outcomes should be considered for inclusion and reported in future trials of bisphosphonates in early breast cancer. </p> <p> <ol id="CD003474-list-0021"> <li> <p>Overall survival</p> </li> <li> <p>Disease‐free survival</p> </li> <li> <p>Bone metastases and</p> </li> <li> <p>Toxicity</p> </li> </ol> </p> <p>In women with advanced breast cancer and bone metastases, the questions still remain regarding: (a) the optimum commencement time of bisphosphonate therapy, (b) the duration of treatment and (c) what to do in participants with progressive bone disease and symptoms, despite bisphosphonates and systemic anti‐cancer therapy. The uniform and standardised reporting of SRE rates would assist efficacy comparisons between drugs. </p> <p>The following outcomes should be considered for inclusion and reported in future trials of bisphosphonates in breast cancer and bone metastases. </p> <p> <ol id="CD003474-list-0022"> <li> <p>Numbers of participants developing individual SREs in the study period (with hypercalcaemia reported separately) </p> </li> <li> <p>Time to the first SRE</p> </li> <li> <p>Validated, participant‐rated measures of bone pain, quality of life and other relevant symptoms </p> </li> <li> <p>Systematic assessment of toxicities, including fever, flare, gastrointestinal symptoms, hypocalcaemia and renal toxicity </p> </li> <li> <p>Measurement of resource use and incorporation of cost‐effectiveness analyses</p> </li> <li> <p>The incidence of ONJ.</p> </li> </ol> </p> <p>Finally, trial authors should consider reporting effect sizes such as the hazard ratio and its confidence interval for survival outcomes, in line with the CONSORT statement. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003474-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003474-sec-0029"></div> <div class="table" id="CD003474-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Bisphosphonates compared to placebo/observation for women with early breast cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Bisphosphonates compared to placebo/observation for women with early breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with early breast cancer<br/> <b>Setting:</b> clinic and at home<br/> <b>Intervention:</b> intravenous bisphosphonates (zoledronate 4 mg every 3 weeks) or oral bisphosphonates (clodronate 1600 mg/day or ibandronate 50 mg/day or pamidronate 300 mg/day)<br/> <b>Comparison:</b> placebo/observation </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo/observation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with bisphosphonates</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Bone metastases</b><br/> Follow‐up: range 1 year to 10 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.86<br/> (0.75 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>15,005<br/> (11 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Additional analysis of iv zoledronate or oral clodronate showed a treatment benefit when compared to placebo/control </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>90 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>77 per 1000<br/> (67 to 89) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b><br/> Follow‐up: range 3 years to 10 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>3‐year risk of death<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.91<br/> (0.83 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13,949<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1000<br/> (67 to 79) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival postmenopausal women</b><br/> Follow‐up: range 7 years to 7.5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000<br/> (33 to 45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.77<br/> (0.66 to 0.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6048<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A sensitivity analysis removing <a href="./references#CD003474-bbs2-0043" title="ColemanR , DeBoerR , EidtmannH , LlombartA , DavidsonN , NevenP , et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO‐FAST study): final 60‐month results. Annals of Oncology2013;24(2):398‐405. ColemanR , DeBoerR , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Influence of delayed zoledronic acid initiation on disease‐free survival in postmenopausal women with endocrine receptor‐positive early breast cancer receiving adjuvant letrozole: exploratory analysis from the ZO‐FAST trial. Cancer Research2011;71(24 Suppl):P2‐17‐01. DeBoerR , BundredN , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Long‐term survival outcomes among postmenopausal women with hormone receptor‐positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5‐year follow‐up of ZO‐FAST. Cancer Research2011;71(24 Suppl):S1‐3. DeBoerR , MartinM , StegerGG , VonMoosR , StopeckA , TonkinK , et al. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMs): a number‐needed‐to‐treat (NNT) analysis. Asia‐Pacific Journal of Clinical Oncology2011;7(3 Suppl):9. EidtmannH , DeBoerR , BundredN , Llombart‐CussacA , DavidsonN , NevenP , et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36‐month results of the ZO‐FAST Study. Annals of Oncology2010;21(11):2188‐94. ">ZO‐FAST 2013</a> (due to the control arm being delayed bisphosphonate) showed equivalent efficacy (HR 0.78, 95% CI 0.66 to 0.92, 3 studies, 4984 women) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival: pre‐ or perimenopausal women</b><br/> Follow‐up: range 5 years to 8 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>51 per 1000<br/> (43 to 60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 1.03<br/> (0.86 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3501<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Disease‐free progression</b><br/> follow‐up: range 3 years to 10 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>3‐year risk of recurrence<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.94<br/> (0.87 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12578<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>113 per 1000<br/> (105 to 122) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐free progression: postmenopausal women</b><br/> Follow‐up: range 3 years to 7.8 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000<sup>e</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000<br/> (83 to 101) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.82<br/> (0.74 to 0.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8314<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A sensitivity analysis removing <a href="./references#CD003474-bbs2-0041" title="BrufskyA ,  BundredN ,  ColemanR ,  Lambert‐FallsR ,  MenaR ,  HadjiP , et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist2008;13(5):503‐14. BrufskyA ,  HarkerWG ,  BeckJT ,  CarrollR ,  Tan‐ChiuE ,  SeidlerC , et al. Zoledronic acid inhibits adjuvant letrozole‐induced bone loss in postmenopausal women with early breast cancer. Journal of Clinical Oncology2007;25(7):829‐36. BrufskyAM , HarkerWG , BeckJT , BossermanL , VogelC , SeidlerC , et al. Final 5‐year results of Z‐FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer2012;118(5):1192‐201. BrufskyAM ,  BossermanLD ,  CaradonnaRR ,  HaleyBB ,  JonesCM ,  MooreHC ,  etal . Zoledronic acid effectively prevents aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z‐FAST study 36‐month follow‐up results. Clinical Breast Cancer2009;9(2):77‐85. ">Z‐FAST 2012</a> and <a href="./references#CD003474-bbs2-0043" title="ColemanR , DeBoerR , EidtmannH , LlombartA , DavidsonN , NevenP , et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO‐FAST study): final 60‐month results. Annals of Oncology2013;24(2):398‐405. ColemanR , DeBoerR , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Influence of delayed zoledronic acid initiation on disease‐free survival in postmenopausal women with endocrine receptor‐positive early breast cancer receiving adjuvant letrozole: exploratory analysis from the ZO‐FAST trial. Cancer Research2011;71(24 Suppl):P2‐17‐01. DeBoerR , BundredN , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Long‐term survival outcomes among postmenopausal women with hormone receptor‐positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5‐year follow‐up of ZO‐FAST. Cancer Research2011;71(24 Suppl):S1‐3. DeBoerR , MartinM , StegerGG , VonMoosR , StopeckA , TonkinK , et al. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMs): a number‐needed‐to‐treat (NNT) analysis. Asia‐Pacific Journal of Clinical Oncology2011;7(3 Suppl):9. EidtmannH , DeBoerR , BundredN , Llombart‐CussacA , DavidsonN , NevenP , et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36‐month results of the ZO‐FAST Study. Annals of Oncology2010;21(11):2188‐94. ">ZO‐FAST 2013</a> (due to the control arm being delayed bisphosphonate), showed equivalent efficacy (HR 0.83, 95% CI 0.74 to 0.93; 5 studies; 6650 women) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐free progression: pre‐ or perimenopausal women</b><br/> Follow‐up: range 3 years to 7.5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000<sup>e</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000<br/> (100 to 124) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 1.01<br/> (0.90 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5493<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fracture incidence</b><br/> Follow‐up: range 5 years to 7.8 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.77<br/> (0.54 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7602<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Three studies used iv bisphosphonate (zoledronate) and three studies used oral bisphosphonate (clodronate or pamidronate) compared to placebo </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000<br/> (31 to 62) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Osteonecrosis of the jaw (ONJ)</b><br/> Follow‐up: range 1 year to 7.5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Bisphosphonates: approximately 35 events of ONJ were recorded in 7047 women</p> <p>Placebo/open: no events of ONJ were recorded in 6195 women</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,242<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Six studies used iv bisphosphonates (zoledronate) and three studies used oral bisphosphonates (ibandronate or clodronate). Most ONJ events came from 2 studies using iv zoledronate (<a href="./references#CD003474-bbs2-0005" title="ColemanR , CameronD , DodwellD , BellR , WilsonC , RathboneE , et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open‐label phase 3 trial. Lancet Oncology2014;15(9):997‐1006. ColemanR , WoodwardE , BrownJ , CameronD , BellR , DodwellD , et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01‐04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment2011;127(2):429‐38. ColemanR , WoodwardE , TurnerL , MarshallH , CollinsonM , DodwellD , et al. Impact of zoledronic acid on fractures, bone mineral density and bone remodeling in the AZURE trial (BIG 01‐04). Cancer Research2011;71(24 Suppl):P2‐19‐01. ColemanRE , MarshallH , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Breast‐cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine2011;365(15):1396‐405. ColemanRE , RathboneEJ , MarshallHC , WilsonC , BrownJE , GossielF , et al. Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study. Cancer Research2012;72(24 Suppl):S6‐4. ColemanRE , ThorpeHC , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Cancer Research2010;70(24 Suppl):S4‐5. ColemanRE , WinterMC , CameronD , BellR , DodwellD , KeaneMM , et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti‐tumour activity in breast cancer. British Journal of Cancer2010;102(7):1099‐105. RathboneEJ , BrownJE , MarshallHC , CollinsonM , LiversedgeV , MurdenGA , et al. Osteonecrosis of the jaw and oral health‐related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). Journal of Clinical Oncology2013;31(21):2685‐91. ">AZURE 2014</a> &amp; <a href="./references#CD003474-bbs2-0026" title="MinckwitzG , RezaiM , TeschH , HuoberJ , GerberB , ZahmDM , et al. Zoledronate for patients with invasive residual disease after anthracyclines‐taxane‐based chemotherapy for early breast cancer ‐ the phase III NeoAdjuvant Trial Add‐oN (NaTaN) study (GBG 36/ABCSG 29). European Journal of Cancer2016;64:12‐21. NCT00512993 . Postoperative use of zoledronic acid in breast cancer patients after neoadjuvant chemotherapy (NATAN). clinicaltrials.gov/ct2/show/NCT00512993 Date first received: 3 August 2007. vonMinckwitzG , RezaiM , EidtmannH , TeschH , HuoberJ , GerberB , et al. Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines‐taxane‐based chemotherapy for primary breast cancer ‐ the phase III NATAN study (GBG 36/ABCSG XX). Cancer Research2013;73(24 Suppl):S5‐05. ">NATAN 2016</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Infusion‐related side effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Seven studies reported 1 or 2 infusion‐related side‐effects (e.g. fever, fatigue, nausea or influenza‐type symptoms). Intravenous bisphosphonate (zoledronate) appeared to slightly increase the incidence of fever (in 3 out of 5 studies), fatigue (in 2 out of 3 studies) and nausea (in 2 out of 3 studies) compared to placebo. However the reporting of the grade toxicity was sometimes unspecified or on different scales. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(7 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>h,i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fever: 6070 women (5 studies), fatigue: 2599 women (3 studies), nausea: 3825 women (3 studies), influenza‐type symptoms: 103 women (1 study) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>HR</b> : hazard ratio; <b>iv</b> : intravenous; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Outcome assessors were either part of an independent adjudication committee or blinded to the treatment allocation in 5 out of 11 studies. We downgraded for risk of bias by 1 point because this outcome measure may be influenced by a lack of blinding in the other 6 studies.<br/> <sup>b</sup>The baseline risk in the control group was based on the average of the 3‐year estimates from nine studies.<br/> <sup>c</sup>The baseline risk in the control group for pre‐ and postmenopausal women were averages of the 3‐year estimates from the contributing studies.<br/> <sup>d</sup>The baseline risk in the control group was based on the average of the 3‐year estimates from seven studies.<br/> <sup>e</sup>The baseline risk in the control group was based on the average of 3‐year estimates from the contributing studies.<br/> <sup>f</sup>The confidence intervals are wide and we downgraded by 1 point for imprecision.<br/> <sup>g</sup>There was a very low event rate so we decided not to downgrade for imprecision.<br/> <sup>h</sup>Differences in reporting of grades of toxicity with some reporting grade 3/4 toxicity and other toxicity scales unspecified. Given this variability, we did not meta‐analyse the data. However the results appeared to be fairly consistent and we did not view this as a serious concern (therefore did not downgrade the quality of evidence).<br/> <sup>i</sup>Three out of the seven studies were open‐label studies and lack of blinding may impact on the patient‐reported subjective outcomes. We downgraded for risk of bias by 1 point. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003474-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Bisphosphonates compared to placebo/observation for women with advanced breast cancer without bone metastases</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Bisphosphonates compared to placebo/observation for women with advanced breast cancer without bone metastases</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with advanced breast cancer without bone metastases<br/> <b>Settings:</b> clinic and at home<br/> <b>Intervention:</b> oral bisphosphonates (clodronate 1600 mg/day or pamidronate 300 mg/day)<br/> <b>Comparison:</b> placebo or observation </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo/observation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with bisphosphonates</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Bone metastases</b><br/> Follow‐up: range 16 months to 84 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/> (0.65 to 1.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>330<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>235 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>225 per 1000<br/> (152 to 335) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median time to a skeletal‐related event (SRE)</b><br/> Follow‐up: median 84 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>We did not observe any statistically significant benefit using the bisphosphonate, oral clodronate. The median time to an SRE with clodronate was 28.4 months compared to 13.4 months with placebo (P = 0.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b><br/> Follow‐up: range 16 months to 84 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Risk of death</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/> (0.73 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>330<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>556 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>494 per 1000<br/> (406 to 606) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life<br/> assessed with 4‐point scale</b><br/> Follow‐up: range 16 months to 20 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Similar quality‐of‐life scores with bisphosphonates (pamidronate) or no bisphosphonates</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for imprecision because the confidence intervals included no effect and appreciable benefit and harm.<br/> <sup>b</sup>12 out of the 73 participants did not receive treatment for at least 2 months and were not followed‐up. We judged this study to be at high risk of bias for incomplete outcome data and we downgraded risk of bias by 1 point.<br/> <sup>c</sup>Only one study that had a small sample size reported this outcome and the estimates of effect appear to have wide confidence intervals. We downgraded for imprecision by 1 point.<br/> <sup>d</sup>We did not downgrade for imprecision as the confidence intervals were considered sufficiently narrow enough for an all‐encompassing outcome such as overall survival. <br/> <sup>e</sup>Quality‐of‐life measures were patient‐reported; the study was an open‐label trial and deemed to be at high risk of bias for not blinding participants to their treatment allocation. We downgraded risk of bias by 1 point. We did not downgrade the quality of evidence on other domains due to only one study contributing to this outcome (as permitted by GRADE guidance). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003474-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Bisphosphonates compared to placebo/observation for women with metastatic breast cancer and bone metastases</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Bisphosphonates compared to placebo/observation for women with metastatic breast cancer with bone metastases</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with metastatic breast cancer with bone metastases<br/> <b>Setting:</b> clinic and at home<br/> <b>Intervention:</b> intravenous bisphosphonates (pamidronate (45 to 90 mg/day) or ibandronate (6 mg) or zoledronate (4 mg)) or oral bisphosphonates (clodronate (1600 mg/day) or ibandronate (50 mg) or pamidronate (300 mg))<br/> <b>Comparison:</b> placebo or observation </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo/observation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with bisphosphonates</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Skeletal‐related event (SRE)</b><br/> Follow‐up: range 12 months to 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/> (0.78 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2810<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Additional analyses of iv or oral bisphosphonates vs placebo showed equivalent efficacy</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>640 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>550 per 1000<br/> (499 to 608) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median time to a skeletal‐related event</b><br/> Follow‐up: range 12 months to 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Bisphosphonates significantly delayed the median time to an SRE compared to placebo/observation (in 11 out of 12 studies that reported results but not sufficiently to be included in a meta‐analysis). The median time to an SRE in the bisphosphonates group ranged from 8.7 to 20.8 months while the placebo group ranged from 4.9 to 14.9 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median ratio 1.43 (1.29 to 1.58)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2891<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant benefits were observed using iv bisphosphonates (7 studies) and oral bisphosphonates (4 studies) vs placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b><br/> Follow‐up: range 12 months to 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Risk of death</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/> (0.91 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1935<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Analyses of iv or oral bisphosphonates vs placebo showed similar results</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>575 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>581 per 1000<br/> (523 to 638) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bone pain</b><br/> assessed with: Brief Pain Inventory, visual analog/pain scales and other validated or unvalidated scales<br/> Follow‐up: range 12 months to 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Bisphosphonates significantly reduced bone pain compared to placebo (in 6 out of 11 studies). Bone pain was reduced with bisphosphonates in another 3 studies but the effect was not statistically significant or P value not reported </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3297<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone pain was assessed using a wide range of scales across studies and only 6 studies used a validated scale (e.g. Brief Pain Inventory). Significant benefits observed using iv bisphosphonates (3 studies) and oral bisphosphonates (3 studies) when compared to placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><br/> assessed with: EORTC Quality of Life Scale ‐ Core 30 questionnaire (QLQ‐C30), trial‐specific questionnaires, Spitzer quality of life, FACT‐G<br/> Follow‐up: range 12 months to 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Quality‐of‐life scores were better with bisphosphonates than placebo at comparable time‐points (in 3 out of 5 studies). Quality‐of‐life scores decreased during the studies as disease progressed </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1888<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies used validated questionnaires (in one study a trial‐specific but validated one) and unvalidated scales </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>iv</b> : intravenous; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We did not downgrade for heterogeneity. This is because when two studies that used relatively low doses of pamidronate (45 mg or 60 mg) and contributed largely to the heterogeneity were removed from the meta‐analysis, the beneficial effect of bisphosphonates compared to placebo persisted.<br/> <sup>b</sup>Not all confidence intervals overlapped and the point estimate varied widely across studies. We downgraded inconsistency by 1 point.<br/> <sup>c</sup>Measures were self‐reported; 8 out of the 17 studies that reported bone pain scores were at high risk of bias for non‐blinding of participants to their treatment allocation. We downgraded risk of bias by 1 point.<br/> <sup>d</sup>Given that bone pain was assessed on various scales, we did not meta‐analyse the data. However the results appeared to be fairly consistent and we did not view this as a serious concern (therefore did not downgrade the quality of evidence).<br/> <sup>e</sup>Measures were patient‐reported; 3 out of the 8 studies that reported on quality of life were at high risk of bias for non‐blinding participants to their treatment allocation. We downgraded risk of bias by 1 point.<br/> <sup>f</sup>Given the variability in reporting quality‐of‐life results across studies, we were unable to meta‐analyse the data. We did not judge inconsistency across the studies as a serious concern and therefore did not downgrade the quality of the evidence. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003474-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003474-sec-0030"></div> <section id="CD003474-sec-0031"> <h3 class="title" id="CD003474-sec-0031">Description of the condition</h3> <p>Breast cancer is the most common cancer, and the most common cause of cancer death in women worldwide (<a href="./references#CD003474-bbs2-0131" title="World Health Organization (WHO). World Cancer Report. The International Agency for Research on Cancer2003. ">WHO 2003</a><i>;</i><a href="./references#CD003474-bbs2-0103" title="FerlayJ , SoerjomataramI , DikshitR , EserS , MathersC , RebeloM , et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer2015;136:E259‐86. ">Ferlay 2015</a>). Bone is the most common site of metastatic involvement, affecting more than half of women during the course of their disease (<a href="./references#CD003474-bbs2-0121" title="ScheidV , BuzdarAU , SmithTL , HortobagyiGN . Clinical course of breast cancer patients with osseous metastases treated with combination chemotherapy. Cancer1986;58:2589‐93. ">Scheid 1986</a>). Although survival is better in women with advanced breast cancer (ABC) if their metastases are confined to bone (<a href="./references#CD003474-bbs2-0092" title="ColemanRE , RubensRD . The clinical course of bone metastases from breast cancer. British Journal of Cancer1987;55(1):61‐6. ">Coleman 1987</a>), bone metastases cause significant morbidity due to pain, pathological fracture, hypercalcaemia and spinal cord compression, as well as contributing to mortality (<a href="./references#CD003474-bbs2-0091" title="ColemanRE , RubensRD . Bone metastases and breast cancer. Cancer Treatment Reviews1985;12:251‐70. ">Coleman 1985</a>). Breast cancers with bone metastases (BCBM) are predominantly osteolytic (50%) or mixed osteolytic and osteoblastic (40%), with only a small proportion (about 10%) being osteoblastic alone (<a href="./references#CD003474-bbs2-0106" title="HarveyHA . Issue concerning the role of chemotherapy and hormonal therapy of bone metastases from breast cancer. Cancer1997;80(8):1646‐56. ">Harvey 1997</a>). </p> <p>The pathophysiology of bone metastases includes increased bone turnover, imbalance and uncoupling of the processes of resorption and remodelling (<a href="./references#CD003474-bbs2-0111" title="KanisJA . Bone and cancer: pathophysiology and treatment of metastases. Bone1995;17(Suppl 2):101‐5. ">Kanis 1995</a>). Osteoclasts are primarily responsible for the bone resorption of lytic metastases (<a href="./references#CD003474-bbs2-0116" title="MundyGR . Mechanisms of bone metastases. Cancer1987;80(8):1546‐56. ">Mundy 1997</a>) and are involved in a complex osteolytic cycle that involves parathyroid hormone‐related peptide (PTHrP), receptor activator of nuclear factor (NF)‐κB ligand (RANK‐L), osteoprotegerin (OPG), transforming growth factor beta (TGF‐b) and many other transcription factors. Tumours secrete PTHrP that stimulates osteoblasts, which respond by secreting RANK‐L and inhibiting OPG. The increased RANK‐L/OPG gradient drives the activation of osteoclasts, which in turn produces TGF‐b and other growth factors, all having a profound effect on tumour growth. In this way, tumour and osteoclasts are engaged in a self‐perpetuating cycle, where tumour and osteoclasts provide fuel for each other (<a href="./references#CD003474-bbs2-0112" title="KozlowW , GuiseT . Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. Journal of Mammary Gland Biology and Neoplasia2005;10(2):169‐80. ">Kozlow 2005</a>). </p> </section> <section id="CD003474-sec-0032"> <h3 class="title" id="CD003474-sec-0032">Description of the intervention</h3> <p>Before the era of bisphosphonates, the management of symptomatic bone disease depended on analgesics, radiotherapy, endocrine therapy and chemotherapy. Despite these frequently effective treatments, progressive skeletal destruction often leads to ongoing symptoms and deterioration of quality of life (<a href="./references#CD003474-bbs2-0115" title="MundyGR . Mechanisms of osteolytic bone destruction. Bone1991;12(Suppl 1):1‐6. ">Mundy 1991</a>). </p> <p>Bisphosphonates inhibit osteoclastic bone resorption (<a href="./references#CD003474-bbs2-0118" title="RogersMJ , WattsDJ , RussellRGG . Overview of bisphosphonates. Cancer1997;80(8):1652‐60. ">Rogers 1997</a>). They are effective in conditions characterised by osteoclast‐mediated bone resorption such as Paget's disease and osteoporosis (<a href="./references#CD003474-bbs2-0119" title="RussellRGG , RogersMJ . Bisphosphonates: from the laboratory to the clinic and back again. Bone1999;25(1):97‐106. ">Russell 1999</a>). In malignancy, they have become standard treatment for tumour‐induced hypercalcaemia (<a href="./references#CD003474-bbs2-0089" title="BodyJJ ,  BartlR ,  BurckhardtP ,  DelmasPD ,  DielIJ ,  FleischH , et al. Current use of bisphosphonates in oncology. Journal of Clinical Oncology1998;16(12):3890‐9. ">Body 1998</a>). </p> </section> <section id="CD003474-sec-0033"> <h3 class="title" id="CD003474-sec-0033">How the intervention might work</h3> <p>RCTs have shown that in multiple myeloma, breast cancer and prostate cancer, bisphosphonates reduce bone pain, improve quality of life, and reduce the number of and time to skeletal‐related event (SREs) (<a href="./references#CD003474-bbs2-0088" title="BloomfieldDJ . Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence‐based review. Journal of Clinical Oncology1998;16(3):1218‐25. ">Bloomfield 1998</a>; <a href="./references#CD003474-bbs2-0089" title="BodyJJ ,  BartlR ,  BurckhardtP ,  DelmasPD ,  DielIJ ,  FleischH , et al. Current use of bisphosphonates in oncology. Journal of Clinical Oncology1998;16(12):3890‐9. ">Body 1998</a>). In addition, pre‐clinical work has suggested that bisphosphonates have an anti‐tumour activity, acting through inhibiting cell migration and invasion, and inducing apoptosis in breast cancer cells (<a href="./references#CD003474-bbs2-0109" title="HiragaT , WilliamsPJ , UedaA , TamuraD , YonedaT . Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clinical Cancer Research2004;10(13):4559‐67. ">Hiraga 2004</a>). </p> </section> <section id="CD003474-sec-0034"> <h3 class="title" id="CD003474-sec-0034">Why it is important to do this review</h3> <p>It is therefore of interest to examine the adjuvant role of bisphosphonates in women with early breast cancer (EBC). Aside from bisphosphonates, many novel agents that specifically target the vicious cycle of bone metastases are being developed. Whilst many are still in the early stages of drug development, RANK‐ligand inhibitor denosumab has already completed phase III clinical trials in breast and prostate cancers (<a href="./references#CD003474-bbs2-0104" title="FizaziK , CarducciM , SmithM , DamiãoR , BrownJ , KarshL , et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration‐resistant prostate cancer: a randomised, double‐blind study. Lancet2011;377(9768):813‐22. ">Fizazi 2011</a>; <a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a>). It is with great anticipation that we see where denosumab, with superior efficacy and good tolerability, fits in to clinical practice for women with BCBM. </p> <p>The aim of this systematic review was to identify, describe and summarise high‐quality evidence regarding the use of bisphosphonates and other bone agents in women with early, advanced and metastatic breast cancer. This review was first published in 2002 and was updated in 2005, 2007, 2012 and now in 2017. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003474-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003474-sec-0035"></div> <p>To assess the effects of bisphosphonates and other bone agents in addition to anti‐cancer treatment: (i) in women with early breast cancer (EBC); (ii) in women with advanced breast cancer without bone metastases (ABC); and (iii) in women with metastatic breast cancer and bone metastases (BCBM). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003474-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003474-sec-0036"></div> <section id="CD003474-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003474-sec-0038"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs).</p> </section> <section id="CD003474-sec-0039"> <h4 class="title">Types of participants</h4> <p>Women with a history of breast cancer.</p> </section> <section id="CD003474-sec-0040"> <h4 class="title">Types of interventions</h4> <p>RCTs in women with either EBC, ABC or BCBM:</p> <p> <ol id="CD003474-list-0001"> <li> <p>one treatment with a bisphosphonate/bone‐acting agent with the same treatment without a bisphosphonate/bone‐acting agent (placebo/observation); </p> </li> <li> <p>treatment with one bisphosphonate compared with treatment with a different bisphosphonate;</p> </li> <li> <p>treatment with a bisphosphonate compared with another bone‐acting agent of a different mechanism of action; and </p> </li> <li> <p>immediate treatment with a bisphosphonate/bone‐acting agent compared with delayed treatment of the same bisphosphonate/bone‐acting agent. </p> </li> </ol> </p> <p>We included studies with:</p> <p> <ol id="CD003474-list-0002"> <li> <p>bisphosphonates administered orally or intravenously, in any dose and for any duration;</p> </li> <li> <p>bone‐acting agents (e.g. denosumab) administered in any dose and for any duration; and </p> </li> <li> <p>placebo groups and studies with open control groups (no treatment)</p> </li> </ol> </p> </section> <section id="CD003474-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD003474-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD003474-list-0003"> <li> <p>For women with EBC (defined by stage I‐III breast cancer with no distant metastases, locally advanced or recurrent disease): </p> <ol id="CD003474-list-0004"> <li> <p>bone metastases</p> </li> </ol> </li> <li> <p>For women with ABC (defined by locally ABC, recurrent breast cancer or metastatic breast cancer with no clinically evident bone metastases): </p> <ol id="CD003474-list-0005"> <li> <p>bone metastases</p> </li> </ol> </li> <li> <p>For women with BCBM:</p> <ol id="CD003474-list-0006"> <li> <p>the proportion of women on treatment experiencing a SRE compared to control, expressed as a risk ratio (RR). (For this systematic review, reducing the proportion of women with a SRE was synonymous with reducing the risk of developing a SRE and preventing a SRE). </p> </li> </ol> </li> </ol> </p> </section> <section id="CD003474-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD003474-list-0007"> <li> <p>For women with EBC (defined by stage I‐III breast cancer with no distant metastases, locally advanced or recurrent disease): </p> <ol id="CD003474-list-0008"> <li> <p>visceral metastases;</p> </li> <li> <p>locoregional recurrence;</p> </li> <li> <p>recurrence (defined by locoregional recurrence and distant recurrence);</p> </li> <li> <p>overall survival (or death);</p> </li> <li> <p>disease‐free survival;</p> </li> <li> <p>fracture incidence;</p> </li> <li> <p>quality of life; and</p> </li> <li> <p>adverse, drug‐related events or toxicity.</p> </li> </ol> </li> <li> <p>For women with ABC (defined by locally ABC, recurrent breast cancer or metastatic breast cancer with no clinically evident bone metastases): </p> <ol id="CD003474-list-0009"> <li> <p>SRE, expressed as a RR (treatment group versus control group);</p> </li> <li> <p>SRE rate (where reported)</p> </li> <li> <p>median time to a SRE, expressed as a median ratio (treatment group versus comparator group); </p> </li> <li> <p>overall survival;</p> </li> <li> <p>quality of life; and</p> </li> <li> <p>adverse, drug‐related events or toxicity.</p> </li> </ol> </li> <li> <p>For women with BCBM:</p> <ol id="CD003474-list-0010"> <li> <p>SRE, expressed as a RR (treatment group versus comparator group);</p> </li> <li> <p>SRE rate (where reported)</p> </li> <li> <p>median time to a SRE, expressed as a median ratio (treatment group versus comparator group); </p> </li> <li> <p>overall survival;</p> </li> <li> <p>bone pain</p> </li> <li> <p>quality of life; and</p> </li> <li> <p>adverse, drug‐related events or toxicity.</p> </li> </ol> </li> </ol> </p> <p>We considered for evaluation studies including at least one of the following outcomes.</p> <p> <ol id="CD003474-list-0011"> <li> <p>SREs (new bone metastases; pathological fractures; spinal cord compression; irradiation or surgery on bone; and bone pain). </p> </li> <li> <p>recurrence; and</p> </li> <li> <p>quality of life.</p> </li> </ol> </p> <p>We did not include studies if they only reported death and none of the above SRE endpoints.</p> </section> </section> </section> <section id="CD003474-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003474-sec-0045"> <h4 class="title">Electronic searches</h4> <p>For this review update, we searched the following databases or registries on the 19 September 2016. </p> <p> <ol id="CD003474-list-0012"> <li> <p>The Specialised Register maintained by Cochrane Breast Cancer. Details of the search strategies used by the group for the identification of studies and the procedure used to code references are outlined in the group's module in The Cochrane Library (<a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/BREASTCA/frame.html" target="_blank">www.mrw.interscience.wiley.com/cochrane/clabout/articles/BREASTCA/frame.html</a>). The Specialised Register includes both published and unpublished (including ongoing) trials. Trials coded with the key or text words 'bisphosphonate/s' or 'diphosphonate/s' as well as each specific bisphosphonate (zoledronate, zoledronic acid, pamidronate, clodronate, ibandronate, etidronate, alendronate, risedronate, incadronate, olpadronate, neridronate) 'RANK ligand inhibitor', 'Denosumab', 'Prolia' and 'Xgeva' were combined with 'breast cancer', and we extracted and considered them for inclusion in the review. </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 8) in the Cochrane Library (searched 19 September 2016). See <a href="./appendices#CD003474-sec-0202">Appendix 1</a> </p> </li> <li> <p>MEDLINE (via OvidSP) on 19 September 2016. See <a href="./appendices#CD003474-sec-0203">Appendix 2</a> </p> </li> <li> <p>Embase (via OvidSP) on 19 September 2016. See <a href="./appendices#CD003474-sec-0204">Appendix 3</a> </p> </li> <li> <p>The WHO International Clinical Trials Registry Platform (ICTRP) search portal (<a href="http://apps.who.int/trialsearch/Default.aspx" target="_blank">apps.who.int/trialsearch/Default.aspx</a>) for all prospectively registered and ongoing trials. See <a href="https://archie.cochrane.org/sections/documents/view?version=z1705170224486385820741848085717%26format=REVMAN#APP-04" target="_blank">Appendix 4</a>. </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov/ct2/home" target="_blank">clinicaltrials.gov/ct2/home</a>). See <a href="https://archie.cochrane.org/sections/documents/view?version=z1705170224486385820741848085717%26format=REVMAN#APP-05" target="_blank">Appendix 5</a>. </p> </li> </ol> </p> <p>We did not apply any restrictions based on language.</p> <p>For details regarding the searches conducted in previous versions of this review, please refer to <a href="./references#CD003474-bbs2-0132" title="PavlakisN , StocklerM . Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews2002, Issue 1. [DOI: 10.1002/14651858.CD003474] ">Pavlakis 2002</a>, <a href="./references#CD003474-bbs2-0133" title="PavlakisN , SchmidtRL , StocklerMR . Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews2005, Issue 3. [DOI: 10.1002/14651858.CD003474.pub2] ">Pavlakis 2005</a> and <a href="./references#CD003474-bbs2-0134" title="Matthew HFWong , MartinStockler , NickPavlakis . Bisphosphonates and other bone agents for breast cancer. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD003474.pub3; PUBMED: 22336790] ">Wong 2012</a>. </p> </section> <section id="CD003474-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We searched databases of major international oncology conferences (i.e. the American Society of Clinical Oncology (ASCO) and San Antonio Breast Cancer Symposium (SABCS)) for relevant references using <a href="https://www.elsevier.com/solutions/embase-biomedical-research" target="_blank">Embase.com</a>. </p> <p>We also evaluated systematic reviews published between 2007 and 2016 and searched their reference lists for any additional trials that may have been missed in the initial database search. We also contacted study sponsors and other bisphosphonates investigators to identify additional studies and results. We received permission from pharmaceutical companies to include these studies. These are found in the <a href="./references#CD003474-sec-0224" title="">Characteristics of ongoing studies</a> section. </p> </section> </section> <section id="CD003474-sec-0047"> <h3 class="title" id="CD003474-sec-0047">Data collection and analysis</h3> <section id="CD003474-sec-0048"> <h4 class="title">Selection of studies</h4> <p>For the original and updated review versions, two review authors (2016 update: BOC, AG) independently screened the abstracts and full‐text articles (where available) against the eligibility criteria. Where necessary, we referred any disagreements to a third reviewer for an additional independent evaluation however this was not required in the 2016 update. Final assessment was then determined by consensus with all authors. </p> </section> <section id="CD003474-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>The primary reference to each study was usually the final or updated published version of each paper, however for some studies, we extracted data from more than one publication. Each review author independently extracted data using data collection forms similar to the <a href="./references#CD003474-sec-0221" title="">Characteristics of included studies</a> (2016 update: BOC, MLW or AG). The data collected included methods, participants, interventions and other treatments, primary and secondary outcomes, statistical analysis, baseline characteristics and results. Where possible, we quoted the study authors' own words so that data extraction was as objective as possible. If there was disagreement between review authors on data extraction then a third review author (MLW or AG) independently extracted the data before we reached a consensus. </p> </section> <section id="CD003474-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the risk of bias (2016 update: BOC, MLW or AG). A third review author resolved any disagreements by consensus (AG). For recent review updates, we assessed the studies by using the Cochrane 'Risk of bias' tool as outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003474-bbs2-0108" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We used the standard 'Risk of bias' tables by default to describe a detailed appraisal of the study with focus on the selection bias (random sequence generation, allocation concealment), measurement bias (blinding), attrition bias (incomplete outcome data analysis), selective outcome reporting and other identified sources of bias. We thoroughly searched each study for these risk of bias domains and extracted information for the purpose of a critical appraisal. We rated each domain as either 'low risk' or 'high risk' of bias. Where the primary references did not provide sufficient details, we resorted to secondary references, abstracts, presentations or protocols. Where there was still insufficient information despite attempts to clarify details, we rated the domain as having an 'unclear risk' of bias. </p> </section> <section id="CD003474-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>For the outcome measure of SREs, we have relied on the total number of SREs reported in each paper, in preference to adding together the numbers of each type of SRE. Unfortunately, the reporting of SREs, and in particular the rate of events over time, varied across the studies. Methodology reviews of multiple event reporting such as events per person per year, which assume constant event rates per participant in a given time, have been criticised as providing inaccurate methods for reporting SRE rates within bisphosphonate studies (<a href="./references#CD003474-bbs2-0096" title="CookRJ , MajorP . Methodology for treatment evaluation in patients with cancer metastatic to bone. Journal of the National Cancer Institute2001;93(7):534‐8. ">Cook 2001</a>). Consistent methods of multiple event analyses suitable for bisphosphonate studies were described but are yet to be consistently used in the more recent studies (<a href="./references#CD003474-bbs2-0085" title="AndersenPK , GillRD . Cox's regression model for counting processes: a large sample study. Annals of Statistics1982;10(4):1100‐20. ">Andersen 1982</a>). Only a post‐hoc re‐analysis of the single zoledronate versus pamidronate study reported SRE rates calculated in this way (<a href="./references#CD003474-bbs2-0085" title="AndersenPK , GillRD . Cox's regression model for counting processes: a large sample study. Annals of Statistics1982;10(4):1100‐20. ">Andersen 1982</a>; <a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a>). </p> <p>Due to the differences in the way outcomes were reported, we have reported SRE data as number of events during the studied period and risk ratios (RRs), and as time to events. We have expressed the size of the difference between time‐to‐event distributions as the ratio of the median time to event in the experimental arm over the same outcome in the comparator arm. For a time to SRE, a value over 1.0 suggests superiority for the experimental arm and a value under 1.0 suggests superiority for the comparator arm. We have not formally combined these ratios of SRE rates. Unlike previous versions of this review, this update has presented the median time to a SRE for bisphosphonates versus control as a meta‐analysis. We used the method proposed by <a href="./references#CD003474-bbs2-0113" title="MichielsS , PiedboisP , BurdettS , SyzN , StewartL , PignonJP . Meta‐analysis when only the median survival times are known: a comparison with individual patient data results. International Journal of Technology Assessment in Health Care2005;21(1):119‐25. ">Michiels 2005</a> by calculating the ratio of the medians and presenting these on a log scale using the general inverse variance method in Review Manager 5 (RevMan 5) (<a href="./references#CD003474-bbs2-0117" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <p>For the endpoint of recurrence in EBC studies, the trial authors often reported recurrence together with death (recurrence‐free survival) or partitioned into bone metastases, visceral metastases and locoregional recurrence. Since this endpoint needed to be integrated from different components to form an aggregate, for the purpose of this review we have clearly defined recurrence as locoregional plus distant metastases only, and have not included a new primary, contralateral or ipsilateral breast cancer. We have cross‐checked the recurrent events by summing up the specified events where the numbers were provided by the trial authors. We have been cautious to include the first event per participant only, so that participants with more than one type of recurrence have not been counted twice. We derived a pooled RR with 95% confidence interval (CI). In addition, we have not presented this outcome as a hazard ratio (HR) due to many studies failing to report the outcome as such and the substantial variation in reporting results across studies. </p> <p>For the outcome measures of disease‐free survival and overall survival in early breast cancer studies, we derived the HR, as it is the most appropriate statistic. When possible, we extracted the HR and associated variances directly from the trial publication(s) or they were provided by the trial authors. If it was not reported, we obtained it indirectly employing the methods described by Tierney and colleagues using other available summary statistics (<a href="https://archie.cochrane.org/sections/documents/view?version=z1506110210085638280979547544922%26format=REVMAN#REF-Tierney-2007" target="_blank">Tierney 2007</a>). A HR less than 1.0 favoured the experimental arm. In addition to reporting these outcomes as time to event, we reported data as events and RRs for each study based on reporting preferences in the previous version of this review. In this review update, we have presented data as both time‐to‐event data and dichotomous outcomes for comparison. </p> <p>For the outcome measures of bone pain and quality of life, the data reported by the trial authors were particularly varied, with some studies utilising nominal visual analogue scales and others using validated questionnaires such as the EORTC‐QLQ‐C30 or Brief Pain Inventory. We have restricted the description and synthesis to those studies from which we have extracted suitable data. We have only included, in the relevant tables, studies for which these outcomes were directly assessed. We have used a qualitative scale to summarise their judgment of whether the results indicated a significant difference, a trend or no difference in bone pain and quality of life between groups. </p> <p>For toxicity, we have reported adverse events descriptively in Tables.</p> </section> <section id="CD003474-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>In the adjuvant setting, <a href="./references#CD003474-bbs2-0001" title="GnantM , MlineritschB , Luschin‐EbengreuthG , StoegerH , DubskyP , JakeszR , et al. Long‐term follow‐up in ABCSG‐12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine‐receptor‐positive early breast cancer. Cancer Research2011;71:S1‐2. GnantM , MlineritschB , SchippingerW , Luschin‐EbengreuthG , PöstlbergerS , MenzelC , et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New England Journal of Medicine2009;360(7):679‐91. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , HeckD , MenzelC , et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early‐stage breast cancer: 62‐month follow‐up from the ABCSG‐12 randomised trial. Lancet Oncology2011;12(7):631‐41. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , KnauerM , MoikM , et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Annals of Oncology2015; Vol. 26, issue 2:313‐20. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , PoestlbergerS , DubskyPC , et al. Mature results from ABCSG‐12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine‐responsive early breast cancer. Journal of Clinical Oncology2010;28(15 Suppl):533. ">ABCSG‐12 2011</a> was a two‐by‐two factorial trial that randomised women to either anastrozole or tamoxifen with or without zoledronate. For the purpose of this review, we included data for the zoledronate versus no‐zoledronate comparison. <a href="./references#CD003474-bbs2-0015" title="MoebusVJ , VonMinckwitzG , JackischC , LueckH‐J , SchneeweissA , TeschH , et al. German Adjuvant Intergroup Node Positive (GAIN) study: a phase III trial to compare IDD‐ETC versus EC‐TX in patients with node‐positive primary breast cancer‐final efficacy analysis. Journal of Clinical Oncology2014;32(5 Suppl):1009. MöbusV , DielI J , HarbeckN , EllingD , JackischC , ThomssenC , et al. GAIN study: a phase III trial to compare ETC vs. EC‐TX and ibandronate vs. observation in patients with node‐positive primary breast cancer ‐ 1st interim efficacy analysis. Cancer Research2011;71(24):S2‐4. NCT00196872 . A study to compare ETC vs EC‐TX and ibandronate vs observation in patients with node‐positive primary breast cancer. clinicaltrials.gov/ct2/show/NCT00196872 Date first received: 12 September 2005. vonMinckwitzG , MobusV , SchneeweissA , HuoberJ , ThomssenC , UntchM , et al. German Adjuvant Intergroup Node‐positive study: a phase III trial to compare oral ibandronate versus observation in patients with high‐risk early breast cancer. Journal of Clinical Oncology2013;31(28):3531‐9. ">GAIN 2013</a> was also a two‐by‐two factorial trial that involved two comparisons: (1) 2:1 ibandronate versus observation and (2) 1:1 different dose‐dense arms. We included the data relating to the ibandronate versus observation comparison in this review. Some participants that did not start the parallel chemotherapy and were excluded from the ibandronate (n = 19) and observation (n = 10) comparison. <a href="./references#CD003474-bbs2-0034" title="GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG‐ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. Journal of Clinical Oncology2015;33(15 Suppl):503. [0732‐183X] GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: comparison of toxicities and patient‐stated preference for oral versus intravenous delivery. Journal of Clinical Oncoloy2014;32(15 Suppl):558. NCT00127205 . Zoledronate, clodronate, or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer. clinicaltrials.gov/ct2/show/NCT00127205 (accessed 30 April 2011); Vol. Date first received: 3 August 2005. ">SWOG‐S0307 2015</a> was a three‐armed study comparing zoledronate, clodronate and ibandronate, and results were reported in two abstracts. Due to limited information in the abstract, we have presented results narratively where possible. </p> <p>In the BCBM setting, six studies were three‐armed trials (<a href="./references#CD003474-bbs2-0006" title="BodyJJ , DielIJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology2003;14(9):1399‐405. BodyJJ , LichinitserMR , DiehlI , SchlosserK , PfarrE , CavalliF , et al. Double‐blind placebo‐controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. DielIJ , BodyJJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Improved quality of life after long‐term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer2004;40(11):1704‐12. LyubimovaN , KushlinkskyNE , LichinitserMR . Long‐term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease. 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003. New York: Supportive Care in Cancer, 2003. ">Body 2003</a>; <a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a>; <a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a>; <a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a>; <a href="./references#CD003474-bbs2-0036" title="TripathyD , LichinitzerM , LazarevA , MacLachianA , ApffelstaedtJ , BuddeM , et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomised, double‐blind, placebo‐controlled trial. Annals of Oncology2004;15(5):743‐50. ">Tripathy 2004</a>; <a href="./references#CD003474-bbs2-0040" title="vonAuA , MillothE , DielI , StefanovicS , HennigsA , WallwienerM , et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open‐label, non‐inferiority phase III trial. OncoTargets and Therapy2016; Vol. 2016, issue 9:4173‐80. ">von Au 2016</a>). The three treatment regimens in <a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a> were eligible for two comparisons: (1) immediate versus delayed administration of a bone‐acting agent (denosumab) and (2) other bone‐acting agent (denosumab) versus bisphosphonate (intravenous zoledronate). For the denosumab‐bisphosphonate comparison, the pharmaceutical company (Amgen) provided data to the review authors with new data integrated in the previous version of this review. In <a href="./references#CD003474-bbs2-0006" title="BodyJJ , DielIJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology2003;14(9):1399‐405. BodyJJ , LichinitserMR , DiehlI , SchlosserK , PfarrE , CavalliF , et al. Double‐blind placebo‐controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. DielIJ , BodyJJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Improved quality of life after long‐term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer2004;40(11):1704‐12. LyubimovaN , KushlinkskyNE , LichinitserMR . Long‐term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease. 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003. New York: Supportive Care in Cancer, 2003. ">Body 2003</a>, there were two experimental arms (intravenous ibandronate 6 mg and 2 mg, every 3 to 4 weeks) and one control (placebo) arm; only data from the 6 mg and placebo were used in the analysis. Similarly, in <a href="./references#CD003474-bbs2-0036" title="TripathyD , LichinitzerM , LazarevA , MacLachianA , ApffelstaedtJ , BuddeM , et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomised, double‐blind, placebo‐controlled trial. Annals of Oncology2004;15(5):743‐50. ">Tripathy 2004</a>, only one of the experimental arms (oral ibandronate 50 mg a day rather than 20 mg a day) was compared against the control (placebo) arm and reported in this review. <a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a> included three experimental arms, intravenous clodronate, oral clodronate and intravenous pamidronate and reported data in abstract form only; we included data from <a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a> narratively in the review for all three arms where available. <a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a> initially tested intravenous zoledronate 8 mg or intravenous zoledronate 4 mg as a 15‐minute infusion against intravenous pamidronate 90 mg as a two‐hour infusion, however the trial authors only reported efficacy data for the 4 mg zoledronate and intravenous pamidronate groups. <a href="./references#CD003474-bbs2-0040" title="vonAuA , MillothE , DielI , StefanovicS , HennigsA , WallwienerM , et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open‐label, non‐inferiority phase III trial. OncoTargets and Therapy2016; Vol. 2016, issue 9:4173‐80. ">von Au 2016</a> used intravenous clodronate (900 mg every 3 weeks) or oral clodronate (2400 mg per day) against intravenous pamidronate (60 mg every 3 weeks); we reported data from all three treatment arms where available. </p> </section> <section id="CD003474-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>We contacted trial authors (<a href="./references#CD003474-bbs2-0003" title="AftR , NaughtonM , TrinkausK , WatsonM , YlaganL , Chavez‐MacGregorM , et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncology2010;11(5):421‐8. AftRL , NaughtonM , TrinkausK , WeilbaecherK . Effect of (neo)adjuvant zoledronic acid on disease‐free and overall survival in clinical stage II/III breast cancer. British Journal of Cancer2012;107(1):7‐11. ">Aft 2012</a>; <a href="./references#CD003474-bbs2-0005" title="ColemanR , CameronD , DodwellD , BellR , WilsonC , RathboneE , et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open‐label phase 3 trial. Lancet Oncology2014;15(9):997‐1006. ColemanR , WoodwardE , BrownJ , CameronD , BellR , DodwellD , et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01‐04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment2011;127(2):429‐38. ColemanR , WoodwardE , TurnerL , MarshallH , CollinsonM , DodwellD , et al. Impact of zoledronic acid on fractures, bone mineral density and bone remodeling in the AZURE trial (BIG 01‐04). Cancer Research2011;71(24 Suppl):P2‐19‐01. ColemanRE , MarshallH , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Breast‐cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine2011;365(15):1396‐405. ColemanRE , RathboneEJ , MarshallHC , WilsonC , BrownJE , GossielF , et al. Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study. Cancer Research2012;72(24 Suppl):S6‐4. ColemanRE , ThorpeHC , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Cancer Research2010;70(24 Suppl):S4‐5. ColemanRE , WinterMC , CameronD , BellR , DodwellD , KeaneMM , et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti‐tumour activity in breast cancer. British Journal of Cancer2010;102(7):1099‐105. RathboneEJ , BrownJE , MarshallHC , CollinsonM , LiversedgeV , MurdenGA , et al. Osteonecrosis of the jaw and oral health‐related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). Journal of Clinical Oncology2013;31(21):2685‐91. ">AZURE 2014</a>; <a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a>; <a href="./references#CD003474-bbs2-0015" title="MoebusVJ , VonMinckwitzG , JackischC , LueckH‐J , SchneeweissA , TeschH , et al. German Adjuvant Intergroup Node Positive (GAIN) study: a phase III trial to compare IDD‐ETC versus EC‐TX in patients with node‐positive primary breast cancer‐final efficacy analysis. Journal of Clinical Oncology2014;32(5 Suppl):1009. MöbusV , DielI J , HarbeckN , EllingD , JackischC , ThomssenC , et al. GAIN study: a phase III trial to compare ETC vs. EC‐TX and ibandronate vs. observation in patients with node‐positive primary breast cancer ‐ 1st interim efficacy analysis. Cancer Research2011;71(24):S2‐4. NCT00196872 . A study to compare ETC vs EC‐TX and ibandronate vs observation in patients with node‐positive primary breast cancer. clinicaltrials.gov/ct2/show/NCT00196872 Date first received: 12 September 2005. vonMinckwitzG , MobusV , SchneeweissA , HuoberJ , ThomssenC , UntchM , et al. German Adjuvant Intergroup Node‐positive study: a phase III trial to compare oral ibandronate versus observation in patients with high‐risk early breast cancer. Journal of Clinical Oncology2013;31(28):3531‐9. ">GAIN 2013</a>; <a href="./references#CD003474-bbs2-0022" title="KristensenB ,  EjlertsenB ,  MouridsenHT ,  JensenMB ,  AndersenJ ,  BjerregaardB , et al. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncologica2008;47(4):740‐6. ">Kristensen 2008</a>; <a href="./references#CD003474-bbs2-0026" title="MinckwitzG , RezaiM , TeschH , HuoberJ , GerberB , ZahmDM , et al. Zoledronate for patients with invasive residual disease after anthracyclines‐taxane‐based chemotherapy for early breast cancer ‐ the phase III NeoAdjuvant Trial Add‐oN (NaTaN) study (GBG 36/ABCSG 29). European Journal of Cancer2016;64:12‐21. NCT00512993 . Postoperative use of zoledronic acid in breast cancer patients after neoadjuvant chemotherapy (NATAN). clinicaltrials.gov/ct2/show/NCT00512993 Date first received: 3 August 2007. vonMinckwitzG , RezaiM , EidtmannH , TeschH , HuoberJ , GerberB , et al. Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines‐taxane‐based chemotherapy for primary breast cancer ‐ the phase III NATAN study (GBG 36/ABCSG XX). Cancer Research2013;73(24 Suppl):S5‐05. ">NATAN 2016</a>) for additional information not in the published trial to permit meta‐analysis. </p> </section> <section id="CD003474-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the Chi<sup>2</sup> test and the I<sup>2</sup> statistic (<a href="./references#CD003474-bbs2-0107" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>) to test for heterogeneity over all studies, as well as visual inspection of forest plots (<a href="./references#CD003474-bbs2-0097" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). For the Chi<sup>2</sup> test, a P value of 0.10 indicated evidence of heterogeneity. We used the I<sup>2</sup> statistic as a rough guide to assess heterogeneity: 0% to 40% might not be important; 30% to 60% may represent moderate heterogeneity; 50% to 90% may represent substantial heterogeneity; and 75% to 100% considerable heterogeneity. We evaluated the value of the I<sup>2</sup> statistic alongside the magnitude and direction of effects, and the P value for the Chi<sup>2</sup> test (<a href="./references#CD003474-bbs2-0097" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> <p>We used the random‐effects model in this systematic review by default unless otherwise stated, as the studies we included (especially EBC studies) were heterogeneous in methodology, design, participant groups, disease stage and other treatment. A random‐effects model assumed a different underlying effect of each study and took into account the weighted average of trials of smaller effect. With this model, the meta‐analyses were more likely to represent the typical effect in the observed studies. </p> <p>We considered and discussed heterogeneity in parts of the <a href="#CD003474-sec-0089">Effects of interventions</a> and <a href="https://archie.cochrane.org/sections/documents/view?version=z1506110210085638280979547544922%26format=REVMAN#DISCUSSION" target="_blank">Discussion</a> sections of the review. </p> </section> <section id="CD003474-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed reporting bias using Cochrane's 'Risk of bias' tool (<a href="./references#CD003474-bbs2-0108" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We used trials registers (WHO ICTRP and ClinicalTrials.gov) and published protocols (where available) to cross‐check the reporting of outcomes in the trial publications. </p> <p>We followed the recommendations for testing for funnel plot asymmetry as described in section 10.4.3.1 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003474-bbs2-0125" title="SterneJAC , EggerM , MoherD (editors) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Sterne 2011</a>). Funnel plot asymmetry may be due to reporting bias and we addressed this possibility in the <a href="#CD003474-sec-0089">Effects of interventions</a> section of the review. </p> </section> <section id="CD003474-sec-0056"> <h4 class="title">Data synthesis</h4> <p>For dichotomous outcomes (i.e. SREs, bone metastases, visceral metastases, locoregional recurrence, overall recurrence), we obtained a pooled RR using the random‐effects model (Mantel‐Haenszel analysis). For SRE data as time to events and rates, we did not formally combine the data due to variations in reporting but collated data in tables and synthesised them narratively. </p> <p>For time‐to‐event outcomes (i.e. disease‐free survival and overall survival), we obtained a pooled HR using the fixed‐effect (inverse‐variance method) analysis. For the median time to a SRE, we obtained a pooled median ratio (with data entered on a log scale) using the fixed‐effect (inverse‐variance method) analysis. </p> <p>We have narratively described and presented bone pain, quality of life and adverse events in tables. </p> <p>We performed all analyses using RevMan 5 software (<a href="./references#CD003474-bbs2-0117" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003474-bbs2-0123" title="SchunemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlaziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Schünemann 2011a</a>). </p> <section id="CD003474-sec-0057"> <h5 class="title">'Summary of findings' tables:</h5> <p>We used the GRADE approach to assess the quality of evidence for the following main outcomes in each setting. </p> <section id="CD003474-sec-0058"> <h6 class="title">EBC</h6> <p> <ol id="CD003474-list-0013"> <li> <p>Bone metastases</p> </li> <li> <p>Overall survival</p> </li> <li> <p>Disease‐free survival</p> </li> <li> <p>Fracture incidence</p> </li> <li> <p>Osteonecrosis of the jaw (ONJ)</p> </li> <li> <p>Infusion‐related side effects</p> </li> </ol> </p> </section> <section id="CD003474-sec-0059"> <h6 class="title">ABC</h6> <p> <ol id="CD003474-list-0014"> <li> <p>Bone metastases</p> </li> <li> <p>SRE</p> </li> <li> <p>Overall survival</p> </li> <li> <p>Quality of life</p> </li> </ol> </p> </section> <section id="CD003474-sec-0060"> <h6 class="title">BCBM</h6> <p> <ol id="CD003474-list-0015"> <li> <p>SRE</p> </li> <li> <p>Median time to a SRE</p> </li> <li> <p>Overall survival</p> </li> <li> <p>Bone pain</p> </li> <li> <p>Quality of life</p> </li> </ol> </p> <p>We used GRADEproGDT software (<a href="./references#CD003474-bbs2-0105" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 19 September 2016. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT 2015</a>) to develop the 'Summary of findings' tables and followed GRADE guidance (<a href="./references#CD003474-bbs2-0124" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011b</a>). Two authors (AG &amp; MLW) graded the quality of the evidence for the most recent review update. </p> <p>To calculate the absolute risk for the control group for time‐to‐event outcomes, we estimated the event rate at a specific time point (i.e. three‐year time point for both overall survival and disease‐free survival) from the Kaplan‐Meier curves. We entered these estimated values in <a href="https://gradepro.org/" target="_blank">GRADEpro GDT</a> software, which automatically populated the corresponding absolute risks for the intervention group at the three‐year time point. </p> </section> </section> </section> <section id="CD003474-sec-0061"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We had planned to conduct subgroup analyses for age, menopausal status, presence of skeletal disease, previous or concomitant chemotherapy, previous or concurrent endocrine therapy, route of administration of drugs, type of bisphosphonate or bone‐acting agent and risk groups in early breast cancer (by nodal status, oestrogen/progesterone and HER2 status). However, subgroup analyses were not possible for many pre‐planned subgroups because not all studies presented sufficient data to be stratified by these subgroups. </p> <p>Thus, in the formal analysis, the only pre‐planned subgroups we included were route of administration of drugs, type of bisphosphonate or bone‐acting agent and menopausal status. For the menopausal status subgroup, some studies specifically recruited premenopausal or postmenopausal women, which enabled us to stratify them in either category. In other studies that recruited both premenopausal and postmenopausal women, we attempted to find out the separate outcomes for each menopausal subgroup. If this was reported, we collated the separate outcomes and analysed them in each subgroup. We were also interested in examining the effect of bisphosphonate in EBC according to the recurrence risk group, especially given the observed discrepancy in results between two large RCTs from two different populations (<a href="./references#CD003474-bbs2-0005" title="ColemanR , CameronD , DodwellD , BellR , WilsonC , RathboneE , et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open‐label phase 3 trial. Lancet Oncology2014;15(9):997‐1006. ColemanR , WoodwardE , BrownJ , CameronD , BellR , DodwellD , et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01‐04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment2011;127(2):429‐38. ColemanR , WoodwardE , TurnerL , MarshallH , CollinsonM , DodwellD , et al. Impact of zoledronic acid on fractures, bone mineral density and bone remodeling in the AZURE trial (BIG 01‐04). Cancer Research2011;71(24 Suppl):P2‐19‐01. ColemanRE , MarshallH , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Breast‐cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine2011;365(15):1396‐405. ColemanRE , RathboneEJ , MarshallHC , WilsonC , BrownJE , GossielF , et al. Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study. Cancer Research2012;72(24 Suppl):S6‐4. ColemanRE , ThorpeHC , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Cancer Research2010;70(24 Suppl):S4‐5. ColemanRE , WinterMC , CameronD , BellR , DodwellD , KeaneMM , et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti‐tumour activity in breast cancer. British Journal of Cancer2010;102(7):1099‐105. RathboneEJ , BrownJE , MarshallHC , CollinsonM , LiversedgeV , MurdenGA , et al. Osteonecrosis of the jaw and oral health‐related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). Journal of Clinical Oncology2013;31(21):2685‐91. ">AZURE 2014</a> in stage II/III; <a href="./references#CD003474-bbs2-0001" title="GnantM , MlineritschB , Luschin‐EbengreuthG , StoegerH , DubskyP , JakeszR , et al. Long‐term follow‐up in ABCSG‐12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine‐receptor‐positive early breast cancer. Cancer Research2011;71:S1‐2. GnantM , MlineritschB , SchippingerW , Luschin‐EbengreuthG , PöstlbergerS , MenzelC , et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New England Journal of Medicine2009;360(7):679‐91. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , HeckD , MenzelC , et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early‐stage breast cancer: 62‐month follow‐up from the ABCSG‐12 randomised trial. Lancet Oncology2011;12(7):631‐41. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , KnauerM , MoikM , et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Annals of Oncology2015; Vol. 26, issue 2:313‐20. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , PoestlbergerS , DubskyPC , et al. Mature results from ABCSG‐12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine‐responsive early breast cancer. Journal of Clinical Oncology2010;28(15 Suppl):533. ">ABCSG‐12 2011</a> in stage I/II breast cancer). This was not possible since many EBC bisphosphonate studies did not report outcomes stratified by tumour stage or recurrence risk group. This would best be done in a meta‐analysis of individual participant data from each study (<a href="./references#CD003474-bbs2-0095" title="ColleoniM , O'NeillA , GoldhirschA , GelberRD , BonettiM , ThurlimannB , et al. Identifying breast cancer patients at high risk for bone metastases. Journal of Clinical Oncology2000;18(23):3925‐35. ">Colleoni 2000</a>). We did, however, summarise the baseline characteristics of each study that reported the percentage of women who were pre‐ or postmenopausal at the point of study recruitment, hormone receptor‐ or oestrogen receptor‐positive, and on chemotherapy or endocrine therapy (<a href="#CD003474-tbl-0004">Table 1</a>). </p> <div class="table" id="CD003474-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Early breast cancer: baseline characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment vs comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age: mean &amp; SD<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Menopausal status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ER status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Chemotherapy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Endocrine therapy</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0001" title="GnantM , MlineritschB , Luschin‐EbengreuthG , StoegerH , DubskyP , JakeszR , et al. Long‐term follow‐up in ABCSG‐12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine‐receptor‐positive early breast cancer. Cancer Research2011;71:S1‐2. GnantM , MlineritschB , SchippingerW , Luschin‐EbengreuthG , PöstlbergerS , MenzelC , et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New England Journal of Medicine2009;360(7):679‐91. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , HeckD , MenzelC , et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early‐stage breast cancer: 62‐month follow‐up from the ABCSG‐12 randomised trial. Lancet Oncology2011;12(7):631‐41. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , KnauerM , MoikM , et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Annals of Oncology2015; Vol. 26, issue 2:313‐20. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , PoestlbergerS , DubskyPC , et al. Mature results from ABCSG‐12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine‐responsive early breast cancer. Journal of Clinical Oncology2010;28(15 Suppl):533. ">ABCSG‐12 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate:<br/> &lt; 40 years: 18%<br/> &gt; 40 years: 82%<br/> Observation: </p> <p>&lt; 40 years: 19%<br/> &gt; 40 years: 81% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Premenopausal when recruited</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive:</p> <p>Bisphosphonate: 93%<br/> Control: 94% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Preoperative chemotherapy</b> </p> <p>Bisphosphonate: 6%<br/> Control: 5% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0002" title="GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer (ABCSG‐18): a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet2015;386(9992):433–43. [NCT00556374] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer: results from 3,425 post‐menopausal patients of the ABCSG18 trial. Journal of Clinical Oncology2015;33(15 Suppl):504. [0732‐183X] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. The impact of adjuvant denosumab on disease‐free survival: results from 3,425 postmenopausal patients of the ABCSG‐18 trial. Cancer Research2016;76(4 Suppl):S2‐02. [0008‐5472] ">ABCSG‐18 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab:</p> <p>&lt; 60 years: 30%<br/> &gt; 60 years: 70%<br/> Placebo: </p> <p>&lt; 60 years: 28%<br/> &gt; 60 years: 72% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Postmenopausal only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive:</p> <p>Bisphosphonate: 99%<br/> Control: 100% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Neo/adjuvant therapy:</b><br/> Bisphosphonate: 25% </p> <p>Control: 25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Endocrine therapy before randomisation:</b> </p> <p>Bisphosphonate: 84%</p> <p>Control: 85%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0003" title="AftR , NaughtonM , TrinkausK , WatsonM , YlaganL , Chavez‐MacGregorM , et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncology2010;11(5):421‐8. AftRL , NaughtonM , TrinkausK , WeilbaecherK . Effect of (neo)adjuvant zoledronic acid on disease‐free and overall survival in clinical stage II/III breast cancer. British Journal of Cancer2012;107(1):7‐11. ">Aft 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate: mean 50 (range 30‐68) years</p> <p>Observation: mean 49.1 (range 32‐69) years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Premenopausal</b> </p> <p>Bisphosphonate: 52%</p> <p>Control: 56%</p> <p><b>Postmenopausal:</b> </p> <p>Bisphosphonate: 48%</p> <p>Control: 44%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive:</p> <p>Bisphosphonate: 53%</p> <p>Control: 58%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0005" title="ColemanR , CameronD , DodwellD , BellR , WilsonC , RathboneE , et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open‐label phase 3 trial. Lancet Oncology2014;15(9):997‐1006. ColemanR , WoodwardE , BrownJ , CameronD , BellR , DodwellD , et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01‐04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment2011;127(2):429‐38. ColemanR , WoodwardE , TurnerL , MarshallH , CollinsonM , DodwellD , et al. Impact of zoledronic acid on fractures, bone mineral density and bone remodeling in the AZURE trial (BIG 01‐04). Cancer Research2011;71(24 Suppl):P2‐19‐01. ColemanRE , MarshallH , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Breast‐cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine2011;365(15):1396‐405. ColemanRE , RathboneEJ , MarshallHC , WilsonC , BrownJE , GossielF , et al. Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study. Cancer Research2012;72(24 Suppl):S6‐4. ColemanRE , ThorpeHC , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Cancer Research2010;70(24 Suppl):S4‐5. ColemanRE , WinterMC , CameronD , BellR , DodwellD , KeaneMM , et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti‐tumour activity in breast cancer. British Journal of Cancer2010;102(7):1099‐105. RathboneEJ , BrownJE , MarshallHC , CollinsonM , LiversedgeV , MurdenGA , et al. Osteonecrosis of the jaw and oral health‐related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). Journal of Clinical Oncology2013;31(21):2685‐91. ">AZURE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate: 51.6 ± 9.9 years<br/> Observation: 51.3 ± 10 years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Premenopausal:</b><br/> Bisphosphonate: 45% </p> <p>Control: 45%</p> <p><b>Postmenopausal:</b> </p> <p>Bisphosphonate: 45%</p> <p>Control: 46%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive:</p> <p>Bisphosphonate: 78%<br/> Control: 78% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intended treatment chemotherapy plan:</b> </p> <p>Bisphosphonate: 22%</p> <p>Control: 21%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intended treatment endocrine therapy plan:</b> </p> <p>Bisphosphonate: 5%<br/> Control: 5% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0010" title="DielIJ , SolomayerEF , CostaSD , GollanC , GoernerR , WallweinerD , et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New England Journal of Medicine1998;339(6):357‐63. DielIJ ,  JaschkeA ,  SolomayerEF ,  GollanC ,  BastertG ,  SohnC , et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long‐term follow‐up. Annals of Oncology2008;19(12):2007‐201. JaschkeA , BastertG , SolomayerEF , CostaS , ScheutzF , DielJJ . Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow: a long‐term follow‐up. Journal of Clinical Oncology2004;22(14 Suppl):529. ">Diel 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Across both groups:</p> <p>Median 51 (range: 24‐78) years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Postmenopausal:</b><br/> Bisphosphonate: 64% </p> <p>Control: 61%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive:</p> <p>Bisphosphonate: 66%</p> <p>Control: 58%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adjuvant chemotherapy:</b><br/> Bisphosphonate: 25%<br/> Control: 28% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adjuvant endocrine therapy:</b><br/> Bisphosphonate: 31% </p> <p>Control: 30%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0015" title="MoebusVJ , VonMinckwitzG , JackischC , LueckH‐J , SchneeweissA , TeschH , et al. German Adjuvant Intergroup Node Positive (GAIN) study: a phase III trial to compare IDD‐ETC versus EC‐TX in patients with node‐positive primary breast cancer‐final efficacy analysis. Journal of Clinical Oncology2014;32(5 Suppl):1009. MöbusV , DielI J , HarbeckN , EllingD , JackischC , ThomssenC , et al. GAIN study: a phase III trial to compare ETC vs. EC‐TX and ibandronate vs. observation in patients with node‐positive primary breast cancer ‐ 1st interim efficacy analysis. Cancer Research2011;71(24):S2‐4. NCT00196872 . A study to compare ETC vs EC‐TX and ibandronate vs observation in patients with node‐positive primary breast cancer. clinicaltrials.gov/ct2/show/NCT00196872 Date first received: 12 September 2005. vonMinckwitzG , MobusV , SchneeweissA , HuoberJ , ThomssenC , UntchM , et al. German Adjuvant Intergroup Node‐positive study: a phase III trial to compare oral ibandronate versus observation in patients with high‐risk early breast cancer. Journal of Clinical Oncology2013;31(28):3531‐9. ">GAIN 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate:<br/> &lt; 60 years: 83%<br/> &gt; 60 years: 17%<br/> Observation: </p> <p>&lt; 60 years: 81%<br/> &gt; 60 years: 19% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Premenopausal:</b> </p> <p>Bisphosphonate: 48%<br/> Control: 47% </p> <p><b>Postmenopausal:</b> </p> <p>Bisphosphonate: 51%<br/> Control: 53% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hormone receptor‐positive:</p> <p>Bisphosphonate: 77%</p> <p>Control: 78%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adjuvant therapy:</b><br/> Bisphosphonate: 66%<br/> Control: 65% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0017" title="HershmanDL , McMahonDJ , CrewKD , CremersS , IraniD , CucchiaraG , et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. Journal of Clinical Endocrinology and Metabolism2010;95(2):559‐66. HershmanDL , McMahonDJ , CrewKD , CremersS , IraniD , CucchiaraG , et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early‐stage breast cancer. Journal of Clinical Oncology2008;26(29):4739‐45. ">Hershman 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate: 43 ± 6 years<br/> Placebo: 42 ± 6 years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Premenopausal only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hormone receptor‐positive:</p> <p>Bisphosphonate: 74%<br/> Control: 70% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonates:<br/> 4 cycles: 18%; 6 to 8 cycles: 78% </p> <p>Control:<br/> 4 cycles: 19%; 6 to 8 cycles: 81% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Endocrine therapy after treatment:</b><br/> Bisphosphonates: 70%<br/> Control: 70% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0022" title="KristensenB ,  EjlertsenB ,  MouridsenHT ,  JensenMB ,  AndersenJ ,  BjerregaardB , et al. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncologica2008;47(4):740‐6. ">Kristensen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate:</p> <p>&lt; 39 years: 16%<br/> 40‐49 years: 45% </p> <p>50‐59 years: 23%</p> <p>60‐69 years: 15%</p> <p>Observation:</p> <p>&lt; 39 years: 15%<br/> 40‐49 years: 48% </p> <p>50‐59 years: 23%</p> <p>60‐69 years: 14%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Premenopausal:</b> </p> <p>Bisphosphonate: 67%</p> <p>Control: 66%</p> <p><b>Postmenopausal:</b> </p> <p>Bisphosphonate: 33%</p> <p>Control: 34%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive:</p> <p>Bisphosphonate: 14%</p> <p>Control: 17%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0026" title="MinckwitzG , RezaiM , TeschH , HuoberJ , GerberB , ZahmDM , et al. Zoledronate for patients with invasive residual disease after anthracyclines‐taxane‐based chemotherapy for early breast cancer ‐ the phase III NeoAdjuvant Trial Add‐oN (NaTaN) study (GBG 36/ABCSG 29). European Journal of Cancer2016;64:12‐21. NCT00512993 . Postoperative use of zoledronic acid in breast cancer patients after neoadjuvant chemotherapy (NATAN). clinicaltrials.gov/ct2/show/NCT00512993 Date first received: 3 August 2007. vonMinckwitzG , RezaiM , EidtmannH , TeschH , HuoberJ , GerberB , et al. Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines‐taxane‐based chemotherapy for primary breast cancer ‐ the phase III NATAN study (GBG 36/ABCSG XX). Cancer Research2013;73(24 Suppl):S5‐05. ">NATAN 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate:</p> <p>&lt; 55 years: 67%</p> <p>&gt; 55 years: 33%</p> <p>Observation:</p> <p>&lt; 55 years: 66%<br/> &gt; 55 years: 34% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Premenopausal:</b> </p> <p>Bisphosphonate: 22%<br/> Control: 25% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive and/or PR‐positive:</p> <p>Bisphosphonate: 78%<br/> Control: 78% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0027" title="PatersonAH , AndersonSJ , LemberskyBC , FehrenbacherL , FalksonCI , KingKM , et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B‐34): a multicentre, placebo‐controlled, randomised trial. Lancet Oncology2012; Vol. 13, issue 7:734‐42. PatersonAHG , AndersonSJ , LemberskyBC , FehrenbacherL , FalksonCI , KingKM , et al. NSABP protocol B‐34: a clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy ‐ final analysis. Cancer Research2011;71(24 Suppl):S2‐3. ">NSABP‐34 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate:<br/> &lt; 49 years: 36% </p> <p>&gt; 50 years: 64%</p> <p>Placebo:</p> <p>&lt; 49 years: 36%</p> <p>&gt; 50 years: 65%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive and/or PR‐positive:</p> <p>Bisphosphonate: 78%<br/> Control: 78% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate: 21%</p> <p>Control: 21%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate: 31%<br/> Control: 31% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0030" title="AtulaST , PatersonAHG , PowlesTJ , McLoskeyEV , NevalainenJI , KanisJA . Extended safety profile of oral clodronate after long‐term use in primary breast cancer patients. Drug Safety2003;26(9):661‐71. McCloskeyE , PatersonA , KanisJ , TahtelaR , PowlesT . Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. European Journal of Cancer2009;46(3):558‐65. PowlesT , McCloskeyE , KurkilahtiM , KurkilahtiM , KanisJ . Oral clodronate for the adjuvant treatment of operable breast cancer: results of a randomised, double‐blind, placebo‐controlled multicenter trial. Journal of Clinical Oncology2004;22(14 Suppl):528. PowlesT ,  PatersonA ,  McCloskeyE ,  ScheinP ,  SchefflerB ,  TidyA , et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Research2006;8(2):13. PowlesT ,  PatersonS ,  KanisJA ,  McCloskeyE ,  AshleyS ,  TidyA , et al. Randomized, placebo‐controlled trial of clodronate in patients with primary operable breast cancer. Journal of Clinical Oncology2002;20(15):3219‐24. ">Powles 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate:</p> <p>52.8 ± 6 years<br/> Placebo: </p> <p>52.7 ± 10.5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Premenopausal:</b> </p> <p>Bisphosphonate: 50%</p> <p>Control: 49%</p> <p><b>Postmenopausal:</b> </p> <p>Bisphosphonate: 50%</p> <p>Control: 51%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive:</p> <p>Bisphosphonate: 46%</p> <p>Control: 45%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate: 16%<br/> Control: 15% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tamoxifen:</p> <p>Bisphosphonate: 32%<br/> Control: 29% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0032" title="SaartoT , BlomqvistC , VirkkunenP , ElomaaI . Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node‐positive breast cancer patients: 5 year results of a randomised controlled study. Journal of Clinical Oncology2001;19(1):10‐17. SaartoT , VehmanenL , VirkkunenP , BlomqvistC . Ten‐year follow‐up of a randomized controlled trial of adjuvant clodronate treatment in node‐positive breast cancer patients. Acta Oncologica2004;43(7):650‐6. ">Saarto 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate:</p> <p>52 years (no SD provided)</p> <p>Observation:<br/> 52 years (no SD provided) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Premenopausal:</b> </p> <p>Bisphosphonate: 48%<br/> Control: 57% </p> <p><b>Postmenopausal:</b> </p> <p>Bisphosphonate: 52%<br/> Control: 43% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive:</p> <p>Bisphosphonate: 61%<br/> Control: 68% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate: 50%</p> <p>Control: 58%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pretreatment antioestrogen:</b> </p> <p>Bisphosphonate: 50%</p> <p>Control: 58%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0034" title="GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG‐ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. Journal of Clinical Oncology2015;33(15 Suppl):503. [0732‐183X] GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: comparison of toxicities and patient‐stated preference for oral versus intravenous delivery. Journal of Clinical Oncoloy2014;32(15 Suppl):558. NCT00127205 . Zoledronate, clodronate, or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer. clinicaltrials.gov/ct2/show/NCT00127205 (accessed 30 April 2011); Vol. Date first received: 3 August 2005. ">SWOG‐S0307 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs clodronate vs ibandronate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 53 years (range not provided)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Postmenopausal or aged 50 plus: 58%<br/> (not reported by group) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive:<br/> 77% of tumours<br/> (not reported by group) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Planned adjuvant chemotherapy:</p> <p>80%</p> <p>(not reported by group)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Planned endocrine therapy:<br/> 76%<br/> (not reported by group) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0035" title="LealT ,  TevaarwerkA ,  LoveR ,  StewartJ ,  BinkleyN ,  EickhoffJ , et al. Randomized trial of adjuvant zoledronic acid in postmenopausal women with high‐risk breast cancer. Clinical Breast Cancer2010;10(6):471‐6. TevaarwerkA , StewartJA , LoveR , BinkleyNC , BlackS , EickhoffS , et al. Randomized trial to assess bone mineral density (BMD) effects of zoledronic acid (ZA) in postmenopausal women (PmW) with breast cancer. Journal of Clinical Oncology2007;25(18 Suppl):19558. ">Tevaarwerk 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Across both groups:<br/> All women older than 60 years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Postmenopausal only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive:</p> <p>Bisphosphonate: 81%<br/> Control: 91% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adjuvant chemotherapy:</b> </p> <p>Bisphosphonate: 92%<br/> Control: 97% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tamoxifen, other SERM or AI:</b> </p> <p>Bisphosphonate: 75%</p> <p>Control: 72%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0013" title="LlombartA , FrassoldatiA , PaijaO , SleeboomHP , JerusalemG , MebisJ , et al. Immediate administration of zoledronic acid reduces aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer: 12‐month analysis of the E‐ZO‐FAST trial. Clinical Breast Cancer2012;12(1):40‐8. LlombartoA , FrassoldatiA , PaijaO , SleeboomHP , JerusalemG , MebisJ , et al. Effect of zoledronic acid on aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E‐ZO‐FAST 36‐month follow‐up. ASCO Breast Cancer Symposium; 2009; Chicago. Chicago: American Society of Clinical Oncology, 2009. ">E‐ZO‐FAST 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate vs delayed zoledronate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate: median 58 (range 40‐81) years<br/> Delayed: median 58 (range 44‐81) years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Postmenopausal only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prior chemotherapy</b> </p> <p>Immediate: 52%<br/> Delayed: 53% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0041" title="BrufskyA ,  BundredN ,  ColemanR ,  Lambert‐FallsR ,  MenaR ,  HadjiP , et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist2008;13(5):503‐14. BrufskyA ,  HarkerWG ,  BeckJT ,  CarrollR ,  Tan‐ChiuE ,  SeidlerC , et al. Zoledronic acid inhibits adjuvant letrozole‐induced bone loss in postmenopausal women with early breast cancer. Journal of Clinical Oncology2007;25(7):829‐36. BrufskyAM , HarkerWG , BeckJT , BossermanL , VogelC , SeidlerC , et al. Final 5‐year results of Z‐FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer2012;118(5):1192‐201. BrufskyAM ,  BossermanLD ,  CaradonnaRR ,  HaleyBB ,  JonesCM ,  MooreHC ,  etal . Zoledronic acid effectively prevents aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z‐FAST study 36‐month follow‐up results. Clinical Breast Cancer2009;9(2):77‐85. ">Z‐FAST 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate vs delayed zoledronate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate: 61.4 ± 9.28 years<br/> Delayed: 61.0 ± 8.92 years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Postmenopausal only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0043" title="ColemanR , DeBoerR , EidtmannH , LlombartA , DavidsonN , NevenP , et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO‐FAST study): final 60‐month results. Annals of Oncology2013;24(2):398‐405. ColemanR , DeBoerR , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Influence of delayed zoledronic acid initiation on disease‐free survival in postmenopausal women with endocrine receptor‐positive early breast cancer receiving adjuvant letrozole: exploratory analysis from the ZO‐FAST trial. Cancer Research2011;71(24 Suppl):P2‐17‐01. DeBoerR , BundredN , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Long‐term survival outcomes among postmenopausal women with hormone receptor‐positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5‐year follow‐up of ZO‐FAST. Cancer Research2011;71(24 Suppl):S1‐3. DeBoerR , MartinM , StegerGG , VonMoosR , StopeckA , TonkinK , et al. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMs): a number‐needed‐to‐treat (NNT) analysis. Asia‐Pacific Journal of Clinical Oncology2011;7(3 Suppl):9. EidtmannH , DeBoerR , BundredN , Llombart‐CussacA , DavidsonN , NevenP , et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36‐month results of the ZO‐FAST Study. Annals of Oncology2010;21(11):2188‐94. ">ZO‐FAST 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate vs delayed zoledronate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate: median 57 (range 36‐87) years<br/> Delayed: median 58 (range 37‐81) years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Postmenopausal only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prior adjuvant therapy</b><br/> Immediate: 54%<br/> Delayed: 53% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>AI:</b> aromatase inhibitor; <b>ER</b> : oestrogen receptor; <b>NR</b> : not reported; <b>PR</b> : progesterone receptor; <b>SD</b> : standard deviation; <b>SERM</b>: selective estrogen receptor modulator<br/> <sup>a</sup>Unless otherwise stated. </p> </div> </div> </section> <section id="CD003474-sec-0062"> <h4 class="title">Sensitivity analysis</h4> <p>For the 2012 and 2016 update, we intended to exclude hypercalcaemia (HCM) from our definition of the total number of SREs, however this was not possible because many studies presented aggregate data for SREs from which it was impossible to subtract the episodes of HCM. We instead chose to perform a sensitivity analysis by evaluating the effect of including or excluding HCM as a primary SRE. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003474-sec-0063" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003474-sec-0063"></div> <section id="CD003474-sec-0064"> <h3 class="title">Description of studies</h3> <section id="CD003474-sec-0065"> <h4 class="title">Results of the search</h4> <p>For the 2016 review update, we have outlined the search process in a PRISMA flow diagram (refer to <a href="#CD003474-fig-0001">Figure 1</a>) (<a href="./references#CD003474-bbs2-0114" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: The PRISMA Statement. PLoS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed1000097] ">Moher 2009</a>). We identified 754 records through searching Cochrane Breast Cancer's Specialised Register, CENTRAL, MEDLINE and Embase, and an additional 322 records from searches of ASCO and SABCS conference proceedings, the WHO ICTRP and ClinicalTrials.gov. After duplicate records were excluded, from 840 unique records we excluded 700 records based on review of the abstracts retrieved. We retrieved 140 full‐text articles of which we excluded 61 due to not fulfilling the selection criteria. The predominant reasons for exclusion were that studies were not RCTs or were primarily studies of bone density without clinical endpoints such as bone metastases, disease‐free survival or overall survival. The remaining 79 records related to 34 studies: </p> <div class="figure" id="CD003474-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram  ABC: advanced breast cancer; ASCO: American Society of Clinical Oncology; BCBM: breast cancer with bone metastases; EBC: early breast cancer; SABCS: San Antonio Breast Cancer Symposium" data-id="CD003474-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram<br/> <b>ABC</b> : advanced breast cancer; <b>ASCO</b> : American Society of Clinical Oncology; <b>BCBM</b> : breast cancer with bone metastases; <b>EBC</b> : early breast cancer; <b>SABCS</b>: San Antonio Breast Cancer Symposium </p> </div> </div> </div> <p> <ol id="CD003474-list-0016"> <li> <p>10 new studies with outcome data: <a href="./references#CD003474-bbs2-0002" title="GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer (ABCSG‐18): a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet2015;386(9992):433–43. [NCT00556374] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer: results from 3,425 post‐menopausal patients of the ABCSG18 trial. Journal of Clinical Oncology2015;33(15 Suppl):504. [0732‐183X] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. The impact of adjuvant denosumab on disease‐free survival: results from 3,425 postmenopausal patients of the ABCSG‐18 trial. Cancer Research2016;76(4 Suppl):S2‐02. [0008‐5472] ">ABCSG‐18 2015</a>; <a href="./references#CD003474-bbs2-0008" title="HimelsteinAL , QinR , NovotnyPJ , SeislerDK , KhatcheressianJL , RobertsJD , et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of Clinical Oncology2015; Vol. 33, issue 15 Suppl:9501. [0732‐183X] NCT00869206 . Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. clinicaltrials.gov/ct2/show/NCT00869206 Date first received: 24 March 2009. ">CALGB‐70604 2015</a>; <a href="./references#CD003474-bbs2-0015" title="MoebusVJ , VonMinckwitzG , JackischC , LueckH‐J , SchneeweissA , TeschH , et al. German Adjuvant Intergroup Node Positive (GAIN) study: a phase III trial to compare IDD‐ETC versus EC‐TX in patients with node‐positive primary breast cancer‐final efficacy analysis. Journal of Clinical Oncology2014;32(5 Suppl):1009. MöbusV , DielI J , HarbeckN , EllingD , JackischC , ThomssenC , et al. GAIN study: a phase III trial to compare ETC vs. EC‐TX and ibandronate vs. observation in patients with node‐positive primary breast cancer ‐ 1st interim efficacy analysis. Cancer Research2011;71(24):S2‐4. NCT00196872 . A study to compare ETC vs EC‐TX and ibandronate vs observation in patients with node‐positive primary breast cancer. clinicaltrials.gov/ct2/show/NCT00196872 Date first received: 12 September 2005. vonMinckwitzG , MobusV , SchneeweissA , HuoberJ , ThomssenC , UntchM , et al. German Adjuvant Intergroup Node‐positive study: a phase III trial to compare oral ibandronate versus observation in patients with high‐risk early breast cancer. Journal of Clinical Oncology2013;31(28):3531‐9. ">GAIN 2013</a>; <a href="./references#CD003474-bbs2-0026" title="MinckwitzG , RezaiM , TeschH , HuoberJ , GerberB , ZahmDM , et al. Zoledronate for patients with invasive residual disease after anthracyclines‐taxane‐based chemotherapy for early breast cancer ‐ the phase III NeoAdjuvant Trial Add‐oN (NaTaN) study (GBG 36/ABCSG 29). European Journal of Cancer2016;64:12‐21. NCT00512993 . Postoperative use of zoledronic acid in breast cancer patients after neoadjuvant chemotherapy (NATAN). clinicaltrials.gov/ct2/show/NCT00512993 Date first received: 3 August 2007. vonMinckwitzG , RezaiM , EidtmannH , TeschH , HuoberJ , GerberB , et al. Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines‐taxane‐based chemotherapy for primary breast cancer ‐ the phase III NATAN study (GBG 36/ABCSG XX). Cancer Research2013;73(24 Suppl):S5‐05. ">NATAN 2016</a>; <a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a>; <a href="./references#CD003474-bbs2-0034" title="GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG‐ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. Journal of Clinical Oncology2015;33(15 Suppl):503. [0732‐183X] GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: comparison of toxicities and patient‐stated preference for oral versus intravenous delivery. Journal of Clinical Oncoloy2014;32(15 Suppl):558. NCT00127205 . Zoledronate, clodronate, or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer. clinicaltrials.gov/ct2/show/NCT00127205 (accessed 30 April 2011); Vol. Date first received: 3 August 2005. ">SWOG‐S0307 2015</a>; <a href="./references#CD003474-bbs2-0040" title="vonAuA , MillothE , DielI , StefanovicS , HennigsA , WallwienerM , et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open‐label, non‐inferiority phase III trial. OncoTargets and Therapy2016; Vol. 2016, issue 9:4173‐80. ">von Au 2016</a>; <a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a>; <a href="./references#CD003474-bbs2-0043" title="ColemanR , DeBoerR , EidtmannH , LlombartA , DavidsonN , NevenP , et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO‐FAST study): final 60‐month results. Annals of Oncology2013;24(2):398‐405. ColemanR , DeBoerR , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Influence of delayed zoledronic acid initiation on disease‐free survival in postmenopausal women with endocrine receptor‐positive early breast cancer receiving adjuvant letrozole: exploratory analysis from the ZO‐FAST trial. Cancer Research2011;71(24 Suppl):P2‐17‐01. DeBoerR , BundredN , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Long‐term survival outcomes among postmenopausal women with hormone receptor‐positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5‐year follow‐up of ZO‐FAST. Cancer Research2011;71(24 Suppl):S1‐3. DeBoerR , MartinM , StegerGG , VonMoosR , StopeckA , TonkinK , et al. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMs): a number‐needed‐to‐treat (NNT) analysis. Asia‐Pacific Journal of Clinical Oncology2011;7(3 Suppl):9. EidtmannH , DeBoerR , BundredN , Llombart‐CussacA , DavidsonN , NevenP , et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36‐month results of the ZO‐FAST Study. Annals of Oncology2010;21(11):2188‐94. ">ZO‐FAST 2013</a>; <a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a>; </p> </li> <li> <p>five previously identified and included studies with new or updated outcome data: <a href="./references#CD003474-bbs2-0003" title="AftR , NaughtonM , TrinkausK , WatsonM , YlaganL , Chavez‐MacGregorM , et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncology2010;11(5):421‐8. AftRL , NaughtonM , TrinkausK , WeilbaecherK . Effect of (neo)adjuvant zoledronic acid on disease‐free and overall survival in clinical stage II/III breast cancer. British Journal of Cancer2012;107(1):7‐11. ">Aft 2012</a>; <a href="./references#CD003474-bbs2-0005" title="ColemanR , CameronD , DodwellD , BellR , WilsonC , RathboneE , et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open‐label phase 3 trial. Lancet Oncology2014;15(9):997‐1006. ColemanR , WoodwardE , BrownJ , CameronD , BellR , DodwellD , et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01‐04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment2011;127(2):429‐38. ColemanR , WoodwardE , TurnerL , MarshallH , CollinsonM , DodwellD , et al. Impact of zoledronic acid on fractures, bone mineral density and bone remodeling in the AZURE trial (BIG 01‐04). Cancer Research2011;71(24 Suppl):P2‐19‐01. ColemanRE , MarshallH , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Breast‐cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine2011;365(15):1396‐405. ColemanRE , RathboneEJ , MarshallHC , WilsonC , BrownJE , GossielF , et al. Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study. Cancer Research2012;72(24 Suppl):S6‐4. ColemanRE , ThorpeHC , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Cancer Research2010;70(24 Suppl):S4‐5. ColemanRE , WinterMC , CameronD , BellR , DodwellD , KeaneMM , et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti‐tumour activity in breast cancer. British Journal of Cancer2010;102(7):1099‐105. RathboneEJ , BrownJE , MarshallHC , CollinsonM , LiversedgeV , MurdenGA , et al. Osteonecrosis of the jaw and oral health‐related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). Journal of Clinical Oncology2013;31(21):2685‐91. ">AZURE 2014</a>; <a href="./references#CD003474-bbs2-0001" title="GnantM , MlineritschB , Luschin‐EbengreuthG , StoegerH , DubskyP , JakeszR , et al. Long‐term follow‐up in ABCSG‐12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine‐receptor‐positive early breast cancer. Cancer Research2011;71:S1‐2. GnantM , MlineritschB , SchippingerW , Luschin‐EbengreuthG , PöstlbergerS , MenzelC , et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New England Journal of Medicine2009;360(7):679‐91. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , HeckD , MenzelC , et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early‐stage breast cancer: 62‐month follow‐up from the ABCSG‐12 randomised trial. Lancet Oncology2011;12(7):631‐41. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , KnauerM , MoikM , et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Annals of Oncology2015; Vol. 26, issue 2:313‐20. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , PoestlbergerS , DubskyPC , et al. Mature results from ABCSG‐12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine‐responsive early breast cancer. Journal of Clinical Oncology2010;28(15 Suppl):533. ">ABCSG‐12 2011</a>; <a href="./references#CD003474-bbs2-0027" title="PatersonAH , AndersonSJ , LemberskyBC , FehrenbacherL , FalksonCI , KingKM , et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B‐34): a multicentre, placebo‐controlled, randomised trial. Lancet Oncology2012; Vol. 13, issue 7:734‐42. PatersonAHG , AndersonSJ , LemberskyBC , FehrenbacherL , FalksonCI , KingKM , et al. NSABP protocol B‐34: a clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy ‐ final analysis. Cancer Research2011;71(24 Suppl):S2‐3. ">NSABP‐34 2012</a>; <a href="./references#CD003474-bbs2-0041" title="BrufskyA ,  BundredN ,  ColemanR ,  Lambert‐FallsR ,  MenaR ,  HadjiP , et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist2008;13(5):503‐14. BrufskyA ,  HarkerWG ,  BeckJT ,  CarrollR ,  Tan‐ChiuE ,  SeidlerC , et al. Zoledronic acid inhibits adjuvant letrozole‐induced bone loss in postmenopausal women with early breast cancer. Journal of Clinical Oncology2007;25(7):829‐36. BrufskyAM , HarkerWG , BeckJT , BossermanL , VogelC , SeidlerC , et al. Final 5‐year results of Z‐FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer2012;118(5):1192‐201. BrufskyAM ,  BossermanLD ,  CaradonnaRR ,  HaleyBB ,  JonesCM ,  MooreHC ,  etal . Zoledronic acid effectively prevents aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z‐FAST study 36‐month follow‐up results. Clinical Breast Cancer2009;9(2):77‐85. ">Z‐FAST 2012</a>; </p> </li> <li> <p>one study awaiting classification: <a href="./references#CD003474-bbs2-0064" title="ColemanRE , WrightJ , HoustonS , AgrawalR , PurohitOP , HaywardL , et al. Randomized trial of marker‐directed versus standard schedule zoledronic acid for bone metastases from breast cancer. Journal of Clinical Oncology2012;30(15 Suppl (May 2012)):511. NCT00458796 . Comparison of two schedules of zoledronic acid in treating patients with breast cancer that has spread to the bone. clinicaltrials.gov/ct2/show/NCT00458796 Date first received: 9 April 2007. ">BISMARK 2012</a>; and, </p> </li> <li> <p>18 ongoing studies, including three newly identified ongoing studies: <a href="./references#CD003474-bbs2-0067" title="El‐IbrashiMM , El‐SaddaWM , bdel‐HalimII , ElashriMS . Zoledronic acid combined with adjuvant tamoxifen with or without ovarian function suppression in premenopausal early breast cancer patients. Cancer Research2016;76(4 Suppl):P5‐15‐04. [0008‐5472] ">El‐Ibrashi 2016</a>; <a href="./references#CD003474-bbs2-0072" title="JiangZ , ShaoZ , ZhangQ , YaoY , HeJ , LiaoW , et al. Efficacy and safety of denosumab from a phase III, randomized, active‐controlled study compared with zoledronic acid in patients of Asian ancestry with bone metastases from solid tumors. Journal of Clinical Oncology2016;34(15 Suppl):10116. [1527‐7755] ">Jiang 2016</a>; <a href="./references#CD003474-bbs2-0074" title="KummelS , VonMG , NekljudovaV , DanCS , DenkertC , HanuschC , et al. Investigating denosumab as add‐on neoadjuvant treatment for hormone receptor‐negative, RANK‐positive or RANK‐negative primary breast cancer and two different nab‐Paclitaxel schedules‐2x2 factorial design (GeparX). Journal of Clinical Oncology2016;34(15 Suppl):TPS635. [1527‐7755] ">Kummel 2016 (GeparX)</a> </p> </li> </ol> </p> <p>Since the previously published review, the study NCT00320710 has been re‐named <a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a> in keeping with published abstracts, and is now an included study. In addition, some studies have been renamed to incorporate their trial name. </p> <p>When combining studies from the original review, previous review updates (<a href="./references#CD003474-bbs2-0132" title="PavlakisN , StocklerM . Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews2002, Issue 1. [DOI: 10.1002/14651858.CD003474] ">Pavlakis 2002</a>; <a href="./references#CD003474-bbs2-0133" title="PavlakisN , SchmidtRL , StocklerMR . Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews2005, Issue 3. [DOI: 10.1002/14651858.CD003474.pub2] ">Pavlakis 2005;</a><a href="./references#CD003474-bbs2-0134" title="Matthew HFWong , MartinStockler , NickPavlakis . Bisphosphonates and other bone agents for breast cancer. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD003474.pub3; PUBMED: 22336790] ">Wong 2012</a>) and the 2016 review update, there were 44 studies included in this updated review (<a href="#CD003474-fig-0001">Figure 1</a>). Seventeen studies involved women with early breast cancer (EBC), three studies involved women with advanced breast cancer (ABC) and 24 studies (contributing to 23 treatment comparisons) involved women with advanced disease and bone metastases (BCBM). </p> <p>The PRISMA flowchart for the original review and previous review updates are located in the previously published version of this review (<a href="./references#CD003474-bbs2-0134" title="Matthew HFWong , MartinStockler , NickPavlakis . Bisphosphonates and other bone agents for breast cancer. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD003474.pub3; PUBMED: 22336790] ">Wong 2012</a>). </p> </section> <section id="CD003474-sec-0066"> <h4 class="title">Included studies</h4> <p>Refer to <a href="./references#CD003474-sec-0221" title="">Characteristics of included studies</a>. </p> <section id="CD003474-sec-0067"> <h5 class="title">Early breast cancer (EBC)</h5> <p>The 17 included studies, involving 26,129 women, contributed to the following treatment comparisons. </p> <p> <ol id="CD003474-list-0017"> <li> <p>Bisphosphonate versus placebo/observation: 12 studies (<a href="./references#CD003474-bbs2-0001" title="GnantM , MlineritschB , Luschin‐EbengreuthG , StoegerH , DubskyP , JakeszR , et al. Long‐term follow‐up in ABCSG‐12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine‐receptor‐positive early breast cancer. Cancer Research2011;71:S1‐2. GnantM , MlineritschB , SchippingerW , Luschin‐EbengreuthG , PöstlbergerS , MenzelC , et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New England Journal of Medicine2009;360(7):679‐91. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , HeckD , MenzelC , et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early‐stage breast cancer: 62‐month follow‐up from the ABCSG‐12 randomised trial. Lancet Oncology2011;12(7):631‐41. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , KnauerM , MoikM , et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Annals of Oncology2015; Vol. 26, issue 2:313‐20. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , PoestlbergerS , DubskyPC , et al. Mature results from ABCSG‐12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine‐responsive early breast cancer. Journal of Clinical Oncology2010;28(15 Suppl):533. ">ABCSG‐12 2011</a>; <a href="./references#CD003474-bbs2-0003" title="AftR , NaughtonM , TrinkausK , WatsonM , YlaganL , Chavez‐MacGregorM , et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncology2010;11(5):421‐8. AftRL , NaughtonM , TrinkausK , WeilbaecherK . Effect of (neo)adjuvant zoledronic acid on disease‐free and overall survival in clinical stage II/III breast cancer. British Journal of Cancer2012;107(1):7‐11. ">Aft 2012</a>; <a href="./references#CD003474-bbs2-0005" title="ColemanR , CameronD , DodwellD , BellR , WilsonC , RathboneE , et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open‐label phase 3 trial. Lancet Oncology2014;15(9):997‐1006. ColemanR , WoodwardE , BrownJ , CameronD , BellR , DodwellD , et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01‐04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment2011;127(2):429‐38. ColemanR , WoodwardE , TurnerL , MarshallH , CollinsonM , DodwellD , et al. Impact of zoledronic acid on fractures, bone mineral density and bone remodeling in the AZURE trial (BIG 01‐04). Cancer Research2011;71(24 Suppl):P2‐19‐01. ColemanRE , MarshallH , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Breast‐cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine2011;365(15):1396‐405. ColemanRE , RathboneEJ , MarshallHC , WilsonC , BrownJE , GossielF , et al. Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study. Cancer Research2012;72(24 Suppl):S6‐4. ColemanRE , ThorpeHC , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Cancer Research2010;70(24 Suppl):S4‐5. ColemanRE , WinterMC , CameronD , BellR , DodwellD , KeaneMM , et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti‐tumour activity in breast cancer. British Journal of Cancer2010;102(7):1099‐105. RathboneEJ , BrownJE , MarshallHC , CollinsonM , LiversedgeV , MurdenGA , et al. Osteonecrosis of the jaw and oral health‐related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). Journal of Clinical Oncology2013;31(21):2685‐91. ">AZURE 2014</a>; <a href="./references#CD003474-bbs2-0010" title="DielIJ , SolomayerEF , CostaSD , GollanC , GoernerR , WallweinerD , et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New England Journal of Medicine1998;339(6):357‐63. DielIJ ,  JaschkeA ,  SolomayerEF ,  GollanC ,  BastertG ,  SohnC , et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long‐term follow‐up. Annals of Oncology2008;19(12):2007‐201. JaschkeA , BastertG , SolomayerEF , CostaS , ScheutzF , DielJJ . Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow: a long‐term follow‐up. Journal of Clinical Oncology2004;22(14 Suppl):529. ">Diel 1998</a>; <a href="./references#CD003474-bbs2-0015" title="MoebusVJ , VonMinckwitzG , JackischC , LueckH‐J , SchneeweissA , TeschH , et al. German Adjuvant Intergroup Node Positive (GAIN) study: a phase III trial to compare IDD‐ETC versus EC‐TX in patients with node‐positive primary breast cancer‐final efficacy analysis. Journal of Clinical Oncology2014;32(5 Suppl):1009. MöbusV , DielI J , HarbeckN , EllingD , JackischC , ThomssenC , et al. GAIN study: a phase III trial to compare ETC vs. EC‐TX and ibandronate vs. observation in patients with node‐positive primary breast cancer ‐ 1st interim efficacy analysis. Cancer Research2011;71(24):S2‐4. NCT00196872 . A study to compare ETC vs EC‐TX and ibandronate vs observation in patients with node‐positive primary breast cancer. clinicaltrials.gov/ct2/show/NCT00196872 Date first received: 12 September 2005. vonMinckwitzG , MobusV , SchneeweissA , HuoberJ , ThomssenC , UntchM , et al. German Adjuvant Intergroup Node‐positive study: a phase III trial to compare oral ibandronate versus observation in patients with high‐risk early breast cancer. Journal of Clinical Oncology2013;31(28):3531‐9. ">GAIN 2013</a>; <a href="./references#CD003474-bbs2-0017" title="HershmanDL , McMahonDJ , CrewKD , CremersS , IraniD , CucchiaraG , et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. Journal of Clinical Endocrinology and Metabolism2010;95(2):559‐66. HershmanDL , McMahonDJ , CrewKD , CremersS , IraniD , CucchiaraG , et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early‐stage breast cancer. Journal of Clinical Oncology2008;26(29):4739‐45. ">Hershman 2008</a>; <a href="./references#CD003474-bbs2-0022" title="KristensenB ,  EjlertsenB ,  MouridsenHT ,  JensenMB ,  AndersenJ ,  BjerregaardB , et al. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncologica2008;47(4):740‐6. ">Kristensen 2008</a>; <a href="./references#CD003474-bbs2-0026" title="MinckwitzG , RezaiM , TeschH , HuoberJ , GerberB , ZahmDM , et al. Zoledronate for patients with invasive residual disease after anthracyclines‐taxane‐based chemotherapy for early breast cancer ‐ the phase III NeoAdjuvant Trial Add‐oN (NaTaN) study (GBG 36/ABCSG 29). European Journal of Cancer2016;64:12‐21. NCT00512993 . Postoperative use of zoledronic acid in breast cancer patients after neoadjuvant chemotherapy (NATAN). clinicaltrials.gov/ct2/show/NCT00512993 Date first received: 3 August 2007. vonMinckwitzG , RezaiM , EidtmannH , TeschH , HuoberJ , GerberB , et al. Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines‐taxane‐based chemotherapy for primary breast cancer ‐ the phase III NATAN study (GBG 36/ABCSG XX). Cancer Research2013;73(24 Suppl):S5‐05. ">NATAN 2016</a>; <a href="./references#CD003474-bbs2-0027" title="PatersonAH , AndersonSJ , LemberskyBC , FehrenbacherL , FalksonCI , KingKM , et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B‐34): a multicentre, placebo‐controlled, randomised trial. Lancet Oncology2012; Vol. 13, issue 7:734‐42. PatersonAHG , AndersonSJ , LemberskyBC , FehrenbacherL , FalksonCI , KingKM , et al. NSABP protocol B‐34: a clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy ‐ final analysis. Cancer Research2011;71(24 Suppl):S2‐3. ">NSABP‐34 2012</a>; <a href="./references#CD003474-bbs2-0030" title="AtulaST , PatersonAHG , PowlesTJ , McLoskeyEV , NevalainenJI , KanisJA . Extended safety profile of oral clodronate after long‐term use in primary breast cancer patients. Drug Safety2003;26(9):661‐71. McCloskeyE , PatersonA , KanisJ , TahtelaR , PowlesT . Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. European Journal of Cancer2009;46(3):558‐65. PowlesT , McCloskeyE , KurkilahtiM , KurkilahtiM , KanisJ . Oral clodronate for the adjuvant treatment of operable breast cancer: results of a randomised, double‐blind, placebo‐controlled multicenter trial. Journal of Clinical Oncology2004;22(14 Suppl):528. PowlesT ,  PatersonA ,  McCloskeyE ,  ScheinP ,  SchefflerB ,  TidyA , et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Research2006;8(2):13. PowlesT ,  PatersonS ,  KanisJA ,  McCloskeyE ,  AshleyS ,  TidyA , et al. Randomized, placebo‐controlled trial of clodronate in patients with primary operable breast cancer. Journal of Clinical Oncology2002;20(15):3219‐24. ">Powles 2006</a>; <a href="./references#CD003474-bbs2-0032" title="SaartoT , BlomqvistC , VirkkunenP , ElomaaI . Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node‐positive breast cancer patients: 5 year results of a randomised controlled study. Journal of Clinical Oncology2001;19(1):10‐17. SaartoT , VehmanenL , VirkkunenP , BlomqvistC . Ten‐year follow‐up of a randomized controlled trial of adjuvant clodronate treatment in node‐positive breast cancer patients. Acta Oncologica2004;43(7):650‐6. ">Saarto 2004</a>; <a href="./references#CD003474-bbs2-0035" title="LealT ,  TevaarwerkA ,  LoveR ,  StewartJ ,  BinkleyN ,  EickhoffJ , et al. Randomized trial of adjuvant zoledronic acid in postmenopausal women with high‐risk breast cancer. Clinical Breast Cancer2010;10(6):471‐6. TevaarwerkA , StewartJA , LoveR , BinkleyNC , BlackS , EickhoffS , et al. Randomized trial to assess bone mineral density (BMD) effects of zoledronic acid (ZA) in postmenopausal women (PmW) with breast cancer. Journal of Clinical Oncology2007;25(18 Suppl):19558. ">Tevaarwerk 2007</a>) </p> </li> <li> <p>Denosumab versus placebo: one study (<a href="./references#CD003474-bbs2-0002" title="GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer (ABCSG‐18): a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet2015;386(9992):433–43. [NCT00556374] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer: results from 3,425 post‐menopausal patients of the ABCSG18 trial. Journal of Clinical Oncology2015;33(15 Suppl):504. [0732‐183X] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. The impact of adjuvant denosumab on disease‐free survival: results from 3,425 postmenopausal patients of the ABCSG‐18 trial. Cancer Research2016;76(4 Suppl):S2‐02. [0008‐5472] ">ABCSG‐18 2015</a>) </p> </li> <li> <p>Bisphosphonate versus a different bisphosphonate: one study (<a href="./references#CD003474-bbs2-0034" title="GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG‐ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. Journal of Clinical Oncology2015;33(15 Suppl):503. [0732‐183X] GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: comparison of toxicities and patient‐stated preference for oral versus intravenous delivery. Journal of Clinical Oncoloy2014;32(15 Suppl):558. NCT00127205 . Zoledronate, clodronate, or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer. clinicaltrials.gov/ct2/show/NCT00127205 (accessed 30 April 2011); Vol. Date first received: 3 August 2005. ">SWOG‐S0307 2015</a>) </p> </li> <li> <p>Immediate versus delayed bisphosphonate (triggered by falling bone mineral density (BMD), minimal trauma or vertebral fracture): three studies (<a href="./references#CD003474-bbs2-0013" title="LlombartA , FrassoldatiA , PaijaO , SleeboomHP , JerusalemG , MebisJ , et al. Immediate administration of zoledronic acid reduces aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer: 12‐month analysis of the E‐ZO‐FAST trial. Clinical Breast Cancer2012;12(1):40‐8. LlombartoA , FrassoldatiA , PaijaO , SleeboomHP , JerusalemG , MebisJ , et al. Effect of zoledronic acid on aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E‐ZO‐FAST 36‐month follow‐up. ASCO Breast Cancer Symposium; 2009; Chicago. Chicago: American Society of Clinical Oncology, 2009. ">E‐ZO‐FAST 2012</a>; <a href="./references#CD003474-bbs2-0041" title="BrufskyA ,  BundredN ,  ColemanR ,  Lambert‐FallsR ,  MenaR ,  HadjiP , et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist2008;13(5):503‐14. BrufskyA ,  HarkerWG ,  BeckJT ,  CarrollR ,  Tan‐ChiuE ,  SeidlerC , et al. Zoledronic acid inhibits adjuvant letrozole‐induced bone loss in postmenopausal women with early breast cancer. Journal of Clinical Oncology2007;25(7):829‐36. BrufskyAM , HarkerWG , BeckJT , BossermanL , VogelC , SeidlerC , et al. Final 5‐year results of Z‐FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer2012;118(5):1192‐201. BrufskyAM ,  BossermanLD ,  CaradonnaRR ,  HaleyBB ,  JonesCM ,  MooreHC ,  etal . Zoledronic acid effectively prevents aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z‐FAST study 36‐month follow‐up results. Clinical Breast Cancer2009;9(2):77‐85. ">Z‐FAST 2012</a>; <a href="./references#CD003474-bbs2-0043" title="ColemanR , DeBoerR , EidtmannH , LlombartA , DavidsonN , NevenP , et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO‐FAST study): final 60‐month results. Annals of Oncology2013;24(2):398‐405. ColemanR , DeBoerR , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Influence of delayed zoledronic acid initiation on disease‐free survival in postmenopausal women with endocrine receptor‐positive early breast cancer receiving adjuvant letrozole: exploratory analysis from the ZO‐FAST trial. Cancer Research2011;71(24 Suppl):P2‐17‐01. DeBoerR , BundredN , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Long‐term survival outcomes among postmenopausal women with hormone receptor‐positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5‐year follow‐up of ZO‐FAST. Cancer Research2011;71(24 Suppl):S1‐3. DeBoerR , MartinM , StegerGG , VonMoosR , StopeckA , TonkinK , et al. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMs): a number‐needed‐to‐treat (NNT) analysis. Asia‐Pacific Journal of Clinical Oncology2011;7(3 Suppl):9. EidtmannH , DeBoerR , BundredN , Llombart‐CussacA , DavidsonN , NevenP , et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36‐month results of the ZO‐FAST Study. Annals of Oncology2010;21(11):2188‐94. ">ZO‐FAST 2013</a>) </p> </li> </ol> </p> <section id="CD003474-sec-0068"> <h6 class="title">Bisphosphonate versus placebo/observation</h6> <p>Five studies evaluated intravenous zoledronate. <a href="./references#CD003474-bbs2-0001" title="GnantM , MlineritschB , Luschin‐EbengreuthG , StoegerH , DubskyP , JakeszR , et al. Long‐term follow‐up in ABCSG‐12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine‐receptor‐positive early breast cancer. Cancer Research2011;71:S1‐2. GnantM , MlineritschB , SchippingerW , Luschin‐EbengreuthG , PöstlbergerS , MenzelC , et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New England Journal of Medicine2009;360(7):679‐91. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , HeckD , MenzelC , et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early‐stage breast cancer: 62‐month follow‐up from the ABCSG‐12 randomised trial. Lancet Oncology2011;12(7):631‐41. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , KnauerM , MoikM , et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Annals of Oncology2015; Vol. 26, issue 2:313‐20. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , PoestlbergerS , DubskyPC , et al. Mature results from ABCSG‐12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine‐responsive early breast cancer. Journal of Clinical Oncology2010;28(15 Suppl):533. ">ABCSG‐12 2011</a> evaluated zoledronate every six months for three years and <a href="./references#CD003474-bbs2-0005" title="ColemanR , CameronD , DodwellD , BellR , WilsonC , RathboneE , et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open‐label phase 3 trial. Lancet Oncology2014;15(9):997‐1006. ColemanR , WoodwardE , BrownJ , CameronD , BellR , DodwellD , et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01‐04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment2011;127(2):429‐38. ColemanR , WoodwardE , TurnerL , MarshallH , CollinsonM , DodwellD , et al. Impact of zoledronic acid on fractures, bone mineral density and bone remodeling in the AZURE trial (BIG 01‐04). Cancer Research2011;71(24 Suppl):P2‐19‐01. ColemanRE , MarshallH , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Breast‐cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine2011;365(15):1396‐405. ColemanRE , RathboneEJ , MarshallHC , WilsonC , BrownJE , GossielF , et al. Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study. Cancer Research2012;72(24 Suppl):S6‐4. ColemanRE , ThorpeHC , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Cancer Research2010;70(24 Suppl):S4‐5. ColemanRE , WinterMC , CameronD , BellR , DodwellD , KeaneMM , et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti‐tumour activity in breast cancer. British Journal of Cancer2010;102(7):1099‐105. RathboneEJ , BrownJE , MarshallHC , CollinsonM , LiversedgeV , MurdenGA , et al. Osteonecrosis of the jaw and oral health‐related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). Journal of Clinical Oncology2013;31(21):2685‐91. ">AZURE 2014</a> evaluated a tapering regimen of zoledronate over five years. Two studies (<a href="./references#CD003474-bbs2-0017" title="HershmanDL , McMahonDJ , CrewKD , CremersS , IraniD , CucchiaraG , et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. Journal of Clinical Endocrinology and Metabolism2010;95(2):559‐66. HershmanDL , McMahonDJ , CrewKD , CremersS , IraniD , CucchiaraG , et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early‐stage breast cancer. Journal of Clinical Oncology2008;26(29):4739‐45. ">Hershman 2008;</a><a href="./references#CD003474-bbs2-0035" title="LealT ,  TevaarwerkA ,  LoveR ,  StewartJ ,  BinkleyN ,  EickhoffJ , et al. Randomized trial of adjuvant zoledronic acid in postmenopausal women with high‐risk breast cancer. Clinical Breast Cancer2010;10(6):471‐6. TevaarwerkA , StewartJA , LoveR , BinkleyNC , BlackS , EickhoffS , et al. Randomized trial to assess bone mineral density (BMD) effects of zoledronic acid (ZA) in postmenopausal women (PmW) with breast cancer. Journal of Clinical Oncology2007;25(18 Suppl):19558. ">Tevaarwerk 2007</a>) were primarily studies of BMD that also reported disease recurrence and survival. <a href="./references#CD003474-bbs2-0003" title="AftR , NaughtonM , TrinkausK , WatsonM , YlaganL , Chavez‐MacGregorM , et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncology2010;11(5):421‐8. AftRL , NaughtonM , TrinkausK , WeilbaecherK . Effect of (neo)adjuvant zoledronic acid on disease‐free and overall survival in clinical stage II/III breast cancer. British Journal of Cancer2012;107(1):7‐11. ">Aft 2012</a> measured disseminated tumour cells in bone marrow as its primary endpoint. </p> <p>Four studies evaluated oral clodronate. Two large, placebo‐controlled, phase III RCTs evaluated oral clodronate 1600 mg a day for either two years (<a href="./references#CD003474-bbs2-0030" title="AtulaST , PatersonAHG , PowlesTJ , McLoskeyEV , NevalainenJI , KanisJA . Extended safety profile of oral clodronate after long‐term use in primary breast cancer patients. Drug Safety2003;26(9):661‐71. McCloskeyE , PatersonA , KanisJ , TahtelaR , PowlesT . Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. European Journal of Cancer2009;46(3):558‐65. PowlesT , McCloskeyE , KurkilahtiM , KurkilahtiM , KanisJ . Oral clodronate for the adjuvant treatment of operable breast cancer: results of a randomised, double‐blind, placebo‐controlled multicenter trial. Journal of Clinical Oncology2004;22(14 Suppl):528. PowlesT ,  PatersonA ,  McCloskeyE ,  ScheinP ,  SchefflerB ,  TidyA , et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Research2006;8(2):13. PowlesT ,  PatersonS ,  KanisJA ,  McCloskeyE ,  AshleyS ,  TidyA , et al. Randomized, placebo‐controlled trial of clodronate in patients with primary operable breast cancer. Journal of Clinical Oncology2002;20(15):3219‐24. ">Powles 2006</a>) or three years (<a href="./references#CD003474-bbs2-0027" title="PatersonAH , AndersonSJ , LemberskyBC , FehrenbacherL , FalksonCI , KingKM , et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B‐34): a multicentre, placebo‐controlled, randomised trial. Lancet Oncology2012; Vol. 13, issue 7:734‐42. PatersonAHG , AndersonSJ , LemberskyBC , FehrenbacherL , FalksonCI , KingKM , et al. NSABP protocol B‐34: a clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy ‐ final analysis. Cancer Research2011;71(24 Suppl):S2‐3. ">NSABP‐34 2012</a>). Two smaller studies with open‐label control arms compared oral clodronate 1600 mg a day for either two years (<a href="./references#CD003474-bbs2-0010" title="DielIJ , SolomayerEF , CostaSD , GollanC , GoernerR , WallweinerD , et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New England Journal of Medicine1998;339(6):357‐63. DielIJ ,  JaschkeA ,  SolomayerEF ,  GollanC ,  BastertG ,  SohnC , et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long‐term follow‐up. Annals of Oncology2008;19(12):2007‐201. JaschkeA , BastertG , SolomayerEF , CostaS , ScheutzF , DielJJ . Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow: a long‐term follow‐up. Journal of Clinical Oncology2004;22(14 Suppl):529. ">Diel 1998</a>) or three years (<a href="./references#CD003474-bbs2-0032" title="SaartoT , BlomqvistC , VirkkunenP , ElomaaI . Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node‐positive breast cancer patients: 5 year results of a randomised controlled study. Journal of Clinical Oncology2001;19(1):10‐17. SaartoT , VehmanenL , VirkkunenP , BlomqvistC . Ten‐year follow‐up of a randomized controlled trial of adjuvant clodronate treatment in node‐positive breast cancer patients. Acta Oncologica2004;43(7):650‐6. ">Saarto 2004</a>). </p> <p>One large, phase III, open‐label study (<a href="./references#CD003474-bbs2-0015" title="MoebusVJ , VonMinckwitzG , JackischC , LueckH‐J , SchneeweissA , TeschH , et al. German Adjuvant Intergroup Node Positive (GAIN) study: a phase III trial to compare IDD‐ETC versus EC‐TX in patients with node‐positive primary breast cancer‐final efficacy analysis. Journal of Clinical Oncology2014;32(5 Suppl):1009. MöbusV , DielI J , HarbeckN , EllingD , JackischC , ThomssenC , et al. GAIN study: a phase III trial to compare ETC vs. EC‐TX and ibandronate vs. observation in patients with node‐positive primary breast cancer ‐ 1st interim efficacy analysis. Cancer Research2011;71(24):S2‐4. NCT00196872 . A study to compare ETC vs EC‐TX and ibandronate vs observation in patients with node‐positive primary breast cancer. clinicaltrials.gov/ct2/show/NCT00196872 Date first received: 12 September 2005. vonMinckwitzG , MobusV , SchneeweissA , HuoberJ , ThomssenC , UntchM , et al. German Adjuvant Intergroup Node‐positive study: a phase III trial to compare oral ibandronate versus observation in patients with high‐risk early breast cancer. Journal of Clinical Oncology2013;31(28):3531‐9. ">GAIN 2013</a>) in women with node‐positive breast cancer and undergoing adjuvant chemotherapy evaluated oral ibandronate. This study was conducted as a 2 x 2 factorial; women were randomised 2:1 to receive oral ibandronate 50 mg a day for two years or observation, with another randomisation 1:1 of two different dose‐dense chemotherapy regimens. </p> <p>One open‐label study (<a href="./references#CD003474-bbs2-0022" title="KristensenB ,  EjlertsenB ,  MouridsenHT ,  JensenMB ,  AndersenJ ,  BjerregaardB , et al. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncologica2008;47(4):740‐6. ">Kristensen 2008</a>) of a heterogeneous population of women with predominantly oestrogen receptor (ER)/progesterone receptor (PR)‐negative EBC (76%) evaluated oral pamidronate. The study took place between 1990 and 1996 in Scandinavian centres, without adjuvant endocrine therapy, and randomised women to two different chemotherapy regimens. Women were also randomised to oral pamidronate (150 mg a day) or observation. Although oral pamidronate is currently not available for clinical use, the study satisfied 'Risk of bias' assessment and we therefore included it in the meta‐analysis. </p> </section> <section id="CD003474-sec-0069"> <h6 class="title">Denosumab versus placebo</h6> <p><a href="./references#CD003474-bbs2-0002" title="GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer (ABCSG‐18): a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet2015;386(9992):433–43. [NCT00556374] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer: results from 3,425 post‐menopausal patients of the ABCSG18 trial. Journal of Clinical Oncology2015;33(15 Suppl):504. [0732‐183X] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. The impact of adjuvant denosumab on disease‐free survival: results from 3,425 postmenopausal patients of the ABCSG‐18 trial. Cancer Research2016;76(4 Suppl):S2‐02. [0008‐5472] ">ABCSG‐18 2015</a> conducted a prospective, double‐blind, placebo‐controlled, phase III trial of postmenopausal women with hormone receptor‐positive early breast cancer receiving treatment with aromatase inhibitors. Women were randomised to receive either ongoing subcutaneous denosumab 60 mg or placebo every six months. </p> </section> <section id="CD003474-sec-0070"> <h6 class="title">Direct comparisons of different bisphosphonate regimens</h6> <p><a href="./references#CD003474-bbs2-0034" title="GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG‐ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. Journal of Clinical Oncology2015;33(15 Suppl):503. [0732‐183X] GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: comparison of toxicities and patient‐stated preference for oral versus intravenous delivery. Journal of Clinical Oncoloy2014;32(15 Suppl):558. NCT00127205 . Zoledronate, clodronate, or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer. clinicaltrials.gov/ct2/show/NCT00127205 (accessed 30 April 2011); Vol. Date first received: 3 August 2005. ">SWOG‐S0307 2015</a> conducted a phase III, open‐label study comparing three bisphosphonates: intravenous zoledronate 4 mg (every four weeks) for six months then once every three months for two‐and‐a‐half years, oral clodronate (1600 mg a day) for three years and oral ibandronate (50 mg a day) for three years in women with stage I to III adenocarcinoma. </p> </section> <section id="CD003474-sec-0071"> <h6 class="title">Immediate versus delayed bisphosphonate</h6> <p>Three similarly designed, geographically diverse studies explored immediate or delayed zoledronate in postmenopausal women with hormone receptor‐positive breast cancer commencing adjuvant treatment with letrozole (<a href="./references#CD003474-bbs2-0013" title="LlombartA , FrassoldatiA , PaijaO , SleeboomHP , JerusalemG , MebisJ , et al. Immediate administration of zoledronic acid reduces aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer: 12‐month analysis of the E‐ZO‐FAST trial. Clinical Breast Cancer2012;12(1):40‐8. LlombartoA , FrassoldatiA , PaijaO , SleeboomHP , JerusalemG , MebisJ , et al. Effect of zoledronic acid on aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E‐ZO‐FAST 36‐month follow‐up. ASCO Breast Cancer Symposium; 2009; Chicago. Chicago: American Society of Clinical Oncology, 2009. ">E‐ZO‐FAST 2012</a>; <a href="./references#CD003474-bbs2-0041" title="BrufskyA ,  BundredN ,  ColemanR ,  Lambert‐FallsR ,  MenaR ,  HadjiP , et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist2008;13(5):503‐14. BrufskyA ,  HarkerWG ,  BeckJT ,  CarrollR ,  Tan‐ChiuE ,  SeidlerC , et al. Zoledronic acid inhibits adjuvant letrozole‐induced bone loss in postmenopausal women with early breast cancer. Journal of Clinical Oncology2007;25(7):829‐36. BrufskyAM , HarkerWG , BeckJT , BossermanL , VogelC , SeidlerC , et al. Final 5‐year results of Z‐FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer2012;118(5):1192‐201. BrufskyAM ,  BossermanLD ,  CaradonnaRR ,  HaleyBB ,  JonesCM ,  MooreHC ,  etal . Zoledronic acid effectively prevents aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z‐FAST study 36‐month follow‐up results. Clinical Breast Cancer2009;9(2):77‐85. ">Z‐FAST 2012</a>; <a href="./references#CD003474-bbs2-0043" title="ColemanR , DeBoerR , EidtmannH , LlombartA , DavidsonN , NevenP , et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO‐FAST study): final 60‐month results. Annals of Oncology2013;24(2):398‐405. ColemanR , DeBoerR , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Influence of delayed zoledronic acid initiation on disease‐free survival in postmenopausal women with endocrine receptor‐positive early breast cancer receiving adjuvant letrozole: exploratory analysis from the ZO‐FAST trial. Cancer Research2011;71(24 Suppl):P2‐17‐01. DeBoerR , BundredN , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Long‐term survival outcomes among postmenopausal women with hormone receptor‐positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5‐year follow‐up of ZO‐FAST. Cancer Research2011;71(24 Suppl):S1‐3. DeBoerR , MartinM , StegerGG , VonMoosR , StopeckA , TonkinK , et al. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMs): a number‐needed‐to‐treat (NNT) analysis. Asia‐Pacific Journal of Clinical Oncology2011;7(3 Suppl):9. EidtmannH , DeBoerR , BundredN , Llombart‐CussacA , DavidsonN , NevenP , et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36‐month results of the ZO‐FAST Study. Annals of Oncology2010;21(11):2188‐94. ">ZO‐FAST 2013</a>). All used common criteria to trigger the commencement of delayed zoledronate: a BMD T‐score that decreased to –2.0 (lumbar spine (LS) or total hip (TH)) or non‐traumatic fracture. All included primary endpoints of percentage change in the LS BMD at 12 months. </p> </section> </section> <section id="CD003474-sec-0072"> <h5 class="title">Advanced breast cancer without bone metastases (ABC)</h5> <p>Three included studies, involving 330 women, contributed to the following treatment‐comparison.</p> <p> <ol id="CD003474-list-0018"> <li> <p>Bisphosphonate versus placebo/observation: three studies (<a href="./references#CD003474-bbs2-0019" title="KanisJA , PowlesT , PatersonAH , McCloskeyEV , AshleyS . Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone1996;19(6):663‐7. ">Kanis 1996</a>; <a href="./references#CD003474-bbs2-0024" title="MardiakJ , BohunickyL , ChovanecJ , SalekT , KozaI . Adjuvant clodronate therapy in patients with locally advanced breast cancer ‐ long term results of a double blind randomised trial. Neoplasma2000;47(3):177‐80. ">Mardiak 2000;</a><a href="./references#CD003474-bbs2-0039" title="VanHolten‐VerzantvoortAT , HermansJ , BeexLVAM , BlijhamG , CletonFJ , VanEck‐SmitBCF , et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients?. European Journal of Cancer1996;32A(3):450‐4. ">Van‐Holten 1996</a>) </p> </li> </ol> </p> <p>Two studies were placebo‐controlled trials of oral clodronate (<a href="./references#CD003474-bbs2-0019" title="KanisJA , PowlesT , PatersonAH , McCloskeyEV , AshleyS . Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone1996;19(6):663‐7. ">Kanis 1996;</a><a href="./references#CD003474-bbs2-0024" title="MardiakJ , BohunickyL , ChovanecJ , SalekT , KozaI . Adjuvant clodronate therapy in patients with locally advanced breast cancer ‐ long term results of a double blind randomised trial. Neoplasma2000;47(3):177‐80. ">Mardiak 2000</a>) while the other study was an open‐label trial of oral pamidronate (<a href="./references#CD003474-bbs2-0039" title="VanHolten‐VerzantvoortAT , HermansJ , BeexLVAM , BlijhamG , CletonFJ , VanEck‐SmitBCF , et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients?. European Journal of Cancer1996;32A(3):450‐4. ">Van‐Holten 1996</a>). <a href="./references#CD003474-bbs2-0019" title="KanisJA , PowlesT , PatersonAH , McCloskeyEV , AshleyS . Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone1996;19(6):663‐7. ">Kanis 1996</a> included a study population with recurrent breast cancer without bone metastases. <a href="./references#CD003474-bbs2-0024" title="MardiakJ , BohunickyL , ChovanecJ , SalekT , KozaI . Adjuvant clodronate therapy in patients with locally advanced breast cancer ‐ long term results of a double blind randomised trial. Neoplasma2000;47(3):177‐80. ">Mardiak 2000</a> included women with breast cancer with previously untreated, locally advanced disease or extra‐skeletal metastases (excluding central nervous system (CNS) metastases). <a href="./references#CD003474-bbs2-0039" title="VanHolten‐VerzantvoortAT , HermansJ , BeexLVAM , BlijhamG , CletonFJ , VanEck‐SmitBCF , et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients?. European Journal of Cancer1996;32A(3):450‐4. ">Van‐Holten 1996</a> studied locally advanced disease as well as breast cancer with extra‐skeletal metastases. </p> </section> <section id="CD003474-sec-0073"> <h5 class="title">Metastatic breast cancer with bone metastases (BCBM)</h5> <p>The 24 included studies (25 treatment comparisons), involving 10,853 women, contributed to the following treatment‐comparison groups. </p> <p> <ol id="CD003474-list-0019"> <li> <p>Bisphosphonate versus placebo/observation:</p> <ol id="CD003474-list-0020"> <li> <p>clodronate: five studies (<a href="./references#CD003474-bbs2-0012" title="ElomaaI , BlomqvistC , GrohnP , PorkkaL , KairentoA‐L , SelanderK , et al. Long‐term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet1983;1(8317):146‐9. ElomaaI , BlomqvistC , Porkka , HoltstromT , TaubeT , Lamberg‐AllardtC , et al. Clodronate for osteolytic metastases due to breast cancer. Biomedicine and Pharmacotherapy1988;42(2):111‐6. ElommaI , BlomqvistL , PorkkaL , Lamberg‐AllardtC , BorgstromGH . Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone1987;8(Suppl 1):53‐6. ">Elomaa 1983</a>; <a href="./references#CD003474-bbs2-0021" title="KristensenB , EjlertsenB , GroenvoldM , HeinS , LoftH , MouridsenHT . Oral clodronate in breast cancer patients with bone metastases: a randomised study. Journal of Internal Medicine1999;246(1):67‐74. ">Kristensen 1999</a>; <a href="./references#CD003474-bbs2-0025" title="MartoniA , GuaraldiM , CameraP , BiagiR , MarriS , BegheF , et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology1991;48(2):97‐101. ">Martoni 1991</a>; <a href="./references#CD003474-bbs2-0029" title="PatersonAHG , KanisJA , PowlesTJ , McCloskeyEV , ArchabaultWT , KurmanMR , et al. A re‐analysis of a trial of clodronate in patients with breast cancer and bone metastases. Anthra Pharmaceuticals. PatersonAHG , PowlesTJ , KanisJA , McCloskeyE , HansonJ , AshleyS . Double‐blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(1):59‐65. ">Paterson 1993</a>; <a href="./references#CD003474-bbs2-0037" title="Tubiana‐HulinM , BeuzebocP , MauriacL , BarbetN , FrenayM , MonnierA , et al. Double‐blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bulletin du Cancer2001;88(7):701‐7. ">Tubiana‐Hulin 2001</a>) </p> </li> <li> <p>pamidronate: four studies (<a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a>; <a href="./references#CD003474-bbs2-0009" title="ContePF , GiannessiPG , LatreilleJ , MauriacL , KolirenL , CabresiF , et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology1994;5(Suppl 7):41‐4. ContePF , LatrielleJ , MauriacL , CalbresiF , SantosR , CamposD , et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology1996;14(9):2552‐9. ">Conte 1996</a>; <a href="./references#CD003474-bbs2-0018" title="HultbornR , GundersenS , RydenS , HolmbergE , CarstensenJ , WallgrenUB , et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double‐blind placebo‐controlled multicenter study. Anticancer Research1999;19(4C):3383‐92. ">Hultborn 1999</a>; <a href="./references#CD003474-bbs2-0038" title="CletonFJ , VanHolten‐VerzantvoortAT , BijvoetOLM . Effect of long‐term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results in Cancer Research. Vol. 116, Berlin‐Heidelberg: Springer‐Verlag, 1989:73‐8. VanHolten‐VaerzantvoortATM , KroonHM , BijvoetOLM , CletonFJ , BeexLVAM , BlijhamG , et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(3):491‐8. VanHolten‐VerzantvoortAT , BijvoetOLM , CletonFJ , HermansJ , KroonHM , HarinckHIJ , et al. Reduced morbidity from skeletal metastases in breast cancer patients during long‐term bisphosphonate (APD) treatment. Lancet1987;330(8566):983‐5. VanHolten‐VerzantvoortATM , ZwindermanAH , AaronsonNK , HermansJ , VanEmmerikB , VanDamFSAM , et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. European Journal of Cancer1991;27(5):544‐9. ">Van‐Holten 1987</a>) </p> </li> <li> <p>ibandronate: four studies (<a href="./references#CD003474-bbs2-0006" title="BodyJJ , DielIJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology2003;14(9):1399‐405. BodyJJ , LichinitserMR , DiehlI , SchlosserK , PfarrE , CavalliF , et al. Double‐blind placebo‐controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. DielIJ , BodyJJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Improved quality of life after long‐term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer2004;40(11):1704‐12. LyubimovaN , KushlinkskyNE , LichinitserMR . Long‐term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease. 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003. New York: Supportive Care in Cancer, 2003. ">Body 2003</a>; <a href="./references#CD003474-bbs2-0007" title="BodyJJ , DielI , BellR , PecherstorferM , LichinitserM , LazarevA , et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111(3):306‐12. BodyJJ , DielIJ , LichinitzerM , LazarevA , PecherstorferM , BellR , et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo‐controlled phase III studies. British Journal of Cancer2004;90(6):1133‐7. ">Body 2004</a>; <a href="./references#CD003474-bbs2-0016" title="HerasP , HatzopoulosA , MitsibounasD . Efficacy of ibandronate for the prevention of skeletal‐related events in breast cancer patients with metastatic bone disease. European Journal of Cancer2005;3(2):121. HerasP , KritikosK , HatzopoulosA , GeorgopoulouAP . Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. European Journal of Cancer Care2009;18(6):653‐6. ">Heras 2009</a>; <a href="./references#CD003474-bbs2-0036" title="TripathyD , LichinitzerM , LazarevA , MacLachianA , ApffelstaedtJ , BuddeM , et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomised, double‐blind, placebo‐controlled trial. Annals of Oncology2004;15(5):743‐50. ">Tripathy 2004</a>) </p> </li> <li> <p>zoledronate: one study (<a href="./references#CD003474-bbs2-0020" title="KohnoN , AogiK , MinamiH , NakamuraS , AsagaT , IinoY , et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo‐controlled trial. Journal of Clinical Oncology2005;23(15):3314‐21. ">Kohno 2005</a>) </p> </li> </ol> </li> <li> <p>Bisphosphonate versus a different bisphosphonate: four studies (<a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a>; <a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a>; <a href="./references#CD003474-bbs2-0040" title="vonAuA , MillothE , DielI , StefanovicS , HennigsA , WallwienerM , et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open‐label, non‐inferiority phase III trial. OncoTargets and Therapy2016; Vol. 2016, issue 9:4173‐80. ">von Au 2016</a>; <a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a>) </p> </li> <li> <p>Denosumab versus bisphosphonate: three studies (<a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a>; <a href="./references#CD003474-bbs2-0023" title="LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clinical Cancer Research2008;14(20):6690‐6. LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Randomized active‐controlled phase II study of denosumab efficacy and safety in patients with breast cancer‐related bone metastases. Journal of Clinical Oncology2007;25(28):4431‐7. ">Lipton 2008</a>; <a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a>) </p> </li> <li> <p>Standard versus reduced frequency (every three to four weeks versus every 12 weeks of bone‐targeted agents: four studies (<a href="./references#CD003474-bbs2-0008" title="HimelsteinAL , QinR , NovotnyPJ , SeislerDK , KhatcheressianJL , RobertsJD , et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of Clinical Oncology2015; Vol. 33, issue 15 Suppl:9501. [0732‐183X] NCT00869206 . Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. clinicaltrials.gov/ct2/show/NCT00869206 Date first received: 24 March 2009. ">CALGB‐70604 2015</a>; <a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a>; <a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a>; <a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a>) </p> </li> </ol> </p> <section id="CD003474-sec-0074"> <h6 class="title">Bisphosphonate versus placebo/observation</h6> <p>Three studies compared bisphosphonates with no‐bisphosphonates control (<a href="./references#CD003474-bbs2-0009" title="ContePF , GiannessiPG , LatreilleJ , MauriacL , KolirenL , CabresiF , et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology1994;5(Suppl 7):41‐4. ContePF , LatrielleJ , MauriacL , CalbresiF , SantosR , CamposD , et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology1996;14(9):2552‐9. ">Conte 1996;</a><a href="./references#CD003474-bbs2-0021" title="KristensenB , EjlertsenB , GroenvoldM , HeinS , LoftH , MouridsenHT . Oral clodronate in breast cancer patients with bone metastases: a randomised study. Journal of Internal Medicine1999;246(1):67‐74. ">Kristensen 1999;</a><a href="./references#CD003474-bbs2-0038" title="CletonFJ , VanHolten‐VerzantvoortAT , BijvoetOLM . Effect of long‐term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results in Cancer Research. Vol. 116, Berlin‐Heidelberg: Springer‐Verlag, 1989:73‐8. VanHolten‐VaerzantvoortATM , KroonHM , BijvoetOLM , CletonFJ , BeexLVAM , BlijhamG , et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(3):491‐8. VanHolten‐VerzantvoortAT , BijvoetOLM , CletonFJ , HermansJ , KroonHM , HarinckHIJ , et al. Reduced morbidity from skeletal metastases in breast cancer patients during long‐term bisphosphonate (APD) treatment. Lancet1987;330(8566):983‐5. VanHolten‐VerzantvoortATM , ZwindermanAH , AaronsonNK , HermansJ , VanEmmerikB , VanDamFSAM , et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. European Journal of Cancer1991;27(5):544‐9. ">Van‐Holten 1987</a>). Eleven studies compared bisphosphonates with a placebo control. Of these studies, there were two studies of intravenous pamidronate (<a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a>; <a href="./references#CD003474-bbs2-0018" title="HultbornR , GundersenS , RydenS , HolmbergE , CarstensenJ , WallgrenUB , et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double‐blind placebo‐controlled multicenter study. Anticancer Research1999;19(4C):3383‐92. ">Hultborn 1999</a>), three studies of oral clodronate (<a href="./references#CD003474-bbs2-0012" title="ElomaaI , BlomqvistC , GrohnP , PorkkaL , KairentoA‐L , SelanderK , et al. Long‐term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet1983;1(8317):146‐9. ElomaaI , BlomqvistC , Porkka , HoltstromT , TaubeT , Lamberg‐AllardtC , et al. Clodronate for osteolytic metastases due to breast cancer. Biomedicine and Pharmacotherapy1988;42(2):111‐6. ElommaI , BlomqvistL , PorkkaL , Lamberg‐AllardtC , BorgstromGH . Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone1987;8(Suppl 1):53‐6. ">Elomaa 1983</a>; <a href="./references#CD003474-bbs2-0029" title="PatersonAHG , KanisJA , PowlesTJ , McCloskeyEV , ArchabaultWT , KurmanMR , et al. A re‐analysis of a trial of clodronate in patients with breast cancer and bone metastases. Anthra Pharmaceuticals. PatersonAHG , PowlesTJ , KanisJA , McCloskeyE , HansonJ , AshleyS . Double‐blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(1):59‐65. ">Paterson 1993;</a><a href="./references#CD003474-bbs2-0037" title="Tubiana‐HulinM , BeuzebocP , MauriacL , BarbetN , FrenayM , MonnierA , et al. Double‐blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bulletin du Cancer2001;88(7):701‐7. ">Tubiana‐Hulin 2001</a>), one study of intravenous or intramuscular clodronate (<a href="./references#CD003474-bbs2-0025" title="MartoniA , GuaraldiM , CameraP , BiagiR , MarriS , BegheF , et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology1991;48(2):97‐101. ">Martoni 1991</a>), two of intravenous ibandronate (<a href="./references#CD003474-bbs2-0006" title="BodyJJ , DielIJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology2003;14(9):1399‐405. BodyJJ , LichinitserMR , DiehlI , SchlosserK , PfarrE , CavalliF , et al. Double‐blind placebo‐controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. DielIJ , BodyJJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Improved quality of life after long‐term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer2004;40(11):1704‐12. LyubimovaN , KushlinkskyNE , LichinitserMR . Long‐term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease. 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003. New York: Supportive Care in Cancer, 2003. ">Body 2003;</a><a href="./references#CD003474-bbs2-0016" title="HerasP , HatzopoulosA , MitsibounasD . Efficacy of ibandronate for the prevention of skeletal‐related events in breast cancer patients with metastatic bone disease. European Journal of Cancer2005;3(2):121. HerasP , KritikosK , HatzopoulosA , GeorgopoulouAP . Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. European Journal of Cancer Care2009;18(6):653‐6. ">Heras 2009</a>), two of oral ibandronate (<a href="./references#CD003474-bbs2-0007" title="BodyJJ , DielI , BellR , PecherstorferM , LichinitserM , LazarevA , et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111(3):306‐12. BodyJJ , DielIJ , LichinitzerM , LazarevA , PecherstorferM , BellR , et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo‐controlled phase III studies. British Journal of Cancer2004;90(6):1133‐7. ">Body 2004;</a><a href="./references#CD003474-bbs2-0036" title="TripathyD , LichinitzerM , LazarevA , MacLachianA , ApffelstaedtJ , BuddeM , et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomised, double‐blind, placebo‐controlled trial. Annals of Oncology2004;15(5):743‐50. ">Tripathy 2004</a>) and one of zoledronate in Japanese women only (<a href="./references#CD003474-bbs2-0020" title="KohnoN , AogiK , MinamiH , NakamuraS , AsagaT , IinoY , et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo‐controlled trial. Journal of Clinical Oncology2005;23(15):3314‐21. ">Kohno 2005</a>). </p> </section> <section id="CD003474-sec-0075"> <h6 class="title">Bisphosphonate versus different bisphosphonate</h6> <p>Accruing in the 1990s, <a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a> (published only as an abstract) and <a href="./references#CD003474-bbs2-0040" title="vonAuA , MillothE , DielI , StefanovicS , HennigsA , WallwienerM , et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open‐label, non‐inferiority phase III trial. OncoTargets and Therapy2016; Vol. 2016, issue 9:4173‐80. ">von Au 2016</a> compared intravenous or oral clodronate to intravenous pamidronate. Accruing in the early 2000s, <a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a> compared intravenous zoledronate to intravenous pamidronate in people with multiple myeloma and women with ABC and clinically evident bone metastases (1648 participants). Separate data for the women with BCBM were provided on request (1130 women) with updated published results available in 2003. <a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a> was a phase III, double‐blinded, non‐inferiority study comparing oral ibandronate to intravenous zoledronate. </p> </section> <section id="CD003474-sec-0076"> <h6 class="title">Denosumab versus bisphosphonate</h6> <p>A randomised phase II trial (<a href="./references#CD003474-bbs2-0023" title="LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clinical Cancer Research2008;14(20):6690‐6. LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Randomized active‐controlled phase II study of denosumab efficacy and safety in patients with breast cancer‐related bone metastases. Journal of Clinical Oncology2007;25(28):4431‐7. ">Lipton 2008</a>) compared differing doses of subcutaneous denosumab every four weeks (30 mg, 120 mg or 180 mg) to the physician's choice of bisphosphonate (zoledronate, pamidronate or ibandronate every four weeks). The phase III trial of denosumab (<a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a>) was a double‐blinded, double‐dummy trial that compared subcutaneous denosumab 120 mg every four weeks (plus intravenous placebo) versus intravenous zoledronate 4 mg every four weeks (plus subcutaneous placebo). <a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a> recruited participants with breast cancer, prostate cancer and multiple myeloma, with data from breast cancer subgroups (n = 46) provided from the study sponsor. This randomised phase II, three‐armed trial compared 1:1:1 subcutaneous denosumab 180 mg every four weeks; subcutaneous denosumab 180 mg every 12 weeks or intravenous bisphosphonate (physician's choice) with consequently small numbers in each arm. </p> </section> <section id="CD003474-sec-0077"> <h6 class="title">Standard versus reduced frequency of bone‐targeted agents</h6> <p><a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a> was a phase III, non‐inferiority trial of women with BCBM who had completed 12 to 15 months of zoledronate every four weeks, then randomised to zoledronate 4 mg every four weeks or every 12 weeks. As described above, the randomised phase II trial conducted by <a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a> included a small number of women who were given either denosumab or bisphosphonate. <a href="./references#CD003474-bbs2-0008" title="HimelsteinAL , QinR , NovotnyPJ , SeislerDK , KhatcheressianJL , RobertsJD , et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of Clinical Oncology2015; Vol. 33, issue 15 Suppl:9501. [0732‐183X] NCT00869206 . Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. clinicaltrials.gov/ct2/show/NCT00869206 Date first received: 24 March 2009. ">CALGB‐70604 2015</a> was a phase III open‐label study of participants with metastatic breast cancer, prostate or multiple myeloma involving bone. Participants were randomised to receive either zoledronate 4 mg every four weeks or 12 weeks for up to two years. <a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a> was a randomised, phase III double‐blind study comparing zoledronate 4 mg every four weeks to every 12 weeks in women with bone metastases from breast cancer. </p> </section> </section> <section id="CD003474-sec-0078"> <h5 class="title">Studies awaiting classification</h5> <p>The <a href="./references#CD003474-bbs2-0064" title="ColemanRE , WrightJ , HoustonS , AgrawalR , PurohitOP , HaywardL , et al. Randomized trial of marker‐directed versus standard schedule zoledronic acid for bone metastases from breast cancer. Journal of Clinical Oncology2012;30(15 Suppl (May 2012)):511. NCT00458796 . Comparison of two schedules of zoledronic acid in treating patients with breast cancer that has spread to the bone. clinicaltrials.gov/ct2/show/NCT00458796 Date first received: 9 April 2007. ">BISMARK 2012</a> study reported results in a 2012 abstract. The comparator group included either intravenous zoledronate every 15 to 16 weeks, 8 to 9 weeks or 3 to 4 weeks. As data were not reported separately for each of these schedules, we were unable to include the data from this study by comparing the standard intervention group (zoledronate intravenous every 3 to 4 weeks) to the reduced‐frequency group (either 16 to 15 weeks or 8 to 9 weeks). We await data from the complete trial publication. </p> </section> <section id="CD003474-sec-0079"> <h5 class="title">Ongoing studies</h5> <p>We identified 18 ongoing studies (<a href="#CD003474-fig-0001">Figure 1</a>) through database searches of the WHO ICTRP, ClinicalTrials.gov and contacting sponsors (Novartis Oncology and Amgen Oncology). Given the large number of ongoing studies, we only included RCTs reporting a primary endpoint of interest (SREs, recurrence or survival) in the <a href="./references#CD003474-sec-0224" title="">Characteristics of ongoing studies</a> table. </p> </section> </section> <section id="CD003474-sec-0080"> <h4 class="title">Excluded studies</h4> <p>The 19 excluded studies are listed in the <a href="./references#CD003474-sec-0222" title="">Characteristics of excluded studies</a> section. </p> <p>Notably, a subset of the studies excluded are listed. We did not include three studies on risedronate and EBC. <a href="./references#CD003474-bbs2-0050" title="HinesS , MinceyB , SloanJ , ThomasS , ChottinerE , LoprinziC , et al. Phase III randomized, placebo‐controlled, double‐blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. Journal of Clinical Oncology2009;27(7):1047‐53. ">Hines 2009</a> was a BMD study randomising women to risedronate or placebo for one year but no SRE endpoints were discussed. <a href="./references#CD003474-bbs2-0049" title="GreenspanS , PereraS , VujevichK , VanLondenG , BrufskyA , LemberskyB , et al. Prevention of bone loss in breast cancer survivors on aromatase inhibitors: results of the Rebbeca II trial. Journal of Bone and Mineral Research2013;28(1 Suppl):1050. GreenspanSL , BrufskyA , LemberskyBC , BhattacharyaR , VujevichKT , PereraS , et al. Risedronate prevents bone loss in breast cancer survivors: 2‐year, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Clinical Oncology2008;26(16):2644‐52. ">Greenspan 2008</a> was another BMD study that randomised women to risedronate or placebo for two years. The authors reported no difference in recurrence between the two arms but have not explicitly expanded quantitatively or qualitatively on this. Likewise, <a href="./references#CD003474-bbs2-0047" title="DelmasPD , BalenaR , ConfravreuxE , HardouinC , HardyP , BremondA . Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double‐blind, placebo‐controlled study. Journal of Clinical Oncology1997;15(3):955‐62. ">Delmas 1997</a>, also randomised women to risedronate or placebo for two years. The text mentioned that two women had died from recurrent breast cancer but no information was given about the type of recurrence that these women had had, total recurrence or overall death rate. Hence, we did not include any of the risedronate studies. </p> <p><a href="./references#CD003474-bbs2-0057" title="SaartoT , TaubeT , BlomqvistC , VehmanenL , ElomaaI . Three‐year oral clodronate treatment does not impair mineralization of newly formed bone‐a histomorphometric study. Calcified Tissue International2005;77(2):84‐90. SaartoT , VehmanenL , VirkkunenP , BlomqvistC . Ten‐year follow‐up of a randomised controlled trial of adjuvant clodronate treatment in node‐positive breast cancer patients. Acta Oncology2004;43(7):650‐6. ">Saarto 2005</a> was a histological study describing the effect of adjuvant clodronate on bone biopsies obtained from a small subset (n = 63) of consenting women within an included adjuvant study by <a href="./references#CD003474-bbs2-0120" title="SaartoT , BlomqvistC , VirkkunenP , ElomaaI . Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node‐positive breast cancer patients: 5 year results of a randomised controlled study. Journal of Clinical Oncology2001;19(1):10‐17. ">Saarto 2001</a>. No additional clinical outcomes were reported. <a href="./references#CD003474-bbs2-0058" title='LiviL , MeattiniI , ScottiV , SaievaC , DesideriI , CartaGA , et al. BONADIUV trial: a single blind, randomized placebo controlled phase II study using oral ibandronate for osteopenic women receiving adjuvant aromatase inhibitors: final safety analysis. Journal of Clinical Oncology2016;34(15 Suppl):e12043. [1527‐7755] ScottiV , MeattiniI , CecchiniS , DeFeoML , SaievaC , DeLuca CardilloC , et al. A single‐blind, randomized, placebo‐controlled phase II study to evaluate the impact of oral bisphosphonate treatment on bone mineral density in osteopenic women receiving adjuvant aromatase inhibitors: Interim analysis of "BONADIUV" trial. Journal of Clinical Oncology2014;32:TPS658. '>Scotti 2014 (BONADIUV)</a> was a single‐blind, randomised, placebo‐controlled phase II study designed to evaluate the impact of oral ibandronate (150 mg monthly) on BMD in osteopenic women receiving aromatase inhibitors in the adjuvant setting. The study evaluated BMD, safety and tolerability endpoints only. <a href="./references#CD003474-bbs2-0059" title="SestakI , SinghS , CuzickJ , BlakeGM , PatelR , GossielF , et al. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS‐II bone substudy: an international, double‐blind, randomised, placebo‐controlled trial. Lancet Oncology2014;15(13):1460‐8. [ISRCTN31488319] SestakI , SinghS , CuzickJ , BlakeGM , PatelR , GossielF , et al. Correction to Lancet Oncology 2014; 15: 1464. Lancet Oncology2014;15(13):e587. ">Sestak 2014 (IBIS‐II)</a> was a bone substudy of the multi‐national IBIS‐II primary prevention trial of anastrozole reporting primary endpoints of BMD only. </p> </section> </section> <section id="CD003474-sec-0081"> <h3 class="title">Risk of bias in included studies</h3> <p>Refer to <a href="#CD003474-fig-0002">Figure 2</a> for a summary of the risk of bias judgements for each 'Risk of bias' domain of the included studies. </p> <div class="figure" id="CD003474-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD003474-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD003474-sec-0082"> <h4 class="title">Allocation</h4> <p>The 44 studies were described as randomised. If the study adequately described the method of random sequence generation and the baseline characteristics in each treatment arm of a study were balanced, we categorised the study to be at low risk of bias. We deemed 17 studies to be at low risk of bias. It was not possible to accurately assess the randomisation process in 26 studies owing to the lack of information presented in the trial publications; we classified these 26 studies as having an unclear risk of bias. One study (<a href="./references#CD003474-bbs2-0035" title="LealT ,  TevaarwerkA ,  LoveR ,  StewartJ ,  BinkleyN ,  EickhoffJ , et al. Randomized trial of adjuvant zoledronic acid in postmenopausal women with high‐risk breast cancer. Clinical Breast Cancer2010;10(6):471‐6. TevaarwerkA , StewartJA , LoveR , BinkleyNC , BlackS , EickhoffS , et al. Randomized trial to assess bone mineral density (BMD) effects of zoledronic acid (ZA) in postmenopausal women (PmW) with breast cancer. Journal of Clinical Oncology2007;25(18 Suppl):19558. ">Tevaarwerk 2007</a>) had significant imbalances between the baseline characteristics in each treatment arm and we assumed that the randomisation process was inadequate for this study. There was more T1 disease in the treatment group compared to control (39% versus 2%) and more N2‐3 disease in the control group compared to treatment (81% versus 56%). This means that there were more women in the control group having disease with intermediate or high‐risk of recurrence than in the treatment group. Therefore, we classified this study at high risk of bias. </p> <p>Fifteen studies out of 44 studies were at low risk of bias for allocation concealment. Twenty‐nine studies did not describe methods of allocation concealment or in sufficient details in the trial publication and we judged them as having unclear risk of bias. </p> </section> <section id="CD003474-sec-0083"> <h4 class="title">Blinding</h4> <section id="CD003474-sec-0084"> <h5 class="title">Blinding of participants and personnel</h5> <p>Nineteen studies were labelled as double‐blind or double‐dummy design and we judged them to be at low risk of bias. A proportion of studies that compared bisphosphonates to usual care were open label and not placebo‐controlled. In addition, studies comparing bisphosphonates of different routes of administration (intravenous versus oral) or administration schedules were often not adequately controlled. Performance bias owing to the lack of blinding of participants and personnel could not be ruled out in these cases and therefore we classified 25 studies as being at high risk of bias. </p> </section> <section id="CD003474-sec-0085"> <h5 class="title">Blinding of outcome assessors</h5> <p>We judged 24 studies to be at low risk of bias. Eighteen studies did not provide any information about blinding of outcome assessment. As outcomes included composite endpoints such as SREs, we judged these 18 studies to be at unclear risk of bias. We judged two studies (<a href="./references#CD003474-bbs2-0040" title="vonAuA , MillothE , DielI , StefanovicS , HennigsA , WallwienerM , et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open‐label, non‐inferiority phase III trial. OncoTargets and Therapy2016; Vol. 2016, issue 9:4173‐80. ">von Au 2016</a>; <a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a>) to be at high risk of bias for stating that no one involved in the trial was masked to treatment allocation. </p> </section> </section> <section id="CD003474-sec-0086"> <h4 class="title">Incomplete outcome data</h4> <p>Thirty‐one studies provided either well‐described CONSORT flow diagrams (<a href="./references#CD003474-bbs2-0122" title="SchulzKF , AltmanDG , MoherD , for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ2010;340:c332. [DOI: 10.1136/bmj.c332] ">Schultz 2010</a>) or complete outcome data sets, and conducted intention‐to‐treat analyses. We judged these studies to be at low risk of bias. Five studies were at high risk of bias owing to a lack of intention‐to‐treat analysis or high dropout rate, or both, with little information on whether the dropouts were different between treatment and comparator arms. The remaining eight studies were at unclear risk of bias due to insufficient information provided in the abstract or trial publication on missing outcome data. </p> </section> <section id="CD003474-sec-0087"> <h4 class="title">Selective reporting</h4> <p>Thirty‐five studies complied with reporting criteria by either reporting results for those outcomes listed in the methods section of the trial publication or listing a trial registration record with the listed outcomes found in the methods and results section of the trial publication. We assessed these studies to be at low risk of bias. Seven studies provided either insufficient detail about the primary or secondary endpoints or did not provide a complete list of the adverse events as expected. We categorised these studies at unclear risk of bias. Two studies were at high risk of bias for failing to report data for one treatment group (i.e. ibandronate 20 mg data; <a href="./references#CD003474-bbs2-0007" title="BodyJJ , DielI , BellR , PecherstorferM , LichinitserM , LazarevA , et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111(3):306‐12. BodyJJ , DielIJ , LichinitzerM , LazarevA , PecherstorferM , BellR , et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo‐controlled phase III studies. British Journal of Cancer2004;90(6):1133‐7. ">Body 2004</a>) or adding a new outcome (i.e. recurrence; <a href="./references#CD003474-bbs2-0017" title="HershmanDL , McMahonDJ , CrewKD , CremersS , IraniD , CucchiaraG , et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. Journal of Clinical Endocrinology and Metabolism2010;95(2):559‐66. HershmanDL , McMahonDJ , CrewKD , CremersS , IraniD , CucchiaraG , et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early‐stage breast cancer. Journal of Clinical Oncology2008;26(29):4739‐45. ">Hershman 2008</a>). </p> </section> <section id="CD003474-sec-0088"> <h4 class="title">Other potential sources of bias</h4> <p>Thirty‐seven studies were generally free of other sources of bias. We judged one study (<a href="./references#CD003474-bbs2-0022" title="KristensenB ,  EjlertsenB ,  MouridsenHT ,  JensenMB ,  AndersenJ ,  BjerregaardB , et al. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncologica2008;47(4):740‐6. ">Kristensen 2008</a>) to be at high risk of bias due to not permitting women to be on endocrine therapy when 17% of participants in the control arm versus 13% in the pamidronate arm were oestrogen receptor‐positive. This may potentially bias results against the control arm since these participants were not treated optimally. The remaining six studies we judged to be at unclear risk of bias due to very little information in the abstract or trial publication to adequately assess whether the trial was free of other sources of bias. </p> </section> </section> <section id="CD003474-sec-0089"> <h3 class="title" id="CD003474-sec-0089">Effects of interventions</h3> <p>See: <a href="./full#CD003474-tbl-0001"><b>Summary of findings for the main comparison</b> Bisphosphonates compared to placebo/observation for women with early breast cancer</a>; <a href="./full#CD003474-tbl-0002"><b>Summary of findings 2</b> Bisphosphonates compared to placebo/observation for women with advanced breast cancer without bone metastases</a>; <a href="./full#CD003474-tbl-0003"><b>Summary of findings 3</b> Bisphosphonates compared to placebo/observation for women with metastatic breast cancer and bone metastases</a> </p> <section id="CD003474-sec-0090"> <h4 class="title">Early breast cancer (EBC)</h4> <p>There were 17 included studies: 12 studies compared bisphosphonates to placebo/observation, one study tested denosumab against placebo, one study compared three different bisphosphonates and three studies examined immediate versus delayed administration of bisphosphonates. However at present data are not mature for the study evaluating denosumab (<a href="./references#CD003474-bbs2-0002" title="GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer (ABCSG‐18): a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet2015;386(9992):433–43. [NCT00556374] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer: results from 3,425 post‐menopausal patients of the ABCSG18 trial. Journal of Clinical Oncology2015;33(15 Suppl):504. [0732‐183X] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. The impact of adjuvant denosumab on disease‐free survival: results from 3,425 postmenopausal patients of the ABCSG‐18 trial. Cancer Research2016;76(4 Suppl):S2‐02. [0008‐5472] ">ABCSG‐18 2015</a>) and very few data were available from one study examining zoledronate (<a href="./references#CD003474-bbs2-0035" title="LealT ,  TevaarwerkA ,  LoveR ,  StewartJ ,  BinkleyN ,  EickhoffJ , et al. Randomized trial of adjuvant zoledronic acid in postmenopausal women with high‐risk breast cancer. Clinical Breast Cancer2010;10(6):471‐6. TevaarwerkA , StewartJA , LoveR , BinkleyNC , BlackS , EickhoffS , et al. Randomized trial to assess bone mineral density (BMD) effects of zoledronic acid (ZA) in postmenopausal women (PmW) with breast cancer. Journal of Clinical Oncology2007;25(18 Suppl):19558. ">Tevaarwerk 2007</a>) and another study comparing different bisphosphonates (<a href="./references#CD003474-bbs2-0034" title="GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG‐ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. Journal of Clinical Oncology2015;33(15 Suppl):503. [0732‐183X] GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: comparison of toxicities and patient‐stated preference for oral versus intravenous delivery. Journal of Clinical Oncoloy2014;32(15 Suppl):558. NCT00127205 . Zoledronate, clodronate, or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer. clinicaltrials.gov/ct2/show/NCT00127205 (accessed 30 April 2011); Vol. Date first received: 3 August 2005. ">SWOG‐S0307 2015</a>). The majority of studies treated women with intravenous zoledronate (n = 10,361 women) or oral clodronate (n = 7132 women). The baseline characteristics of participants in each study are summarised in <a href="#CD003474-tbl-0004">Table 1</a>. </p> <section id="CD003474-sec-0091"> <h5 class="title">Bone metastases</h5> <section id="CD003474-sec-0092"> <h6 class="title">Bisphosphonate versus placebo/no bisphosphonate</h6> <p>Bisphosphonates were associated with a reduced risk of bone metastases compared to control (RR 0.86, 95% CI 0.75 to 0.99; 11 studies; I<sup>2</sup> = 32%, P = 0.03; <a href="./references#CD003474-fig-0011" title="">Analysis 1.1</a> (subtotal 1.1.1); moderate‐quality evidence). There were 1200 events in 15,005 women randomised (<a href="#CD003474-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD003474-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Early breast cancer (EBC), outcome: 3.1 Incidence of bone metastases in EBC: bisphosphonate versus control" data-id="CD003474-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Early breast cancer (EBC), outcome: 3.1 Incidence of bone metastases in EBC: bisphosphonate versus control </p> </div> </div> </div> </section> <section id="CD003474-sec-0093"> <h6 class="title">Intravenous bisphosphonate versus control</h6> <section id="CD003474-sec-0094"> <p><b>Intraveous zoledronate versus control</b></p> <p>Eight studies examined intravenous zoledronate (e.g. 4 mg every three to four weeks or every three to six months for over one to five years, or upfront schedule over five years) compared to placebo/observation or delayed administration of zoledronate. Intravenous zoledronate was associated with a reduced risk of bone metastases compared to control (RR 0.77, 95% CI 0.60 to 0.99; P = 0.04; <a href="./references#CD003474-fig-0012" title="">Analysis 1.2</a>) and there was no significant heterogeneity (I<sup>2</sup> = 25%, P = 0.24). There were 544 events in 8267 randomised women. </p> </section> </section> <section id="CD003474-sec-0095"> <h6 class="title">Oral bisphosphonate versus placebo/observation</h6> <section id="CD003474-sec-0096"> <p><b>Oral clodronate versus placebo/observation</b></p> <p>Four studies compared oral clodronate (1600 mg daily for two to three years) compared to control. Clodronate appeared to provide some benefit on preventing bone metastases compared to placebo/no bisphosphonate (RR 0.84, 95% CI 0.70 to 1.00; P = 0.05; <a href="./references#CD003474-fig-0012" title="">Analysis 1.2</a>). We observed no heterogeneity. There were 426 events in 4981 women randomised. </p> </section> <section id="CD003474-sec-0097"> <p><b>Oral pamidronate versus placebo</b></p> <p>One study compared oral pamidronate (150 mg twice a day for four years) to placebo. The RR was 1.15 (95% CI 0.88 to 1.50; <a href="./references#CD003474-fig-0012" title="">Analysis 1.2</a>). There were 176 events in 953 women randomised. </p> </section> <section id="CD003474-sec-0098"> <p><b>Oral ibandronate versus observation</b></p> <p>One study compared oral ibandronate (50 mg daily for two years) to observation. The RR was 0.80 (95% CI 0.56 to 1.13; <a href="./references#CD003474-fig-0012" title="">Analysis 1.2</a>). There were 127 events in 2994 women randomised. </p> </section> </section> <section id="CD003474-sec-0099"> <h6 class="title">Denosumab versus placebo</h6> <p>Data for this outcome have been collected by <a href="./references#CD003474-bbs2-0002" title="GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer (ABCSG‐18): a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet2015;386(9992):433–43. [NCT00556374] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer: results from 3,425 post‐menopausal patients of the ABCSG18 trial. Journal of Clinical Oncology2015;33(15 Suppl):504. [0732‐183X] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. The impact of adjuvant denosumab on disease‐free survival: results from 3,425 postmenopausal patients of the ABCSG‐18 trial. Cancer Research2016;76(4 Suppl):S2‐02. [0008‐5472] ">ABCSG‐18 2015</a> but are yet to be published. </p> </section> <section id="CD003474-sec-0100"> <h6 class="title">Immediate versus delayed bisphosphonate</h6> <p>The incidence of bone metastases did not differ significantly between immediate and delayed administration of bisphosphonates (RR 0.67, 95% 0.38 to 1.19; 3 studies; <a href="./references#CD003474-fig-0011" title="">Analysis 1.1</a>) however the confidence intervals were wide. There was no significant heterogeneity (I<sup>2</sup> = 28%, P = 0.25). There were 73 events in 2190 women randomised. The three studies comparing immediate versus delayed bisphosphonates were BMD studies (<a href="./references#CD003474-bbs2-0013" title="LlombartA , FrassoldatiA , PaijaO , SleeboomHP , JerusalemG , MebisJ , et al. Immediate administration of zoledronic acid reduces aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer: 12‐month analysis of the E‐ZO‐FAST trial. Clinical Breast Cancer2012;12(1):40‐8. LlombartoA , FrassoldatiA , PaijaO , SleeboomHP , JerusalemG , MebisJ , et al. Effect of zoledronic acid on aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E‐ZO‐FAST 36‐month follow‐up. ASCO Breast Cancer Symposium; 2009; Chicago. Chicago: American Society of Clinical Oncology, 2009. ">E‐ZO‐FAST 2012</a>; <a href="./references#CD003474-bbs2-0041" title="BrufskyA ,  BundredN ,  ColemanR ,  Lambert‐FallsR ,  MenaR ,  HadjiP , et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist2008;13(5):503‐14. BrufskyA ,  HarkerWG ,  BeckJT ,  CarrollR ,  Tan‐ChiuE ,  SeidlerC , et al. Zoledronic acid inhibits adjuvant letrozole‐induced bone loss in postmenopausal women with early breast cancer. Journal of Clinical Oncology2007;25(7):829‐36. BrufskyAM , HarkerWG , BeckJT , BossermanL , VogelC , SeidlerC , et al. Final 5‐year results of Z‐FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer2012;118(5):1192‐201. BrufskyAM ,  BossermanLD ,  CaradonnaRR ,  HaleyBB ,  JonesCM ,  MooreHC ,  etal . Zoledronic acid effectively prevents aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z‐FAST study 36‐month follow‐up results. Clinical Breast Cancer2009;9(2):77‐85. ">Z‐FAST 2012</a>; <a href="./references#CD003474-bbs2-0043" title="ColemanR , DeBoerR , EidtmannH , LlombartA , DavidsonN , NevenP , et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO‐FAST study): final 60‐month results. Annals of Oncology2013;24(2):398‐405. ColemanR , DeBoerR , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Influence of delayed zoledronic acid initiation on disease‐free survival in postmenopausal women with endocrine receptor‐positive early breast cancer receiving adjuvant letrozole: exploratory analysis from the ZO‐FAST trial. Cancer Research2011;71(24 Suppl):P2‐17‐01. DeBoerR , BundredN , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Long‐term survival outcomes among postmenopausal women with hormone receptor‐positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5‐year follow‐up of ZO‐FAST. Cancer Research2011;71(24 Suppl):S1‐3. DeBoerR , MartinM , StegerGG , VonMoosR , StopeckA , TonkinK , et al. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMs): a number‐needed‐to‐treat (NNT) analysis. Asia‐Pacific Journal of Clinical Oncology2011;7(3 Suppl):9. EidtmannH , DeBoerR , BundredN , Llombart‐CussacA , DavidsonN , NevenP , et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36‐month results of the ZO‐FAST Study. Annals of Oncology2010;21(11):2188‐94. ">ZO‐FAST 2013</a>) that were only powered to study the effects of bisphosphonates on BMD and not the prevention of bone metastases or recurrence. </p> </section> </section> <section id="CD003474-sec-0101"> <h5 class="title">Visceral metastases</h5> <section id="CD003474-sec-0102"> <h6 class="title">Bisphosphonate versus placebo/observation</h6> <p>The incidence of visceral metastases did not differ significantly between bisphosphonates and placebo/observation (RR 1.04, 95% CI 0.92 to 1.18; P = 0.50; 10 studies; <a href="./references#CD003474-fig-0013" title="">Analysis 1.3</a> (subtotal 1.3.1)) and no significant heterogeneity (I<sup>2</sup> = 24%, P = 0.22). There were 1267 events in 14,902 women randomised. </p> <p><b>Denosumab versus placebo</b> </p> <p>No data for this outcome.</p> </section> <section id="CD003474-sec-0103"> <h6 class="title">Immediate versus delayed bisphosphonate</h6> <p>The incidence of visceral metastases did not differ significantly between immediate and delayed administration of bisphosphonates however the confidence interval was very wide (RR 0.85, 95% CI 0.46 to 1.60; P = 0.62; 3 studies; <a href="./references#CD003474-fig-0013" title="">Analysis 1.3</a> (subtotal 1.3.2), no significant heterogeneity (I<sup>2</sup> = 25%, P = 0.27)). There were 59 events in 2190 women randomised. </p> </section> </section> <section id="CD003474-sec-0104"> <h5 class="title">Locoregional recurrence</h5> <section id="CD003474-sec-0105"> <h6 class="title">Bisphosphonate versus placebo/observation</h6> <p>Locoregional recurrence did not differ significantly between bisphosphonates and placebo/observation (RR 1.01, 95% CI 0.85 to 1.20; P = 0.89; 8 studies; <a href="./references#CD003474-fig-0014" title="">Analysis 1.4</a> (subtotal 1.4.1)) and no significant heterogeneity (I<sup>2</sup> = 26%, P = 0.22). There were 755 recurrences in 13,531 women. </p> <p><b>Denosumab versus placebo</b> </p> <p>No data for this outcome.</p> </section> <section id="CD003474-sec-0106"> <h6 class="title">Immediate versus delayed bisphosphonate</h6> <p>Locoregional recurrence did not differ significantly between immediate and delayed administration of bisphosphonates however the confidence interval was very wide (RR 1.08, 95% CI 0.26 to 4.48; P = 0.92; 3 studies; <a href="./references#CD003474-fig-0014" title="">Analysis 1.4</a> (subtotal 1.4.2)) and there was moderate heterogeneity (I<sup>2</sup> = 51%, P = 0.13). In these three studies, there were 25 recurrences in 2190 women randomised. </p> </section> </section> <section id="CD003474-sec-0107"> <h5 class="title">Recurrence (locoregional and distant recurrence)</h5> <section id="CD003474-sec-0108"> <h6 class="title">Bisphosphonate versus placebo/observation</h6> <p>Overall recurrence did not differ significantly between groups with a RR of 1.00 (95% CI 0.89 to 1.13; P = 0.95; 11 studies; <a href="./references#CD003474-fig-0015" title="">Analysis 1.5</a> (subtotal 1.5.1)). There was significant heterogeneity (I<sup>2</sup> = 68%, P = 0.001). In total, there were 3034 recurrences in 15,005 women randomised. </p> <p><b>Denosumab</b> versus<b>placebo</b> </p> <p>No data for this outcome.</p> </section> <section id="CD003474-sec-0109"> <h6 class="title">Immediate versus delayed bisphosphonate</h6> <p>Overall recurrence did not differ significantly between immediate and delayed bisphosphonates with a RR of 0.87 however the confidence interval was wide (95% CI 0.52 to 1.46; P = 0.60; 3 studies; <a href="./references#CD003474-fig-0015" title="">Analysis 1.5</a> (subtotal 1.5.2)). There was considerable heterogeneity (I<sup>2</sup> = 58%, P = 0.09). There were 153 recurrences in 2191 women. </p> </section> <section id="CD003474-sec-0110"> <h6 class="title">Intravenous or oral bisphosphonates versus control</h6> <p>When comparing the different bisphosphonate groups (i.e. zoledronate, immediate administration of zoledronate, clodronate, pamidronate or ibandronate) to their respective control (i.e. placebo, observation or delayed administration of zoledronate), overall recurrence did not differ significantly (<a href="./references#CD003474-fig-0016" title="">Analysis 1.6</a>). </p> <p>For zoledronate studies versus control: RR = 0.97 (95% CI 0.76 to 1.23; P = 0.78; 8 studies; 8268 women); clodronate versus control: RR = 1.00 (95% CI 0.84 to 1.19; P = 0.98; 4 studies; 4981 women); pamidronate versus control: RR = 1.08 (95% CI 0.94 to 1.24; P = 0.27; 1 study; 953 women) and ibandronate versus control: RR = 1.00 (95% CI 0.82 to 1.22; P = 1.00; 1 study; 2994 women). There was substantial heterogeneity across the zoledronate (I<sup>2</sup> = 76%, P &lt; 0.001) and clodronate studies (I<sup>2</sup> = 55%, P = 0.08). </p> </section> </section> <section id="CD003474-sec-0111"> <h5 class="title">Overall survival</h5> <section id="CD003474-sec-0112"> <h6 class="title">Bisphosphonate versus placebo/observation</h6> <p>Five study authors provided unpublished data in various formats (<a href="./references#CD003474-bbs2-0003" title="AftR , NaughtonM , TrinkausK , WatsonM , YlaganL , Chavez‐MacGregorM , et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncology2010;11(5):421‐8. AftRL , NaughtonM , TrinkausK , WeilbaecherK . Effect of (neo)adjuvant zoledronic acid on disease‐free and overall survival in clinical stage II/III breast cancer. British Journal of Cancer2012;107(1):7‐11. ">Aft 2012</a>; <a href="./references#CD003474-bbs2-0005" title="ColemanR , CameronD , DodwellD , BellR , WilsonC , RathboneE , et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open‐label phase 3 trial. Lancet Oncology2014;15(9):997‐1006. ColemanR , WoodwardE , BrownJ , CameronD , BellR , DodwellD , et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01‐04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment2011;127(2):429‐38. ColemanR , WoodwardE , TurnerL , MarshallH , CollinsonM , DodwellD , et al. Impact of zoledronic acid on fractures, bone mineral density and bone remodeling in the AZURE trial (BIG 01‐04). Cancer Research2011;71(24 Suppl):P2‐19‐01. ColemanRE , MarshallH , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Breast‐cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine2011;365(15):1396‐405. ColemanRE , RathboneEJ , MarshallHC , WilsonC , BrownJE , GossielF , et al. Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study. Cancer Research2012;72(24 Suppl):S6‐4. ColemanRE , ThorpeHC , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Cancer Research2010;70(24 Suppl):S4‐5. ColemanRE , WinterMC , CameronD , BellR , DodwellD , KeaneMM , et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti‐tumour activity in breast cancer. British Journal of Cancer2010;102(7):1099‐105. RathboneEJ , BrownJE , MarshallHC , CollinsonM , LiversedgeV , MurdenGA , et al. Osteonecrosis of the jaw and oral health‐related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). Journal of Clinical Oncology2013;31(21):2685‐91. ">AZURE 2014</a>; <a href="./references#CD003474-bbs2-0015" title="MoebusVJ , VonMinckwitzG , JackischC , LueckH‐J , SchneeweissA , TeschH , et al. German Adjuvant Intergroup Node Positive (GAIN) study: a phase III trial to compare IDD‐ETC versus EC‐TX in patients with node‐positive primary breast cancer‐final efficacy analysis. Journal of Clinical Oncology2014;32(5 Suppl):1009. MöbusV , DielI J , HarbeckN , EllingD , JackischC , ThomssenC , et al. GAIN study: a phase III trial to compare ETC vs. EC‐TX and ibandronate vs. observation in patients with node‐positive primary breast cancer ‐ 1st interim efficacy analysis. Cancer Research2011;71(24):S2‐4. NCT00196872 . A study to compare ETC vs EC‐TX and ibandronate vs observation in patients with node‐positive primary breast cancer. clinicaltrials.gov/ct2/show/NCT00196872 Date first received: 12 September 2005. vonMinckwitzG , MobusV , SchneeweissA , HuoberJ , ThomssenC , UntchM , et al. German Adjuvant Intergroup Node‐positive study: a phase III trial to compare oral ibandronate versus observation in patients with high‐risk early breast cancer. Journal of Clinical Oncology2013;31(28):3531‐9. ">GAIN 2013</a>; <a href="./references#CD003474-bbs2-0022" title="KristensenB ,  EjlertsenB ,  MouridsenHT ,  JensenMB ,  AndersenJ ,  BjerregaardB , et al. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncologica2008;47(4):740‐6. ">Kristensen 2008</a>; <a href="./references#CD003474-bbs2-0026" title="MinckwitzG , RezaiM , TeschH , HuoberJ , GerberB , ZahmDM , et al. Zoledronate for patients with invasive residual disease after anthracyclines‐taxane‐based chemotherapy for early breast cancer ‐ the phase III NeoAdjuvant Trial Add‐oN (NaTaN) study (GBG 36/ABCSG 29). European Journal of Cancer2016;64:12‐21. NCT00512993 . Postoperative use of zoledronic acid in breast cancer patients after neoadjuvant chemotherapy (NATAN). clinicaltrials.gov/ct2/show/NCT00512993 Date first received: 3 August 2007. vonMinckwitzG , RezaiM , EidtmannH , TeschH , HuoberJ , GerberB , et al. Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines‐taxane‐based chemotherapy for primary breast cancer ‐ the phase III NATAN study (GBG 36/ABCSG XX). Cancer Research2013;73(24 Suppl):S5‐05. ">NATAN 2016</a>). </p> <p>In the analysis using time‐to event data, data were available from nine out of the 12 studies. There was an benefit from bisphosphonates compared to placebo/observation with a HR of 0.91 (95% CI 0.83 to 0.99; P = 0.04; 13,949 women; <a href="./references#CD003474-fig-0017" title="">Analysis 1.7</a> (<a href="#CD003474-fig-0004">Figure 4</a>), subtotal 1.13.1; high‐quality evidence; funnel plot: <a href="#CD003474-fig-0005">Figure 5</a>) with some heterogeneity (I<sup>2</sup> = 39%, P = 0.11). In the analysis using dichotomous data, data on overall survival were available from 10 out of the 12 studies. Overall survival did not differ significantly between bisphosphonates and placebo/observation with a RR of 0.91 (95% CI 0.80 to 1.03; P = 0.14; 14,902 women; <a href="./references#CD003474-fig-0018" title="">Analysis 1.8</a>, subtotal 1.14.1). There were 2394 deaths in 14,902 women randomised. Heterogeneity was substantial across these studies (I<sup>2</sup> = 66%, P = 0.002). </p> <div class="figure" id="CD003474-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Early Breast Cancer (EBC), outcome: 1.7 Overall survival: time‐to‐event outcome." data-id="CD003474-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Early Breast Cancer (EBC), outcome: 1.7 Overall survival: time‐to‐event outcome. </p> </div> </div> </div> <div class="figure" id="CD003474-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Early Breast Cancer (EBC), outcome: 1.7 Overall survival: time‐to‐event outcome." data-id="CD003474-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Early Breast Cancer (EBC), outcome: 1.7 Overall survival: time‐to‐event outcome. </p> </div> </div> </div> </section> <section id="CD003474-sec-0113"> <h6 class="title">Denosumab versus placebo</h6> <p>Data for this outcome have been collected by <a href="./references#CD003474-bbs2-0002" title="GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer (ABCSG‐18): a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet2015;386(9992):433–43. [NCT00556374] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer: results from 3,425 post‐menopausal patients of the ABCSG18 trial. Journal of Clinical Oncology2015;33(15 Suppl):504. [0732‐183X] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. The impact of adjuvant denosumab on disease‐free survival: results from 3,425 postmenopausal patients of the ABCSG‐18 trial. Cancer Research2016;76(4 Suppl):S2‐02. [0008‐5472] ">ABCSG‐18 2015</a> but are yet to be published. </p> </section> <section id="CD003474-sec-0114"> <h6 class="title">Immediate versus delayed bisphosphonate</h6> <p>In the analysis using time‐to‐event data, data from only one study were available (<a href="./references#CD003474-bbs2-0043" title="ColemanR , DeBoerR , EidtmannH , LlombartA , DavidsonN , NevenP , et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO‐FAST study): final 60‐month results. Annals of Oncology2013;24(2):398‐405. ColemanR , DeBoerR , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Influence of delayed zoledronic acid initiation on disease‐free survival in postmenopausal women with endocrine receptor‐positive early breast cancer receiving adjuvant letrozole: exploratory analysis from the ZO‐FAST trial. Cancer Research2011;71(24 Suppl):P2‐17‐01. DeBoerR , BundredN , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Long‐term survival outcomes among postmenopausal women with hormone receptor‐positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5‐year follow‐up of ZO‐FAST. Cancer Research2011;71(24 Suppl):S1‐3. DeBoerR , MartinM , StegerGG , VonMoosR , StopeckA , TonkinK , et al. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMs): a number‐needed‐to‐treat (NNT) analysis. Asia‐Pacific Journal of Clinical Oncology2011;7(3 Suppl):9. EidtmannH , DeBoerR , BundredN , Llombart‐CussacA , DavidsonN , NevenP , et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36‐month results of the ZO‐FAST Study. Annals of Oncology2010;21(11):2188‐94. ">ZO‐FAST 2013</a>) with the HR of 0.69 (95% CI 0.42 to 1.13; 1064 women; <a href="./references#CD003474-fig-0017" title="">Analysis 1.7</a>, subtotal 1.13.2). In the analysis using dichotomous data, information on overall survival were available from two out of the three studies. Overall survival did not differ significantly between immediate bisphosphonates and delayed treatment with a RR of 2.14 however with very wide confidence intervals (95% CI 0.69 to 6.60; <a href="./references#CD003474-fig-0018" title="">Analysis 1.8</a>, subtotal 1.14.2; no heterogeneity). There were 14 deaths in 1126 women randomised. </p> </section> <section id="CD003474-sec-0115"> <h6 class="title">Intravenous or oral bisphosphonates versus control</h6> <section id="CD003474-sec-0116"> <p><b>Intravenous zoledronate versus control</b></p> <p>In the analysis using time‐to‐event data, intravenous zoledronate did not appear to provide a benefit in overall survival compared to placebo/delayed zoledronate (HR 0.91; 95% CI 0.81 to 1.03; P = 0.13; 5 studies; 7038 women; I<sup>2</sup> = 23%, P = 0.27; <a href="./references#CD003474-fig-0019" title="">Analysis 1.9</a>). This result was confirmed when analysing data as dichotomous outcomes with a RR of 0.94 (95% CI 0.80 to 1.11; P = 0.45; 6 studies; I<sup>2</sup> = 26%, P = 0.24; <a href="./references#CD003474-fig-0020" title="">Analysis 1.10</a>). There were 980 deaths in 7100 women randomised. In addition, if the <a href="./references#CD003474-bbs2-0041" title="BrufskyA ,  BundredN ,  ColemanR ,  Lambert‐FallsR ,  MenaR ,  HadjiP , et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist2008;13(5):503‐14. BrufskyA ,  HarkerWG ,  BeckJT ,  CarrollR ,  Tan‐ChiuE ,  SeidlerC , et al. Zoledronic acid inhibits adjuvant letrozole‐induced bone loss in postmenopausal women with early breast cancer. Journal of Clinical Oncology2007;25(7):829‐36. BrufskyAM , HarkerWG , BeckJT , BossermanL , VogelC , SeidlerC , et al. Final 5‐year results of Z‐FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer2012;118(5):1192‐201. BrufskyAM ,  BossermanLD ,  CaradonnaRR ,  HaleyBB ,  JonesCM ,  MooreHC ,  etal . Zoledronic acid effectively prevents aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z‐FAST study 36‐month follow‐up results. Clinical Breast Cancer2009;9(2):77‐85. ">Z‐FAST 2012</a> or <a href="./references#CD003474-bbs2-0043" title="ColemanR , DeBoerR , EidtmannH , LlombartA , DavidsonN , NevenP , et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO‐FAST study): final 60‐month results. Annals of Oncology2013;24(2):398‐405. ColemanR , DeBoerR , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Influence of delayed zoledronic acid initiation on disease‐free survival in postmenopausal women with endocrine receptor‐positive early breast cancer receiving adjuvant letrozole: exploratory analysis from the ZO‐FAST trial. Cancer Research2011;71(24 Suppl):P2‐17‐01. DeBoerR , BundredN , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Long‐term survival outcomes among postmenopausal women with hormone receptor‐positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5‐year follow‐up of ZO‐FAST. Cancer Research2011;71(24 Suppl):S1‐3. DeBoerR , MartinM , StegerGG , VonMoosR , StopeckA , TonkinK , et al. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMs): a number‐needed‐to‐treat (NNT) analysis. Asia‐Pacific Journal of Clinical Oncology2011;7(3 Suppl):9. EidtmannH , DeBoerR , BundredN , Llombart‐CussacA , DavidsonN , NevenP , et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36‐month results of the ZO‐FAST Study. Annals of Oncology2010;21(11):2188‐94. ">ZO‐FAST 2013</a> study was removed from the time‐to‐event or dichotomous data analyses due to involving delayed bisphosphonate in the control arm, the non‐significant finding persisted in these two analyses. </p> </section> <section id="CD003474-sec-0117"> <p><b>Oral clodronate versus placebo/observation</b></p> <p>Data were available from all four studies. In the analysis of time‐to‐event outcome, there was a benefit from clodronate compared to placebo/observation with a HR of 0.86 (95% CI 0.74 to 0.99; P = 0.04; 4981 women; <a href="./references#CD003474-fig-0019" title="">Analysis 1.9</a>) with significant heterogeneity (I<sup>2</sup> = 61%, P = 0.05). In the analysis of dichotomous data, overall survival did not differ significantly between clodronate and placebo/observation with a RR of 0.80 (95% CI 0.60 to 1.06; P = 0.12; <a href="./references#CD003474-fig-0020" title="">Analysis 1.10</a>) with considerable heterogeneity (I<sup>2</sup> = 78%, P = 0.004). There were 744 deaths in 4981 women randomised. </p> </section> <section id="CD003474-sec-0118"> <p><b>Oral pamidronate versus observation</b></p> <p>One study compared pamidronate to observation and there appeared to be no effect of pamidronate on overall survival (RR 1.06, 95% CI 0.94 to 1.20; P = 0.32; 1 study; <a href="./references#CD003474-fig-0020" title="">Analysis 1.10</a>). There were 498 deaths in 953 women randomised. </p> </section> <section id="CD003474-sec-0119"> <p><b>Oral ibandronate versus observation</b></p> <p>One study compared ibandronate to observation with the hazard ratio reported in the trial publication as 1.04 (95% CI 0.76 to 1.42; P = 0.81; <a href="./references#CD003474-fig-0019" title="">Analysis 1.9</a>). This result was confirmed using dichotomous data (RR 1.10, 95% CI 0.82 to 1.49; P = 0.52; 1 study; <a href="./references#CD003474-fig-0020" title="">Analysis 1.10</a>). There were 186 deaths in 2994 women randomised. </p> </section> </section> <section id="CD003474-sec-0120"> <h6 class="title">Direct comparisons of different bisphosphonate regimens</h6> <p>Data from one three‐arm study (<a href="./references#CD003474-bbs2-0034" title="GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG‐ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. Journal of Clinical Oncology2015;33(15 Suppl):503. [0732‐183X] GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: comparison of toxicities and patient‐stated preference for oral versus intravenous delivery. Journal of Clinical Oncoloy2014;32(15 Suppl):558. NCT00127205 . Zoledronate, clodronate, or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer. clinicaltrials.gov/ct2/show/NCT00127205 (accessed 30 April 2011); Vol. Date first received: 3 August 2005. ">SWOG‐S0307 2015</a>), comparing zoledronate intravenous, oral clodronate and oral ibandronate, reported that overall survival was 93% in all three groups. </p> </section> <section id="CD003474-sec-0121"> <h6 class="title">Menopausal status</h6> <p>Five study authors provided unpublished data based on menopausal status (<a href="./references#CD003474-bbs2-0003" title="AftR , NaughtonM , TrinkausK , WatsonM , YlaganL , Chavez‐MacGregorM , et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncology2010;11(5):421‐8. AftRL , NaughtonM , TrinkausK , WeilbaecherK . Effect of (neo)adjuvant zoledronic acid on disease‐free and overall survival in clinical stage II/III breast cancer. British Journal of Cancer2012;107(1):7‐11. ">Aft 2012</a>; <a href="./references#CD003474-bbs2-0005" title="ColemanR , CameronD , DodwellD , BellR , WilsonC , RathboneE , et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open‐label phase 3 trial. Lancet Oncology2014;15(9):997‐1006. ColemanR , WoodwardE , BrownJ , CameronD , BellR , DodwellD , et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01‐04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment2011;127(2):429‐38. ColemanR , WoodwardE , TurnerL , MarshallH , CollinsonM , DodwellD , et al. Impact of zoledronic acid on fractures, bone mineral density and bone remodeling in the AZURE trial (BIG 01‐04). Cancer Research2011;71(24 Suppl):P2‐19‐01. ColemanRE , MarshallH , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Breast‐cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine2011;365(15):1396‐405. ColemanRE , RathboneEJ , MarshallHC , WilsonC , BrownJE , GossielF , et al. Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study. Cancer Research2012;72(24 Suppl):S6‐4. ColemanRE , ThorpeHC , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Cancer Research2010;70(24 Suppl):S4‐5. ColemanRE , WinterMC , CameronD , BellR , DodwellD , KeaneMM , et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti‐tumour activity in breast cancer. British Journal of Cancer2010;102(7):1099‐105. RathboneEJ , BrownJE , MarshallHC , CollinsonM , LiversedgeV , MurdenGA , et al. Osteonecrosis of the jaw and oral health‐related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). Journal of Clinical Oncology2013;31(21):2685‐91. ">AZURE 2014</a>; <a href="./references#CD003474-bbs2-0015" title="MoebusVJ , VonMinckwitzG , JackischC , LueckH‐J , SchneeweissA , TeschH , et al. German Adjuvant Intergroup Node Positive (GAIN) study: a phase III trial to compare IDD‐ETC versus EC‐TX in patients with node‐positive primary breast cancer‐final efficacy analysis. Journal of Clinical Oncology2014;32(5 Suppl):1009. MöbusV , DielI J , HarbeckN , EllingD , JackischC , ThomssenC , et al. GAIN study: a phase III trial to compare ETC vs. EC‐TX and ibandronate vs. observation in patients with node‐positive primary breast cancer ‐ 1st interim efficacy analysis. Cancer Research2011;71(24):S2‐4. NCT00196872 . A study to compare ETC vs EC‐TX and ibandronate vs observation in patients with node‐positive primary breast cancer. clinicaltrials.gov/ct2/show/NCT00196872 Date first received: 12 September 2005. vonMinckwitzG , MobusV , SchneeweissA , HuoberJ , ThomssenC , UntchM , et al. German Adjuvant Intergroup Node‐positive study: a phase III trial to compare oral ibandronate versus observation in patients with high‐risk early breast cancer. Journal of Clinical Oncology2013;31(28):3531‐9. ">GAIN 2013</a>; <a href="./references#CD003474-bbs2-0022" title="KristensenB ,  EjlertsenB ,  MouridsenHT ,  JensenMB ,  AndersenJ ,  BjerregaardB , et al. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncologica2008;47(4):740‐6. ">Kristensen 2008</a>; <a href="./references#CD003474-bbs2-0026" title="MinckwitzG , RezaiM , TeschH , HuoberJ , GerberB , ZahmDM , et al. Zoledronate for patients with invasive residual disease after anthracyclines‐taxane‐based chemotherapy for early breast cancer ‐ the phase III NeoAdjuvant Trial Add‐oN (NaTaN) study (GBG 36/ABCSG 29). European Journal of Cancer2016;64:12‐21. NCT00512993 . Postoperative use of zoledronic acid in breast cancer patients after neoadjuvant chemotherapy (NATAN). clinicaltrials.gov/ct2/show/NCT00512993 Date first received: 3 August 2007. vonMinckwitzG , RezaiM , EidtmannH , TeschH , HuoberJ , GerberB , et al. Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines‐taxane‐based chemotherapy for primary breast cancer ‐ the phase III NATAN study (GBG 36/ABCSG XX). Cancer Research2013;73(24 Suppl):S5‐05. ">NATAN 2016</a>). </p> <p>For the analysis using time‐to‐event data, two studies provided data specifically on pre‐ or perimenopausal women, four studies on postmenopausal women and five studies categorised as including pre‐ or postmenopausal women or menopausal status unknown. There was a benefit from adjuvant or immediate bisphosphonates in postmenopausal women (HR 0.77, 95% CI 0.66 to 0.90; P = 0.001; 4 studies; 6048 women; no heterogeneity; high‐quality evidence; <a href="./references#CD003474-fig-0021" title="">Analysis 1.11</a>, subtotal 1.17.2) while there was evidence of no effect of bisphosphonates in premenopausal women (HR 1.03, 95% CI 0.86 to 1.22; P = 0.78; 2 studies; 3501 women; no heterogeneity; high‐quality evidence; <a href="./references#CD003474-fig-0021" title="">Analysis 1.11</a>, subtotal 1.17.1) or where study data were not reported separately based on menopausal status (HR 0.95, 95% CI 0.81 to 1.10; P = 0.48; no significant heterogeneity I<sup>2</sup> = 42%, P = 0.07; <a href="./references#CD003474-fig-0021" title="">Analysis 1.11</a>, subtotal 1.17.3). The test for subgroup differences was significant (P = 0.05). If the study examining immediate versus delayed bisphosphonates (<a href="./references#CD003474-bbs2-0043" title="ColemanR , DeBoerR , EidtmannH , LlombartA , DavidsonN , NevenP , et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO‐FAST study): final 60‐month results. Annals of Oncology2013;24(2):398‐405. ColemanR , DeBoerR , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Influence of delayed zoledronic acid initiation on disease‐free survival in postmenopausal women with endocrine receptor‐positive early breast cancer receiving adjuvant letrozole: exploratory analysis from the ZO‐FAST trial. Cancer Research2011;71(24 Suppl):P2‐17‐01. DeBoerR , BundredN , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Long‐term survival outcomes among postmenopausal women with hormone receptor‐positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5‐year follow‐up of ZO‐FAST. Cancer Research2011;71(24 Suppl):S1‐3. DeBoerR , MartinM , StegerGG , VonMoosR , StopeckA , TonkinK , et al. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMs): a number‐needed‐to‐treat (NNT) analysis. Asia‐Pacific Journal of Clinical Oncology2011;7(3 Suppl):9. EidtmannH , DeBoerR , BundredN , Llombart‐CussacA , DavidsonN , NevenP , et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36‐month results of the ZO‐FAST Study. Annals of Oncology2010;21(11):2188‐94. ">ZO‐FAST 2013</a>) was removed from the analysis for postmenopausal women due to the delayed bisphosphonate not being a pure control comparison, the treatment effect still persisted using time‐to‐event data (HR 0.78, 95% CI 0.66 to 0.92; P = 0.004; 3 studies; 4984 women) (<a href="#CD003474-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD003474-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Early Breast Cancer (EBC), outcome: 1.11 Overall survival by menopausal status: time‐to‐event outcome." data-id="CD003474-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Early Breast Cancer (EBC), outcome: 1.11 Overall survival by menopausal status: time‐to‐event outcome. </p> </div> </div> </div> <p>For the analysis using dichotomous data, six studies provided data specifically on pre‐ or perimenopausal women, nine studies on postmenopausal women and three studies were categorised as including pre‐ or postmenopausal women or menopausal status unknown. There appeared to be no effect of adjuvant bisphosphonates in postmenopausal women (RR 0.90, 95% CI 0.78 to 1.03; P = 0.14; 8150 women; no significant heterogeneity; <a href="./references#CD003474-fig-0022" title="">Analysis 1.12</a>, subtotal 1.18.2), pre‐ or perimenopausal women (RR 1.06, 95% CI 0.96 to 1.18; P = 0.26; 6191 women; no heterogeneity; <a href="./references#CD003474-fig-0022" title="">Analysis 1.12</a>, subtotal 1.18.1) or in studies where data on menopausal status were combined or unknown (RR 0.78, 95% CI 0.50 to 1.20; P = 0.26; 1670 women; significant heterogeneity I<sup>2</sup> = 85%, P = 0.001; <a href="./references#CD003474-fig-0022" title="">Analysis 1.12</a>, subtotal 1.18.3). The test for subgroup differences was not significant (P = 0.09). If the studies examining immediate versus delayed bisphosphonates (<a href="./references#CD003474-bbs2-0013" title="LlombartA , FrassoldatiA , PaijaO , SleeboomHP , JerusalemG , MebisJ , et al. Immediate administration of zoledronic acid reduces aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer: 12‐month analysis of the E‐ZO‐FAST trial. Clinical Breast Cancer2012;12(1):40‐8. LlombartoA , FrassoldatiA , PaijaO , SleeboomHP , JerusalemG , MebisJ , et al. Effect of zoledronic acid on aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E‐ZO‐FAST 36‐month follow‐up. ASCO Breast Cancer Symposium; 2009; Chicago. Chicago: American Society of Clinical Oncology, 2009. ">E‐ZO‐FAST 2012</a>; <a href="./references#CD003474-bbs2-0041" title="BrufskyA ,  BundredN ,  ColemanR ,  Lambert‐FallsR ,  MenaR ,  HadjiP , et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist2008;13(5):503‐14. BrufskyA ,  HarkerWG ,  BeckJT ,  CarrollR ,  Tan‐ChiuE ,  SeidlerC , et al. Zoledronic acid inhibits adjuvant letrozole‐induced bone loss in postmenopausal women with early breast cancer. Journal of Clinical Oncology2007;25(7):829‐36. BrufskyAM , HarkerWG , BeckJT , BossermanL , VogelC , SeidlerC , et al. Final 5‐year results of Z‐FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer2012;118(5):1192‐201. BrufskyAM ,  BossermanLD ,  CaradonnaRR ,  HaleyBB ,  JonesCM ,  MooreHC ,  etal . Zoledronic acid effectively prevents aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z‐FAST study 36‐month follow‐up results. Clinical Breast Cancer2009;9(2):77‐85. ">Z‐FAST 2012</a>) were removed from the analysis of postmenopausal women, the treatment effect remained non‐significant (P = 0.09) with a RR of 0.89 (95% CI 0.78 to 1.02; 7 studies; 7024 women). </p> <p>One study that compared different bisphosphonates (<a href="./references#CD003474-bbs2-0034" title="GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG‐ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. Journal of Clinical Oncology2015;33(15 Suppl):503. [0732‐183X] GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: comparison of toxicities and patient‐stated preference for oral versus intravenous delivery. Journal of Clinical Oncoloy2014;32(15 Suppl):558. NCT00127205 . Zoledronate, clodronate, or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer. clinicaltrials.gov/ct2/show/NCT00127205 (accessed 30 April 2011); Vol. Date first received: 3 August 2005. ">SWOG‐S0307 2015</a>) reported no evidence of treatment differences based on menopausal status. </p> </section> </section> <section id="CD003474-sec-0122"> <h5 class="title">Disease‐free survival</h5> <section id="CD003474-sec-0123"> <h6 class="title">Bisphosphonate versus placebo/observation</h6> <p>Five study authors provided unpublished data (<a href="./references#CD003474-bbs2-0003" title="AftR , NaughtonM , TrinkausK , WatsonM , YlaganL , Chavez‐MacGregorM , et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncology2010;11(5):421‐8. AftRL , NaughtonM , TrinkausK , WeilbaecherK . Effect of (neo)adjuvant zoledronic acid on disease‐free and overall survival in clinical stage II/III breast cancer. British Journal of Cancer2012;107(1):7‐11. ">Aft 2012</a>; <a href="./references#CD003474-bbs2-0005" title="ColemanR , CameronD , DodwellD , BellR , WilsonC , RathboneE , et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open‐label phase 3 trial. Lancet Oncology2014;15(9):997‐1006. ColemanR , WoodwardE , BrownJ , CameronD , BellR , DodwellD , et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01‐04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment2011;127(2):429‐38. ColemanR , WoodwardE , TurnerL , MarshallH , CollinsonM , DodwellD , et al. Impact of zoledronic acid on fractures, bone mineral density and bone remodeling in the AZURE trial (BIG 01‐04). Cancer Research2011;71(24 Suppl):P2‐19‐01. ColemanRE , MarshallH , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Breast‐cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine2011;365(15):1396‐405. ColemanRE , RathboneEJ , MarshallHC , WilsonC , BrownJE , GossielF , et al. Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study. Cancer Research2012;72(24 Suppl):S6‐4. ColemanRE , ThorpeHC , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Cancer Research2010;70(24 Suppl):S4‐5. ColemanRE , WinterMC , CameronD , BellR , DodwellD , KeaneMM , et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti‐tumour activity in breast cancer. British Journal of Cancer2010;102(7):1099‐105. RathboneEJ , BrownJE , MarshallHC , CollinsonM , LiversedgeV , MurdenGA , et al. Osteonecrosis of the jaw and oral health‐related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). Journal of Clinical Oncology2013;31(21):2685‐91. ">AZURE 2014</a>; <a href="./references#CD003474-bbs2-0015" title="MoebusVJ , VonMinckwitzG , JackischC , LueckH‐J , SchneeweissA , TeschH , et al. German Adjuvant Intergroup Node Positive (GAIN) study: a phase III trial to compare IDD‐ETC versus EC‐TX in patients with node‐positive primary breast cancer‐final efficacy analysis. Journal of Clinical Oncology2014;32(5 Suppl):1009. MöbusV , DielI J , HarbeckN , EllingD , JackischC , ThomssenC , et al. GAIN study: a phase III trial to compare ETC vs. EC‐TX and ibandronate vs. observation in patients with node‐positive primary breast cancer ‐ 1st interim efficacy analysis. Cancer Research2011;71(24):S2‐4. NCT00196872 . A study to compare ETC vs EC‐TX and ibandronate vs observation in patients with node‐positive primary breast cancer. clinicaltrials.gov/ct2/show/NCT00196872 Date first received: 12 September 2005. vonMinckwitzG , MobusV , SchneeweissA , HuoberJ , ThomssenC , UntchM , et al. German Adjuvant Intergroup Node‐positive study: a phase III trial to compare oral ibandronate versus observation in patients with high‐risk early breast cancer. Journal of Clinical Oncology2013;31(28):3531‐9. ">GAIN 2013</a>; <a href="./references#CD003474-bbs2-0022" title="KristensenB ,  EjlertsenB ,  MouridsenHT ,  JensenMB ,  AndersenJ ,  BjerregaardB , et al. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncologica2008;47(4):740‐6. ">Kristensen 2008</a>; <a href="./references#CD003474-bbs2-0026" title="MinckwitzG , RezaiM , TeschH , HuoberJ , GerberB , ZahmDM , et al. Zoledronate for patients with invasive residual disease after anthracyclines‐taxane‐based chemotherapy for early breast cancer ‐ the phase III NeoAdjuvant Trial Add‐oN (NaTaN) study (GBG 36/ABCSG 29). European Journal of Cancer2016;64:12‐21. NCT00512993 . Postoperative use of zoledronic acid in breast cancer patients after neoadjuvant chemotherapy (NATAN). clinicaltrials.gov/ct2/show/NCT00512993 Date first received: 3 August 2007. vonMinckwitzG , RezaiM , EidtmannH , TeschH , HuoberJ , GerberB , et al. Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines‐taxane‐based chemotherapy for primary breast cancer ‐ the phase III NATAN study (GBG 36/ABCSG XX). Cancer Research2013;73(24 Suppl):S5‐05. ">NATAN 2016</a>). </p> <p>In the analysis using time‐to‐event data, data were available from seven out of the 12 studies. There was no observed benefit from bisphosphonates compared to placebo/observation with a HR of 0.94 (95% CI 0.87 to 1.02; P = 0.13; 12,578 women; <a href="./references#CD003474-fig-0023" title="">Analysis 1.13</a>; subtotal 1.7.1; high‐quality evidence; funnel plot: <a href="#CD003474-fig-0007">Figure 7</a>) and heterogeneity was apparent across studies (I<sup>2</sup> = 49%, P = 0.07). In the analysis using dichotomous data, information on disease‐free survival was available from eight out of the 12 studies. Disease‐free survival did not differ significantly between bisphosphonates and placebo/observation with a RR of 0.97 (95% CI 0.89 to 1.06; P = 0.47; <a href="./references#CD003474-fig-0024" title="">Analysis 1.14</a>; subtotal 1.8.1). There were 3116 women who progressed out of 13,538 randomised. Heterogeneity was apparent across these studies (I<sup>2</sup> = 48%, P = 0.06). </p> <div class="figure" id="CD003474-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Early Breast Cancer (EBC), outcome: 1.13 Disease‐free survival: time‐to‐event outcome." data-id="CD003474-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Early Breast Cancer (EBC), outcome: 1.13 Disease‐free survival: time‐to‐event outcome. </p> </div> </div> </div> </section> <section id="CD003474-sec-0124"> <h6 class="title">Denosumab versus placebo</h6> <p>Data for this outcome have been collected by <a href="./references#CD003474-bbs2-0002" title="GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer (ABCSG‐18): a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet2015;386(9992):433–43. [NCT00556374] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer: results from 3,425 post‐menopausal patients of the ABCSG18 trial. Journal of Clinical Oncology2015;33(15 Suppl):504. [0732‐183X] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. The impact of adjuvant denosumab on disease‐free survival: results from 3,425 postmenopausal patients of the ABCSG‐18 trial. Cancer Research2016;76(4 Suppl):S2‐02. [0008‐5472] ">ABCSG‐18 2015</a> but are yet to be published. </p> </section> <section id="CD003474-sec-0125"> <h6 class="title">Immediate versus delayed bisphosphonate</h6> <p>In the analysis using time‐to‐event data, data were available from two out of the three studies. Overall, there was a trend towards a disease‐free survival benefit from upfront bisphosphonates compared to delayed bisphosphonates with a HR of 0.72 (95% CI 0.52 to 1.01, P = 0.06; 2 studies; 1664 women; <a href="./references#CD003474-fig-0023" title="">Analysis 1.13</a>; subtotal 1.7.2) with no heterogeneity. Using dichotomous data, a similar trend was observed with a RR of 0.75 (95% CI 0.55 to 1.02; P = 0.06; <a href="./references#CD003474-fig-0024" title="">Analysis 1.14</a>; subtotal 1.8.2) with no heterogeneity. There were 152 women who progressed out of 1664 randomised. </p> </section> <section id="CD003474-sec-0126"> <h6 class="title">Intravenous or oral bisphosphonates versus control</h6> <section id="CD003474-sec-0127"> <p><b>Intravenous zoledronate versus control</b></p> <p>Data were available for six out of the nine studies. In the analysis of time‐to‐event data, intravenous zoledronate was associated with improved disease‐free survival compared to placebo/delayed zoledronate (HR 0.89; 95% CI 0.80 to 0.98; P = 0.02; 7638 women; <a href="./references#CD003474-fig-0025" title="">Analysis 1.15</a>) with no heterogeneity. This result was confirmed when analysing data as dichotomous outcomes with a RR of 0.88 (95% CI 0.79 to 0.98; P = 0.02; 6 studies; <a href="./references#CD003474-fig-0026" title="">Analysis 1.16</a>) and there was no significant heterogeneity (I<sup>2</sup> = 17%, P = 0.30). There were 1685 women who progressed out of 7638 randomised. If the two studies examining immediate versus delayed bisphosphonates (<a href="./references#CD003474-bbs2-0041" title="BrufskyA ,  BundredN ,  ColemanR ,  Lambert‐FallsR ,  MenaR ,  HadjiP , et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist2008;13(5):503‐14. BrufskyA ,  HarkerWG ,  BeckJT ,  CarrollR ,  Tan‐ChiuE ,  SeidlerC , et al. Zoledronic acid inhibits adjuvant letrozole‐induced bone loss in postmenopausal women with early breast cancer. Journal of Clinical Oncology2007;25(7):829‐36. BrufskyAM , HarkerWG , BeckJT , BossermanL , VogelC , SeidlerC , et al. Final 5‐year results of Z‐FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer2012;118(5):1192‐201. BrufskyAM ,  BossermanLD ,  CaradonnaRR ,  HaleyBB ,  JonesCM ,  MooreHC ,  etal . Zoledronic acid effectively prevents aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z‐FAST study 36‐month follow‐up results. Clinical Breast Cancer2009;9(2):77‐85. ">Z‐FAST 2012</a>; <a href="./references#CD003474-bbs2-0043" title="ColemanR , DeBoerR , EidtmannH , LlombartA , DavidsonN , NevenP , et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO‐FAST study): final 60‐month results. Annals of Oncology2013;24(2):398‐405. ColemanR , DeBoerR , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Influence of delayed zoledronic acid initiation on disease‐free survival in postmenopausal women with endocrine receptor‐positive early breast cancer receiving adjuvant letrozole: exploratory analysis from the ZO‐FAST trial. Cancer Research2011;71(24 Suppl):P2‐17‐01. DeBoerR , BundredN , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Long‐term survival outcomes among postmenopausal women with hormone receptor‐positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5‐year follow‐up of ZO‐FAST. Cancer Research2011;71(24 Suppl):S1‐3. DeBoerR , MartinM , StegerGG , VonMoosR , StopeckA , TonkinK , et al. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMs): a number‐needed‐to‐treat (NNT) analysis. Asia‐Pacific Journal of Clinical Oncology2011;7(3 Suppl):9. EidtmannH , DeBoerR , BundredN , Llombart‐CussacA , DavidsonN , NevenP , et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36‐month results of the ZO‐FAST Study. Annals of Oncology2010;21(11):2188‐94. ">ZO‐FAST 2013</a>) were removed from these analyses due to not strictly conforming to the bisphosphonates versus control comparison, the treatment effect still persisted when using dichotomous data though it became non‐significant (at P = 0.06) with time‐to‐event data (HR 0.91, 95% CI 0.82 to 1.01; 4 studies; 5974 women). </p> </section> <section id="CD003474-sec-0128"> <p><b>Oral clodronate versus placebo/observation</b></p> <p>Data were available for two out the four studies. In the analysis of time‐to‐event data, oral clodronate did not improve disease‐free survival compared to placebo/observation (HR 1.00, 95% CI 0.87 to 1.15; P = 0.97; 2 studies; 3610 women; I<sup>2</sup> = 88%, P = 0.004; <a href="./references#CD003474-fig-0025" title="">Analysis 1.15</a>). This result was confirmed when analysing data as dichotomous outcomes (RR 1.02; 95% CI 0.79 to 1.32; P = 0.86; 2 studies; I<sup>2</sup> = 72%, P = 0.06; <a href="./references#CD003474-fig-0026" title="">Analysis 1.16</a>). There were 746 women who progressed out of 3617 randomised. </p> </section> <section id="CD003474-sec-0129"> <p><b>Oral pamidronate versus observation</b></p> <p>One study compared oral pamidronate to observation. Pamidronate did not improve disease‐free survival compared to control (RR 1.12, 95% CI 0.98 to 1.29; P = 0.10; 953 women; <a href="./references#CD003474-fig-0026" title="">Analysis 1.16</a>). There were 432 women who progressed out of 953 women. </p> </section> <section id="CD003474-sec-0130"> <p><b>Oral ibandronate versus observation</b></p> <p>One study compared oral ibandronate to control and ibandronate did not improve disease‐free survival compared to observation (HR 0.95, 95% CI 0.77 to 1.17, P = 0.63; <a href="./references#CD003474-fig-0025" title="">Analysis 1.15</a>). This result was confirmed using dichotomous data (RR 1.00, 95% CI 0.83 to 1.21; P = 1.00; 1 study, 2994 women; <a href="./references#CD003474-fig-0026" title="">Analysis 1.16</a>). </p> </section> </section> <section id="CD003474-sec-0131"> <h6 class="title">Direct comparisons of different bisphosphonate regimens</h6> <p>Data from one three‐armed study (<a href="./references#CD003474-bbs2-0034" title="GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG‐ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. Journal of Clinical Oncology2015;33(15 Suppl):503. [0732‐183X] GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: comparison of toxicities and patient‐stated preference for oral versus intravenous delivery. Journal of Clinical Oncoloy2014;32(15 Suppl):558. NCT00127205 . Zoledronate, clodronate, or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer. clinicaltrials.gov/ct2/show/NCT00127205 (accessed 30 April 2011); Vol. Date first received: 3 August 2005. ">SWOG‐S0307 2015</a>), comparing intravenous zoledronate, oral clodronate and oral ibandronate, reported that disease‐free survival did not differ across groups (P = 0.71). Five‐year disease‐free survival was 88% in the zoledronate and clodronate groups and 87% in the ibandronate group. </p> </section> <section id="CD003474-sec-0132"> <h6 class="title">Menopausal status</h6> <p>Five study authors provided unpublished data based on menopausal status in various formats (<a href="./references#CD003474-bbs2-0003" title="AftR , NaughtonM , TrinkausK , WatsonM , YlaganL , Chavez‐MacGregorM , et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncology2010;11(5):421‐8. AftRL , NaughtonM , TrinkausK , WeilbaecherK . Effect of (neo)adjuvant zoledronic acid on disease‐free and overall survival in clinical stage II/III breast cancer. British Journal of Cancer2012;107(1):7‐11. ">Aft 2012</a>; <a href="./references#CD003474-bbs2-0005" title="ColemanR , CameronD , DodwellD , BellR , WilsonC , RathboneE , et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open‐label phase 3 trial. Lancet Oncology2014;15(9):997‐1006. ColemanR , WoodwardE , BrownJ , CameronD , BellR , DodwellD , et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01‐04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment2011;127(2):429‐38. ColemanR , WoodwardE , TurnerL , MarshallH , CollinsonM , DodwellD , et al. Impact of zoledronic acid on fractures, bone mineral density and bone remodeling in the AZURE trial (BIG 01‐04). Cancer Research2011;71(24 Suppl):P2‐19‐01. ColemanRE , MarshallH , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Breast‐cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine2011;365(15):1396‐405. ColemanRE , RathboneEJ , MarshallHC , WilsonC , BrownJE , GossielF , et al. Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study. Cancer Research2012;72(24 Suppl):S6‐4. ColemanRE , ThorpeHC , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Cancer Research2010;70(24 Suppl):S4‐5. ColemanRE , WinterMC , CameronD , BellR , DodwellD , KeaneMM , et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti‐tumour activity in breast cancer. British Journal of Cancer2010;102(7):1099‐105. RathboneEJ , BrownJE , MarshallHC , CollinsonM , LiversedgeV , MurdenGA , et al. Osteonecrosis of the jaw and oral health‐related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). Journal of Clinical Oncology2013;31(21):2685‐91. ">AZURE 2014</a>; <a href="./references#CD003474-bbs2-0015" title="MoebusVJ , VonMinckwitzG , JackischC , LueckH‐J , SchneeweissA , TeschH , et al. German Adjuvant Intergroup Node Positive (GAIN) study: a phase III trial to compare IDD‐ETC versus EC‐TX in patients with node‐positive primary breast cancer‐final efficacy analysis. Journal of Clinical Oncology2014;32(5 Suppl):1009. MöbusV , DielI J , HarbeckN , EllingD , JackischC , ThomssenC , et al. GAIN study: a phase III trial to compare ETC vs. EC‐TX and ibandronate vs. observation in patients with node‐positive primary breast cancer ‐ 1st interim efficacy analysis. Cancer Research2011;71(24):S2‐4. NCT00196872 . A study to compare ETC vs EC‐TX and ibandronate vs observation in patients with node‐positive primary breast cancer. clinicaltrials.gov/ct2/show/NCT00196872 Date first received: 12 September 2005. vonMinckwitzG , MobusV , SchneeweissA , HuoberJ , ThomssenC , UntchM , et al. German Adjuvant Intergroup Node‐positive study: a phase III trial to compare oral ibandronate versus observation in patients with high‐risk early breast cancer. Journal of Clinical Oncology2013;31(28):3531‐9. ">GAIN 2013</a>; <a href="./references#CD003474-bbs2-0022" title="KristensenB ,  EjlertsenB ,  MouridsenHT ,  JensenMB ,  AndersenJ ,  BjerregaardB , et al. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncologica2008;47(4):740‐6. ">Kristensen 2008</a>; <a href="./references#CD003474-bbs2-0026" title="MinckwitzG , RezaiM , TeschH , HuoberJ , GerberB , ZahmDM , et al. Zoledronate for patients with invasive residual disease after anthracyclines‐taxane‐based chemotherapy for early breast cancer ‐ the phase III NeoAdjuvant Trial Add‐oN (NaTaN) study (GBG 36/ABCSG 29). European Journal of Cancer2016;64:12‐21. NCT00512993 . Postoperative use of zoledronic acid in breast cancer patients after neoadjuvant chemotherapy (NATAN). clinicaltrials.gov/ct2/show/NCT00512993 Date first received: 3 August 2007. vonMinckwitzG , RezaiM , EidtmannH , TeschH , HuoberJ , GerberB , et al. Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines‐taxane‐based chemotherapy for primary breast cancer ‐ the phase III NATAN study (GBG 36/ABCSG XX). Cancer Research2013;73(24 Suppl):S5‐05. ">NATAN 2016</a>). For the analysis using time‐to‐event data, four studies provided data specifically on pre‐ or perimenopausal women, seven studies on postmenopausal women and one study was categorised as including pre‐ or postmenopausal women or menopausal status unknown. There was a benefit from adjuvant or immediate bisphosphonates in postmenopausal women (HR 0.82, 95% CI 0.74 to 0.91; P &lt; 0.001; 8314 women; no heterogeneity; high‐quality evidence; <a href="./references#CD003474-fig-0027" title="">Analysis 1.17</a>, subtotal 1.11.2) while no benefit was observed in premenopausal women (HR 1.01, 95% CI 0.90 to 1.13; P = 0.84; 5493 women; no heterogeneity; high‐quality evidence; <a href="./references#CD003474-fig-0027" title="">Analysis 1.17</a>, subtotal 1.11.1). In the one study where data on menopausal status were combined, there was an apparent increased risk of disease‐free survival events in the bisphosphonates arm (<a href="./references#CD003474-bbs2-0032" title="SaartoT , BlomqvistC , VirkkunenP , ElomaaI . Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node‐positive breast cancer patients: 5 year results of a randomised controlled study. Journal of Clinical Oncology2001;19(1):10‐17. SaartoT , VehmanenL , VirkkunenP , BlomqvistC . Ten‐year follow‐up of a randomized controlled trial of adjuvant clodronate treatment in node‐positive breast cancer patients. Acta Oncologica2004;43(7):650‐6. ">Saarto 2004</a>; HR 1.53, 95% CI 1.11 to 2.11; 299 women; P = 0.009; <a href="./references#CD003474-fig-0027" title="">Analysis 1.17</a>, subtotal 1.11.3). The test for subgroup differences was significant (P = 0.0002). If the study examining immediate versus delayed bisphosphonates (<a href="./references#CD003474-bbs2-0041" title="BrufskyA ,  BundredN ,  ColemanR ,  Lambert‐FallsR ,  MenaR ,  HadjiP , et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist2008;13(5):503‐14. BrufskyA ,  HarkerWG ,  BeckJT ,  CarrollR ,  Tan‐ChiuE ,  SeidlerC , et al. Zoledronic acid inhibits adjuvant letrozole‐induced bone loss in postmenopausal women with early breast cancer. Journal of Clinical Oncology2007;25(7):829‐36. BrufskyAM , HarkerWG , BeckJT , BossermanL , VogelC , SeidlerC , et al. Final 5‐year results of Z‐FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer2012;118(5):1192‐201. BrufskyAM ,  BossermanLD ,  CaradonnaRR ,  HaleyBB ,  JonesCM ,  MooreHC ,  etal . Zoledronic acid effectively prevents aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z‐FAST study 36‐month follow‐up results. Clinical Breast Cancer2009;9(2):77‐85. ">Z‐FAST 2012</a>) was removed from the analysis for postmenopausal women due to not strictly conforming to the bisphosphonates versus control comparison, the treatment benefit still persisted using time‐to‐event data (HR 0.83, 95% BCI 0.74 to 0.93; 5 studies; 6650 women). </p> <p>For the analysis using dichotomous data, new data were added from <a href="./references#CD003474-bbs2-0003" title="AftR , NaughtonM , TrinkausK , WatsonM , YlaganL , Chavez‐MacGregorM , et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncology2010;11(5):421‐8. AftRL , NaughtonM , TrinkausK , WeilbaecherK . Effect of (neo)adjuvant zoledronic acid on disease‐free and overall survival in clinical stage II/III breast cancer. British Journal of Cancer2012;107(1):7‐11. ">Aft 2012</a> and <a href="./references#CD003474-bbs2-0022" title="KristensenB ,  EjlertsenB ,  MouridsenHT ,  JensenMB ,  AndersenJ ,  BjerregaardB , et al. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncologica2008;47(4):740‐6. ">Kristensen 2008</a> for women who were pre‐ or postmenopausal. Similar to the time‐to‐event analysis, there was an observed benefit of adjuvant bisphosphonates in postmenopausal women (RR 0.86; 95% CI 0.77 to 0.97; P = 0.02; 8 studies; 6536 women; <a href="./references#CD003474-fig-0028" title="">Analysis 1.18</a>, subtotal 1.12.2) with no significant heterogeneity across studies (I<sup>2</sup> = 31%, P = 0.18). There appeared to be no effect of adjuvant bisphosphonates in pre‐ or perimenopausal women (RR 1.05, 95% CI 0.96 to 1.15, P = 0.31; 5 studies; 4997 women; no heterogeneity; <a href="./references#CD003474-fig-0028" title="">Analysis 1.18</a>, subtotal 1.12.1) or in studies where data on menopausal status were combined or unknown (RR 1.02, 95% CI 0.79 to 1.32; P = 0.86; 2 studies; 3617 women; <a href="./references#CD003474-fig-0028" title="">Analysis 1.18</a>, subtotal 1.12.3). The test for subgroup differences was significant (P = 0.04). If the studies examining immediate versus delayed bisphosphonates (<a href="./references#CD003474-bbs2-0041" title="BrufskyA ,  BundredN ,  ColemanR ,  Lambert‐FallsR ,  MenaR ,  HadjiP , et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist2008;13(5):503‐14. BrufskyA ,  HarkerWG ,  BeckJT ,  CarrollR ,  Tan‐ChiuE ,  SeidlerC , et al. Zoledronic acid inhibits adjuvant letrozole‐induced bone loss in postmenopausal women with early breast cancer. Journal of Clinical Oncology2007;25(7):829‐36. BrufskyAM , HarkerWG , BeckJT , BossermanL , VogelC , SeidlerC , et al. Final 5‐year results of Z‐FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer2012;118(5):1192‐201. BrufskyAM ,  BossermanLD ,  CaradonnaRR ,  HaleyBB ,  JonesCM ,  MooreHC ,  etal . Zoledronic acid effectively prevents aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z‐FAST study 36‐month follow‐up results. Clinical Breast Cancer2009;9(2):77‐85. ">Z‐FAST 2012</a>; <a href="./references#CD003474-bbs2-0043" title="ColemanR , DeBoerR , EidtmannH , LlombartA , DavidsonN , NevenP , et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO‐FAST study): final 60‐month results. Annals of Oncology2013;24(2):398‐405. ColemanR , DeBoerR , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Influence of delayed zoledronic acid initiation on disease‐free survival in postmenopausal women with endocrine receptor‐positive early breast cancer receiving adjuvant letrozole: exploratory analysis from the ZO‐FAST trial. Cancer Research2011;71(24 Suppl):P2‐17‐01. DeBoerR , BundredN , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Long‐term survival outcomes among postmenopausal women with hormone receptor‐positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5‐year follow‐up of ZO‐FAST. Cancer Research2011;71(24 Suppl):S1‐3. DeBoerR , MartinM , StegerGG , VonMoosR , StopeckA , TonkinK , et al. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMs): a number‐needed‐to‐treat (NNT) analysis. Asia‐Pacific Journal of Clinical Oncology2011;7(3 Suppl):9. EidtmannH , DeBoerR , BundredN , Llombart‐CussacA , DavidsonN , NevenP , et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36‐month results of the ZO‐FAST Study. Annals of Oncology2010;21(11):2188‐94. ">ZO‐FAST 2013</a>) were removed from the analysis of postmenopausal women, the treatment effect did not reach statistical significance (P = 0.06) with a RR of 0.88 (95% CI 0.77 to 1.00; 6 studies; 4872 women). </p> <p>One study that compared different bisphosphonates (<a href="./references#CD003474-bbs2-0034" title="GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG‐ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. Journal of Clinical Oncology2015;33(15 Suppl):503. [0732‐183X] GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: comparison of toxicities and patient‐stated preference for oral versus intravenous delivery. Journal of Clinical Oncoloy2014;32(15 Suppl):558. NCT00127205 . Zoledronate, clodronate, or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer. clinicaltrials.gov/ct2/show/NCT00127205 (accessed 30 April 2011); Vol. Date first received: 3 August 2005. ">SWOG‐S0307 2015</a>) reported no evidence of treatment differences based on menopausal status. </p> </section> </section> <section id="CD003474-sec-0133"> <h5 class="title">Fracture incidence</h5> <section id="CD003474-sec-0134"> <h6 class="title">Bisphosphonate versus placebo/observation</h6> <p>Overall, bisphosphonates did not significantly reduce the incidence of fractures when compared to placebo/observation with a RR of 0.77 (95% CI 0.54 to 1.08; P = 0.13; 6 studies; <a href="./references#CD003474-fig-0029" title="">Analysis 1.19</a> (subtotal 1.19.1); moderate‐quality evidence due to wide confidence intervals). There were 385 events in 7602 women randomised. There was moderate heterogeneity (I<sup>2</sup> = 48%, P = 0.10). </p> </section> <section id="CD003474-sec-0135"> <h6 class="title">Denosumab versus placebo</h6> <p>Fracture incidence was reduced with denosumab (60 mg sc every 6 months) compared to placebo with a RR of 0.52 (95% CI 0.41 to 0.67; 1 study; <a href="./references#CD003474-fig-0029" title="">Analysis 1.19</a> (subtotal 1.19.2)). There were 268 events in 3420 women randomised. </p> </section> <section id="CD003474-sec-0136"> <h6 class="title">Direct comparisons of different bisphosphonate regimens</h6> <p>Based on one study, there was no significant difference in fracture incidence between the different bisphosphonates. There were 94 fractures in 2094 randomised participants (4.5%) in the zoledronate group, 103 fractures in 2151 randomised women (4.8%) in the clodronate group and 62 fractures in the 1507 women randomised (4.1%) in the ibandronate group. </p> </section> <section id="CD003474-sec-0137"> <h6 class="title">Immediate versus delayed bisphosphonate</h6> <p>Fracture incidence did not appear to differ significantly when comparing immediate and delayed bisphosphonates however the confidence intervals were wide (RR 0.81, 95% CI 0.57 to 1.13; P = 0.21; 3 studies; no heterogeneity; <a href="./references#CD003474-fig-0029" title="">Analysis 1.19</a> (subtotal 1.19.3)). There were 126 events in 2190 women. </p> </section> </section> <section id="CD003474-sec-0138"> <h5 class="title">Quality of life</h5> <p>None of the studies collected and reported data on quality of life.</p> </section> <section id="CD003474-sec-0139"> <h5 class="title">Adverse, drug‐related events or toxicity</h5> <p>We have described specific toxicities in detail by treatment comparison in <a href="#CD003474-tbl-0005">Table 2</a> and <a href="#CD003474-tbl-0006">Table 3</a>. In general, few serious adverse events were reported. For the purpose of this section, we have provided a brief narrative summary. </p> <div class="table" id="CD003474-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Early breast cancer: toxicity ‐ osteonecrosis of the jaw, hypocalcaemia, renal dysfunction &amp; drug‐related death</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Treatment vs comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>ONJ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Hypocalcaemia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Renal dysfunction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Drug‐related death</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0001" title="GnantM , MlineritschB , Luschin‐EbengreuthG , StoegerH , DubskyP , JakeszR , et al. Long‐term follow‐up in ABCSG‐12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine‐receptor‐positive early breast cancer. Cancer Research2011;71:S1‐2. GnantM , MlineritschB , SchippingerW , Luschin‐EbengreuthG , PöstlbergerS , MenzelC , et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New England Journal of Medicine2009;360(7):679‐91. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , HeckD , MenzelC , et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early‐stage breast cancer: 62‐month follow‐up from the ABCSG‐12 randomised trial. Lancet Oncology2011;12(7):631‐41. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , KnauerM , MoikM , et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Annals of Oncology2015; Vol. 26, issue 2:313‐20. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , PoestlbergerS , DubskyPC , et al. Mature results from ABCSG‐12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine‐responsive early breast cancer. Journal of Clinical Oncology2010;28(15 Suppl):533. ">ABCSG‐12 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/904</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0002" title="GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer (ABCSG‐18): a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet2015;386(9992):433–43. [NCT00556374] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer: results from 3,425 post‐menopausal patients of the ABCSG18 trial. Journal of Clinical Oncology2015;33(15 Suppl):504. [0732‐183X] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. The impact of adjuvant denosumab on disease‐free survival: results from 3,425 postmenopausal patients of the ABCSG‐18 trial. Cancer Research2016;76(4 Suppl):S2‐02. [0008‐5472] ">ABCSG‐18 2015</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/1709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/1690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/1709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/1690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2<sup>a</sup>/1709 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3<sup>a</sup>/1690 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/1709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/1690</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0003" title="AftR , NaughtonM , TrinkausK , WatsonM , YlaganL , Chavez‐MacGregorM , et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncology2010;11(5):421‐8. AftRL , NaughtonM , TrinkausK , WeilbaecherK . Effect of (neo)adjuvant zoledronic acid on disease‐free and overall survival in clinical stage II/III breast cancer. British Journal of Cancer2012;107(1):7‐11. ">Aft 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0005" title="ColemanR , CameronD , DodwellD , BellR , WilsonC , RathboneE , et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open‐label phase 3 trial. Lancet Oncology2014;15(9):997‐1006. ColemanR , WoodwardE , BrownJ , CameronD , BellR , DodwellD , et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01‐04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment2011;127(2):429‐38. ColemanR , WoodwardE , TurnerL , MarshallH , CollinsonM , DodwellD , et al. Impact of zoledronic acid on fractures, bone mineral density and bone remodeling in the AZURE trial (BIG 01‐04). Cancer Research2011;71(24 Suppl):P2‐19‐01. ColemanRE , MarshallH , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Breast‐cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine2011;365(15):1396‐405. ColemanRE , RathboneEJ , MarshallHC , WilsonC , BrownJE , GossielF , et al. Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study. Cancer Research2012;72(24 Suppl):S6‐4. ColemanRE , ThorpeHC , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Cancer Research2010;70(24 Suppl):S4‐5. ColemanRE , WinterMC , CameronD , BellR , DodwellD , KeaneMM , et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti‐tumour activity in breast cancer. British Journal of Cancer2010;102(7):1099‐105. RathboneEJ , BrownJE , MarshallHC , CollinsonM , LiversedgeV , MurdenGA , et al. Osteonecrosis of the jaw and oral health‐related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). Journal of Clinical Oncology2013;31(21):2685‐91. ">AZURE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/1685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/1667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>188/1685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>158/1667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/1685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/1667</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0010" title="DielIJ , SolomayerEF , CostaSD , GollanC , GoernerR , WallweinerD , et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New England Journal of Medicine1998;339(6):357‐63. DielIJ ,  JaschkeA ,  SolomayerEF ,  GollanC ,  BastertG ,  SohnC , et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long‐term follow‐up. Annals of Oncology2008;19(12):2007‐201. JaschkeA , BastertG , SolomayerEF , CostaS , ScheutzF , DielJJ . Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow: a long‐term follow‐up. Journal of Clinical Oncology2004;22(14 Suppl):529. ">Diel 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0015" title="MoebusVJ , VonMinckwitzG , JackischC , LueckH‐J , SchneeweissA , TeschH , et al. German Adjuvant Intergroup Node Positive (GAIN) study: a phase III trial to compare IDD‐ETC versus EC‐TX in patients with node‐positive primary breast cancer‐final efficacy analysis. Journal of Clinical Oncology2014;32(5 Suppl):1009. MöbusV , DielI J , HarbeckN , EllingD , JackischC , ThomssenC , et al. GAIN study: a phase III trial to compare ETC vs. EC‐TX and ibandronate vs. observation in patients with node‐positive primary breast cancer ‐ 1st interim efficacy analysis. Cancer Research2011;71(24):S2‐4. NCT00196872 . A study to compare ETC vs EC‐TX and ibandronate vs observation in patients with node‐positive primary breast cancer. clinicaltrials.gov/ct2/show/NCT00196872 Date first received: 12 September 2005. vonMinckwitzG , MobusV , SchneeweissA , HuoberJ , ThomssenC , UntchM , et al. German Adjuvant Intergroup Node‐positive study: a phase III trial to compare oral ibandronate versus observation in patients with high‐risk early breast cancer. Journal of Clinical Oncology2013;31(28):3531‐9. ">GAIN 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/1832</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/1832</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/968</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0017" title="HershmanDL , McMahonDJ , CrewKD , CremersS , IraniD , CucchiaraG , et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. Journal of Clinical Endocrinology and Metabolism2010;95(2):559‐66. HershmanDL , McMahonDJ , CrewKD , CremersS , IraniD , CucchiaraG , et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early‐stage breast cancer. Journal of Clinical Oncology2008;26(29):4739‐45. ">Hershman 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0022" title="KristensenB ,  EjlertsenB ,  MouridsenHT ,  JensenMB ,  AndersenJ ,  BjerregaardB , et al. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncologica2008;47(4):740‐6. ">Kristensen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0026" title="MinckwitzG , RezaiM , TeschH , HuoberJ , GerberB , ZahmDM , et al. Zoledronate for patients with invasive residual disease after anthracyclines‐taxane‐based chemotherapy for early breast cancer ‐ the phase III NeoAdjuvant Trial Add‐oN (NaTaN) study (GBG 36/ABCSG 29). European Journal of Cancer2016;64:12‐21. NCT00512993 . Postoperative use of zoledronic acid in breast cancer patients after neoadjuvant chemotherapy (NATAN). clinicaltrials.gov/ct2/show/NCT00512993 Date first received: 3 August 2007. vonMinckwitzG , RezaiM , EidtmannH , TeschH , HuoberJ , GerberB , et al. Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines‐taxane‐based chemotherapy for primary breast cancer ‐ the phase III NATAN study (GBG 36/ABCSG XX). Cancer Research2013;73(24 Suppl):S5‐05. ">NATAN 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7<sup>b</sup>/343 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4<sup>b</sup>/350 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/350</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0027" title="PatersonAH , AndersonSJ , LemberskyBC , FehrenbacherL , FalksonCI , KingKM , et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B‐34): a multicentre, placebo‐controlled, randomised trial. Lancet Oncology2012; Vol. 13, issue 7:734‐42. PatersonAHG , AndersonSJ , LemberskyBC , FehrenbacherL , FalksonCI , KingKM , et al. NSABP protocol B‐34: a clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy ‐ final analysis. Cancer Research2011;71(24 Suppl):S2‐3. ">NSABP‐34 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/1612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/1623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/1612 (G3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/1523 (G3/4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/1612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/1623</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0030" title="AtulaST , PatersonAHG , PowlesTJ , McLoskeyEV , NevalainenJI , KanisJA . Extended safety profile of oral clodronate after long‐term use in primary breast cancer patients. Drug Safety2003;26(9):661‐71. McCloskeyE , PatersonA , KanisJ , TahtelaR , PowlesT . Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. European Journal of Cancer2009;46(3):558‐65. PowlesT , McCloskeyE , KurkilahtiM , KurkilahtiM , KanisJ . Oral clodronate for the adjuvant treatment of operable breast cancer: results of a randomised, double‐blind, placebo‐controlled multicenter trial. Journal of Clinical Oncology2004;22(14 Suppl):528. PowlesT ,  PatersonA ,  McCloskeyE ,  ScheinP ,  SchefflerB ,  TidyA , et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Research2006;8(2):13. PowlesT ,  PatersonS ,  KanisJA ,  McCloskeyE ,  AshleyS ,  TidyA , et al. Randomized, placebo‐controlled trial of clodronate in patients with primary operable breast cancer. Journal of Clinical Oncology2002;20(15):3219‐24. ">Powles 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/539</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/539</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/539</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0032" title="SaartoT , BlomqvistC , VirkkunenP , ElomaaI . Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node‐positive breast cancer patients: 5 year results of a randomised controlled study. Journal of Clinical Oncology2001;19(1):10‐17. SaartoT , VehmanenL , VirkkunenP , BlomqvistC . Ten‐year follow‐up of a randomized controlled trial of adjuvant clodronate treatment in node‐positive breast cancer patients. Acta Oncologica2004;43(7):650‐6. ">Saarto 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0034" title="GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG‐ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. Journal of Clinical Oncology2015;33(15 Suppl):503. [0732‐183X] GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: comparison of toxicities and patient‐stated preference for oral versus intravenous delivery. Journal of Clinical Oncoloy2014;32(15 Suppl):558. NCT00127205 . Zoledronate, clodronate, or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer. clinicaltrials.gov/ct2/show/NCT00127205 (accessed 30 April 2011); Vol. Date first received: 3 August 2005. ">SWOG‐S0307 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs clodronate<br/> vs ibandronate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate:</p> <p>24/2094</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate: 6/2151<br/> Ibandronate: 10/1507 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0035" title="LealT ,  TevaarwerkA ,  LoveR ,  StewartJ ,  BinkleyN ,  EickhoffJ , et al. Randomized trial of adjuvant zoledronic acid in postmenopausal women with high‐risk breast cancer. Clinical Breast Cancer2010;10(6):471‐6. TevaarwerkA , StewartJA , LoveR , BinkleyNC , BlackS , EickhoffS , et al. Randomized trial to assess bone mineral density (BMD) effects of zoledronic acid (ZA) in postmenopausal women (PmW) with breast cancer. Journal of Clinical Oncology2007;25(18 Suppl):19558. ">Tevaarwerk 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<sup>c</sup>/36 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<sup>c</sup>/32 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0013" title="LlombartA , FrassoldatiA , PaijaO , SleeboomHP , JerusalemG , MebisJ , et al. Immediate administration of zoledronic acid reduces aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer: 12‐month analysis of the E‐ZO‐FAST trial. Clinical Breast Cancer2012;12(1):40‐8. LlombartoA , FrassoldatiA , PaijaO , SleeboomHP , JerusalemG , MebisJ , et al. Effect of zoledronic acid on aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E‐ZO‐FAST 36‐month follow‐up. ASCO Breast Cancer Symposium; 2009; Chicago. Chicago: American Society of Clinical Oncology, 2009. ">E‐ZO‐FAST 2012</a><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate vs delayed zoledronate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/270</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0041" title="BrufskyA ,  BundredN ,  ColemanR ,  Lambert‐FallsR ,  MenaR ,  HadjiP , et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist2008;13(5):503‐14. BrufskyA ,  HarkerWG ,  BeckJT ,  CarrollR ,  Tan‐ChiuE ,  SeidlerC , et al. Zoledronic acid inhibits adjuvant letrozole‐induced bone loss in postmenopausal women with early breast cancer. Journal of Clinical Oncology2007;25(7):829‐36. BrufskyAM , HarkerWG , BeckJT , BossermanL , VogelC , SeidlerC , et al. Final 5‐year results of Z‐FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer2012;118(5):1192‐201. BrufskyAM ,  BossermanLD ,  CaradonnaRR ,  HaleyBB ,  JonesCM ,  MooreHC ,  etal . Zoledronic acid effectively prevents aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z‐FAST study 36‐month follow‐up results. Clinical Breast Cancer2009;9(2):77‐85. ">Z‐FAST 2012</a><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate vs delayed zoledronate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/300 (G1 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/300 (G1 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/300</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0043" title="ColemanR , DeBoerR , EidtmannH , LlombartA , DavidsonN , NevenP , et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO‐FAST study): final 60‐month results. Annals of Oncology2013;24(2):398‐405. ColemanR , DeBoerR , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Influence of delayed zoledronic acid initiation on disease‐free survival in postmenopausal women with endocrine receptor‐positive early breast cancer receiving adjuvant letrozole: exploratory analysis from the ZO‐FAST trial. Cancer Research2011;71(24 Suppl):P2‐17‐01. DeBoerR , BundredN , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Long‐term survival outcomes among postmenopausal women with hormone receptor‐positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5‐year follow‐up of ZO‐FAST. Cancer Research2011;71(24 Suppl):S1‐3. DeBoerR , MartinM , StegerGG , VonMoosR , StopeckA , TonkinK , et al. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMs): a number‐needed‐to‐treat (NNT) analysis. Asia‐Pacific Journal of Clinical Oncology2011;7(3 Suppl):9. EidtmannH , DeBoerR , BundredN , Llombart‐CussacA , DavidsonN , NevenP , et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36‐month results of the ZO‐FAST Study. Annals of Oncology2010;21(11):2188‐94. ">ZO‐FAST 2013</a><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate vs delayed zoledronate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/524 (G1/2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/536 (G1/2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/536</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>G</b> : grade; <b>n</b> : number of events; <b>N</b> : number of women studied in each group; <b>NR</b> : not reported; <b>ONJ</b>: osteonecrosis of the jaw<br/> <sup>a</sup>Number of events for renal dysfunction refers to renal failure.<br/> <sup>b</sup>Any grade.<br/> <sup>c</sup>"No clinically significant changes in calcium" (<a href="./references#CD003474-bbs2-0035" title="LealT ,  TevaarwerkA ,  LoveR ,  StewartJ ,  BinkleyN ,  EickhoffJ , et al. Randomized trial of adjuvant zoledronic acid in postmenopausal women with high‐risk breast cancer. Clinical Breast Cancer2010;10(6):471‐6. TevaarwerkA , StewartJA , LoveR , BinkleyNC , BlackS , EickhoffS , et al. Randomized trial to assess bone mineral density (BMD) effects of zoledronic acid (ZA) in postmenopausal women (PmW) with breast cancer. Journal of Clinical Oncology2007;25(18 Suppl):19558. ">Tevaarwerk 2007</a>).<br/> <sup>d</sup>Control arm was delayed zoledronate. </p> </div> </div> <div class="table" id="CD003474-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Early breast cancer: toxicity ‐ nausea, fatigue, fever &amp; influenza symptoms</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Treatment vs comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Nausea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fatigue</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fever</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Influenza‐type symptoms</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0001" title="GnantM , MlineritschB , Luschin‐EbengreuthG , StoegerH , DubskyP , JakeszR , et al. Long‐term follow‐up in ABCSG‐12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine‐receptor‐positive early breast cancer. Cancer Research2011;71:S1‐2. GnantM , MlineritschB , SchippingerW , Luschin‐EbengreuthG , PöstlbergerS , MenzelC , et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New England Journal of Medicine2009;360(7):679‐91. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , HeckD , MenzelC , et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early‐stage breast cancer: 62‐month follow‐up from the ABCSG‐12 randomised trial. Lancet Oncology2011;12(7):631‐41. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , KnauerM , MoikM , et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Annals of Oncology2015; Vol. 26, issue 2:313‐20. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , PoestlbergerS , DubskyPC , et al. Mature results from ABCSG‐12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine‐responsive early breast cancer. Journal of Clinical Oncology2010;28(15 Suppl):533. ">ABCSG‐12 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79/899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55/904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>192/899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>169/904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85/899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0002" title="GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer (ABCSG‐18): a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet2015;386(9992):433–43. [NCT00556374] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer: results from 3,425 post‐menopausal patients of the ABCSG18 trial. Journal of Clinical Oncology2015;33(15 Suppl):504. [0732‐183X] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. The impact of adjuvant denosumab on disease‐free survival: results from 3,425 postmenopausal patients of the ABCSG‐18 trial. Cancer Research2016;76(4 Suppl):S2‐02. [0008‐5472] ">ABCSG‐18 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49/1709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42/1690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108/1709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98/1690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/1709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/1690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/1709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/1690</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0003" title="AftR , NaughtonM , TrinkausK , WatsonM , YlaganL , Chavez‐MacGregorM , et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncology2010;11(5):421‐8. AftRL , NaughtonM , TrinkausK , WeilbaecherK . Effect of (neo)adjuvant zoledronic acid on disease‐free and overall survival in clinical stage II/III breast cancer. British Journal of Cancer2012;107(1):7‐11. ">Aft 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0005" title="ColemanR , CameronD , DodwellD , BellR , WilsonC , RathboneE , et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open‐label phase 3 trial. Lancet Oncology2014;15(9):997‐1006. ColemanR , WoodwardE , BrownJ , CameronD , BellR , DodwellD , et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01‐04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment2011;127(2):429‐38. ColemanR , WoodwardE , TurnerL , MarshallH , CollinsonM , DodwellD , et al. Impact of zoledronic acid on fractures, bone mineral density and bone remodeling in the AZURE trial (BIG 01‐04). Cancer Research2011;71(24 Suppl):P2‐19‐01. ColemanRE , MarshallH , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Breast‐cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine2011;365(15):1396‐405. ColemanRE , RathboneEJ , MarshallHC , WilsonC , BrownJE , GossielF , et al. Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study. Cancer Research2012;72(24 Suppl):S6‐4. ColemanRE , ThorpeHC , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Cancer Research2010;70(24 Suppl):S4‐5. ColemanRE , WinterMC , CameronD , BellR , DodwellD , KeaneMM , et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti‐tumour activity in breast cancer. British Journal of Cancer2010;102(7):1099‐105. RathboneEJ , BrownJE , MarshallHC , CollinsonM , LiversedgeV , MurdenGA , et al. Osteonecrosis of the jaw and oral health‐related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). Journal of Clinical Oncology2013;31(21):2685‐91. ">AZURE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37/1685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24/1667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0010" title="DielIJ , SolomayerEF , CostaSD , GollanC , GoernerR , WallweinerD , et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New England Journal of Medicine1998;339(6):357‐63. DielIJ ,  JaschkeA ,  SolomayerEF ,  GollanC ,  BastertG ,  SohnC , et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long‐term follow‐up. Annals of Oncology2008;19(12):2007‐201. JaschkeA , BastertG , SolomayerEF , CostaS , ScheutzF , DielJJ . Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow: a long‐term follow‐up. Journal of Clinical Oncology2004;22(14 Suppl):529. ">Diel 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0015" title="MoebusVJ , VonMinckwitzG , JackischC , LueckH‐J , SchneeweissA , TeschH , et al. German Adjuvant Intergroup Node Positive (GAIN) study: a phase III trial to compare IDD‐ETC versus EC‐TX in patients with node‐positive primary breast cancer‐final efficacy analysis. Journal of Clinical Oncology2014;32(5 Suppl):1009. MöbusV , DielI J , HarbeckN , EllingD , JackischC , ThomssenC , et al. GAIN study: a phase III trial to compare ETC vs. EC‐TX and ibandronate vs. observation in patients with node‐positive primary breast cancer ‐ 1st interim efficacy analysis. Cancer Research2011;71(24):S2‐4. NCT00196872 . A study to compare ETC vs EC‐TX and ibandronate vs observation in patients with node‐positive primary breast cancer. clinicaltrials.gov/ct2/show/NCT00196872 Date first received: 12 September 2005. vonMinckwitzG , MobusV , SchneeweissA , HuoberJ , ThomssenC , UntchM , et al. German Adjuvant Intergroup Node‐positive study: a phase III trial to compare oral ibandronate versus observation in patients with high‐risk early breast cancer. Journal of Clinical Oncology2013;31(28):3531‐9. ">GAIN 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0017" title="HershmanDL , McMahonDJ , CrewKD , CremersS , IraniD , CucchiaraG , et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. Journal of Clinical Endocrinology and Metabolism2010;95(2):559‐66. HershmanDL , McMahonDJ , CrewKD , CremersS , IraniD , CucchiaraG , et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early‐stage breast cancer. Journal of Clinical Oncology2008;26(29):4739‐45. ">Hershman 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24/50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0022" title="KristensenB ,  EjlertsenB ,  MouridsenHT ,  JensenMB ,  AndersenJ ,  BjerregaardB , et al. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncologica2008;47(4):740‐6. ">Kristensen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>324<sup>a</sup>/460 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>337<sup>a</sup>/493 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0026" title="MinckwitzG , RezaiM , TeschH , HuoberJ , GerberB , ZahmDM , et al. Zoledronate for patients with invasive residual disease after anthracyclines‐taxane‐based chemotherapy for early breast cancer ‐ the phase III NeoAdjuvant Trial Add‐oN (NaTaN) study (GBG 36/ABCSG 29). European Journal of Cancer2016;64:12‐21. NCT00512993 . Postoperative use of zoledronic acid in breast cancer patients after neoadjuvant chemotherapy (NATAN). clinicaltrials.gov/ct2/show/NCT00512993 Date first received: 3 August 2007. vonMinckwitzG , RezaiM , EidtmannH , TeschH , HuoberJ , GerberB , et al. Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines‐taxane‐based chemotherapy for primary breast cancer ‐ the phase III NATAN study (GBG 36/ABCSG XX). Cancer Research2013;73(24 Suppl):S5‐05. ">NATAN 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65<sup>b</sup>/343 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36<sup>b</sup>/350 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28<sup>b</sup>/343 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1<sup>b</sup>/350 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0027" title="PatersonAH , AndersonSJ , LemberskyBC , FehrenbacherL , FalksonCI , KingKM , et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B‐34): a multicentre, placebo‐controlled, randomised trial. Lancet Oncology2012; Vol. 13, issue 7:734‐42. PatersonAHG , AndersonSJ , LemberskyBC , FehrenbacherL , FalksonCI , KingKM , et al. NSABP protocol B‐34: a clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy ‐ final analysis. Cancer Research2011;71(24 Suppl):S2‐3. ">NSABP‐34 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0030" title="AtulaST , PatersonAHG , PowlesTJ , McLoskeyEV , NevalainenJI , KanisJA . Extended safety profile of oral clodronate after long‐term use in primary breast cancer patients. Drug Safety2003;26(9):661‐71. McCloskeyE , PatersonA , KanisJ , TahtelaR , PowlesT . Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. European Journal of Cancer2009;46(3):558‐65. PowlesT , McCloskeyE , KurkilahtiM , KurkilahtiM , KanisJ . Oral clodronate for the adjuvant treatment of operable breast cancer: results of a randomised, double‐blind, placebo‐controlled multicenter trial. Journal of Clinical Oncology2004;22(14 Suppl):528. PowlesT ,  PatersonA ,  McCloskeyE ,  ScheinP ,  SchefflerB ,  TidyA , et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Research2006;8(2):13. PowlesT ,  PatersonS ,  KanisJA ,  McCloskeyE ,  AshleyS ,  TidyA , et al. Randomized, placebo‐controlled trial of clodronate in patients with primary operable breast cancer. Journal of Clinical Oncology2002;20(15):3219‐24. ">Powles 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>143/530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>161/539</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0032" title="SaartoT , BlomqvistC , VirkkunenP , ElomaaI . Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node‐positive breast cancer patients: 5 year results of a randomised controlled study. Journal of Clinical Oncology2001;19(1):10‐17. SaartoT , VehmanenL , VirkkunenP , BlomqvistC . Ten‐year follow‐up of a randomized controlled trial of adjuvant clodronate treatment in node‐positive breast cancer patients. Acta Oncologica2004;43(7):650‐6. ">Saarto 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0034" title="GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG‐ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. Journal of Clinical Oncology2015;33(15 Suppl):503. [0732‐183X] GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: comparison of toxicities and patient‐stated preference for oral versus intravenous delivery. Journal of Clinical Oncoloy2014;32(15 Suppl):558. NCT00127205 . Zoledronate, clodronate, or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer. clinicaltrials.gov/ct2/show/NCT00127205 (accessed 30 April 2011); Vol. Date first received: 3 August 2005. ">SWOG‐S0307 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs clodronate<br/> vs ibandronate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0035" title="LealT ,  TevaarwerkA ,  LoveR ,  StewartJ ,  BinkleyN ,  EickhoffJ , et al. Randomized trial of adjuvant zoledronic acid in postmenopausal women with high‐risk breast cancer. Clinical Breast Cancer2010;10(6):471‐6. TevaarwerkA , StewartJA , LoveR , BinkleyNC , BlackS , EickhoffS , et al. Randomized trial to assess bone mineral density (BMD) effects of zoledronic acid (ZA) in postmenopausal women (PmW) with breast cancer. Journal of Clinical Oncology2007;25(18 Suppl):19558. ">Tevaarwerk 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0013" title="LlombartA , FrassoldatiA , PaijaO , SleeboomHP , JerusalemG , MebisJ , et al. Immediate administration of zoledronic acid reduces aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer: 12‐month analysis of the E‐ZO‐FAST trial. Clinical Breast Cancer2012;12(1):40‐8. LlombartoA , FrassoldatiA , PaijaO , SleeboomHP , JerusalemG , MebisJ , et al. Effect of zoledronic acid on aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E‐ZO‐FAST 36‐month follow‐up. ASCO Breast Cancer Symposium; 2009; Chicago. Chicago: American Society of Clinical Oncology, 2009. ">E‐ZO‐FAST 2012</a><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate vs delated zoledronate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38/252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50/270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/270</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0041" title="BrufskyA ,  BundredN ,  ColemanR ,  Lambert‐FallsR ,  MenaR ,  HadjiP , et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist2008;13(5):503‐14. BrufskyA ,  HarkerWG ,  BeckJT ,  CarrollR ,  Tan‐ChiuE ,  SeidlerC , et al. Zoledronic acid inhibits adjuvant letrozole‐induced bone loss in postmenopausal women with early breast cancer. Journal of Clinical Oncology2007;25(7):829‐36. BrufskyAM , HarkerWG , BeckJT , BossermanL , VogelC , SeidlerC , et al. Final 5‐year results of Z‐FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer2012;118(5):1192‐201. BrufskyAM ,  BossermanLD ,  CaradonnaRR ,  HaleyBB ,  JonesCM ,  MooreHC ,  etal . Zoledronic acid effectively prevents aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z‐FAST study 36‐month follow‐up results. Clinical Breast Cancer2009;9(2):77‐85. ">Z‐FAST 2012</a><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate vs delated zoledronate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41/300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40/300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101/300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88/300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0043" title="ColemanR , DeBoerR , EidtmannH , LlombartA , DavidsonN , NevenP , et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO‐FAST study): final 60‐month results. Annals of Oncology2013;24(2):398‐405. ColemanR , DeBoerR , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Influence of delayed zoledronic acid initiation on disease‐free survival in postmenopausal women with endocrine receptor‐positive early breast cancer receiving adjuvant letrozole: exploratory analysis from the ZO‐FAST trial. Cancer Research2011;71(24 Suppl):P2‐17‐01. DeBoerR , BundredN , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Long‐term survival outcomes among postmenopausal women with hormone receptor‐positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5‐year follow‐up of ZO‐FAST. Cancer Research2011;71(24 Suppl):S1‐3. DeBoerR , MartinM , StegerGG , VonMoosR , StopeckA , TonkinK , et al. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMs): a number‐needed‐to‐treat (NNT) analysis. Asia‐Pacific Journal of Clinical Oncology2011;7(3 Suppl):9. EidtmannH , DeBoerR , BundredN , Llombart‐CussacA , DavidsonN , NevenP , et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36‐month results of the ZO‐FAST Study. Annals of Oncology2010;21(11):2188‐94. ">ZO‐FAST 2013</a><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate vs delated zoledronate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46/524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42/536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84/524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81/536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78/524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45/524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/536</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>n</b> : number of events; <b>N</b> : number of women studied in each group; <b>NR</b>: not reported<br/> <sup>a</sup>Nausea and vomited reported together.<br/> <sup>b</sup>Any grade.<br/> <sup>c</sup>Control arm was delayed zoledronate. </p> </div> </div> <p>Trial publications frequently collected data on osteonecrosis of the jaw (ONJ; 12 out of 16 studies), renal dysfunction (10 out of 12 studies), drug‐related death (10 out of 12 studies) and fever (9 out of 12 studies). Other adverse events were collected such as infusion‐type side effects incorporating nausea (7 studies), fatigue (7 studies) and influenza‐type symptoms (4 studies), and hypocalcaemia (3 studies). </p> <p>The zoledronate studies reported between 0 and 26 ONJ cases in each arm of each trial. In <a href="./references#CD003474-bbs2-0005" title="ColemanR , CameronD , DodwellD , BellR , WilsonC , RathboneE , et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open‐label phase 3 trial. Lancet Oncology2014;15(9):997‐1006. ColemanR , WoodwardE , BrownJ , CameronD , BellR , DodwellD , et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01‐04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment2011;127(2):429‐38. ColemanR , WoodwardE , TurnerL , MarshallH , CollinsonM , DodwellD , et al. Impact of zoledronic acid on fractures, bone mineral density and bone remodeling in the AZURE trial (BIG 01‐04). Cancer Research2011;71(24 Suppl):P2‐19‐01. ColemanRE , MarshallH , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Breast‐cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine2011;365(15):1396‐405. ColemanRE , RathboneEJ , MarshallHC , WilsonC , BrownJE , GossielF , et al. Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study. Cancer Research2012;72(24 Suppl):S6‐4. ColemanRE , ThorpeHC , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Cancer Research2010;70(24 Suppl):S4‐5. ColemanRE , WinterMC , CameronD , BellR , DodwellD , KeaneMM , et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti‐tumour activity in breast cancer. British Journal of Cancer2010;102(7):1099‐105. RathboneEJ , BrownJE , MarshallHC , CollinsonM , LiversedgeV , MurdenGA , et al. Osteonecrosis of the jaw and oral health‐related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). Journal of Clinical Oncology2013;31(21):2685‐91. ">AZURE 2014</a>, there were 17 confirmed cases of ONJ and nine suspected cases of ONJ in the intervention arm (zoledronate) against no cases of ONJ in the control arm (<a href="#CD003474-tbl-0005">Table 2</a>). Overall, the incidence of ONJ was less than 0.5% in the bisphosphonates groups (high‐quality evidence). Intravenous bisphosphonates (zoledronate) appeared to slightly increase the incidence of fever, fatigue and nausea compared to placebo however the reporting of the grade of toxicity often was unspecified. The quality of evidence for infusion‐related side‐effects was considered to be moderate. Of the bisphosphonates administrated intravenously, the two zoledronate studies (<a href="./references#CD003474-bbs2-0001" title="GnantM , MlineritschB , Luschin‐EbengreuthG , StoegerH , DubskyP , JakeszR , et al. Long‐term follow‐up in ABCSG‐12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine‐receptor‐positive early breast cancer. Cancer Research2011;71:S1‐2. GnantM , MlineritschB , SchippingerW , Luschin‐EbengreuthG , PöstlbergerS , MenzelC , et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New England Journal of Medicine2009;360(7):679‐91. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , HeckD , MenzelC , et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early‐stage breast cancer: 62‐month follow‐up from the ABCSG‐12 randomised trial. Lancet Oncology2011;12(7):631‐41. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , KnauerM , MoikM , et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Annals of Oncology2015; Vol. 26, issue 2:313‐20. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , PoestlbergerS , DubskyPC , et al. Mature results from ABCSG‐12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine‐responsive early breast cancer. Journal of Clinical Oncology2010;28(15 Suppl):533. ">ABCSG‐12 2011</a>; <a href="./references#CD003474-bbs2-0026" title="MinckwitzG , RezaiM , TeschH , HuoberJ , GerberB , ZahmDM , et al. Zoledronate for patients with invasive residual disease after anthracyclines‐taxane‐based chemotherapy for early breast cancer ‐ the phase III NeoAdjuvant Trial Add‐oN (NaTaN) study (GBG 36/ABCSG 29). European Journal of Cancer2016;64:12‐21. NCT00512993 . Postoperative use of zoledronic acid in breast cancer patients after neoadjuvant chemotherapy (NATAN). clinicaltrials.gov/ct2/show/NCT00512993 Date first received: 3 August 2007. vonMinckwitzG , RezaiM , EidtmannH , TeschH , HuoberJ , GerberB , et al. Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines‐taxane‐based chemotherapy for primary breast cancer ‐ the phase III NATAN study (GBG 36/ABCSG XX). Cancer Research2013;73(24 Suppl):S5‐05. ">NATAN 2016</a>) reported incidences of a cutaneous reaction in both the bisphosphonate and control groups. The number of cutaneous reactions in the one study examining denosumab were the same in both the intervention and control groups. There were no apparent differences in the adverse events between immediate and delayed bisphosphonate studies. </p> </section> </section> <section id="CD003474-sec-0140"> <h4 class="title">Advanced breast cancer without bone metastases (ABC)</h4> <p>Three studies, involving 330 women, evaluated bisphosphonates compared to placebo in women with ABC without clinically evident bone metastases. Oral clodronate at 1600 mg a day was evaluated in two placebo‐controlled studies (<a href="./references#CD003474-bbs2-0019" title="KanisJA , PowlesT , PatersonAH , McCloskeyEV , AshleyS . Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone1996;19(6):663‐7. ">Kanis 1996</a>: clodronate taken for three years, women observed for four years; <a href="./references#CD003474-bbs2-0024" title="MardiakJ , BohunickyL , ChovanecJ , SalekT , KozaI . Adjuvant clodronate therapy in patients with locally advanced breast cancer ‐ long term results of a double blind randomised trial. Neoplasma2000;47(3):177‐80. ">Mardiak 2000</a>: clodronate taken for two years, women observed for seven years). Oral pamidronate 300 mg a day was evaluated by one study (<a href="./references#CD003474-bbs2-0039" title="VanHolten‐VerzantvoortAT , HermansJ , BeexLVAM , BlijhamG , CletonFJ , VanEck‐SmitBCF , et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients?. European Journal of Cancer1996;32A(3):450‐4. ">Van‐Holten 1996</a>). </p> <section id="CD003474-sec-0141"> <h5 class="title">Bone metastases</h5> <p>The incidence of bone metastases did not differ significantly between the bisphosphonate and placebo groups (RR 0.96, 95% CI 0.65 to 1.43; P = 0.86, 3 studies; <a href="./references#CD003474-fig-0030" title="">Analysis 2.1</a>; moderate‐quality evidence). In total, there were 76 events in 330 women randomised (<a href="#CD003474-fig-0008">Figure 8</a>). </p> <div class="figure" id="CD003474-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Advanced breast cancer (ABC), outcome: 2.1 Incidence of bone metastases in ABC (Stage III/IV)" data-id="CD003474-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Advanced breast cancer (ABC), outcome: 2.1 Incidence of bone metastases in ABC (Stage III/IV) </p> </div> </div> </div> </section> <section id="CD003474-sec-0142"> <h5 class="title">Skeletal‐related event (SRE) rate</h5> <p><a href="./references#CD003474-bbs2-0019" title="KanisJA , PowlesT , PatersonAH , McCloskeyEV , AshleyS . Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone1996;19(6):663‐7. ">Kanis 1996</a> reported a 36% reduction in the SRE rate (P &lt; 0.01, 133 women; <a href="#CD003474-tbl-0007">Table 4</a>) in the clodronate group compared to placebo group. </p> <div class="table" id="CD003474-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Advanced breast cancer: skeletal‐related event expressed as a risk ratio</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Number of skeletal‐related events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Ratio: Bisphosphonate/comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0019" title="KanisJA , PowlesT , PatersonAH , McCloskeyEV , AshleyS . Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone1996;19(6):663‐7. ">Kanis 1996</a><br/> (N = 133) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> <p>Event rate = event/100 patient years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0024" title="MardiakJ , BohunickyL , ChovanecJ , SalekT , KozaI . Adjuvant clodronate therapy in patients with locally advanced breast cancer ‐ long term results of a double blind randomised trial. Neoplasma2000;47(3):177‐80. ">Mardiak 2000</a><br/> (N = 73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0039" title="VanHolten‐VerzantvoortAT , HermansJ , BeexLVAM , BlijhamG , CletonFJ , VanEck‐SmitBCF , et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients?. European Journal of Cancer1996;32A(3):450‐4. ">Van‐Holten 1996</a> </p> <p>(N = 124)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 300 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>N</b> : total number of women in the study; <b>NR</b>: not reported </p> </div> </div> </section> <section id="CD003474-sec-0143"> <h5 class="title">Median time to a skeletal‐related event (SRE)</h5> <p><a href="./references#CD003474-bbs2-0024" title="MardiakJ , BohunickyL , ChovanecJ , SalekT , KozaI . Adjuvant clodronate therapy in patients with locally advanced breast cancer ‐ long term results of a double blind randomised trial. Neoplasma2000;47(3):177‐80. ">Mardiak 2000</a> reported a trend towards an extended period of time without a SRE when women were taking clodronate (median time: 28.4 months) compared to placebo (median time: 13.4 months) but this difference was not statistically significant (P = 0.42, 73 women; <a href="#CD003474-tbl-0008">Table 5</a>; low‐quality evidence). </p> <div class="table" id="CD003474-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Advanced breast cancer: median time to skeletal‐related event</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Median time to event (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Ratio ‐ Bisphosphonate/Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0019" title="KanisJA , PowlesT , PatersonAH , McCloskeyEV , AshleyS . Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone1996;19(6):663‐7. ">Kanis 1996</a><br/> (N = 133) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<br/> Reported no. of people "event free" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0024" title="MardiakJ , BohunickyL , ChovanecJ , SalekT , KozaI . Adjuvant clodronate therapy in patients with locally advanced breast cancer ‐ long term results of a double blind randomised trial. Neoplasma2000;47(3):177‐80. ">Mardiak 2000</a><br/> (N = 73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0039" title="VanHolten‐VerzantvoortAT , HermansJ , BeexLVAM , BlijhamG , CletonFJ , VanEck‐SmitBCF , et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients?. European Journal of Cancer1996;32A(3):450‐4. ">Van‐Holten 1996</a> </p> <p>(N = 124)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 300 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reached.</p> <p>First bone event was not within the first 36 months of the analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reached</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>N</b> : total number of women in the study; <b>NR</b>: not reported </p> </div> </div> </section> <section id="CD003474-sec-0144"> <h5 class="title">Overall survival</h5> <p>Bisphosphonates did not alter survival in women with ABC (RR 0.89, 95% CI 0.73 to 1.09; P = 0.28, 3 studies, 330 women; <a href="./references#CD003474-fig-0031" title="">Analysis 2.2</a>; high‐quality evidence). There were 172 deaths in total. <a href="./references#CD003474-bbs2-0024" title="MardiakJ , BohunickyL , ChovanecJ , SalekT , KozaI . Adjuvant clodronate therapy in patients with locally advanced breast cancer ‐ long term results of a double blind randomised trial. Neoplasma2000;47(3):177‐80. ">Mardiak 2000</a> and <a href="./references#CD003474-bbs2-0039" title="VanHolten‐VerzantvoortAT , HermansJ , BeexLVAM , BlijhamG , CletonFJ , VanEck‐SmitBCF , et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients?. European Journal of Cancer1996;32A(3):450‐4. ">Van‐Holten 1996</a> reported no significant difference in median survival time between bisphosphonate and placebo groups (<a href="#CD003474-tbl-0009">Table 6</a>). </p> <div class="table" id="CD003474-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Advanced breast cancer: median survival time</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Median survival time (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Ratio ‐ Bisphosphonate/comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0019" title="KanisJA , PowlesT , PatersonAH , McCloskeyEV , AshleyS . Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone1996;19(6):663‐7. ">Kanis 1996</a><br/> (N = 133) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<br/> Reported no. of events in each group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not significantly different</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0024" title="MardiakJ , BohunickyL , ChovanecJ , SalekT , KozaI . Adjuvant clodronate therapy in patients with locally advanced breast cancer ‐ long term results of a double blind randomised trial. Neoplasma2000;47(3):177‐80. ">Mardiak 2000</a><br/> (N = 73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0039" title="VanHolten‐VerzantvoortAT , HermansJ , BeexLVAM , BlijhamG , CletonFJ , VanEck‐SmitBCF , et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients?. European Journal of Cancer1996;32A(3):450‐4. ">Van‐Holten 1996</a> </p> <p>(N = 124)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 300 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.30</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>N</b> : total number of women in the study; <b>NR</b>: not reported </p> </div> </div> </section> <section id="CD003474-sec-0145"> <h5 class="title">Quality of life</h5> <p>One study, <a href="./references#CD003474-bbs2-0039" title="VanHolten‐VerzantvoortAT , HermansJ , BeexLVAM , BlijhamG , CletonFJ , VanEck‐SmitBCF , et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients?. European Journal of Cancer1996;32A(3):450‐4. ">Van‐Holten 1996</a>, asked women to complete a questionnaire (i.e. using a 4‐point scale) and concluded that there was no difference in quality of life scores between oral pamidronate or placebo groups (<a href="#CD003474-tbl-0010">Table 7</a>; moderate‐quality evidence). </p> <div class="table" id="CD003474-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Advanced breast cancer: quality of life</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Questionnaires used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Summary of findings</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0019" title="KanisJA , PowlesT , PatersonAH , McCloskeyEV , AshleyS . Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone1996;19(6):663‐7. ">Kanis 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0024" title="MardiakJ , BohunickyL , ChovanecJ , SalekT , KozaI . Adjuvant clodronate therapy in patients with locally advanced breast cancer ‐ long term results of a double blind randomised trial. Neoplasma2000;47(3):177‐80. ">Mardiak 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0039" title="VanHolten‐VerzantvoortAT , HermansJ , BeexLVAM , BlijhamG , CletonFJ , VanEck‐SmitBCF , et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients?. European Journal of Cancer1996;32A(3):450‐4. ">Van‐Holten 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants scored questionnaire items on a 4‐point scale (0 = none, 3 = very severe)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At baseline, mean scores were similar across the 2 groups however pamidronate had a worse score for fatigue compared to control. At follow‐up, the mean scores were similar in the 2 groups with similar worsening over time in mobility and gastrointestinal toxicity. There was no change in bone pain and fatigue over time or between the 2 groups </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>NR</b>: not reported </p> </div> </div> </section> <section id="CD003474-sec-0146"> <h5 class="title">Adverse, drug‐related events or toxicity</h5> <p>The three studies reported very little information (<a href="#CD003474-tbl-0011">Table 8</a>; <a href="#CD003474-tbl-0012">Table 9</a>). Of the adverse events reported, bone pain appeared to be similar in both groups (<a href="./references#CD003474-bbs2-0019" title="KanisJA , PowlesT , PatersonAH , McCloskeyEV , AshleyS . Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone1996;19(6):663‐7. ">Kanis 1996</a>; <a href="./references#CD003474-bbs2-0039" title="VanHolten‐VerzantvoortAT , HermansJ , BeexLVAM , BlijhamG , CletonFJ , VanEck‐SmitBCF , et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients?. European Journal of Cancer1996;32A(3):450‐4. ">Van‐Holten 1996</a>). Fatigue was reported to be worse in the pamidronate group than placebo group in one study (<a href="./references#CD003474-bbs2-0039" title="VanHolten‐VerzantvoortAT , HermansJ , BeexLVAM , BlijhamG , CletonFJ , VanEck‐SmitBCF , et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients?. European Journal of Cancer1996;32A(3):450‐4. ">Van‐Holten 1996</a>). </p> <div class="table" id="CD003474-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Advanced breast cancer: toxicity ‐ osteonecrosis of the jaw, renal dysfunction, bone pain, drug‐related death</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Treatment vs comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Osteonecrosis of the jaw</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Renal dysfunction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Bone pain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Drug‐related death</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Additional comment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0019" title="KanisJA , PowlesT , PatersonAH , McCloskeyEV , AshleyS . Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone1996;19(6):663‐7. ">Kanis 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13<sup>a</sup>/66 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17<sup>a</sup>/67 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No hypocalcaemia observed in either group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0024" title="MardiakJ , BohunickyL , ChovanecJ , SalekT , KozaI . Adjuvant clodronate therapy in patients with locally advanced breast cancer ‐ long term results of a double blind randomised trial. Neoplasma2000;47(3):177‐80. ">Mardiak 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 participant with rash (clodronate); 2 participants with gastrointestinal toxicity (1 clodronate, 1 placebo); 1 participant with abdominal pain (placebo) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0039" title="VanHolten‐VerzantvoortAT , HermansJ , BeexLVAM , BlijhamG , CletonFJ , VanEck‐SmitBCF , et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients?. European Journal of Cancer1996;32A(3):450‐4. ">Van‐Holten 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 300 mg oral vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>"...did not change over time and there was no effect of pamidronate treatment"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 participants with gastrointestinal intolerance in pamidronate group</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>n</b> : number of events; <b>N</b> : number of women studied in each group; <b>NR</b>: not reported<br/> <sup>a</sup>Received radiotherapy for bone pain. </p> </div> </div> <div class="table" id="CD003474-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Advanced breast cancer: toxicity ‐ nausea, fatigue, fever &amp; influenza symptoms</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Treatment vs comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Nausea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fatigue</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fever</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Influenza‐type symptoms</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0019" title="KanisJA , PowlesT , PatersonAH , McCloskeyEV , AshleyS . Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone1996;19(6):663‐7. ">Kanis 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0024" title="MardiakJ , BohunickyL , ChovanecJ , SalekT , KozaI . Adjuvant clodronate therapy in patients with locally advanced breast cancer ‐ long term results of a double blind randomised trial. Neoplasma2000;47(3):177‐80. ">Mardiak 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0039" title="VanHolten‐VerzantvoortAT , HermansJ , BeexLVAM , BlijhamG , CletonFJ , VanEck‐SmitBCF , et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients?. European Journal of Cancer1996;32A(3):450‐4. ">Van‐Holten 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 300 mg oral vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scored 0.6 (worse than control arm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scored 0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>n</b> : number of events; <b>N</b> : number of women studied in each group; <b>NR</b>: not reported </p> </div> </div> </section> </section> <section id="CD003474-sec-0147"> <h4 class="title">Metastatic breast cancer and bone metastases (BCBM)</h4> <p>There were 24 studies referring to 25 treatment comparisons: 14 studies compared bisphosphonates to placebo/no bisphosphonates, four studies compared directly different types of bisphosphonates, three studies tested denosumab against intravenous bisphosphonate and four studies tested standard versus reduced frequency of bisphosphonate or denosumab. Of the 14 studies that compared bisphosphonates to placebo/no bisphosphonate, bisphosphonates were administered intravenously in six studies and orally in eight studies. The four studies that compared different bisphosphonates included intravenous pamidronate versus intravenous clodronate or oral clodronate (three‐armed studies: <a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a>; <a href="./references#CD003474-bbs2-0040" title="vonAuA , MillothE , DielI , StefanovicS , HennigsA , WallwienerM , et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open‐label, non‐inferiority phase III trial. OncoTargets and Therapy2016; Vol. 2016, issue 9:4173‐80. ">von Au 2016</a>), intravenous zoledronate versus intravenous pamidronate (<a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a>) or intravenous zoledronate versus oral ibandronate (<a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a>). One study that compared standard versus reduced frequency of bisphosphonate (<a href="./references#CD003474-bbs2-0008" title="HimelsteinAL , QinR , NovotnyPJ , SeislerDK , KhatcheressianJL , RobertsJD , et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of Clinical Oncology2015; Vol. 33, issue 15 Suppl:9501. [0732‐183X] NCT00869206 . Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. clinicaltrials.gov/ct2/show/NCT00869206 Date first received: 24 March 2009. ">CALGB‐70604 2015</a>) reported data mostly for all cancers rather than specifically for breast cancer. </p> <section id="CD003474-sec-0148"> <h5 class="title">Proportion of participants with skeletal‐related events (SREs)</h5> <section id="CD003474-sec-0149"> <h6 class="title">Bisphosphonate versus placebo/no bisphosphonate</h6> <p>Eight out of 14 studies reported the risk of developing a SRE (including hypercalcaemia). Bisphosphonates reduced the risk of an SRE compared with placebo/no bisphosphonate by 15% (RR 0.85; 95% CI 0.77 to 0.95; P = 0.003; <a href="./references#CD003474-fig-0032" title="">Analysis 3.1</a>). There were 1371 SRE events in 2193 randomised women with BCBM. There was significant heterogeneity (I<sup>2</sup> = 56%; P = 0.02). The heterogeneity was largely contributed by <a href="./references#CD003474-bbs2-0009" title="ContePF , GiannessiPG , LatreilleJ , MauriacL , KolirenL , CabresiF , et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology1994;5(Suppl 7):41‐4. ContePF , LatrielleJ , MauriacL , CalbresiF , SantosR , CamposD , et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology1996;14(9):2552‐9. ">Conte 1996</a> and <a href="./references#CD003474-bbs2-0018" title="HultbornR , GundersenS , RydenS , HolmbergE , CarstensenJ , WallgrenUB , et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double‐blind placebo‐controlled multicenter study. Anticancer Research1999;19(4C):3383‐92. ">Hultborn 1999</a> as both studies assigned a relatively low dose of pamidronate in the treatment arm; 45 mg in <a href="./references#CD003474-bbs2-0009" title="ContePF , GiannessiPG , LatreilleJ , MauriacL , KolirenL , CabresiF , et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology1994;5(Suppl 7):41‐4. ContePF , LatrielleJ , MauriacL , CalbresiF , SantosR , CamposD , et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology1996;14(9):2552‐9. ">Conte 1996</a> and 60 mg in <a href="./references#CD003474-bbs2-0018" title="HultbornR , GundersenS , RydenS , HolmbergE , CarstensenJ , WallgrenUB , et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double‐blind placebo‐controlled multicenter study. Anticancer Research1999;19(4C):3383‐92. ">Hultborn 1999</a>. By removing these two studies in a sensitivity analysis, there was minimal heterogeneity in the remaining six studies (I<sup>2</sup> = 9%; P = 0.36) and the RR was 0.80 (95% CI 0.73 to 0.87; forest plot not shown). </p> <p>Nine studies reported the risk of developing a SRE (excluding hypercalcaemia). Bisphosphonates reduced the risk of developing a SRE compared with placebo/no bisphosphonate by 14% (RR 0.86; 95% CI 0.78 to 0.95; P = 0.003; <a href="./references#CD003474-fig-0033" title="">Analysis 3.2</a>; <a href="#CD003474-fig-0009">Figure 9</a>; high‐quality evidence). There were 1489 SRE events in 2810 randomised women. There was no significant heterogeneity (I<sup>2</sup> = 45%; P = 0.07). Examining the funnel plots, it appeared that there was a paucity of negative trials with a high standard error (SE). This suggested that despite our best attempt to search for all relevant studies that examined bisphosphonate versus placebo in this setting, there may be a publication bias due to the absence of smaller negative studies. </p> <div class="figure" id="CD003474-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Breast cancer and Bone Metastases (BCBM), outcome: 1.2 Overall risk of SREs in BCBM: bisphosphonate versus control (excluding hypercalcaemia)." data-id="CD003474-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Breast cancer and Bone Metastases (BCBM), outcome: 1.2 Overall risk of SREs in BCBM: bisphosphonate versus control (excluding hypercalcaemia). </p> </div> </div> </div> </section> <section id="CD003474-sec-0150"> <h6 class="title">Intravenous bisphosphonate versus placebo/no bisphosphonate</h6> <p>Data were available from all six studies. The overall risk of developing a SRE was reduced by 17% in the intravenous bisphosphonates group compared to placebo/no bisphosphonate (RR 0.83; 95% CI 0.73 to 0.95; P = 0.006; <a href="./references#CD003474-fig-0034" title="">Analysis 3.3</a>: <a href="./references#CD003474-fig-0034" title="">Analysis 3.3</a>.1). There were 1251 SRE events in 2072 randomised women. There was significant heterogeneity (I<sup>2</sup> = 69%; P = 0.006), owing to the low‐dose pamidronate studies by <a href="./references#CD003474-bbs2-0009" title="ContePF , GiannessiPG , LatreilleJ , MauriacL , KolirenL , CabresiF , et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology1994;5(Suppl 7):41‐4. ContePF , LatrielleJ , MauriacL , CalbresiF , SantosR , CamposD , et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology1996;14(9):2552‐9. ">Conte 1996</a> and <a href="./references#CD003474-bbs2-0018" title="HultbornR , GundersenS , RydenS , HolmbergE , CarstensenJ , WallgrenUB , et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double‐blind placebo‐controlled multicenter study. Anticancer Research1999;19(4C):3383‐92. ">Hultborn 1999</a>. Apart from the three pamidronate studies (<a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a>; <a href="./references#CD003474-bbs2-0009" title="ContePF , GiannessiPG , LatreilleJ , MauriacL , KolirenL , CabresiF , et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology1994;5(Suppl 7):41‐4. ContePF , LatrielleJ , MauriacL , CalbresiF , SantosR , CamposD , et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology1996;14(9):2552‐9. ">Conte 1996</a>; <a href="./references#CD003474-bbs2-0018" title="HultbornR , GundersenS , RydenS , HolmbergE , CarstensenJ , WallgrenUB , et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double‐blind placebo‐controlled multicenter study. Anticancer Research1999;19(4C):3383‐92. ">Hultborn 1999</a>) using differing doses of pamidronate, other reasons for the observed heterogeneity may include between‐study differences in the duration of bisphosphonate treatment, participant‐ and disease‐related differences in the study populations such as timing of treatment in the women's natural history, the extent of bone metastases and the concomitant anti‐cancer treatments used in the studies. The 90 mg pamidronate dose was the registered dose for use in most parts of the world. Therefore, we used the <a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a> study alone for the analysis of individual bisphosphonates in <a href="./references#CD003474-fig-0035" title="">Analysis 3.4</a>. </p> <section id="CD003474-sec-0151"> <p><b>Intravenous zoledronate versus placebo</b></p> <p>Based on one study, intravenous zoledronic acid (4 mg) reduced the risk of developing a SRE by 41% (RR 0.59; 95% CI 0.43 to 0.82; P = 0.002; 228 participants; <a href="./references#CD003474-fig-0035" title="">Analysis 3.4</a>). </p> </section> <section id="CD003474-sec-0152"> <p><b>Intravenous pamidronate versus placebo</b></p> <p>Based on one study using 90 mg pamidronate, there was a reduced risk of developing a SRE (RR 0.78, 95% CI 0.69 to 0.88; P &lt; 0.0001; 754 participants; <a href="./references#CD003474-fig-0035" title="">Analysis 3.4</a>). </p> </section> <section id="CD003474-sec-0153"> <p><b>Intravenous ibandronate versus placebo</b></p> <p>In two studies, intravenous ibandronate (6 mg) reduced the risk of developing a SRE by 20% (RR 0.80; 95% CI 0.67 to 0.96; P = 0.01; 462 participants; <a href="./references#CD003474-fig-0035" title="">Analysis 3.4</a>). There was no heterogeneity. </p> </section> </section> <section id="CD003474-sec-0154"> <h6 class="title">Oral bisphosphonate versus placebo/no bisphosphonate</h6> <p>Data were available from five out of the eight studies. Overall, oral bisphosphonates reduced the risk of SREs by 16% compared to placebo/no bisphosphonate (RR 0.84, 95% CI 0.76 to 0.93; P = 0.0007; <a href="./references#CD003474-fig-0034" title="">Analysis 3.3</a>: <a href="./references#CD003474-fig-0013" title="">Analysis 1.3</a>.2). There was no heterogeneity. In total, there were 639 SRE events in 1147 women randomised. </p> <section id="CD003474-sec-0155"> <p><b>Oral clodronate versus placebo/no bisphosphonate</b></p> <p>In the three studies using oral clodronate (1600 mg), clodronate appeared to reduce the risk of developing an SRE by 18% (RR 0.82, 95% CI 0.71 to 0.96; P = 0.01; 422 participants; <a href="./references#CD003474-fig-0035" title="">Analysis 3.4</a>) and there was no heterogeneity. </p> </section> <section id="CD003474-sec-0156"> <p><b>Oral ibandronate versus placebo</b></p> <p>Based on one study, developing an SRE did not differ between oral ibandronate (50 mg) and placebo (RR 0.86, 95% CI 0.73 to 1.02; P = 0.09; 564 participants; <a href="./references#CD003474-fig-0035" title="">Analysis 3.4</a>). </p> </section> <section id="CD003474-sec-0157"> <p><b>Oral pamidronate versus no bisphosphonate</b></p> <p>Based on one study, there was no significant difference in the risk of development a SRE between oral pamidronate (300 mg a day) and no bisphosphonate (RR 0.86, 95% CI 0.70 to 1.05; P = 0.14; 161 participants; <a href="./references#CD003474-fig-0035" title="">Analysis 3.4</a>). </p> <p>Due to the difference in treatment populations between studies (in terms of participant characteristics, tumour characteristics and other treatments), we avoided direct comparisons of the RR reduction between each bisphosphonate. </p> </section> </section> <section id="CD003474-sec-0158"> <h6 class="title">Direct comparisons of different bisphosphonate regimens</h6> <p><a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a> compared oral ibandronate (50 mg daily) and intravenous zoledronate (4 mg every three to four weeks over 96 weeks) in a non‐inferiority trial and involved 1404 randomised women. Annual rates of SREs were 0.499 (95% CI 0.454 to 0.549) with ibandronate and 0.435 (95% CI 0.393 to 0.480) with zoledronate. The rate ratio for SREs was 1.148 (95% CI 0.967 to 1.362), the upper CI exceeded the pre‐defined margin of non‐inferiority of 1.08. </p> <p><a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a>, a three‐arm study, compared intravenous zoledronate (4 mg or 8 mg) and intravenous pamidronate (90 mg) (every three to four weeks for 24 months) using a non‐inferiority design and involved 1130 women with breast cancer. In the analysis comparing intravenous zoledronate (4 mg) and pamidronate (90 mg), there was no difference in the proportion of women developing a SRE (excluding hypercalcaemia): 46% (zoledronate (4 mg)) and 49% (pamidronate (90 mg). There was no significant difference seen in the time to first SRE or skeletal morbidity rate (events per year). Within the lytic metastases subgroup in the study (47% of participants), zoledronate produced a significant prolongation of time to first SRE (310 versus 174 days; P = 0.013), a significant reduction in skeletal morbidity rate (1.2 versus 2.4 events; P = 0.008) and a significant reduction in the SRE rate of 30% (P = 0.010). </p> <p><a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a>, a three‐arm study, compared intravenous pamidronate (60 mg) and clodronate (oral 2400 mg and intravenous 900 mg). At interim analysis, fewer women were reported to have vertebral fractures with oral clodronate (2400 mg; 11 out of 112) than with intravenous clodronate (900 mg; 25 out of 103) or intravenous pamidronate (60 mg; 26 out of 103). However, <a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a> has not been published in full and the endpoint of fracture rate was not the same as the SRE, therefore we have not included the results from this study. </p> <p><a href="./references#CD003474-bbs2-0040" title="vonAuA , MillothE , DielI , StefanovicS , HennigsA , WallwienerM , et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open‐label, non‐inferiority phase III trial. OncoTargets and Therapy2016; Vol. 2016, issue 9:4173‐80. ">von Au 2016</a>, a three‐arm study, compared intravenous pamidronate (60 mg) and clodronate (oral 2400 mg and intravenous 900 mg). The secondary endpoint, pathologic fractures, indicated a trend to increased pathologic fractures with oral clodronate (18%; 19 out of 107 women) compared to intravenous pamidronate (7%; 8 out of 109 women) or intravenous clodronate (14%; 8 out of 105 women). </p> </section> <section id="CD003474-sec-0159"> <h6 class="title">Denosumab versus bisphosphonate</h6> <p>Three RCTs compared denosumab with zoledronate in women with BCBM (<a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a> (denosumab 180 mg every four weeks versus intravenous bisphosphonate); <a href="./references#CD003474-bbs2-0023" title="LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clinical Cancer Research2008;14(20):6690‐6. LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Randomized active‐controlled phase II study of denosumab efficacy and safety in patients with breast cancer‐related bone metastases. Journal of Clinical Oncology2007;25(28):4431‐7. ">Lipton 2008;</a><a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a>) and included 2345 women with advanced BCBM. Denosumab reduced the risk of developing a SRE compared with bisphosphonates by 22% (RR 0.78; 95% CI 0.72 to 0.85; P &lt; 0.00001; <a href="./references#CD003474-fig-0036" title="">Analysis 3.5</a>; <a href="#CD003474-fig-0010">Figure 10</a>). There was no heterogeneity. Both <a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a> and <a href="./references#CD003474-bbs2-0023" title="LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clinical Cancer Research2008;14(20):6690‐6. LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Randomized active‐controlled phase II study of denosumab efficacy and safety in patients with breast cancer‐related bone metastases. Journal of Clinical Oncology2007;25(28):4431‐7. ">Lipton 2008</a> compared a range of denosumab regimens to the clinician's choice of bisphosphonate. <a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a> was a second‐line study that enrolled patients with breast cancer, prostate cancer and multiple myeloma after unsuccessful treatment with bisphosphonates. Separate outcomes for the breast cancer subgroup (40% of the treatment population; 46 women) were kindly made available by the study sponsors upon enquiry. </p> <div class="figure" id="CD003474-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Breast cancer with bone metastases (BCBM), outcome: 1.3 Overall risk of skeletal events in BCBM: denosumab versus bisphosphonate" data-id="CD003474-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Breast cancer with bone metastases (BCBM), outcome: 1.3 Overall risk of skeletal events in BCBM: denosumab versus bisphosphonate </p> </div> </div> </div> </section> <section id="CD003474-sec-0160"> <h6 class="title">Standard versus reduced frequency bisphosphonate/bone agent</h6> <p>Three RCTs (<a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a>; <a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a>; <a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a>), examined standard versus reduced frequency of bisphosphonates/bone agents on the risk of developing SREs and there appeared to be no significant difference in risk (RR 0.96, 95% CI 0.72 to 1.26; P = 0.75; <a href="./references#CD003474-fig-0037" title="">Analysis 3.6</a>). There were 161 events in 901 randomised women, and no heterogeneity. In <a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a>, the primary outcome was SRE morbidity rate (SRE per patient per year). The reduced‐frequency bisphosphonate group (every 12 weeks) had a SRE morbidity rate of 0.26 (95% CI 0.15 to 0.37) compared to the standard‐frequency group of 0.22 (95% 0.14 to 0.29). The between‐group difference was 0.04 and the upper limit of one‐tailed 97.5% CI was 0.17, within the pre‐specified non‐inferiority margin (0.19). The data should be interpreted with caution as the study was hampered by a lower event rate than anticipated and potentially under‐powered; the short, 12‐month follow‐up may be inadequate to capture cumulative differences in efficacy and a rise in bone‐turnover markers among the reduced‐frequency group. An additional study, <a href="./references#CD003474-bbs2-0008" title="HimelsteinAL , QinR , NovotnyPJ , SeislerDK , KhatcheressianJL , RobertsJD , et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of Clinical Oncology2015; Vol. 33, issue 15 Suppl:9501. [0732‐183X] NCT00869206 . Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. clinicaltrials.gov/ct2/show/NCT00869206 Date first received: 24 March 2009. ">CALGB‐70604 2015</a>, reported the proportion of participants in each group who had more than one SRE. In participants with breast cancer (820 out of 1822 participants), there were 113 SREs in those women receiving zoledronate intravenously every four weeks and 119 SREs in those receiving zoledronate every 12 weeks (P = 0.43). The denominators were not reported in the abstract so these data could not be included in <a href="./references#CD003474-fig-0037" title="">Analysis 3.6</a>. </p> </section> </section> <section id="CD003474-sec-0161"> <h5 class="title">Skeletal‐related event rate</h5> <p>The overall SRE rate was reported in 16 of the 25 treatment comparisons (<a href="#CD003474-tbl-0013">Table 10</a>). We did not include data from <a href="./references#CD003474-bbs2-0025" title="MartoniA , GuaraldiM , CameraP , BiagiR , MarriS , BegheF , et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology1991;48(2):97‐101. ">Martoni 1991</a> because follow‐up imaging was incomplete for many participants. SREs were reported differently across studies and the data were summarised rather than formally combined. </p> <div class="table" id="CD003474-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Breast cancer with bone metastases: skeletal‐related event rate</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>No. of skeletal‐related events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Ratio: Bisphosphonate/comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bisphosphonate vs placebo/open</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a><br/> (N = 751) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 90 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4<br/> Event rate = mean no. of events/year </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0006" title="BodyJJ , DielIJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology2003;14(9):1399‐405. BodyJJ , LichinitserMR , DiehlI , SchlosserK , PfarrE , CavalliF , et al. Double‐blind placebo‐controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. DielIJ , BodyJJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Improved quality of life after long‐term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer2004;40(11):1704‐12. LyubimovaN , KushlinkskyNE , LichinitserMR . Long‐term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease. 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003. New York: Supportive Care in Cancer, 2003. ">Body 2003</a> </p> <p>(N = 312)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56<br/> Event rate = events/patient year </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0007" title="BodyJJ , DielI , BellR , PecherstorferM , LichinitserM , LazarevA , et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111(3):306‐12. BodyJJ , DielIJ , LichinitzerM , LazarevA , PecherstorferM , BellR , et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo‐controlled phase III studies. British Journal of Cancer2004;90(6):1133‐7. ">Body 2004</a><br/> (N = 564) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99<br/> Rate assessed using SMPR; pooled results of 50 mg ibandronate versus placebo from studies MF4434 and MF4414 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.041</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0009" title="ContePF , GiannessiPG , LatreilleJ , MauriacL , KolirenL , CabresiF , et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology1994;5(Suppl 7):41‐4. ContePF , LatrielleJ , MauriacL , CalbresiF , SantosR , CamposD , et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology1996;14(9):2552‐9. ">Conte 1996</a><br/> (N = 224) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 45 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135<br/> Event rate = total events per arm </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0012" title="ElomaaI , BlomqvistC , GrohnP , PorkkaL , KairentoA‐L , SelanderK , et al. Long‐term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet1983;1(8317):146‐9. ElomaaI , BlomqvistC , Porkka , HoltstromT , TaubeT , Lamberg‐AllardtC , et al. Clodronate for osteolytic metastases due to breast cancer. Biomedicine and Pharmacotherapy1988;42(2):111‐6. ElommaI , BlomqvistL , PorkkaL , Lamberg‐AllardtC , BorgstromGH . Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone1987;8(Suppl 1):53‐6. ">Elomaa 1983</a><br/> (N = 34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0016" title="HerasP , HatzopoulosA , MitsibounasD . Efficacy of ibandronate for the prevention of skeletal‐related events in breast cancer patients with metastatic bone disease. European Journal of Cancer2005;3(2):121. HerasP , KritikosK , HatzopoulosA , GeorgopoulouAP . Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. European Journal of Cancer Care2009;18(6):653‐6. ">Heras 2009</a><br/> (N = 150) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0018" title="HultbornR , GundersenS , RydenS , HolmbergE , CarstensenJ , WallgrenUB , et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double‐blind placebo‐controlled multicenter study. Anticancer Research1999;19(4C):3383‐92. ">Hultborn 1999</a><br/> (N = 404) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98</p> <p>Event rate = cumulative events/follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0020" title="KohnoN , AogiK , MinamiH , NakamuraS , AsagaT , IinoY , et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo‐controlled trial. Journal of Clinical Oncology2005;23(15):3314‐21. ">Kohno 2005</a><br/> (N = 227) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63<br/> Event rate = events per year </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.016</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0021" title="KristensenB , EjlertsenB , GroenvoldM , HeinS , LoftH , MouridsenHT . Oral clodronate in breast cancer patients with bone metastases: a randomised study. Journal of Internal Medicine1999;246(1):67‐74. ">Kristensen 1999</a><br/> (N = 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral, 2/d for 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4<br/> Event rate = cumulative proportion of skeletal events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0025" title="MartoniA , GuaraldiM , CameraP , BiagiR , MarriS , BegheF , et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology1991;48(2):97‐101. ">Martoni 1991</a><br/> (N = 38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 300 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0029" title="PatersonAHG , KanisJA , PowlesTJ , McCloskeyEV , ArchabaultWT , KurmanMR , et al. A re‐analysis of a trial of clodronate in patients with breast cancer and bone metastases. Anthra Pharmaceuticals. PatersonAHG , PowlesTJ , KanisJA , McCloskeyE , HansonJ , AshleyS . Double‐blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(1):59‐65. ">Paterson 1993</a><br/> (N = 173) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral, 2/d for up to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>218.6<br/> Event rate = cumulative proportion of skeletal events per 100 patient‐years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>304.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0036" title="TripathyD , LichinitzerM , LazarevA , MacLachianA , ApffelstaedtJ , BuddeM , et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomised, double‐blind, placebo‐controlled trial. Annals of Oncology2004;15(5):743‐50. ">Tripathy 2004</a><br/> (N = 287) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98<br/> Rate assessed using SMPR; refers only to the results of the 50 mg ibandronate arm versus placebo within study MF4434 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.037</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0037" title="Tubiana‐HulinM , BeuzebocP , MauriacL , BarbetN , FrenayM , MonnierA , et al. Double‐blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bulletin du Cancer2001;88(7):701‐7. ">Tubiana‐Hulin 2001</a><br/> (N = 144) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<br/> "No difference between groups" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0038" title="CletonFJ , VanHolten‐VerzantvoortAT , BijvoetOLM . Effect of long‐term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results in Cancer Research. Vol. 116, Berlin‐Heidelberg: Springer‐Verlag, 1989:73‐8. VanHolten‐VaerzantvoortATM , KroonHM , BijvoetOLM , CletonFJ , BeexLVAM , BlijhamG , et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(3):491‐8. VanHolten‐VerzantvoortAT , BijvoetOLM , CletonFJ , HermansJ , KroonHM , HarinckHIJ , et al. Reduced morbidity from skeletal metastases in breast cancer patients during long‐term bisphosphonate (APD) treatment. Lancet1987;330(8566):983‐5. VanHolten‐VerzantvoortATM , ZwindermanAH , AaronsonNK , HermansJ , VanEmmerikB , VanDamFSAM , et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. European Journal of Cancer1991;27(5):544‐9. ">Van‐Holten 1987</a><br/> (N = 161) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 150 mg oral, 2/d indefinitely</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90<br/> Event rate = total number of events. Events = "complications" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.003</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Direct comparisons of different bisphosphonate regimens</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a> </p> <p>(N = 318)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 2400 mg oral or 900 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> <p>Event = number of people with fractures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate oral = 11</p> <p>Clodronate iv = 19</p> <p>Event = number of people with fractures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a><br/> (N = 1130) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 90 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.037</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0040" title="vonAuA , MillothE , DielI , StefanovicS , HennigsA , WallwienerM , et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open‐label, non‐inferiority phase III trial. OncoTargets and Therapy2016; Vol. 2016, issue 9:4173‐80. ">von Au 2016</a><br/> (N = 375) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 900 mg iv every 3 weeks or 2400 mg/d oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3%<br/> Event rate = fracture rate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.3% or 17.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.07 (pamidronate versus clodronate oral)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a><br/> (N = 1404) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.507<br/> Event rate = annual rate of SRE </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.035</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bone‐targeted agents vs bisphosphonate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a><br/> (N = 44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate iv (clinician choice)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0023" title="LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clinical Cancer Research2008;14(20):6690‐6. LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Randomized active‐controlled phase II study of denosumab efficacy and safety in patients with breast cancer‐related bone metastases. Journal of Clinical Oncology2007;25(28):4431‐7. ">Lipton 2008</a><br/> (N = 255) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab sc every 4 weeks (30 mg, 120 mg or 180 mg) or every 12 weeks (60 mg or 180 mg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate iv (either zoledronate, pamidronate or ibandronate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a> </p> <p>(N = 2046)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 120 mg sc (iv placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv (sc placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58<br/> Event rate assessed using SMPR, defined as the ratio of the number of SREs per participant divided by the participant’s time at risk. An exploratory endpoint </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.004</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Standard vs reduced bisphosphonate/bone agent</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0008" title="HimelsteinAL , QinR , NovotnyPJ , SeislerDK , KhatcheressianJL , RobertsJD , et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of Clinical Oncology2015; Vol. 33, issue 15 Suppl:9501. [0732‐183X] NCT00869206 . Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. clinicaltrials.gov/ct2/show/NCT00869206 Date first received: 24 March 2009. ">CALGB‐70604 2015</a><br/> (N = 820) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a><br/> (N = 73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a> </p> <p>(N = 403)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46<br/> Event rate assessed using SMR, defined as the number of events per year </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a><br/> (N = 425) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22</p> <p>Event rate = skeletal morbidity rate (SRE/patient/year)</p> <p>Non‐inferiority not demonstrated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>iv</b> : intravenous; <b>N</b> : total number of women in each study; <b>NR</b> : not reported; <b>sc</b> : subcutaneous; <b>SMPR</b> : skeletal morbidity period rate; <b>SRE</b>: skeletal related event </p> </div> </div> <p>The SRE rate was lower with bisphosphonates compared to placebo in 10 studies (median reduction of 28%; range from 14% to 48%), with statistically significant reductions reported in eight studies. In <a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a>, the skeletal morbidity rate (events per year, excluding hypercalcaemia) for the 4 mg zoledronate arm was 0.9 compared with 1.49 for the 90 mg pamidronate arm (P = 0.125). Multiple‐event analysis, using the method of Andersen‐Gill (<a href="./references#CD003474-bbs2-0085" title="AndersenPK , GillRD . Cox's regression model for counting processes: a large sample study. Annals of Statistics1982;10(4):1100‐20. ">Andersen 1982</a>), was reported to show a reduction in the risk of developing any skeletal complication (including hypercalcaemia) by 20% (zoledronate (4 mg) compared with pamidronate (90 mg), RR = 0.80, 95% CI 0.66 to 0.97; P = 0.025), suggesting a possible advantage of zoledronate (4 mg) compared with pamidronate (90 mg). In <a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a>, denosumab was superior to zoledronate in reducing the mean skeletal morbidity rate (RR 0.78, denosumab: 0.45 events; zoledronate: 0.58 events per participant per year; P = 0.004). This study defined the mean skeletal morbidity rate as "the ratio of the number of SREs per patient divided by the patient’s time at risk". </p> <p>Overall, the results were largely concordant with the findings in the analysis of the proportion of women with SREs (<a href="./references#CD003474-fig-0033" title="">Analysis 3.2</a>). </p> </section> <section id="CD003474-sec-0162"> <h5 class="title">Median time to skeletal‐related event</h5> <p>Data were available from 14 out of 25 treatment comparisons. All results are presented in <a href="#CD003474-tbl-0014">Table 11</a>. </p> <div class="table" id="CD003474-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Breast cancer with bone metastases: median time to skeletal‐related event</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Median time to event (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Ratio: bisphosphonate/comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bisphosphonate vs placebo/open</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a><br/> (N = 751) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 90 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0006" title="BodyJJ , DielIJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology2003;14(9):1399‐405. BodyJJ , LichinitserMR , DiehlI , SchlosserK , PfarrE , CavalliF , et al. Double‐blind placebo‐controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. DielIJ , BodyJJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Improved quality of life after long‐term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer2004;40(11):1704‐12. LyubimovaN , KushlinkskyNE , LichinitserMR . Long‐term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease. 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003. New York: Supportive Care in Cancer, 2003. ">Body 2003</a> </p> <p>(N = 312)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.018</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0007" title="BodyJJ , DielI , BellR , PecherstorferM , LichinitserM , LazarevA , et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111(3):306‐12. BodyJJ , DielIJ , LichinitzerM , LazarevA , PecherstorferM , BellR , et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo‐controlled phase III studies. British Journal of Cancer2004;90(6):1133‐7. ">Body 2004</a><br/> (N = 564) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.8<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.9<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.089</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0009" title="ContePF , GiannessiPG , LatreilleJ , MauriacL , KolirenL , CabresiF , et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology1994;5(Suppl 7):41‐4. ContePF , LatrielleJ , MauriacL , CalbresiF , SantosR , CamposD , et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology1996;14(9):2552‐9. ">Conte 1996</a><br/> (N = 224) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 45 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0012" title="ElomaaI , BlomqvistC , GrohnP , PorkkaL , KairentoA‐L , SelanderK , et al. Long‐term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet1983;1(8317):146‐9. ElomaaI , BlomqvistC , Porkka , HoltstromT , TaubeT , Lamberg‐AllardtC , et al. Clodronate for osteolytic metastases due to breast cancer. Biomedicine and Pharmacotherapy1988;42(2):111‐6. ElommaI , BlomqvistL , PorkkaL , Lamberg‐AllardtC , BorgstromGH . Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone1987;8(Suppl 1):53‐6. ">Elomaa 1983</a><br/> (N = 34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0016" title="HerasP , HatzopoulosA , MitsibounasD . Efficacy of ibandronate for the prevention of skeletal‐related events in breast cancer patients with metastatic bone disease. European Journal of Cancer2005;3(2):121. HerasP , KritikosK , HatzopoulosA , GeorgopoulouAP . Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. European Journal of Cancer Care2009;18(6):653‐6. ">Heras 2009</a><br/> (N = 150) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.2<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.1<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.007</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0018" title="HultbornR , GundersenS , RydenS , HolmbergE , CarstensenJ , WallgrenUB , et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double‐blind placebo‐controlled multicenter study. Anticancer Research1999;19(4C):3383‐92. ">Hultborn 1999</a><br/> (N = 404) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.006</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0020" title="KohnoN , AogiK , MinamiH , NakamuraS , AsagaT , IinoY , et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo‐controlled trial. Journal of Clinical Oncology2005;23(15):3314‐21. ">Kohno 2005</a><br/> (N = 228) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12^</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<br/> The median time to first SRE was not reached in the zoledronic acid arm, versus 364 days in the placebo arm </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.007</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0021" title="KristensenB , EjlertsenB , GroenvoldM , HeinS , LoftH , MouridsenHT . Oral clodronate in breast cancer patients with bone metastases: a randomised study. Journal of Internal Medicine1999;246(1):67‐74. ">Kristensen 1999</a><br/> (N = 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral, 2/d for 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<br/> Time to skeletal event delayed with clodronate according to Kaplan‐Meier curves </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.015</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0025" title="MartoniA , GuaraldiM , CameraP , BiagiR , MarriS , BegheF , et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology1991;48(2):97‐101. ">Martoni 1991</a><br/> (N = 38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 300 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0029" title="PatersonAHG , KanisJA , PowlesTJ , McCloskeyEV , ArchabaultWT , KurmanMR , et al. A re‐analysis of a trial of clodronate in patients with breast cancer and bone metastases. Anthra Pharmaceuticals. PatersonAHG , PowlesTJ , KanisJA , McCloskeyE , HansonJ , AshleyS . Double‐blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(1):59‐65. ">Paterson 1993</a><br/> (N = 173) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral, 2/d for up to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.022</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0036" title="TripathyD , LichinitzerM , LazarevA , MacLachianA , ApffelstaedtJ , BuddeM , et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomised, double‐blind, placebo‐controlled trial. Annals of Oncology2004;15(5):743‐50. ">Tripathy 2004</a><br/> (N = 287) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.5<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.1<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0037" title="Tubiana‐HulinM , BeuzebocP , MauriacL , BarbetN , FrenayM , MonnierA , et al. Double‐blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bulletin du Cancer2001;88(7):701‐7. ">Tubiana‐Hulin 2001</a><br/> (N = 144) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0038" title="CletonFJ , VanHolten‐VerzantvoortAT , BijvoetOLM . Effect of long‐term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results in Cancer Research. Vol. 116, Berlin‐Heidelberg: Springer‐Verlag, 1989:73‐8. VanHolten‐VaerzantvoortATM , KroonHM , BijvoetOLM , CletonFJ , BeexLVAM , BlijhamG , et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(3):491‐8. VanHolten‐VerzantvoortAT , BijvoetOLM , CletonFJ , HermansJ , KroonHM , HarinckHIJ , et al. Reduced morbidity from skeletal metastases in breast cancer patients during long‐term bisphosphonate (APD) treatment. Lancet1987;330(8566):983‐5. VanHolten‐VerzantvoortATM , ZwindermanAH , AaronsonNK , HermansJ , VanEmmerikB , VanDamFSAM , et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. European Journal of Cancer1991;27(5):544‐9. ">Van‐Holten 1987</a><br/> (N = 161) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 150 mg oral, 2/d indefinitely</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Direct comparisons of different bisphosphonate regimens</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a> </p> <p>(N = 318)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 2400 mg oral or 900 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a><br/> (N = 1130) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 90 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.013</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0040" title="vonAuA , MillothE , DielI , StefanovicS , HennigsA , WallwienerM , et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open‐label, non‐inferiority phase III trial. OncoTargets and Therapy2016; Vol. 2016, issue 9:4173‐80. ">von Au 2016</a><br/> (N = 375) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 900 mg iv every 3 weeks or 2400 mg/d oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a><br/> (N = 1404) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.4<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.9<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.034</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bone‐targeted agents vs bisphosphonate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a><br/> (N = 44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate iv (clinician choice)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0023" title="LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clinical Cancer Research2008;14(20):6690‐6. LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Randomized active‐controlled phase II study of denosumab efficacy and safety in patients with breast cancer‐related bone metastases. Journal of Clinical Oncology2007;25(28):4431‐7. ">Lipton 2008</a><br/> (N = 255) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab sc every 4 weeks (30 mg, 120 mg or 180 mg) or every 12 weeks (60 mg or 180 mg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate iv (either zoledronate, pamidronate or ibandronate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a> </p> <p>(N = 2046)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 120 mg sc (iv placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv (sc placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not yet reached</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Standard vs reduced bisphosphonate/bone agent</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0008" title="HimelsteinAL , QinR , NovotnyPJ , SeislerDK , KhatcheressianJL , RobertsJD , et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of Clinical Oncology2015; Vol. 33, issue 15 Suppl:9501. [0732‐183X] NCT00869206 . Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. clinicaltrials.gov/ct2/show/NCT00869206 Date first received: 24 March 2009. ">CALGB‐70604 2015</a><br/> (N = 820) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a><br/> (N = 73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a> </p> <p>(N = 403)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<br/> "Median time to first SRE was not estimable because there were too few events to calculate the median" (clinical trials registry record) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a><br/> (N = 425) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<br/> "Median time to first on‐study skeletal‐related event could not be calculated because of the very low event rate." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>iv</b> : intravenous; <b>N</b> : total number of women in each study; <b>NR</b> : not reported; <b>NS</b> : not significant; <b>sc</b> : subcutaneous; <b>SMPR</b> : skeletal morbidity period rate; <b>SRE</b>: skeletal‐related event.<br/> <sup>a</sup>We converted data from weeks or days into months.<br/> <sup>b</sup>Trial authors did not provided numerical value for median TSE of control and treatment groups. </p> </div> </div> <p>Twelve studies compared bisphosphonates to placebo. Bisphosphonates delayed the median time to an SRE with a median ratio of 1.43 (95% CI 1.29 to 1.58; P = &lt; 0.00001, 9 studies, 2891 participants, no heterogeneity; <a href="./references#CD003474-fig-0038" title="">Analysis 3.7</a>). Three of the 12 studies did not report sufficient data to calculate the median time to an SRE (i.e. no P value reported or an SRE was not reached) but two of these three studies reported results in favour of bisphosphonates. Further details are presented in <a href="#CD003474-tbl-0014">Table 11</a>. In general, in 11 out of 12 studies, the median time to an SRE in the bisphosphonates group ranged from 8.7 months to 20.8 months and in the placebo group ranged from 4.9 months to 14.9 months. Three studies of intravenous pamidronate showed significant delays in the median time to a SRE compared with placebo/no bisphosphonate (<a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a>; <a href="./references#CD003474-bbs2-0009" title="ContePF , GiannessiPG , LatreilleJ , MauriacL , KolirenL , CabresiF , et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology1994;5(Suppl 7):41‐4. ContePF , LatrielleJ , MauriacL , CalbresiF , SantosR , CamposD , et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology1996;14(9):2552‐9. ">Conte 1996</a>; <a href="./references#CD003474-bbs2-0018" title="HultbornR , GundersenS , RydenS , HolmbergE , CarstensenJ , WallgrenUB , et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double‐blind placebo‐controlled multicenter study. Anticancer Research1999;19(4C):3383‐92. ">Hultborn 1999</a>). Event‐free survival was also reported to be longer with intravenous ibandronate (6 mg) than with placebo (<a href="./references#CD003474-bbs2-0006" title="BodyJJ , DielIJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology2003;14(9):1399‐405. BodyJJ , LichinitserMR , DiehlI , SchlosserK , PfarrE , CavalliF , et al. Double‐blind placebo‐controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. DielIJ , BodyJJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Improved quality of life after long‐term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer2004;40(11):1704‐12. LyubimovaN , KushlinkskyNE , LichinitserMR . Long‐term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease. 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003. New York: Supportive Care in Cancer, 2003. ">Body 2003</a>, T/C (treatment/control) 1.34; P = 0.018; <a href="./references#CD003474-bbs2-0016" title="HerasP , HatzopoulosA , MitsibounasD . Efficacy of ibandronate for the prevention of skeletal‐related events in breast cancer patients with metastatic bone disease. European Journal of Cancer2005;3(2):121. HerasP , KritikosK , HatzopoulosA , GeorgopoulouAP . Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. European Journal of Cancer Care2009;18(6):653‐6. ">Heras 2009</a>, T/C 1.50; P = 0.007). Three studies of oral clodronate reported a statistically significant delay in the time to a SRE (<a href="./references#CD003474-bbs2-0021" title="KristensenB , EjlertsenB , GroenvoldM , HeinS , LoftH , MouridsenHT . Oral clodronate in breast cancer patients with bone metastases: a randomised study. Journal of Internal Medicine1999;246(1):67‐74. ">Kristensen 1999</a>; <a href="./references#CD003474-bbs2-0029" title="PatersonAHG , KanisJA , PowlesTJ , McCloskeyEV , ArchabaultWT , KurmanMR , et al. A re‐analysis of a trial of clodronate in patients with breast cancer and bone metastases. Anthra Pharmaceuticals. PatersonAHG , PowlesTJ , KanisJA , McCloskeyE , HansonJ , AshleyS . Double‐blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(1):59‐65. ">Paterson 1993</a>; <a href="./references#CD003474-bbs2-0037" title="Tubiana‐HulinM , BeuzebocP , MauriacL , BarbetN , FrenayM , MonnierA , et al. Double‐blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bulletin du Cancer2001;88(7):701‐7. ">Tubiana‐Hulin 2001</a>). One study of intravenous zoledronate demonstrated significant improvement in median time to a SRE (<a href="./references#CD003474-bbs2-0020" title="KohnoN , AogiK , MinamiH , NakamuraS , AsagaT , IinoY , et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo‐controlled trial. Journal of Clinical Oncology2005;23(15):3314‐21. ">Kohno 2005</a>). Overall, we rated the quality of evidence as high. </p> <p>One study, <a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a>, reported no significant difference in the time to a SRE between intravenous zoledronate and intravenous pamidronate in the overall breast cancer study population in the single comparison study (<a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a>). However, as described previously, in the subgroup of participants with lytic‐only metastases, 4 mg zoledronate significantly prolonged the median time to the first SRE compared with 90 mg pamidronate (median, 310 days versus 174 days respectively; P = 0.013; <a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a>). Similarly, in the breast‐cancer subgroup treated with hormonal therapy, 4 mg zoledronate significantly prolonged the median time to the first SRE compared with 90 mg pamidronate (median, 415 days versus 370 days respectively; P = 0.047). </p> <p>One study reported that denosumab significantly improved median time to a SRE compared to zoledronate (<a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a>). </p> </section> <section id="CD003474-sec-0163"> <h5 class="title">Overall survival</h5> <section id="CD003474-sec-0164"> <h6 class="title">Bisphosphonate versus placebo/no bisphosphonate</h6> <p>Data were available from seven out of the 14 studies comparing bisphosphonates and placebo/no bisphosphonate. Overall, there was no significant difference in overall survival between two groups (RR 1.01; 95% CI 0.91 to 1.11; P = 0.85; <a href="./references#CD003474-fig-0039" title="">Analysis 3.8</a>; with some heterogeneity: I<sup>2</sup> = 49%, P = 0.07; moderate‐quality evidence). There were 1111 deaths in 1935 randomised women. </p> </section> <section id="CD003474-sec-0165"> <h6 class="title">Direct comparisons of different bisphosphonate regimens</h6> <p>Data from studies directly comparing different bisphosphonates were sparse with only one out of four studies reporting overall survival (<a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a>). <a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a> compared oral ibandronate 50 mg and intravenous zoledronate 4 mg, and observed no significant difference in survival between the groups (HR 1.086, 95% CI 0.948 to 1.245, P = 0.24). There were 831 deaths in 1401 randomised women. </p> </section> <section id="CD003474-sec-0166"> <h6 class="title">Denosumab versus bisphosphonate</h6> <p>Only one study (<a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a>) out of three studies comparing denosumab to a bisphosphonate reported overall survival. <a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a> observed no difference in survival between denosumab and zoledronate (P = 0.49; <a href="#CD003474-tbl-0015">Table 12</a>). </p> <div class="table" id="CD003474-tbl-0015"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Breast cancer with bone metastases: median survival time</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Median survival (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Ratio: bisphosphonate/comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bisphosphonate vs placebo/open</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a><br/> (N = 751) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 90 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0006" title="BodyJJ , DielIJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology2003;14(9):1399‐405. BodyJJ , LichinitserMR , DiehlI , SchlosserK , PfarrE , CavalliF , et al. Double‐blind placebo‐controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. DielIJ , BodyJJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Improved quality of life after long‐term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer2004;40(11):1704‐12. LyubimovaN , KushlinkskyNE , LichinitserMR . Long‐term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease. 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003. New York: Supportive Care in Cancer, 2003. ">Body 2003</a> </p> <p>(N = 312)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.3<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.7<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0007" title="BodyJJ , DielI , BellR , PecherstorferM , LichinitserM , LazarevA , et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111(3):306‐12. BodyJJ , DielIJ , LichinitzerM , LazarevA , PecherstorferM , BellR , et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo‐controlled phase III studies. British Journal of Cancer2004;90(6):1133‐7. ">Body 2004</a><br/> (N = 564) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0009" title="ContePF , GiannessiPG , LatreilleJ , MauriacL , KolirenL , CabresiF , et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology1994;5(Suppl 7):41‐4. ContePF , LatrielleJ , MauriacL , CalbresiF , SantosR , CamposD , et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology1996;14(9):2552‐9. ">Conte 1996</a><br/> (N = 295) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 45 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0012" title="ElomaaI , BlomqvistC , GrohnP , PorkkaL , KairentoA‐L , SelanderK , et al. Long‐term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet1983;1(8317):146‐9. ElomaaI , BlomqvistC , Porkka , HoltstromT , TaubeT , Lamberg‐AllardtC , et al. Clodronate for osteolytic metastases due to breast cancer. Biomedicine and Pharmacotherapy1988;42(2):111‐6. ElommaI , BlomqvistL , PorkkaL , Lamberg‐AllardtC , BorgstromGH . Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone1987;8(Suppl 1):53‐6. ">Elomaa 1983</a><br/> (N = 34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.004</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0016" title="HerasP , HatzopoulosA , MitsibounasD . Efficacy of ibandronate for the prevention of skeletal‐related events in breast cancer patients with metastatic bone disease. European Journal of Cancer2005;3(2):121. HerasP , KritikosK , HatzopoulosA , GeorgopoulouAP . Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. European Journal of Cancer Care2009;18(6):653‐6. ">Heras 2009</a><br/> (N = 150) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0018" title="HultbornR , GundersenS , RydenS , HolmbergE , CarstensenJ , WallgrenUB , et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double‐blind placebo‐controlled multicenter study. Anticancer Research1999;19(4C):3383‐92. ">Hultborn 1999</a><br/> (N = 404) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0020" title="KohnoN , AogiK , MinamiH , NakamuraS , AsagaT , IinoY , et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo‐controlled trial. Journal of Clinical Oncology2005;23(15):3314‐21. ">Kohno 2005</a><br/> (N = 228) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0021" title="KristensenB , EjlertsenB , GroenvoldM , HeinS , LoftH , MouridsenHT . Oral clodronate in breast cancer patients with bone metastases: a randomised study. Journal of Internal Medicine1999;246(1):67‐74. ">Kristensen 1999</a><br/> (N = 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral, 2/d for 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0025" title="MartoniA , GuaraldiM , CameraP , BiagiR , MarriS , BegheF , et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology1991;48(2):97‐101. ">Martoni 1991</a><br/> (N = 38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 300 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0029" title="PatersonAHG , KanisJA , PowlesTJ , McCloskeyEV , ArchabaultWT , KurmanMR , et al. A re‐analysis of a trial of clodronate in patients with breast cancer and bone metastases. Anthra Pharmaceuticals. PatersonAHG , PowlesTJ , KanisJA , McCloskeyE , HansonJ , AshleyS . Double‐blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(1):59‐65. ">Paterson 1993</a><br/> (N = 173) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral, 2/d for up to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.198</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0036" title="TripathyD , LichinitzerM , LazarevA , MacLachianA , ApffelstaedtJ , BuddeM , et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomised, double‐blind, placebo‐controlled trial. Annals of Oncology2004;15(5):743‐50. ">Tripathy 2004</a><br/> (N = 287) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0037" title="Tubiana‐HulinM , BeuzebocP , MauriacL , BarbetN , FrenayM , MonnierA , et al. Double‐blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bulletin du Cancer2001;88(7):701‐7. ">Tubiana‐Hulin 2001</a><br/> (N = 144) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0038" title="CletonFJ , VanHolten‐VerzantvoortAT , BijvoetOLM . Effect of long‐term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results in Cancer Research. Vol. 116, Berlin‐Heidelberg: Springer‐Verlag, 1989:73‐8. VanHolten‐VaerzantvoortATM , KroonHM , BijvoetOLM , CletonFJ , BeexLVAM , BlijhamG , et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(3):491‐8. VanHolten‐VerzantvoortAT , BijvoetOLM , CletonFJ , HermansJ , KroonHM , HarinckHIJ , et al. Reduced morbidity from skeletal metastases in breast cancer patients during long‐term bisphosphonate (APD) treatment. Lancet1987;330(8566):983‐5. VanHolten‐VerzantvoortATM , ZwindermanAH , AaronsonNK , HermansJ , VanEmmerikB , VanDamFSAM , et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. European Journal of Cancer1991;27(5):544‐9. ">Van‐Holten 1987</a><br/> (N = 161) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 150 mg oral, 2/d indefinitely</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Direct comparisons of different bisphosphonate regimens</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a> </p> <p>(N = 318)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 2400 mg oral or 900 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a><br/> (N = 1130) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 90 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0040" title="vonAuA , MillothE , DielI , StefanovicS , HennigsA , WallwienerM , et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open‐label, non‐inferiority phase III trial. OncoTargets and Therapy2016; Vol. 2016, issue 9:4173‐80. ">von Au 2016</a><br/> (N = 375) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 900 mg iv every 3 weeks or 2400 mg/d oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a><br/> (N = 1404) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02<br/> Hazard ratio = 1.086 (95% confidence interval 0.948 to 1.245) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bone‐targeted agents vs bisphosphonate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a><br/> (N = 44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate iv (clinician choice)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0023" title="LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clinical Cancer Research2008;14(20):6690‐6. LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Randomized active‐controlled phase II study of denosumab efficacy and safety in patients with breast cancer‐related bone metastases. Journal of Clinical Oncology2007;25(28):4431‐7. ">Lipton 2008</a><br/> (N = 255) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab sc every 4 weeks (30 mg, 120 mg or 180 mg) or every 12 weeks (60 mg or 180 mg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate iv (either zoledronate, pamidronate or ibandronate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a> </p> <p>(N = 2046)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 120 mg sc (iv placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv (sc placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95<br/> Actual median overall survival values are not reported, but about 60% of participants alive at 27 months in both arms according to Kaplan‐Meier curve </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Standard vs reduced bisphosphonate/bone agent</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0008" title="HimelsteinAL , QinR , NovotnyPJ , SeislerDK , KhatcheressianJL , RobertsJD , et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of Clinical Oncology2015; Vol. 33, issue 15 Suppl:9501. [0732‐183X] NCT00869206 . Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. clinicaltrials.gov/ct2/show/NCT00869206 Date first received: 24 March 2009. ">CALGB‐70604 2015</a><br/> (N = 820) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a><br/> (N = 73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a> </p> <p>(N = 403)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a><br/> (N = 425) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>iv</b> : intravenous; <b>N</b> : total number of women in each study; <b>NR</b> : not reported; <b>NS</b> : not significant; <b>sc</b>: subcutaneous<br/> <sup>a</sup>We converted data from weeks into months. </p> </div> </div> </section> <section id="CD003474-sec-0167"> <h6 class="title">Standard versus reduced frequency bisphosphonate/bone agent</h6> <p>For the two studies comparing standard versus reduced frequency bisphosphonate/denosumab, overall survival was not reported in either study. A summary of studies reporting median survival time for each study is provided in <a href="#CD003474-tbl-0015">Table 12</a>. </p> </section> </section> <section id="CD003474-sec-0168"> <h5 class="title">Bone pain</h5> <p>Eleven out of 14 studies tested the effects of bisphosphonates (compared with placebo or no bisphosphonate) on bone pain while all studies examining direct comparisons of different bisphosphonates or denosumab compared to bisphosphonates reported on bone pain (see <a href="#CD003474-tbl-0016">Table 13</a>; moderate‐quality evidence). Only one study reported the frequency of bone pain when comparing standard versus reduced therapy (<a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a>). Various pain assessment tools were used across studies, ranging from the 4‐point visual analogue scales to referenced pain scales (e.g. Brief Pain Inventory). </p> <div class="table" id="CD003474-tbl-0016"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Breast cancer with bone metastases: bone pain</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Bone pain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Pain tool used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bisphosphonate vs placebo/open</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a><br/> (N = 751) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 90 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>A significant difference in mean change from baseline pain score favouring pamidronate was first noted at 24 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reference to validation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.015</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0006" title="BodyJJ , DielIJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology2003;14(9):1399‐405. BodyJJ , LichinitserMR , DiehlI , SchlosserK , PfarrE , CavalliF , et al. Double‐blind placebo‐controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. DielIJ , BodyJJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Improved quality of life after long‐term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer2004;40(11):1704‐12. LyubimovaN , KushlinkskyNE , LichinitserMR . Long‐term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease. 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003. New York: Supportive Care in Cancer, 2003. ">Body 2003</a> </p> <p>(N = 312)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Significantly improved bone pain score over time favouring the ibandronate 6 mg group compared to placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐point scale. No reference to validation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0007" title="BodyJJ , DielI , BellR , PecherstorferM , LichinitserM , LazarevA , et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111(3):306‐12. BodyJJ , DielIJ , LichinitzerM , LazarevA , PecherstorferM , BellR , et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo‐controlled phase III studies. British Journal of Cancer2004;90(6):1133‐7. ">Body 2004</a><br/> (N = 564) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>At week 96, mean bone pain scores were significantly reduced from baseline with ibandronate compared to placebo (‐0.10, 95% CI ‐0.32 to 0.02 vs 0.20, 95% CI 0.07 to 0.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant‐rated scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0009" title="ContePF , GiannessiPG , LatreilleJ , MauriacL , KolirenL , CabresiF , et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology1994;5(Suppl 7):41‐4. ContePF , LatrielleJ , MauriacL , CalbresiF , SantosR , CamposD , et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology1996;14(9):2552‐9. ">Conte 1996</a><br/> (N = 268) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 45 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>No significant difference between the groups at the predefined time points; most symptomatic variables showed a greater degree of improvement in the pamidronate group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6‐point self‐assessment scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0012" title="ElomaaI , BlomqvistC , GrohnP , PorkkaL , KairentoA‐L , SelanderK , et al. Long‐term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet1983;1(8317):146‐9. ElomaaI , BlomqvistC , Porkka , HoltstromT , TaubeT , Lamberg‐AllardtC , et al. Clodronate for osteolytic metastases due to breast cancer. Biomedicine and Pharmacotherapy1988;42(2):111‐6. ElommaI , BlomqvistL , PorkkaL , Lamberg‐AllardtC , BorgstromGH . Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone1987;8(Suppl 1):53‐6. ">Elomaa 1983</a><br/> (N = 34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0016" title="HerasP , HatzopoulosA , MitsibounasD . Efficacy of ibandronate for the prevention of skeletal‐related events in breast cancer patients with metastatic bone disease. European Journal of Cancer2005;3(2):121. HerasP , KritikosK , HatzopoulosA , GeorgopoulouAP . Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. European Journal of Cancer Care2009;18(6):653‐6. ">Heras 2009</a><br/> (N = 150) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0018" title="HultbornR , GundersenS , RydenS , HolmbergE , CarstensenJ , WallgrenUB , et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double‐blind placebo‐controlled multicenter study. Anticancer Research1999;19(4C):3383‐92. ">Hultborn 1999</a><br/> (N = 404) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>"...results favoured pamidronate however insignificant when corrected for the prestudy values" (page 3387) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Questionnaire &amp; VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0020" title="KohnoN , AogiK , MinamiH , NakamuraS , AsagaT , IinoY , et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo‐controlled trial. Journal of Clinical Oncology2005;23(15):3314‐21. ">Kohno 2005</a><br/> (N = 268) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>From weeks 4‐52, a chart of mean change in the BPI was statistically significant in favour of a reduction by zoledronic acid </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0021" title="KristensenB , EjlertsenB , GroenvoldM , HeinS , LoftH , MouridsenHT . Oral clodronate in breast cancer patients with bone metastases: a randomised study. Journal of Internal Medicine1999;246(1):67‐74. ">Kristensen 1999</a><br/> (N = 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral, 2/d for 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>No difference between groups using a physician‐rated scale (no reference to validation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physician‐rated scale. No reference to validation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0025" title="MartoniA , GuaraldiM , CameraP , BiagiR , MarriS , BegheF , et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology1991;48(2):97‐101. ">Martoni 1991</a><br/> (N = 38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 300 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>No significant difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scott‐Huskinsson Visual Analog method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0029" title="PatersonAHG , KanisJA , PowlesTJ , McCloskeyEV , ArchabaultWT , KurmanMR , et al. A re‐analysis of a trial of clodronate in patients with breast cancer and bone metastases. Anthra Pharmaceuticals. PatersonAHG , PowlesTJ , KanisJA , McCloskeyE , HansonJ , AshleyS . Double‐blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(1):59‐65. ">Paterson 1993</a><br/> (N = 173) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral, 2/d for up to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0036" title="TripathyD , LichinitzerM , LazarevA , MacLachianA , ApffelstaedtJ , BuddeM , et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomised, double‐blind, placebo‐controlled trial. Annals of Oncology2004;15(5):743‐50. ">Tripathy 2004</a><br/> (N = 287) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>From baseline to study end point, bone pain scores increased by +0.21 in the placebo group and a slight increase of +0.03 in the ibandronate 50 mg group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.201</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0037" title="Tubiana‐HulinM , BeuzebocP , MauriacL , BarbetN , FrenayM , MonnierA , et al. Double‐blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bulletin du Cancer2001;88(7):701‐7. ">Tubiana‐Hulin 2001</a><br/> (N = 144) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Significant reduction in pain in clodronate group compared to control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Visual pain scale. No reference to validation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0038" title="CletonFJ , VanHolten‐VerzantvoortAT , BijvoetOLM . Effect of long‐term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results in Cancer Research. Vol. 116, Berlin‐Heidelberg: Springer‐Verlag, 1989:73‐8. VanHolten‐VaerzantvoortATM , KroonHM , BijvoetOLM , CletonFJ , BeexLVAM , BlijhamG , et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(3):491‐8. VanHolten‐VerzantvoortAT , BijvoetOLM , CletonFJ , HermansJ , KroonHM , HarinckHIJ , et al. Reduced morbidity from skeletal metastases in breast cancer patients during long‐term bisphosphonate (APD) treatment. Lancet1987;330(8566):983‐5. VanHolten‐VerzantvoortATM , ZwindermanAH , AaronsonNK , HermansJ , VanEmmerikB , VanDamFSAM , et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. European Journal of Cancer1991;27(5):544‐9. ">Van‐Holten 1987</a><br/> (N = 161) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 150 mg oral, 2/d indefinitely</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Bone scores were significantly higher in the control group with an early reduction in bone pain within the first 3 months of pamidronate. However, bone pain then increased significantly over time (P = 0.005) in both groups although more rapidly in the control than pamidronate group (P = 0.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 items on bone pain within a quality‐of‐life questionnaire designed specifically for this trial. Reliability of the questionnaire tested at first observation point of participants </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.007 (pamidronate vs control at 3 months)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Direct comparisons of different bisphosphonate regimens</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a> </p> <p>(N = 318)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 2400 mg oral or 900 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Trend to improvement with iv bisphosphonates (30% reduction with pamidronate iv, 25% reduction with clodronate iv) compared with oral clodronate (15%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain tool not reported in abstract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a><br/> (N = 766) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 90 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0040" title="vonAuA , MillothE , DielI , StefanovicS , HennigsA , WallwienerM , et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open‐label, non‐inferiority phase III trial. OncoTargets and Therapy2016; Vol. 2016, issue 9:4173‐80. ">von Au 2016</a><br/> (N = 375) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 900 mg iv every 3 weeks or 2400 mg/d oral</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Pain scores at baseline and final examinations were not significantly different among the groups. Overall, a slight increase in pain scores over time with no significant differences among the groups (P = 0.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a><br/> (N = 1404) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Pain scores reduced from baseline at 12 weeks and were maintained over 96 weeks. There was no difference between the groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bone‐targeted agents vs bisphosphonate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a><br/> (N = 44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate iv (clinician choice)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0023" title="LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clinical Cancer Research2008;14(20):6690‐6. LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Randomized active‐controlled phase II study of denosumab efficacy and safety in patients with breast cancer‐related bone metastases. Journal of Clinical Oncology2007;25(28):4431‐7. ">Lipton 2008</a><br/> (N = 255) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab sc every 4 weeks (30 mg, 120 mg or 180 mg) or every 12 weeks (60 mg or 180 mg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate iv (either zoledronate, pamidronate or ibandronate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a> </p> <p>(N = 2046)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 120 mg sc (iv placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv (sc placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Prolonged median time to develop moderate/severe pain from no pain on baseline (denosumab: zoledronate hazard ratio 0.78). Lower proportion of participants with moderate/severe pain from no pain on baseline (denosumab 14.8% vs zoledronate 26.7% at week 73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Standard vs reduced bisphosphonate/bone agent</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0008" title="HimelsteinAL , QinR , NovotnyPJ , SeislerDK , KhatcheressianJL , RobertsJD , et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of Clinical Oncology2015; Vol. 33, issue 15 Suppl:9501. [0732‐183X] NCT00869206 . Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. clinicaltrials.gov/ct2/show/NCT00869206 Date first received: 24 March 2009. ">CALGB‐70604 2015</a><br/> (N = 820) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a><br/> (N = 73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a> </p> <p>(N = 189)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Change from baseline in mean BPI score was 0.24 (standard deviation 1.976) in zoledronate every 4 weeks while the change from baseline score was 0.31 (standard deviation 2.099) in zoledronate every 12 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a><br/> (N = 425) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Most people had a score &lt; 4; median pain at rest and pain on movement scores were &lt; 4 at all points in both groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Validated 6‐point Verbal Rating Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>BPI</b> : Brief Pain Inventory; <b>CI</b> : confidence interval; <b>iv</b> : intravenous; <b>N</b> : total number of women in each study; <b>NR</b> : not reported; <b>NS</b> : not significantly different; <b>sc</b> : subcutaneous; <b>VAS</b>: visual analogue scale </p> </div> </div> <p>For those studies comparing a bisphosphonate to placebo, there were significant differences in pain in one study of intravenous pamidronate (90 mg) (<a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a>), one study of intravenous ibandronate (6 mg) (<a href="./references#CD003474-bbs2-0006" title="BodyJJ , DielIJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology2003;14(9):1399‐405. BodyJJ , LichinitserMR , DiehlI , SchlosserK , PfarrE , CavalliF , et al. Double‐blind placebo‐controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. DielIJ , BodyJJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Improved quality of life after long‐term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer2004;40(11):1704‐12. LyubimovaN , KushlinkskyNE , LichinitserMR . Long‐term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease. 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003. New York: Supportive Care in Cancer, 2003. ">Body 2003</a>), one study of intravenous zoledronate (<a href="./references#CD003474-bbs2-0020" title="KohnoN , AogiK , MinamiH , NakamuraS , AsagaT , IinoY , et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo‐controlled trial. Journal of Clinical Oncology2005;23(15):3314‐21. ">Kohno 2005</a>), one study of oral clodronate (<a href="./references#CD003474-bbs2-0037" title="Tubiana‐HulinM , BeuzebocP , MauriacL , BarbetN , FrenayM , MonnierA , et al. Double‐blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bulletin du Cancer2001;88(7):701‐7. ">Tubiana‐Hulin 2001</a>), one study of oral pamidronate (<a href="./references#CD003474-bbs2-0038" title="CletonFJ , VanHolten‐VerzantvoortAT , BijvoetOLM . Effect of long‐term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results in Cancer Research. Vol. 116, Berlin‐Heidelberg: Springer‐Verlag, 1989:73‐8. VanHolten‐VaerzantvoortATM , KroonHM , BijvoetOLM , CletonFJ , BeexLVAM , BlijhamG , et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(3):491‐8. VanHolten‐VerzantvoortAT , BijvoetOLM , CletonFJ , HermansJ , KroonHM , HarinckHIJ , et al. Reduced morbidity from skeletal metastases in breast cancer patients during long‐term bisphosphonate (APD) treatment. Lancet1987;330(8566):983‐5. VanHolten‐VerzantvoortATM , ZwindermanAH , AaronsonNK , HermansJ , VanEmmerikB , VanDamFSAM , et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. European Journal of Cancer1991;27(5):544‐9. ">Van‐Holten 1987</a>) and the pooled studies of 50 mg oral ibandronate (<a href="./references#CD003474-bbs2-0007" title="BodyJJ , DielI , BellR , PecherstorferM , LichinitserM , LazarevA , et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111(3):306‐12. BodyJJ , DielIJ , LichinitzerM , LazarevA , PecherstorferM , BellR , et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo‐controlled phase III studies. British Journal of Cancer2004;90(6):1133‐7. ">Body 2004</a>). The two lower‐dose pamidronate studies (<a href="./references#CD003474-bbs2-0009" title="ContePF , GiannessiPG , LatreilleJ , MauriacL , KolirenL , CabresiF , et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology1994;5(Suppl 7):41‐4. ContePF , LatrielleJ , MauriacL , CalbresiF , SantosR , CamposD , et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology1996;14(9):2552‐9. ">Conte 1996</a>; <a href="./references#CD003474-bbs2-0018" title="HultbornR , GundersenS , RydenS , HolmbergE , CarstensenJ , WallgrenUB , et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double‐blind placebo‐controlled multicenter study. Anticancer Research1999;19(4C):3383‐92. ">Hultborn 1999</a>), one study of oral ibandronate (<a href="./references#CD003474-bbs2-0036" title="TripathyD , LichinitzerM , LazarevA , MacLachianA , ApffelstaedtJ , BuddeM , et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomised, double‐blind, placebo‐controlled trial. Annals of Oncology2004;15(5):743‐50. ">Tripathy 2004</a>) and two clodronate studies (<a href="./references#CD003474-bbs2-0021" title="KristensenB , EjlertsenB , GroenvoldM , HeinS , LoftH , MouridsenHT . Oral clodronate in breast cancer patients with bone metastases: a randomised study. Journal of Internal Medicine1999;246(1):67‐74. ">Kristensen 1999</a>; <a href="./references#CD003474-bbs2-0025" title="MartoniA , GuaraldiM , CameraP , BiagiR , MarriS , BegheF , et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology1991;48(2):97‐101. ">Martoni 1991</a>) reported no significant difference in bone pain between bisphosphonate and placebo/no bisphosphonate. </p> <p>Four bisphosphonate comparison trials studied relative benefits of ibandronate, pamidronate, clodronate, zoledronate and denosumab on bone pain. In <a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a>, better pain reduction was reported with the use of intravenous bisphosphonates (clodronate or pamidronate) than with oral clodronate, however the final report of this study has not yet been published. In <a href="./references#CD003474-bbs2-0040" title="vonAuA , MillothE , DielI , StefanovicS , HennigsA , WallwienerM , et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open‐label, non‐inferiority phase III trial. OncoTargets and Therapy2016; Vol. 2016, issue 9:4173‐80. ">von Au 2016</a>, no significant differences in pain scores were noted among the groups (intravenous pamidronate versus intravenous or oral clodronate). In <a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a>, no difference in overall pain was observed between intravenous zoledronate or intravenous pamidronate compared with baseline. <a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a> reported no difference in bone pain between intravenous zoledronate and oral ibandronate. </p> <p>For the comparison of denosumab and bisphosphonate, <a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a> reported prolonged median time to develop moderate/severe pain for participants with no pain at baseline (denosumab versus zoledronate: HR 0.78; P = 0.0024) and had a lower proportion of participants who had no pain at baseline, and had moderate/severe pain at week 73 (denosumab 14.8% versus zoledronate 26.7%). The median time to pain improvement was similar between treatment arms (denosumab 82 days versus zoledronate 85 days: HR 1.02; P = 0.72). Neither <a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a> nor <a href="./references#CD003474-bbs2-0023" title="LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clinical Cancer Research2008;14(20):6690‐6. LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Randomized active‐controlled phase II study of denosumab efficacy and safety in patients with breast cancer‐related bone metastases. Journal of Clinical Oncology2007;25(28):4431‐7. ">Lipton 2008</a> collected data using pain assessment tools. </p> <p>For the comparison of standard versus reduced bisphosphonate, <a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a> reported no significant difference in bone pain. <a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a> reported preliminary data in the clinical trial record where the change from baseline in the mean composite Brief Pain Inventory score was 0.24 in the standard bisphosphonate group and 0.31 in the reduced bisphosphonate group. We await statistical analysis. </p> </section> <section id="CD003474-sec-0169"> <h5 class="title">Quality of life</h5> <p>Eight out of the 25 treatment comparisons provided quality‐of‐life information (<a href="#CD003474-tbl-0017">Table 14</a>; moderate‐quality evidence). Five studies tested the effect of bisphosphonates compared with placebo on participant‐rated quality of life using a validated quality‐of‐life scale (Spitzer Quality of Life Index: <a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a>, EORTC QLQ‐C30: <a href="./references#CD003474-bbs2-0006" title="BodyJJ , DielIJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology2003;14(9):1399‐405. BodyJJ , LichinitserMR , DiehlI , SchlosserK , PfarrE , CavalliF , et al. Double‐blind placebo‐controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. DielIJ , BodyJJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Improved quality of life after long‐term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer2004;40(11):1704‐12. LyubimovaN , KushlinkskyNE , LichinitserMR . Long‐term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease. 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003. New York: Supportive Care in Cancer, 2003. ">Body 2003</a>, <a href="./references#CD003474-bbs2-0007" title="BodyJJ , DielI , BellR , PecherstorferM , LichinitserM , LazarevA , et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111(3):306‐12. BodyJJ , DielIJ , LichinitzerM , LazarevA , PecherstorferM , BellR , et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo‐controlled phase III studies. British Journal of Cancer2004;90(6):1133‐7. ">Body 2004</a>, <a href="./references#CD003474-bbs2-0021" title="KristensenB , EjlertsenB , GroenvoldM , HeinS , LoftH , MouridsenHT . Oral clodronate in breast cancer patients with bone metastases: a randomised study. Journal of Internal Medicine1999;246(1):67‐74. ">Kristensen 1999</a>, validated 4‐point ordinal scale: <a href="./references#CD003474-bbs2-0038" title="CletonFJ , VanHolten‐VerzantvoortAT , BijvoetOLM . Effect of long‐term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results in Cancer Research. Vol. 116, Berlin‐Heidelberg: Springer‐Verlag, 1989:73‐8. VanHolten‐VaerzantvoortATM , KroonHM , BijvoetOLM , CletonFJ , BeexLVAM , BlijhamG , et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(3):491‐8. VanHolten‐VerzantvoortAT , BijvoetOLM , CletonFJ , HermansJ , KroonHM , HarinckHIJ , et al. Reduced morbidity from skeletal metastases in breast cancer patients during long‐term bisphosphonate (APD) treatment. Lancet1987;330(8566):983‐5. VanHolten‐VerzantvoortATM , ZwindermanAH , AaronsonNK , HermansJ , VanEmmerikB , VanDamFSAM , et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. European Journal of Cancer1991;27(5):544‐9. ">Van‐Holten 1987</a>). Overall, global quality‐of‐life scores decreased to a lesser extent in participants receiving intravenous ibandronate 6 mg (<a href="./references#CD003474-bbs2-0006" title="BodyJJ , DielIJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology2003;14(9):1399‐405. BodyJJ , LichinitserMR , DiehlI , SchlosserK , PfarrE , CavalliF , et al. Double‐blind placebo‐controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. DielIJ , BodyJJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Improved quality of life after long‐term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer2004;40(11):1704‐12. LyubimovaN , KushlinkskyNE , LichinitserMR . Long‐term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease. 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003. New York: Supportive Care in Cancer, 2003. ">Body 2003</a>), oral ibandronate 50 mg (<a href="./references#CD003474-bbs2-0007" title="BodyJJ , DielI , BellR , PecherstorferM , LichinitserM , LazarevA , et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111(3):306‐12. BodyJJ , DielIJ , LichinitzerM , LazarevA , PecherstorferM , BellR , et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo‐controlled phase III studies. British Journal of Cancer2004;90(6):1133‐7. ">Body 2004</a>) and intravenous pamidronate 90 mg (<a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a>) compared to placebo. There was no significant change in overall quality of life between clodronate oral 800 mg twice a day compared to no bisphosphonate (<a href="./references#CD003474-bbs2-0021" title="KristensenB , EjlertsenB , GroenvoldM , HeinS , LoftH , MouridsenHT . Oral clodronate in breast cancer patients with bone metastases: a randomised study. Journal of Internal Medicine1999;246(1):67‐74. ">Kristensen 1999</a>). </p> <div class="table" id="CD003474-tbl-0017"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Breast cancer with bone metastases: quality of life</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Questionnaires used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Summary of findings</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Bisphosphonate vs placebo/open</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spitzer Quality‐of‐Life Index scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"...quality of life scores worsened from baseline to the last visit in both groups, although less so in the pamidronate group (P = 0.057 and 0.088, respectively)" (page 1087) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0006" title="BodyJJ , DielIJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology2003;14(9):1399‐405. BodyJJ , LichinitserMR , DiehlI , SchlosserK , PfarrE , CavalliF , et al. Double‐blind placebo‐controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. DielIJ , BodyJJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Improved quality of life after long‐term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer2004;40(11):1704‐12. LyubimovaN , KushlinkskyNE , LichinitserMR . Long‐term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease. 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003. New York: Supportive Care in Cancer, 2003. ">Body 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EORTC Quality of Life Scale ‐ Core 30 questionnaire (QLQ‐C30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"...overall quality of life scores decreased to a lesser extent between baseline and last assessment for patients receiving 2 mg ibandronate (‐18.1) and 6 mg ibandronate (‐10.3) compared with patients receiving placebo (‐45.4)" (page 1709) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0007" title="BodyJJ , DielI , BellR , PecherstorferM , LichinitserM , LazarevA , et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111(3):306‐12. BodyJJ , DielIJ , LichinitzerM , LazarevA , PecherstorferM , BellR , et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo‐controlled phase III studies. British Journal of Cancer2004;90(6):1133‐7. ">Body 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EORTC QLQ‐C30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global quality of life scores decreased significantly during the study, though significantly less with ibandronate than with placebo (‐8.3, 95% CI ‐20.6 to 4.1 vs ‐26.8, 95% CI ‐39.4 to 14.3, P = 0.03) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0009" title="ContePF , GiannessiPG , LatreilleJ , MauriacL , KolirenL , CabresiF , et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology1994;5(Suppl 7):41‐4. ContePF , LatrielleJ , MauriacL , CalbresiF , SantosR , CamposD , et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology1996;14(9):2552‐9. ">Conte 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0012" title="ElomaaI , BlomqvistC , GrohnP , PorkkaL , KairentoA‐L , SelanderK , et al. Long‐term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet1983;1(8317):146‐9. ElomaaI , BlomqvistC , Porkka , HoltstromT , TaubeT , Lamberg‐AllardtC , et al. Clodronate for osteolytic metastases due to breast cancer. Biomedicine and Pharmacotherapy1988;42(2):111‐6. ElommaI , BlomqvistL , PorkkaL , Lamberg‐AllardtC , BorgstromGH . Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone1987;8(Suppl 1):53‐6. ">Elomaa 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0016" title="HerasP , HatzopoulosA , MitsibounasD . Efficacy of ibandronate for the prevention of skeletal‐related events in breast cancer patients with metastatic bone disease. European Journal of Cancer2005;3(2):121. HerasP , KritikosK , HatzopoulosA , GeorgopoulouAP . Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. European Journal of Cancer Care2009;18(6):653‐6. ">Heras 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0018" title="HultbornR , GundersenS , RydenS , HolmbergE , CarstensenJ , WallgrenUB , et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double‐blind placebo‐controlled multicenter study. Anticancer Research1999;19(4C):3383‐92. ">Hultborn 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0020" title="KohnoN , AogiK , MinamiH , NakamuraS , AsagaT , IinoY , et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo‐controlled trial. Journal of Clinical Oncology2005;23(15):3314‐21. ">Kohno 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0021" title="KristensenB , EjlertsenB , GroenvoldM , HeinS , LoftH , MouridsenHT . Oral clodronate in breast cancer patients with bone metastases: a randomised study. Journal of Internal Medicine1999;246(1):67‐74. ">Kristensen 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EORTC QLQ‐C30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"There was no significant difference between patients receiving clodronate and controls in the change from baseline to 3 or 6 months in any of the 17 quality‐of‐life variables" (page 71) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0025" title="MartoniA , GuaraldiM , CameraP , BiagiR , MarriS , BegheF , et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology1991;48(2):97‐101. ">Martoni 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0029" title="PatersonAHG , KanisJA , PowlesTJ , McCloskeyEV , ArchabaultWT , KurmanMR , et al. A re‐analysis of a trial of clodronate in patients with breast cancer and bone metastases. Anthra Pharmaceuticals. PatersonAHG , PowlesTJ , KanisJA , McCloskeyE , HansonJ , AshleyS . Double‐blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(1):59‐65. ">Paterson 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0036" title="TripathyD , LichinitzerM , LazarevA , MacLachianA , ApffelstaedtJ , BuddeM , et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomised, double‐blind, placebo‐controlled trial. Annals of Oncology2004;15(5):743‐50. ">Tripathy 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0037" title="Tubiana‐HulinM , BeuzebocP , MauriacL , BarbetN , FrenayM , MonnierA , et al. Double‐blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bulletin du Cancer2001;88(7):701‐7. ">Tubiana‐Hulin 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0038" title="CletonFJ , VanHolten‐VerzantvoortAT , BijvoetOLM . Effect of long‐term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results in Cancer Research. Vol. 116, Berlin‐Heidelberg: Springer‐Verlag, 1989:73‐8. VanHolten‐VaerzantvoortATM , KroonHM , BijvoetOLM , CletonFJ , BeexLVAM , BlijhamG , et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(3):491‐8. VanHolten‐VerzantvoortAT , BijvoetOLM , CletonFJ , HermansJ , KroonHM , HarinckHIJ , et al. Reduced morbidity from skeletal metastases in breast cancer patients during long‐term bisphosphonate (APD) treatment. Lancet1987;330(8566):983‐5. VanHolten‐VerzantvoortATM , ZwindermanAH , AaronsonNK , HermansJ , VanEmmerikB , VanDamFSAM , et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. European Journal of Cancer1991;27(5):544‐9. ">Van‐Holten 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A questionnaire was developed specifically for the trial (validated 4‐point ordinal scale). The 4 items were related to mobility impairment, gastrointestinal toxicity, bone pain and fatigue </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The mean mobility impairment score was higher in the control group than the pamidronate group (P = 0.03). Similarly, bone pain scores were higher in the control group compared to pamidronate (P = 0.007). No differences were noted in fatigue or gastrointestinal toxicity between the two groups </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Direct comparisons of different bisphosphonate regimens</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FACT‐G</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference between groups. Quality‐of‐life data reported in conference presentation only </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0040" title="vonAuA , MillothE , DielI , StefanovicS , HennigsA , WallwienerM , et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open‐label, non‐inferiority phase III trial. OncoTargets and Therapy2016; Vol. 2016, issue 9:4173‐80. ">von Au 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EORTC QLQ‐C30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Bone‐targeted agents vs bisphosphonate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0023" title="LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clinical Cancer Research2008;14(20):6690‐6. LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Randomized active‐controlled phase II study of denosumab efficacy and safety in patients with breast cancer‐related bone metastases. Journal of Clinical Oncology2007;25(28):4431‐7. ">Lipton 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FACT‐G</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"...over monthly time points during an 18‐month period, an average of 10% more patients in the denosumab group compared with the zoledronic acid group had a clinically meaningful improvement in HRQoL ( &gt; 5‐point increase in FACT‐G total score) over the course of the study. An average of 7% fewer patients in the denosumab group than in the zoledronic acid group had worsening of HRQoL on study" (page 7, Clinical Cancer Research) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Standard vs reduced bisphosphonate/bone agent</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0008" title="HimelsteinAL , QinR , NovotnyPJ , SeislerDK , KhatcheressianJL , RobertsJD , et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of Clinical Oncology2015; Vol. 33, issue 15 Suppl:9501. [0732‐183X] NCT00869206 . Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. clinicaltrials.gov/ct2/show/NCT00869206 Date first received: 24 March 2009. ">CALGB‐70604 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>CI</b> : confidence interval; <b>EORTC</b> : European Organisation for the Research and Treatment of Cancer; <b>NR</b>: not reported </p> </div> </div> <p>Two studies comparing different bisphosphonate regimens reported no significant difference between groups in quality‐of‐life scores using the FACT‐G or EORTC QLQ‐30 (<a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a>: intravenous zoledronate 4 mg or 8 mg versus intravenous pamidronate 90 mg; <a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a>: oral ibandronate 50 mg versus zoledronate 4 mg). One study that compared a bone‐targeted agent to bisphosphonate reported that participants in the denosumab group had a clinically meaningful improvement in quality of life (on FACT‐G) compared to zoledronate (<a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a>). Quality of life was not collected and reported in the four studies comparing standard versus reduced bisphosphonate/bone agent (<a href="./references#CD003474-bbs2-0008" title="HimelsteinAL , QinR , NovotnyPJ , SeislerDK , KhatcheressianJL , RobertsJD , et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of Clinical Oncology2015; Vol. 33, issue 15 Suppl:9501. [0732‐183X] NCT00869206 . Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. clinicaltrials.gov/ct2/show/NCT00869206 Date first received: 24 March 2009. ">CALGB‐70604 2015</a>; <a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a>; <a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a>; <a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a>). </p> </section> <section id="CD003474-sec-0170"> <h5 class="title">Adverse, drug‐related events or toxicity</h5> <section id="CD003474-sec-0171"> <h6 class="title">Osteonecrosis of the jaw (ONJ)</h6> <p>Six studies reported ONJ (<a href="./references#CD003474-bbs2-0016" title="HerasP , HatzopoulosA , MitsibounasD . Efficacy of ibandronate for the prevention of skeletal‐related events in breast cancer patients with metastatic bone disease. European Journal of Cancer2005;3(2):121. HerasP , KritikosK , HatzopoulosA , GeorgopoulouAP . Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. European Journal of Cancer Care2009;18(6):653‐6. ">Heras 2009</a>; <a href="./references#CD003474-bbs2-0023" title="LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clinical Cancer Research2008;14(20):6690‐6. LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Randomized active‐controlled phase II study of denosumab efficacy and safety in patients with breast cancer‐related bone metastases. Journal of Clinical Oncology2007;25(28):4431‐7. ">Lipton 2008</a>; <a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a>; <a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a>; <a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a>; <a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a>) with no reported differences between groups (<a href="#CD003474-tbl-0018">Table 15</a>). </p> <div class="table" id="CD003474-tbl-0018"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Breast cancer with bone metastases: toxicity ‐ osteonecrosis of the jaw, hypocalcaemia, renal dysfunction &amp; drug‐related death</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Treatment vs comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Osteonecrosis of the jaw</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Hypocalcaemia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Renal dysfunction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Drug‐related death</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Bisphosphonate vs placebo/open</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 90 mg iv vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One participant had a "symptomatic hypocalcemia episode" (page 1088): 1/367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/189</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0006" title="BodyJJ , DielIJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology2003;14(9):1399‐405. BodyJJ , LichinitserMR , DiehlI , SchlosserK , PfarrE , CavalliF , et al. Double‐blind placebo‐controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. DielIJ , BodyJJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Improved quality of life after long‐term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer2004;40(11):1704‐12. LyubimovaN , KushlinkskyNE , LichinitserMR . Long‐term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease. 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003. New York: Supportive Care in Cancer, 2003. ">Body 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>No difference between ibandronate and control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/158</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0007" title="BodyJJ , DielI , BellR , PecherstorferM , LichinitserM , LazarevA , et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111(3):306‐12. BodyJJ , DielIJ , LichinitzerM , LazarevA , PecherstorferM , BellR , et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo‐controlled phase III studies. British Journal of Cancer2004;90(6):1133‐7. ">Body 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/286 "renal AEs".</p> <p>"No reports of serious AEs (renal failure) in the active treatment group" (page 1136)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/277 "renal AEs"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/277</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0009" title="ContePF , GiannessiPG , LatreilleJ , MauriacL , KolirenL , CabresiF , et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology1994;5(Suppl 7):41‐4. ContePF , LatrielleJ , MauriacL , CalbresiF , SantosR , CamposD , et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology1996;14(9):2552‐9. ">Conte 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 45 mg iv vs open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transient asymptomatic hypocalcemia: 24/143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transient asymptomatic hypocalcaemia: 9/152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0012" title="ElomaaI , BlomqvistC , GrohnP , PorkkaL , KairentoA‐L , SelanderK , et al. Long‐term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet1983;1(8317):146‐9. ElomaaI , BlomqvistC , Porkka , HoltstromT , TaubeT , Lamberg‐AllardtC , et al. Clodronate for osteolytic metastases due to breast cancer. Biomedicine and Pharmacotherapy1988;42(2):111‐6. ElommaI , BlomqvistL , PorkkaL , Lamberg‐AllardtC , BorgstromGH . Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone1987;8(Suppl 1):53‐6. ">Elomaa 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0016" title="HerasP , HatzopoulosA , MitsibounasD . Efficacy of ibandronate for the prevention of skeletal‐related events in breast cancer patients with metastatic bone disease. European Journal of Cancer2005;3(2):121. HerasP , KritikosK , HatzopoulosA , GeorgopoulouAP . Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. European Journal of Cancer Care2009;18(6):653‐6. ">Heras 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>No comparable differences between ibandronate and control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0018" title="HultbornR , GundersenS , RydenS , HolmbergE , CarstensenJ , WallgrenUB , et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double‐blind placebo‐controlled multicenter study. Anticancer Research1999;19(4C):3383‐92. ">Hultborn 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0020" title="KohnoN , AogiK , MinamiH , NakamuraS , AsagaT , IinoY , et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo‐controlled trial. Journal of Clinical Oncology2005;23(15):3314‐21. ">Kohno 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G1: 44/114, G2&amp;3: 0/114;</p> <p>G4: 1/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G1: 8/113; G2&amp;3: 0/113; G4: 1/113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0021" title="KristensenB , EjlertsenB , GroenvoldM , HeinS , LoftH , MouridsenHT . Oral clodronate in breast cancer patients with bone metastases: a randomised study. Journal of Internal Medicine1999;246(1):67‐74. ">Kristensen 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral, 2/d for 2 years</p> <p>vs open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0025" title="MartoniA , GuaraldiM , CameraP , BiagiR , MarriS , BegheF , et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology1991;48(2):97‐101. ">Martoni 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 300 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0029" title="PatersonAHG , KanisJA , PowlesTJ , McCloskeyEV , ArchabaultWT , KurmanMR , et al. A re‐analysis of a trial of clodronate in patients with breast cancer and bone metastases. Anthra Pharmaceuticals. PatersonAHG , PowlesTJ , KanisJA , McCloskeyE , HansonJ , AshleyS . Double‐blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(1):59‐65. ">Paterson 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral bid for up to 3 years vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0036" title="TripathyD , LichinitzerM , LazarevA , MacLachianA , ApffelstaedtJ , BuddeM , et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomised, double‐blind, placebo‐controlled trial. Annals of Oncology2004;15(5):743‐50. ">Tripathy 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/143</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0037" title="Tubiana‐HulinM , BeuzebocP , MauriacL , BarbetN , FrenayM , MonnierA , et al. Double‐blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bulletin du Cancer2001;88(7):701‐7. ">Tubiana‐Hulin 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0038" title="CletonFJ , VanHolten‐VerzantvoortAT , BijvoetOLM . Effect of long‐term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results in Cancer Research. Vol. 116, Berlin‐Heidelberg: Springer‐Verlag, 1989:73‐8. VanHolten‐VaerzantvoortATM , KroonHM , BijvoetOLM , CletonFJ , BeexLVAM , BlijhamG , et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(3):491‐8. VanHolten‐VerzantvoortAT , BijvoetOLM , CletonFJ , HermansJ , KroonHM , HarinckHIJ , et al. Reduced morbidity from skeletal metastases in breast cancer patients during long‐term bisphosphonate (APD) treatment. Lancet1987;330(8566):983‐5. VanHolten‐VerzantvoortATM , ZwindermanAH , AaronsonNK , HermansJ , VanEmmerikB , VanDamFSAM , et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. European Journal of Cancer1991;27(5):544‐9. ">Van‐Holten 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 150 mg oral, 2/d indefinitely</p> <p>vs open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/81 "gradual deterioration in kidney function during 40 months of study"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Direct comparisons of different bisphosphonate regimens</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv vs</p> <p>Clodronate 2400 mg oral or</p> <p>900 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv vs</p> <p>Pamidronate 90 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Renal toxicity was greater in the zoledronate arm and was dependent on the dose and infusion time, compared to the pamidronate arm </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0040" title="vonAuA , MillothE , DielI , StefanovicS , HennigsA , WallwienerM , et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open‐label, non‐inferiority phase III trial. OncoTargets and Therapy2016; Vol. 2016, issue 9:4173‐80. ">von Au 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv vs</p> <p>Clodronate 900 mg iv</p> <p>every 3 weeks</p> <p>or</p> <p>2400 mg/d oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral vs</p> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/697</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 4/704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 4/697</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>172/704 "renal toxic effects"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>226/697 "renal toxic effects"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/697</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Bone‐targeted agents vs bisphosphonate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks</p> <p>or every 12 weeks vs</p> <p>Bisphosphonate iv (clinician choice)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 7/73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G/3/4: 1/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0023" title="LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clinical Cancer Research2008;14(20):6690‐6. LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Randomized active‐controlled phase II study of denosumab efficacy and safety in patients with breast cancer‐related bone metastases. Journal of Clinical Oncology2007;25(28):4431‐7. ">Lipton 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab sc every 4 weeks (30 mg, 120 mg or 180 mg) or every 12 weeks (60 mg or 180 mg) vs </p> <p>Bisphosphonate iv (either zoledronate, pamidronate or ibandronate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>No significant renal impairment in either arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 120 mg sc (iv placebo)</p> <p>vs</p> <p>Zoledronate 4 mg iv (sc placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/1020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/1013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62/1020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37/1013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50/1020. Renal failure: 2/1020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86/1013. Renal failure: 25/1013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Standard vs reduced bisphosphonate/bone agent</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0008" title="HimelsteinAL , QinR , NovotnyPJ , SeislerDK , KhatcheressianJL , RobertsJD , et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of Clinical Oncology2015; Vol. 33, issue 15 Suppl:9501. [0732‐183X] NCT00869206 . Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. clinicaltrials.gov/ct2/show/NCT00869206 Date first received: 24 March 2009. ">CALGB‐70604 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> <p>vs</p> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR (reported for breast, prostate and multiple myeloma patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks</p> <p>vs</p> <p>Denosumab 180 mg sc every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>"denosumab did not affect renal function" (page 1569). Data were not reported separately for denosumab every 4 weeks and every 12 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> <p>vs</p> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2<sup>a</sup>/198 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2<sup>a</sup>/202 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1<sup>a</sup>/198 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2<sup>a</sup>/202 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Renal failure: 0<sup>a</sup>/198 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Renal failure: 2<sup>a</sup>/202 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> <p>vs</p> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/209 "renal adverse event"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/216 "renal adverse event"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/216</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>AE</b> : adverse event; <b>G</b> : grade; <b>iv</b> : intravenous; <b>n</b> : number of events; <b>N</b> : number of women studies in each group; <b>NR</b> : not reported; <b>sc</b>: subcutaneous<br/> <sup>a</sup>Reported as serious adverse events. </p> </div> </div> </section> <section id="CD003474-sec-0172"> <h6 class="title">Hypocalcaemia</h6> <p>Of the 10 studies that reported hypocalcaemia, four studies reported an increased incidence of hypocalcaemia when administering oral ibandronate (<a href="./references#CD003474-bbs2-0007" title="BodyJJ , DielI , BellR , PecherstorferM , LichinitserM , LazarevA , et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111(3):306‐12. BodyJJ , DielIJ , LichinitzerM , LazarevA , PecherstorferM , BellR , et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo‐controlled phase III studies. British Journal of Cancer2004;90(6):1133‐7. ">Body 2004</a>), intravenous, low‐dose pamidronate (<a href="./references#CD003474-bbs2-0009" title="ContePF , GiannessiPG , LatreilleJ , MauriacL , KolirenL , CabresiF , et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology1994;5(Suppl 7):41‐4. ContePF , LatrielleJ , MauriacL , CalbresiF , SantosR , CamposD , et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology1996;14(9):2552‐9. ">Conte 1996</a>), intravenous zoledronate (<a href="./references#CD003474-bbs2-0020" title="KohnoN , AogiK , MinamiH , NakamuraS , AsagaT , IinoY , et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo‐controlled trial. Journal of Clinical Oncology2005;23(15):3314‐21. ">Kohno 2005</a>; grade I hypocalcaemia) and oral‐clodronate groups (<a href="./references#CD003474-bbs2-0021" title="KristensenB , EjlertsenB , GroenvoldM , HeinS , LoftH , MouridsenHT . Oral clodronate in breast cancer patients with bone metastases: a randomised study. Journal of Internal Medicine1999;246(1):67‐74. ">Kristensen 1999</a>) compared to placebo/open. Denosumab (every 4 or 8 weeks) had a higher incidence of hypocalcaemia compared to clinician's choice of intravenous bisphosphonate or intravenous zoledronate (two studies: <a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a>; <a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a>; <a href="#CD003474-tbl-0018">Table 15</a>). There was no difference in hypocalcaemia in the one study comparing standard to reduced‐frequency zoledronate (<a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a>). </p> </section> <section id="CD003474-sec-0173"> <h6 class="title">Renal dysfunction</h6> <p>Fourteen studies reported on renal dysfunction and most of the studies did not observe significant differences between treatment and comparator groups except for <a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a>, where renal toxicity was greater in the intravenous‐zoledronate than intravenous‐pamidronate arm, <a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a>, where renal toxicity occurred more frequently in the intravenous‐zoledronate group than denosumab group (<a href="#CD003474-tbl-0018">Table 15</a>). We compared grade 3/4 renal toxicity events between treatment and comparator groups where reported (<a href="#CD003474-tbl-0018">Table 15</a>). </p> </section> <section id="CD003474-sec-0174"> <h6 class="title">Drug‐related death</h6> <p>In the nine studies that collected data on treatment‐related deaths, no differences were observed between groups (<a href="#CD003474-tbl-0018">Table 15</a>). </p> </section> <section id="CD003474-sec-0175"> <h6 class="title">Nausea</h6> <p>Eleven studies reported nausea and none observed substantial differences between the groups (<a href="#CD003474-tbl-0019">Table 16</a>). </p> <div class="table" id="CD003474-tbl-0019"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Breast cancer with bone metastases: toxicity ‐ nausea, gastrointestinal events, fatigue &amp; fever</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Treatment vs comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Nausea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>GI events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fatigue</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fever</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Bisphosphonate vs placebo/open</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 90 mg iv vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>147/367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112/386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51/367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/386</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0006" title="BodyJJ , DielIJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology2003;14(9):1399‐405. BodyJJ , LichinitserMR , DiehlI , SchlosserK , PfarrE , CavalliF , et al. Double‐blind placebo‐controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. DielIJ , BodyJJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Improved quality of life after long‐term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer2004;40(11):1704‐12. LyubimovaN , KushlinkskyNE , LichinitserMR . Long‐term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease. 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003. New York: Supportive Care in Cancer, 2003. ">Body 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0007" title="BodyJJ , DielI , BellR , PecherstorferM , LichinitserM , LazarevA , et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111(3):306‐12. BodyJJ , DielIJ , LichinitzerM , LazarevA , PecherstorferM , BellR , et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo‐controlled phase III studies. British Journal of Cancer2004;90(6):1133‐7. ">Body 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0009" title="ContePF , GiannessiPG , LatreilleJ , MauriacL , KolirenL , CabresiF , et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology1994;5(Suppl 7):41‐4. ContePF , LatrielleJ , MauriacL , CalbresiF , SantosR , CamposD , et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology1996;14(9):2552‐9. ">Conte 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 45 mg iv vs open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/152</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0012" title="ElomaaI , BlomqvistC , GrohnP , PorkkaL , KairentoA‐L , SelanderK , et al. Long‐term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet1983;1(8317):146‐9. ElomaaI , BlomqvistC , Porkka , HoltstromT , TaubeT , Lamberg‐AllardtC , et al. Clodronate for osteolytic metastases due to breast cancer. Biomedicine and Pharmacotherapy1988;42(2):111‐6. ElommaI , BlomqvistL , PorkkaL , Lamberg‐AllardtC , BorgstromGH . Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone1987;8(Suppl 1):53‐6. ">Elomaa 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0016" title="HerasP , HatzopoulosA , MitsibounasD . Efficacy of ibandronate for the prevention of skeletal‐related events in breast cancer patients with metastatic bone disease. European Journal of Cancer2005;3(2):121. HerasP , KritikosK , HatzopoulosA , GeorgopoulouAP . Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. European Journal of Cancer Care2009;18(6):653‐6. ">Heras 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0018" title="HultbornR , GundersenS , RydenS , HolmbergE , CarstensenJ , WallgrenUB , et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double‐blind placebo‐controlled multicenter study. Anticancer Research1999;19(4C):3383‐92. ">Hultborn 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0020" title="KohnoN , AogiK , MinamiH , NakamuraS , AsagaT , IinoY , et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo‐controlled trial. Journal of Clinical Oncology2005;23(15):3314‐21. ">Kohno 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60/113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36/113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37/113</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0021" title="KristensenB , EjlertsenB , GroenvoldM , HeinS , LoftH , MouridsenHT . Oral clodronate in breast cancer patients with bone metastases: a randomised study. Journal of Internal Medicine1999;246(1):67‐74. ">Kristensen 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral, 2/d for 2 years</p> <p>vs open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0025" title="MartoniA , GuaraldiM , CameraP , BiagiR , MarriS , BegheF , et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology1991;48(2):97‐101. ">Martoni 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 300 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0029" title="PatersonAHG , KanisJA , PowlesTJ , McCloskeyEV , ArchabaultWT , KurmanMR , et al. A re‐analysis of a trial of clodronate in patients with breast cancer and bone metastases. Anthra Pharmaceuticals. PatersonAHG , PowlesTJ , KanisJA , McCloskeyE , HansonJ , AshleyS . Double‐blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(1):59‐65. ">Paterson 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral, 2/d for up to 3 years<br/> vs placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐specific GI symptoms: 2/85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐specific GI symptoms: 1/88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0036" title="TripathyD , LichinitzerM , LazarevA , MacLachianA , ApffelstaedtJ , BuddeM , et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomised, double‐blind, placebo‐controlled trial. Annals of Oncology2004;15(5):743‐50. ">Tripathy 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/143</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Upper GIT events: 10% and similar to placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0037" title="Tubiana‐HulinM , BeuzebocP , MauriacL , BarbetN , FrenayM , MonnierA , et al. Double‐blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bulletin du Cancer2001;88(7):701‐7. ">Tubiana‐Hulin 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0038" title="CletonFJ , VanHolten‐VerzantvoortAT , BijvoetOLM . Effect of long‐term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results in Cancer Research. Vol. 116, Berlin‐Heidelberg: Springer‐Verlag, 1989:73‐8. VanHolten‐VaerzantvoortATM , KroonHM , BijvoetOLM , CletonFJ , BeexLVAM , BlijhamG , et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(3):491‐8. VanHolten‐VerzantvoortAT , BijvoetOLM , CletonFJ , HermansJ , KroonHM , HarinckHIJ , et al. Reduced morbidity from skeletal metastases in breast cancer patients during long‐term bisphosphonate (APD) treatment. Lancet1987;330(8566):983‐5. VanHolten‐VerzantvoortATM , ZwindermanAH , AaronsonNK , HermansJ , VanEmmerikB , VanDamFSAM , et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. European Journal of Cancer1991;27(5):544‐9. ">Van‐Holten 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 150 mg oral, 2/d indefinitely</p> <p>vs open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Direct comparisons of different bisphosphonate regimens</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv vs</p> <p>Clodronate 2400 mg oral or 900 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv vs</p> <p>Pamidronate 90 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>355/742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>179/388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>294/742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>159/388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>231/742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103/388</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0040" title="vonAuA , MillothE , DielI , StefanovicS , HennigsA , WallwienerM , et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open‐label, non‐inferiority phase III trial. OncoTargets and Therapy2016; Vol. 2016, issue 9:4173‐80. ">von Au 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv vs</p> <p>Clodronate 900 mg iv every 3 weeks</p> <p>or 2400 mg/d oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>900 mg iv every 3 weeks: 11/105;</p> <p>2400 mg oral daily: 24/107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral vs</p> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 41/704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4:38/697</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 8/704 "dyspepsia"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 2/697 "dyspepsia"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 98/704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 97/697</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4:12/704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 18/697</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Bone‐targeted agents vs bisphosphonate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks or every 12 weeks vs</p> <p>Bisphosphonate iv (clinician choice)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0023" title="LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clinical Cancer Research2008;14(20):6690‐6. LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Randomized active‐controlled phase II study of denosumab efficacy and safety in patients with breast cancer‐related bone metastases. Journal of Clinical Oncology2007;25(28):4431‐7. ">Lipton 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab sc every 4 weeks (30 mg, 120 mg or 180 mg)</p> <p>or every 12 weeks (60 mg or 180 mg)</p> <p>vs</p> <p>Bisphosphonate iv</p> <p>(either zoledronate, pamidronate or ibandronate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36/211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 120 mg sc (iv placebo) vs</p> <p>Zoledronate 4 mg iv (sc placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>356/1020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>384/1013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>301/1020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>324/1013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>170/1020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>247/1013</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Standard vs reduced bisphosphonate/bone agent</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0008" title="HimelsteinAL , QinR , NovotnyPJ , SeislerDK , KhatcheressianJL , RobertsJD , et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of Clinical Oncology2015; Vol. 33, issue 15 Suppl:9501. [0732‐183X] NCT00869206 . Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. clinicaltrials.gov/ct2/show/NCT00869206 Date first received: 24 March 2009. ">CALGB‐70604 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> <p>vs</p> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks</p> <p>vs</p> <p>Denosumab 180 mg sc every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> <p>vs</p> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/198<br/> "abdominal pain" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/202<br/> "abdominal pain" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/202</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> <p>vs</p> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 24/209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 33/216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65/209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91/216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4:18/209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 19/216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 22/209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 28/216</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>G</b> : grade; <b>iv</b> : intravenous; <b>n</b> : number of events; <b>N</b> : number of women studies in each group; <b>NR</b> : not reported; <b>sc</b>: subcutaneous </p> </div> </div> </section> <section id="CD003474-sec-0176"> <h6 class="title">Gastrointestinal events</h6> <p>In the 11 studies reporting gastrointestinal toxicity, there were no significant differences observed except in three studies (<a href="#CD003474-tbl-0019">Table 16</a>). In <a href="./references#CD003474-bbs2-0020" title="KohnoN , AogiK , MinamiH , NakamuraS , AsagaT , IinoY , et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo‐controlled trial. Journal of Clinical Oncology2005;23(15):3314‐21. ">Kohno 2005</a>, abdominal pain was higher in the intravenous‐zoledronate group than placebo; in <a href="./references#CD003474-bbs2-0038" title="CletonFJ , VanHolten‐VerzantvoortAT , BijvoetOLM . Effect of long‐term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results in Cancer Research. Vol. 116, Berlin‐Heidelberg: Springer‐Verlag, 1989:73‐8. VanHolten‐VaerzantvoortATM , KroonHM , BijvoetOLM , CletonFJ , BeexLVAM , BlijhamG , et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(3):491‐8. VanHolten‐VerzantvoortAT , BijvoetOLM , CletonFJ , HermansJ , KroonHM , HarinckHIJ , et al. Reduced morbidity from skeletal metastases in breast cancer patients during long‐term bisphosphonate (APD) treatment. Lancet1987;330(8566):983‐5. VanHolten‐VerzantvoortATM , ZwindermanAH , AaronsonNK , HermansJ , VanEmmerikB , VanDamFSAM , et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. European Journal of Cancer1991;27(5):544‐9. ">Van‐Holten 1987</a>, gastrointestinal toxicity was the cause of withdrawal in 20 (25%) participants treated with oral pamidronate and in <a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a>, the incidence of gastrointestinal events was significantly higher in the intravenous‐zoledronate, 4‐week group (42%) than 12‐week group (31%). </p> </section> <section id="CD003474-sec-0177"> <h6 class="title">Fatigue</h6> <p>Of the 10 studies that reported fatigue, there were no significant differences between treatment and comparator groups except in two studies (<a href="#CD003474-tbl-0019">Table 16</a>). In <a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a>, there was an increase in fatigue in the intravenous‐pamidronate 90 mg versus placebo group and the same was observed in the intravenous‐zoledronate 4 mg group compared to placebo in <a href="./references#CD003474-bbs2-0020" title="KohnoN , AogiK , MinamiH , NakamuraS , AsagaT , IinoY , et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo‐controlled trial. Journal of Clinical Oncology2005;23(15):3314‐21. ">Kohno 2005</a>. </p> </section> <section id="CD003474-sec-0178"> <h6 class="title">Fever</h6> <p>Of the nine studies that reported fever, two studies observed an increase in fever in the bisphosphonate arm compared to placebo (<a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a>: pamidronate 90 mg intravenous versus placebo; <a href="./references#CD003474-bbs2-0020" title="KohnoN , AogiK , MinamiH , NakamuraS , AsagaT , IinoY , et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo‐controlled trial. Journal of Clinical Oncology2005;23(15):3314‐21. ">Kohno 2005</a>: zoledronate 4 mg intravenous versus placebo) and one study had an increase in the incidence of fever in the intravenous‐bisphosphonates group compared to denosumab (every 4 or 12 weeks) (<a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a>). We compared grade 3/4 fever or influenza‐type events between treatment and comparator groups where reported (<a href="#CD003474-tbl-0019">Table 16</a>). </p> </section> </section> <section id="CD003474-sec-0179"> <h5 class="title">Sensitivity analysis: including poor‐quality trials in BCBM analysis</h5> <p>We included two studies with poor overall quality ratings in the overall review (<a href="./references#CD003474-bbs2-0012" title="ElomaaI , BlomqvistC , GrohnP , PorkkaL , KairentoA‐L , SelanderK , et al. Long‐term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet1983;1(8317):146‐9. ElomaaI , BlomqvistC , Porkka , HoltstromT , TaubeT , Lamberg‐AllardtC , et al. Clodronate for osteolytic metastases due to breast cancer. Biomedicine and Pharmacotherapy1988;42(2):111‐6. ElommaI , BlomqvistL , PorkkaL , Lamberg‐AllardtC , BorgstromGH . Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone1987;8(Suppl 1):53‐6. ">Elomaa 1983</a>; <a href="./references#CD003474-bbs2-0025" title="MartoniA , GuaraldiM , CameraP , BiagiR , MarriS , BegheF , et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology1991;48(2):97‐101. ">Martoni 1991</a>). We did not include the data from these two studies in the primary analysis of the proportion of participants developing SREs because of unclear or unreported data. When we included the <a href="./references#CD003474-bbs2-0025" title="MartoniA , GuaraldiM , CameraP , BiagiR , MarriS , BegheF , et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology1991;48(2):97‐101. ">Martoni 1991</a> study (6 events, 18 participants), the RR for developing a SRE changed negligibly. Similarly, when we included data from the <a href="./references#CD003474-bbs2-0012" title="ElomaaI , BlomqvistC , GrohnP , PorkkaL , KairentoA‐L , SelanderK , et al. Long‐term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet1983;1(8317):146‐9. ElomaaI , BlomqvistC , Porkka , HoltstromT , TaubeT , Lamberg‐AllardtC , et al. Clodronate for osteolytic metastases due to breast cancer. Biomedicine and Pharmacotherapy1988;42(2):111‐6. ElommaI , BlomqvistL , PorkkaL , Lamberg‐AllardtC , BorgstromGH . Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone1987;8(Suppl 1):53‐6. ">Elomaa 1983</a> study (19 events, 34 participants) in overall survival analysis, there was a negligible change in the risk of death. The inclusion or exclusion of either study did not affect the conclusions of this review. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003474-sec-0180" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003474-sec-0180"></div> <section id="CD003474-sec-0181"> <h3 class="title" id="CD003474-sec-0181">Summary of main results</h3> <section id="CD003474-sec-0182"> <h4 class="title">Early breast cancer</h4> <p>This review update provides moderate‐ to high‐quality evidence that the use of bisphosphonates as part of the treatment plan for women with early breast cancer provides a beneficial effect in reducing the incidence of bone metastases compared to placebo or observation. Most of these studies used either intravenous zoledronate (4 mg every three to six months for one to five years) or oral clodronate (1600 mg daily for two to three years). As expected, there appeared to be no reduction in the incidence of visceral metastases, locoregional recurrence, recurrence (defined as locoregional plus distant recurrence) or fractures with bisphosphonates compared to placebo or observation. However, the confidence intervals were wide in some cases (for example, fracture incidence) suggesting that studies may not be adequately powered for these endpoints. Similarly, in the three recent studies comparing immediate versus delayed bisphosphonate administration, there did not appear to be a significant effect of immediate or delayed bisphosphonates on the incidence of bone metastases, and this lack of an effect was evident when assessing visceral metastases, locoregional recurrence and recurrence. </p> <p>In this review update, we introduced a new analysis of overall survival using time‐to‐event data, as this approach is considered to be a more appropriate method rather than using dichotomous data (<a href="./references#CD003474-bbs2-0128" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8:16. ">Tierney 2007</a>). By analysing published and unpublished aggregate data, there was an overall survival benefit in women with early breast cancer receiving bisphosphonates treatment (based on nine studies involving 13,949 women). The bisphosphonates administered were mainly intravenous zoledronate or oral clodronate (four studies each). There was significant heterogeneity, which appears to be due to different effects based upon menopausal status. The group as a whole had significant heterogeneity for the overall survival and disease‐free survival outcomes. This heterogeneity was removed when assessed by menopausal status. </p> <p>Bisphosphonates were found to provide a significant benefit for overall survival in postmenopausal women only. This analysis was based on four studies involving 6048 women who received either intravenous zoledronate (including immediate zoledronate) or oral clodronate. This beneficial effect was not observed in premenopausal women (two studies, 3501 women). The finding was replicated in the analysis of disease‐free survival that suggested bisphosphonates improved disease‐free survival in postmenopausal women and not premenopausal women (postmenopausal studies: seven studies, 8314 women; premenopausal studies: four studies, 5493 women). </p> <p>Whilst this benefit is based on a subgroup analysis of these trials, the data are suggestive of a differential effect of treatment based on menopausal status since heterogeneity was removed. There are ongoing trials testing this hypothesis and, once completed, these trials will provided robust evidence of whether bisphosphonates improve survival for menopausal women.  </p> <p>Adjuvant denosumab reduced the incidence of fractures compared to placebo (based on one study) and data for mature overall survival and disease‐free survival are awaited. None of the studies reported quality‐of‐life measures. </p> </section> <section id="CD003474-sec-0183"> <h4 class="title">Advanced breast cancer without bone metastases</h4> <p>As per the original review, the evidence was based on three studies published in 1996 and 2000. Oral bisphosphonates (either clodronate 1600 mg a day for two to three years or pamidronate 300 mg a day) in women with advanced disease, without clinically evident bone metastases, did not appear to have an effect on the incidence of skeletal metastases compared to placebo, and did not provide a survival benefit. However, the confidence intervals were very wide and only three studies involving 330 women were included. Only one study collected and reported the incidence of SREs with a 36% reduction in events in women receiving oral clodronate compared to placebo. One study reported quality of life and there was no apparent difference in quality‐of‐life scores between oral pamidronate and placebo. </p> </section> <section id="CD003474-sec-0184"> <h4 class="title">Metastatic breast cancer and bone metastases</h4> <p>Overall, bisphosphonates (intravenous or oral) reduced the incidence of SREs and rate of SREs when compared to placebo/observation. Intravenous and oral bisphosphonate reduced the risk of a SRE by 17% and 16%, respectively. The studies treating intravenously used a wide range of bisphosphonates: zoledronate 4 mg (one study), pamidronate 45 mg to 90 mg (three studies) and ibandronate 6 mg (two studies), while oral bisphosphonates included clodronate 1600 mg a day (three studies), ibandronate 50 mg (one study) or pamidronate 300 mg (one study). Similarly, there was reduced risk of SREs (by 22%) in women receiving denosumab (range: 30 mg, 120 mg or 180 mg subcutaneous every 4 weeks) compared to intravenous bisphosphonate. There was at least equivalent efficacy (or no worse) in the incidence of SREs when different bisphosphonate regimens were compared (e.g. intravenous zoledronate versus intravenous pamidronate) or when standard versus delayed frequency of bisphosphonates was tested. The only exception was that oral ibandronate appeared inferior to intravenous zoledronate (<a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a>). The median time to a SRE was significantly longer in the bisphosphonates group than placebo/observation. </p> <p>In this review update, half of the studies reported survival data for the comparison of bisphosphonate versus placebo. Of these, there was no evidence of an effect of bisphosphonates on survival. Only one study testing the effects of denosumab reported on overall survival and this study reported no significant effect of denosumab when compared to bisphosphonate. None of the studies on standard versus delayed frequency of bisphosphonates collected or reported overall survival data. </p> <p>In the majority of cases, quality‐of‐life measures were better with bisphosphonates than with placebo. A similar trend was observed with women receiving denosumab than bisphosphonates. None of the studies on standard versus delayed frequency of bisphosphonates collected or reported quality‐of‐life data. </p> </section> <section id="CD003474-sec-0185"> <h4 class="title">Toxicity</h4> <p>Following a thorough review of toxicity, adverse events for bisphosphonates or denosumab of any grade were generally uncommon, and grade 3/4 adverse events were rare but did include impaired renal function and osteonecrosis of the jaw. Bisphosphonates carried a small excess risk of acute‐phase reactions (such as fever, fatigue and nausea) but these were mostly grade 1 or 2, or the toxicity grade was unspecified. </p> </section> </section> <section id="CD003474-sec-0186"> <h3 class="title" id="CD003474-sec-0186">Overall completeness and applicability of evidence</h3> <p>Many second‐generation EBC studies that were specifically designed to detect differences in overall survival or disease‐free survival between treatment and control arms have completed accrual and are awaiting analysis (<a href="./references#CD003474-sec-0224" title="">Characteristics of ongoing studies</a>). Among the large RCTs that use recurrence as their primary endpoints, there are four zoledronate versus placebo studies (<a href="./references#CD003474-bbs2-0067" title="El‐IbrashiMM , El‐SaddaWM , bdel‐HalimII , ElashriMS . Zoledronic acid combined with adjuvant tamoxifen with or without ovarian function suppression in premenopausal early breast cancer patients. Cancer Research2016;76(4 Suppl):P5‐15‐04. [0008‐5472] ">El‐Ibrashi 2016</a>; <a href="./references#CD003474-bbs2-0070" title="NCT00412022 . HOBOE: a phase 3 study of adjuvant triptorelin and tamoxifen, letrozole, or letrozole and zoledronic acid in premenopausal patients with breast cancer. clinicaltrials.gov/ct2/show/NCT00412022 Date first received: 14 December 2006. NuzzoF , GalloC , LastoriaS , DiMaioM , PiccirilloMC , GravinaA , et al. Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early‐stage breast cancer: the randomized phase 3 HOBOE study. Annals of Oncology2012;23:2027‐33. ">HOBOE 2013</a>; <a href="./references#CD003474-bbs2-0073" title="HasegawaY , TaninoH , HoriguchiJ , MiuraD , IshikawaT , HayashiM , et al. Randomized controlled trial of zoledronic acid plus chemotherapy versus chemotherapy alone as neoadjuvant treatment of HER2‐negative primary breast cancer (JONIE Study). PLoS ONE2015;10(12):e0143643. MiuraD , HasegawaY , HoriguchiJ , IshikawaT , HayashiM , TakaoS , et al. Disease‐free survival and Ki67 analysis of a randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2‐negative primary breast cancer (JONIE‐1 study). Cancer Research2013;73(24 Suppl):PD3‐7. SangaiT , IshikawaT , KohnoN , MiuraD , SatoE , KaiseH , et al. Exploring biomarkers of response to zoledronic acid in breast cancer from clinical trial result of neoadjuvant chemotherapy with zoledronic acid: JONIE‐1 study. Cancer Research2015;75(9 Suppl):P6‐01‐02. [0008‐5472] SangaiT , SatoE , IshikawaT , KaiseH , HasegawaY , MiuraD , et al. Exploring immunomodulatory effects of zoledronic acid in breast cancer from clinical trial result of neoadjuvant chemotherapy with zoledronic acid: JONIE‐1 study. Cancer Research2016; Vol. 76, issue 4 Suppl:P4‐09‐25. [0008‐5472] ">JONIE‐1 2013</a>; <a href="./references#CD003474-bbs2-0079" title="CharehbiliA , HamdyNAT , SmitVTHB , KesselsL , VanBochoveA , VanLaarhovenHW , et al. Vitamin D (25‐0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10‐01). Breast2016;25:69‐74. [0960‐9776] CharehbiliA , HamdyNAT , SmitVTHB , LiefersGJ , PutterH , Meershoek‐Klein KranenbargE , et al. Changes in circulating vitamin D levels as a predictor for pathological response to neoadjuvant chemotherapy (NAC) in breast cancer (BC): a Dutch breast cancer trialists group (BOOG) side‐study. Cancer Research2013;73(24 Suppl):P1‐08‐19. CharehbiliA , Van deVenS , SmitVT , Meershoek‐Klein KranenbargE , HamdyNA , PutterH , et al. Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2‐negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010‐01). Annals of Oncology2014;25(5):998‐1004. DekkerTJA , CharehbiliA , SmitVTHB , TenDP , Meershoek‐KleinKE , Van deVenS , et al. Disorganised stroma determined on pre‐treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: results from the NEOZOTAC trial. Molecular Oncology2015;9(6):1120‐8. [1574‐7891] DekkerTJA , CharehbiliA , SmitVTHB , WasserMNJM , HeijnsJB , VanWarmerdamLJ , et al. The predictive value of tumor‐stroma ratio for radiological and pathological response to neoadjuvant chemotherapy in breast cancer (BC): a Dutch breast cancer trialists group (BOOG) side‐study. Cancer Research2013;73(24 Suppl):P1‐06‐04. Van deVenS , LiefersG , PutterH , VanWarmerdamLJ , KesselsLW , DercksenW , et al. NEO‐ZOTAC: toxicity data of a phase III randomized trial with NEOadjuvant chemotherapy (TAC) with or without ZOledronic acid (ZA) for patients with HER2‐negative large resectable or locally advanced breast cancer (BC). Cancer Research2012;72(24 Suppl):PD07‐06. Van deVenS , NortierJWR , LiefersGJ , TenTijeA , KesselsLW , VanLaarhovenHWM , et al. NEO‐ZOTAC: a phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with HER2‐negative large resectable or locally advanced breast cancer. Cancer Research2011;71(24 Suppl):OT1‐01‐04. ">NEOZOTAC</a>). In addition, <a href="./references#CD003474-bbs2-0034" title="GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG‐ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. Journal of Clinical Oncology2015;33(15 Suppl):503. [0732‐183X] GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: comparison of toxicities and patient‐stated preference for oral versus intravenous delivery. Journal of Clinical Oncoloy2014;32(15 Suppl):558. NCT00127205 . Zoledronate, clodronate, or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer. clinicaltrials.gov/ct2/show/NCT00127205 (accessed 30 April 2011); Vol. Date first received: 3 August 2005. ">SWOG‐S0307 2015</a> is investigating the relative potency between zoledronate, clodronate and oral ibandronate for 36 months; we have contacted the trialists. Denosumab is also pushing forward to be studied in preventing recurrence in EBC studies with two ongoing studies; one closed to recruitment (<a href="./references#CD003474-bbs2-0066" title="BellR , GossPE , BarriosCH , FinkelsteinD , IwataH , MartinM , et al. A randomised, double‐blind, placebo‐controlled multicentre phase 3 study comparing denosumab with placebo as adjuvant treatment for women with early‐stage breast cancer who are at high risk of disease recurrence (D‐care). Asia‐Pacific Journal of Clinical Oncology2011;7:150. GossPE , BarriosCH , BellR , FinkelsteinD , IwataH , MartinM , et al. A phase 3 randomized, double‐blind, placebo‐controlled multicenter study comparing denosumab with placebo as adjuvant treatment for women with early‐stage breast cancer who are at high risk of disease recurrence (D‐CARE). Cancer Research2011;71(24 Suppl):OT1‐01. GossPE , BarriosCH , BellR , FinkelsteinD , IwataH , MartinM , et al. A randomized, double‐blind, placebo‐controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early‐stage breast cancer who are at high risk of disease recurrence (D‐CARE). Journal of Clinical Oncology2011;29(15 Suppl):published online before print. GossPE , BarriosCH , BellR , FinkelsteinDM , IwataH , MartinM , et al. Denosumab versus placebo as adjuvant treatment for women with early‐stage breast cancer who are at high risk of disease recurrence (D‐CARE): an international, randomized, double‐blind, placebo‐controlled phase III clinical trial. Journal of Clinical Oncology2012;30(15 Suppl):Published online before print. GossPE , BarriosCH , ChanA , FinkelsteinDM , IwataH , MartinM , et al. Denosumab versus placebo as adjuvant treatment for women with early‐stage breast cancer at high risk of disease recurrence (D‐CARE): a global, placebo‐controlled, randomized, double‐blind, phase 3 clinical trial. Cancer Research2013;73:OT2‐6. GossPE , BarriosCH , ChanA , FinkelsteinDM , IwataH , MartinM , et al. Denosumab versus placebo as adjuvant treatment for women with early‐stage breast cancer at high risk of disease recurrence (D‐CARE): an international, placebo‐controlled, randomized, double‐blind phase III clinical trial. Journal of Clinical Oncology2013;31(15 Suppl):published online before print. GossPE , BarriosCH , ChanA , FinkelsteinDM , IwataH , MartinM , et al. Denosumab versus placebo as adjuvant treatment for women with early‐stage breast cancer at high risk of disease recurrence (D‐CARE): an international, randomized, double‐blind, placebo‐controlled phase 3 clinical trial. Cancer Research2012;72(24 Suppl):OT2‐3‐03. NCT01077154 . Study of denosumab as adjuvant treatment for women with high risk early breast cancer receiving neoadjuvant or adjuvant therapy (D‐CARE). clinicaltrials.gov/ct2/show/NCT01077154 Date first received: 4 February 2010. ">D‐CARE 2011</a>) and the other having commenced recruitment (<a href="./references#CD003474-bbs2-0074" title="KummelS , VonMG , NekljudovaV , DanCS , DenkertC , HanuschC , et al. Investigating denosumab as add‐on neoadjuvant treatment for hormone receptor‐negative, RANK‐positive or RANK‐negative primary breast cancer and two different nab‐Paclitaxel schedules‐2x2 factorial design (GeparX). Journal of Clinical Oncology2016;34(15 Suppl):TPS635. [1527‐7755] ">Kummel 2016 (GeparX)</a>). </p> <p>The included studies used a range of bisphosphonates and schedules. In the majority of cases, the duration of treatment ranged from two to five years. The variations in bisphosphonate regimens involved: (a) zoledronate: 4 mg every six months for three years (<a href="./references#CD003474-bbs2-0001" title="GnantM , MlineritschB , Luschin‐EbengreuthG , StoegerH , DubskyP , JakeszR , et al. Long‐term follow‐up in ABCSG‐12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine‐receptor‐positive early breast cancer. Cancer Research2011;71:S1‐2. GnantM , MlineritschB , SchippingerW , Luschin‐EbengreuthG , PöstlbergerS , MenzelC , et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New England Journal of Medicine2009;360(7):679‐91. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , HeckD , MenzelC , et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early‐stage breast cancer: 62‐month follow‐up from the ABCSG‐12 randomised trial. Lancet Oncology2011;12(7):631‐41. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , KnauerM , MoikM , et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Annals of Oncology2015; Vol. 26, issue 2:313‐20. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , PoestlbergerS , DubskyPC , et al. Mature results from ABCSG‐12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine‐responsive early breast cancer. Journal of Clinical Oncology2010;28(15 Suppl):533. ">ABCSG‐12 2011</a>) or five years (<a href="./references#CD003474-bbs2-0013" title="LlombartA , FrassoldatiA , PaijaO , SleeboomHP , JerusalemG , MebisJ , et al. Immediate administration of zoledronic acid reduces aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer: 12‐month analysis of the E‐ZO‐FAST trial. Clinical Breast Cancer2012;12(1):40‐8. LlombartoA , FrassoldatiA , PaijaO , SleeboomHP , JerusalemG , MebisJ , et al. Effect of zoledronic acid on aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E‐ZO‐FAST 36‐month follow‐up. ASCO Breast Cancer Symposium; 2009; Chicago. Chicago: American Society of Clinical Oncology, 2009. ">E‐ZO‐FAST 2012</a>; <a href="./references#CD003474-bbs2-0041" title="BrufskyA ,  BundredN ,  ColemanR ,  Lambert‐FallsR ,  MenaR ,  HadjiP , et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist2008;13(5):503‐14. BrufskyA ,  HarkerWG ,  BeckJT ,  CarrollR ,  Tan‐ChiuE ,  SeidlerC , et al. Zoledronic acid inhibits adjuvant letrozole‐induced bone loss in postmenopausal women with early breast cancer. Journal of Clinical Oncology2007;25(7):829‐36. BrufskyAM , HarkerWG , BeckJT , BossermanL , VogelC , SeidlerC , et al. Final 5‐year results of Z‐FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer2012;118(5):1192‐201. BrufskyAM ,  BossermanLD ,  CaradonnaRR ,  HaleyBB ,  JonesCM ,  MooreHC ,  etal . Zoledronic acid effectively prevents aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z‐FAST study 36‐month follow‐up results. Clinical Breast Cancer2009;9(2):77‐85. ">Z‐FAST 2012</a>; <a href="./references#CD003474-bbs2-0043" title="ColemanR , DeBoerR , EidtmannH , LlombartA , DavidsonN , NevenP , et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO‐FAST study): final 60‐month results. Annals of Oncology2013;24(2):398‐405. ColemanR , DeBoerR , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Influence of delayed zoledronic acid initiation on disease‐free survival in postmenopausal women with endocrine receptor‐positive early breast cancer receiving adjuvant letrozole: exploratory analysis from the ZO‐FAST trial. Cancer Research2011;71(24 Suppl):P2‐17‐01. DeBoerR , BundredN , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Long‐term survival outcomes among postmenopausal women with hormone receptor‐positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5‐year follow‐up of ZO‐FAST. Cancer Research2011;71(24 Suppl):S1‐3. DeBoerR , MartinM , StegerGG , VonMoosR , StopeckA , TonkinK , et al. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMs): a number‐needed‐to‐treat (NNT) analysis. Asia‐Pacific Journal of Clinical Oncology2011;7(3 Suppl):9. EidtmannH , DeBoerR , BundredN , Llombart‐CussacA , DavidsonN , NevenP , et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36‐month results of the ZO‐FAST Study. Annals of Oncology2010;21(11):2188‐94. ">ZO‐FAST 2013</a>), or 4 mg de‐escalating schedule over five years (<a href="./references#CD003474-bbs2-0005" title="ColemanR , CameronD , DodwellD , BellR , WilsonC , RathboneE , et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open‐label phase 3 trial. Lancet Oncology2014;15(9):997‐1006. ColemanR , WoodwardE , BrownJ , CameronD , BellR , DodwellD , et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01‐04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment2011;127(2):429‐38. ColemanR , WoodwardE , TurnerL , MarshallH , CollinsonM , DodwellD , et al. Impact of zoledronic acid on fractures, bone mineral density and bone remodeling in the AZURE trial (BIG 01‐04). Cancer Research2011;71(24 Suppl):P2‐19‐01. ColemanRE , MarshallH , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Breast‐cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine2011;365(15):1396‐405. ColemanRE , RathboneEJ , MarshallHC , WilsonC , BrownJE , GossielF , et al. Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study. Cancer Research2012;72(24 Suppl):S6‐4. ColemanRE , ThorpeHC , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Cancer Research2010;70(24 Suppl):S4‐5. ColemanRE , WinterMC , CameronD , BellR , DodwellD , KeaneMM , et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti‐tumour activity in breast cancer. British Journal of Cancer2010;102(7):1099‐105. RathboneEJ , BrownJE , MarshallHC , CollinsonM , LiversedgeV , MurdenGA , et al. Osteonecrosis of the jaw and oral health‐related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). Journal of Clinical Oncology2013;31(21):2685‐91. ">AZURE 2014</a>); (b) clodronate: oral 1600 mg a day for two to three years (<a href="./references#CD003474-bbs2-0027" title="PatersonAH , AndersonSJ , LemberskyBC , FehrenbacherL , FalksonCI , KingKM , et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B‐34): a multicentre, placebo‐controlled, randomised trial. Lancet Oncology2012; Vol. 13, issue 7:734‐42. PatersonAHG , AndersonSJ , LemberskyBC , FehrenbacherL , FalksonCI , KingKM , et al. NSABP protocol B‐34: a clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy ‐ final analysis. Cancer Research2011;71(24 Suppl):S2‐3. ">NSABP‐34 2012</a>; <a href="./references#CD003474-bbs2-0030" title="AtulaST , PatersonAHG , PowlesTJ , McLoskeyEV , NevalainenJI , KanisJA . Extended safety profile of oral clodronate after long‐term use in primary breast cancer patients. Drug Safety2003;26(9):661‐71. McCloskeyE , PatersonA , KanisJ , TahtelaR , PowlesT . Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. European Journal of Cancer2009;46(3):558‐65. PowlesT , McCloskeyE , KurkilahtiM , KurkilahtiM , KanisJ . Oral clodronate for the adjuvant treatment of operable breast cancer: results of a randomised, double‐blind, placebo‐controlled multicenter trial. Journal of Clinical Oncology2004;22(14 Suppl):528. PowlesT ,  PatersonA ,  McCloskeyE ,  ScheinP ,  SchefflerB ,  TidyA , et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Research2006;8(2):13. PowlesT ,  PatersonS ,  KanisJA ,  McCloskeyE ,  AshleyS ,  TidyA , et al. Randomized, placebo‐controlled trial of clodronate in patients with primary operable breast cancer. Journal of Clinical Oncology2002;20(15):3219‐24. ">Powles 2006</a>; <a href="./references#CD003474-bbs2-0032" title="SaartoT , BlomqvistC , VirkkunenP , ElomaaI . Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node‐positive breast cancer patients: 5 year results of a randomised controlled study. Journal of Clinical Oncology2001;19(1):10‐17. SaartoT , VehmanenL , VirkkunenP , BlomqvistC . Ten‐year follow‐up of a randomized controlled trial of adjuvant clodronate treatment in node‐positive breast cancer patients. Acta Oncologica2004;43(7):650‐6. ">Saarto 2004</a>) or (c) pamidronate: oral 300 mg a day for two years (<a href="./references#CD003474-bbs2-0022" title="KristensenB ,  EjlertsenB ,  MouridsenHT ,  JensenMB ,  AndersenJ ,  BjerregaardB , et al. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncologica2008;47(4):740‐6. ">Kristensen 2008</a>). </p> <p>The immediate commencement of adjuvant bisphosphonates was not superior to a delayed start, triggered by falling BMD or fracture, in preventing recurrence (or any recurrence sub‐set) or improving survival. These trials were primarily powered to detect differences in BMD at 12 months and were not powered for clinical outcome data such as recurrence, disease‐free survival or overall survival. </p> <p>The majority of recently published studies examining the effects of bisphosphonates or bone‐modifying agents in metastatic breast cancer with bone metastases did not collect or report data on overall survival. The ongoing studies intend to use bone pain or SREs, or both, as the primary endpoints (<a href="./references#CD003474-sec-0224" title="">Characteristics of ongoing studies</a>). Five of these studies will be investigating upfront versus delayed bisphosphonates or denosumab while the others are comparing different bisphosphonates head‐to‐head (e.g. zoledronate versus pamidronate, denosumab versus zoledronate). </p> <p>Similar to the EBC studies, the included studies in the BCBM setting used a wide range of bisphosphonate agents and schedules. The duration of treatment ranged from 25 weeks (<a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a>) to three years (<a href="./references#CD003474-bbs2-0029" title="PatersonAHG , KanisJA , PowlesTJ , McCloskeyEV , ArchabaultWT , KurmanMR , et al. A re‐analysis of a trial of clodronate in patients with breast cancer and bone metastases. Anthra Pharmaceuticals. PatersonAHG , PowlesTJ , KanisJA , McCloskeyE , HansonJ , AshleyS . Double‐blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(1):59‐65. ">Paterson 1993</a>). The optimal timing and duration of treatment for women with BCBM remains uncertain. </p> </section> <section id="CD003474-sec-0187"> <h3 class="title" id="CD003474-sec-0187">Quality of the evidence</h3> <p>In general, we judged the overall body of evidence to be moderate or high quality across the three treatment settings (see: <a href="./full#CD003474-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD003474-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD003474-tbl-0003">summary of findings Table 3</a>). In the cases where some heterogeneity was observed in the meta‐analyses, the heterogeneity could be explained by removing studies that used sub‐optimal doses of pamidronate (45 mg or 60 mg) that are rarely used in practice today or by analysing data by menopausal status (as in the case for overall survival in the EBC studies). Therefore in the majority of these cases, we did not downgrade the quality of the evidence. Most of the outcomes presented in the 'Summary of findings' table indicated consistent findings across the studies, and this held true when we carried out additional analyses by considering mode of drug administration (e.g. intravenous bisphosphonate versus placebo; oral bisphosphonate versus placebo). </p> <p>We downgraded the quality of the evidence primarily in those cases where outcomes (such as bone pain or quality of life) were measured on unvalidated scales or questionnaires and involved participant self‐reporting when the participant was aware of the drug received. </p> </section> <section id="CD003474-sec-0188"> <h3 class="title" id="CD003474-sec-0188">Potential biases in the review process</h3> <p>This review has aimed to provide a thorough overview of the benefits and toxicities from bisphosphonates and denosumab across studies and treatment settings. Despite having conducted a comprehensive search of medical databases and key conference proceedings, we may not have identified all potentially relevant studies. We conducted tests for funnel plot asymmetry for main outcomes and the plots did not strongly indicate publication/reporting bias or other sources of bias (e.g. true heterogeneity). In the review update, we contacted study authors if (a) data were not fully reported in the full‐text article or (b) overall survival or disease‐free survival were not reported by menopausal status. In some cases, data were available in abstract form (e.g. <a href="./references#CD003474-bbs2-0008" title="HimelsteinAL , QinR , NovotnyPJ , SeislerDK , KhatcheressianJL , RobertsJD , et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of Clinical Oncology2015; Vol. 33, issue 15 Suppl:9501. [0732‐183X] NCT00869206 . Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. clinicaltrials.gov/ct2/show/NCT00869206 Date first received: 24 March 2009. ">CALGB‐70604 2015</a>; <a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a>; <a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a>; <a href="./references#CD003474-bbs2-0034" title="GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG‐ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. Journal of Clinical Oncology2015;33(15 Suppl):503. [0732‐183X] GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: comparison of toxicities and patient‐stated preference for oral versus intravenous delivery. Journal of Clinical Oncoloy2014;32(15 Suppl):558. NCT00127205 . Zoledronate, clodronate, or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer. clinicaltrials.gov/ct2/show/NCT00127205 (accessed 30 April 2011); Vol. Date first received: 3 August 2005. ">SWOG‐S0307 2015</a>). Clinical trials registries were also searched and matched against eligible trials though some ongoing trials in the registries may have been missed due to the large number of trial records retrieved on this topic. </p> <p>For a number of studies, we are still awaiting more mature follow‐up data, particularly in the BCBM studies and a number of studies poorly reported toxicities that in part reflects the age of some of these studies (e.g. from the late 1990s particularly in the ABC studies). </p> <p>We have indicated throughout the review that a number of large trials are awaiting final completion and publication in EBC and BCBM before firm conclusions can be drawn. </p> </section> <section id="CD003474-sec-0189"> <h3 class="title" id="CD003474-sec-0189">Agreements and disagreements with other studies or reviews</h3> <section id="CD003474-sec-0190"> <h4 class="title">Early breast cancer</h4> <p>The finding of this systematic review replicate the main findings presented in the American Society of Clinical Oncology (ASCO) <a href="./references#CD003474-bbs2-0087" title="Dhesy‐ThindS , FletcherGG , BlanchettePS , ClemonsMJ , DillmonMS , FrankES , et al. Use of adjuvant bisphosphonates and other bone‐modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology2017;35(18):2062‐81. ">ASCO Guidelines 2017</a>. The individual participant meta‐analysis (IPD) conducted by the Early Breast Cancer Trialists Collaborative Group (<a href="./references#CD003474-bbs2-0099" title="Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta‐analyses of individual patient data from randomised trials. Lancet 3;386(10001):1353‐61. ">EBCTCG 2015</a>) that involved 18,766 women described reductions in overall recurrence (RR 0.94, 95 % CI 0.87 to 1.01; P = 0.08, heterogeneity across trials P = 0.04) and distant recurrence (RR 0.92, 95% CI 0.85 to 0.99; P = 0.03, heterogeneity across trials P = 0.04) but highlighted these to be of modest effect size and/or borderline statistical significance. The <a href="./references#CD003474-bbs2-0099" title="Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta‐analyses of individual patient data from randomised trials. Lancet 3;386(10001):1353‐61. ">EBCTCG 2015</a> meta‐analysis also reported that adjuvant bisphosphonates among premenopausal women had no apparent effect on any outcome; but among 11,767 postmenopausal women it produced highly significant reductions in recurrence (RR 0.86, 95% CI 0.78 to 0.98; P = 0.002), distant recurrence (RR 0.82, 95% CI 0.74 to 0.92, P = 0.0003), bone recurrence (RR 0.72, 95% CI 0.60 to 0.86; P = 0.0002), and breast cancer mortality (RR 0.82, 95% CI 0.73 to 0.93, P = 0.002). In our analyses, we did not detect an effect of bisphosphonates for visceral metastases, overall recurrence (locoregional plus distant recurrence) or locoregional recurrence. However we did observe a benefit from bisphosphonates for bone recurrence and also noted for overall survival (HR 0.91, 95% CI 0.83 to 0.99) and disease‐free survival (specifically comparing intravenous zoledronate versus placebo/delayed zoledronate: HR 0.89; 95% CI 0.80 to 0.98; P = 0.02) when analysing data using time‐to‐event outcomes. We did not collect information specifically on breast cancer‐specific mortality. Our aggregate meta‐analysis for disease‐free survival and overall survival (using time‐to‐event outcomes) was limited to nine trials for overall survival (13,949 women) and seven trials for disease‐free survival (12,578 women) and outcome data stratified by menopausal status were not available for all these studies. In those studies where data were available for postmenopausal women, preliminary evidence suggested a benefit from adjuvant bisphosphonates for overall survival and disease‐free survival. These overall survival findings concur with <a href="./references#CD003474-bbs2-0087" title="Dhesy‐ThindS , FletcherGG , BlanchettePS , ClemonsMJ , DillmonMS , FrankES , et al. Use of adjuvant bisphosphonates and other bone‐modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology2017;35(18):2062‐81. ">ASCO Guidelines 2017</a>. </p> </section> <section id="CD003474-sec-0191"> <h4 class="title">Advanced breast cancer without bone metastases</h4> <p>No other publications are on this topic; all new studies are undertaken in women with BCBM. </p> </section> <section id="CD003474-sec-0192"> <h4 class="title">Breast cancer with bone metastases</h4> <p>The results of the meta‐analyses in this review are largely consistent with the <a href="./references#CD003474-bbs2-0086" title="PoznakCHV , TeminS , YeeGC , JanjanNA , BarlowWE , BiermannJS , et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone‐modifying agents in metastatic breast cancer. Journal of Clinical Oncology2011; Vol. 29, issue 9:1221‐7. ">ASCO Guidelines 2011</a> on the use of bisphosphonate treatment in women with BCBM. The guideline recommends the use of intravenous bisphosphonates (pamidronate, zoledronate) in BCBM. <a href="./references#CD003474-bbs2-0086" title="PoznakCHV , TeminS , YeeGC , JanjanNA , BarlowWE , BiermannJS , et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone‐modifying agents in metastatic breast cancer. Journal of Clinical Oncology2011; Vol. 29, issue 9:1221‐7. ">ASCO Guidelines 2011</a> also recommends the use of denosumab and acknowledges the fact that ibandronate and clodronate are used for the management of BCBM in countries other than the USA, but it has not discussed the relevance of these two drugs or included them in its recommendations because these two drugs are not Federal Drug Agency (FDA)‐approved in the USA for the indication of BCBM. </p> <p>Both ASCO Guidelines and European Society for Medical Oncology (ESMO) Guidelines (<a href="./references#CD003474-bbs2-0102" title="ColemanR , BodyJJ , AaproM , HadjiP , HerrstedtJ . Bone health in cancer patients: ESMO Clinical Practice Guidelines. Annals of Oncology2014; Vol. 25, issue suppl 3:iii124‐37. ">ESMO Clinical Practice Guidelines 2014</a>) recognise the paucity of evidence of treatment beyond two years. None of the studies included in this Cochrane Review update included data beyond two years. </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003474-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram  ABC: advanced breast cancer; ASCO: American Society of Clinical Oncology; BCBM: breast cancer with bone metastases; EBC: early breast cancer; SABCS: San Antonio Breast Cancer Symposium" data-id="CD003474-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram<br/> <b>ABC</b> : advanced breast cancer; <b>ASCO</b> : American Society of Clinical Oncology; <b>BCBM</b> : breast cancer with bone metastases; <b>EBC</b> : early breast cancer; <b>SABCS</b>: San Antonio Breast Cancer Symposium </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD003474-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Early breast cancer (EBC), outcome: 3.1 Incidence of bone metastases in EBC: bisphosphonate versus control" data-id="CD003474-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Early breast cancer (EBC), outcome: 3.1 Incidence of bone metastases in EBC: bisphosphonate versus control </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Early Breast Cancer (EBC), outcome: 1.7 Overall survival: time‐to‐event outcome." data-id="CD003474-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Early Breast Cancer (EBC), outcome: 1.7 Overall survival: time‐to‐event outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Early Breast Cancer (EBC), outcome: 1.7 Overall survival: time‐to‐event outcome." data-id="CD003474-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Early Breast Cancer (EBC), outcome: 1.7 Overall survival: time‐to‐event outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Early Breast Cancer (EBC), outcome: 1.11 Overall survival by menopausal status: time‐to‐event outcome." data-id="CD003474-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Early Breast Cancer (EBC), outcome: 1.11 Overall survival by menopausal status: time‐to‐event outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Early Breast Cancer (EBC), outcome: 1.13 Disease‐free survival: time‐to‐event outcome." data-id="CD003474-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Early Breast Cancer (EBC), outcome: 1.13 Disease‐free survival: time‐to‐event outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Advanced breast cancer (ABC), outcome: 2.1 Incidence of bone metastases in ABC (Stage III/IV)" data-id="CD003474-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Advanced breast cancer (ABC), outcome: 2.1 Incidence of bone metastases in ABC (Stage III/IV) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Breast cancer and Bone Metastases (BCBM), outcome: 1.2 Overall risk of SREs in BCBM: bisphosphonate versus control (excluding hypercalcaemia)." data-id="CD003474-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Breast cancer and Bone Metastases (BCBM), outcome: 1.2 Overall risk of SREs in BCBM: bisphosphonate versus control (excluding hypercalcaemia). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Breast cancer with bone metastases (BCBM), outcome: 1.3 Overall risk of skeletal events in BCBM: denosumab versus bisphosphonate" data-id="CD003474-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Breast cancer with bone metastases (BCBM), outcome: 1.3 Overall risk of skeletal events in BCBM: denosumab versus bisphosphonate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Early Breast Cancer (EBC), Outcome 1 Bone metastases." data-id="CD003474-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Early Breast Cancer (EBC), Outcome 1 Bone metastases.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Early Breast Cancer (EBC), Outcome 2 Bone metastases by bisphosphonate." data-id="CD003474-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Early Breast Cancer (EBC), Outcome 2 Bone metastases by bisphosphonate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Early Breast Cancer (EBC), Outcome 3 Visceral recurrence." data-id="CD003474-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Early Breast Cancer (EBC), Outcome 3 Visceral recurrence.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Early Breast Cancer (EBC), Outcome 4 Locoregional recurrence." data-id="CD003474-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Early Breast Cancer (EBC), Outcome 4 Locoregional recurrence.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Early Breast Cancer (EBC), Outcome 5 Overall recurrence." data-id="CD003474-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Early Breast Cancer (EBC), Outcome 5 Overall recurrence.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Early Breast Cancer (EBC), Outcome 6 Overall recurrence by bisphosphonate." data-id="CD003474-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Early Breast Cancer (EBC), Outcome 6 Overall recurrence by bisphosphonate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-001-07.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Early Breast Cancer (EBC), Outcome 7 Overall survival: time‐to‐event outcome." data-id="CD003474-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Early Breast Cancer (EBC), Outcome 7 Overall survival: time‐to‐event outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Early Breast Cancer (EBC), Outcome 8 Overall survival: dichotomous outcome." data-id="CD003474-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Early Breast Cancer (EBC), Outcome 8 Overall survival: dichotomous outcome.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Early Breast Cancer (EBC), Outcome 9 Overall survival by bisphosphonate: time‐to‐event outcome." data-id="CD003474-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Early Breast Cancer (EBC), Outcome 9 Overall survival by bisphosphonate: time‐to‐event outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Early Breast Cancer (EBC), Outcome 10 Overall survival by bisphosphonate: dichotomous outcome." data-id="CD003474-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Early Breast Cancer (EBC), Outcome 10 Overall survival by bisphosphonate: dichotomous outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-001-11.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Early Breast Cancer (EBC), Outcome 11 Overall survival by menopausal status: time‐to‐event outcome." data-id="CD003474-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Early Breast Cancer (EBC), Outcome 11 Overall survival by menopausal status: time‐to‐event outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Early Breast Cancer (EBC), Outcome 12 Overall survival by menopausal status: dichotomous outcome." data-id="CD003474-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Early Breast Cancer (EBC), Outcome 12 Overall survival by menopausal status: dichotomous outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-001-13.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Early Breast Cancer (EBC), Outcome 13 Disease‐free survival: time‐to‐event outcome." data-id="CD003474-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Early Breast Cancer (EBC), Outcome 13 Disease‐free survival: time‐to‐event outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Early Breast Cancer (EBC), Outcome 14 Disease‐free survival: dichotomous outcome." data-id="CD003474-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Early Breast Cancer (EBC), Outcome 14 Disease‐free survival: dichotomous outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Early Breast Cancer (EBC), Outcome 15 Disease‐free survival by bisphosphonate: time‐to‐event outcome." data-id="CD003474-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Early Breast Cancer (EBC), Outcome 15 Disease‐free survival by bisphosphonate: time‐to‐event outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Early Breast Cancer (EBC), Outcome 16 Disease‐free survival by bisphosphonate: dichotomous outcome." data-id="CD003474-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Early Breast Cancer (EBC), Outcome 16 Disease‐free survival by bisphosphonate: dichotomous outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Early Breast Cancer (EBC), Outcome 17 Disease‐free survival by menopausal status: time‐to‐event outcome." data-id="CD003474-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Early Breast Cancer (EBC), Outcome 17 Disease‐free survival by menopausal status: time‐to‐event outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Early Breast Cancer (EBC), Outcome 18 Disease‐free survival by menopausal status: dichotomous outcome." data-id="CD003474-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Early Breast Cancer (EBC), Outcome 18 Disease‐free survival by menopausal status: dichotomous outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Early Breast Cancer (EBC), Outcome 19 Fracture incidence." data-id="CD003474-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Early Breast Cancer (EBC), Outcome 19 Fracture incidence.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Advanced Breast Cancer (ABC), Outcome 1 Bone metastases." data-id="CD003474-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Advanced Breast Cancer (ABC), Outcome 1 Bone metastases.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Advanced Breast Cancer (ABC), Outcome 2 Overall survival." data-id="CD003474-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Advanced Breast Cancer (ABC), Outcome 2 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Breast cancer and bone metastases (BCBM), Outcome 1 SREs: bisphosphonate vs placebo/observation (including hypercalcaemia)." data-id="CD003474-fig-0032" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Breast cancer and bone metastases (BCBM), Outcome 1 SREs: bisphosphonate vs placebo/observation (including hypercalcaemia). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-003-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Breast cancer and bone metastases (BCBM), Outcome 2 SREs: bisphosphonate vs placebo/observation (excluding hypercalcaemia)." data-id="CD003474-fig-0033" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Breast cancer and bone metastases (BCBM), Outcome 2 SREs: bisphosphonate vs placebo/observation (excluding hypercalcaemia). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Breast cancer and bone metastases (BCBM), Outcome 3 SREs: by route of administration." data-id="CD003474-fig-0034" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Breast cancer and bone metastases (BCBM), Outcome 3 SREs: by route of administration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Breast cancer and bone metastases (BCBM), Outcome 4 SREs: by bisphosphonate." data-id="CD003474-fig-0035" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Breast cancer and bone metastases (BCBM), Outcome 4 SREs: by bisphosphonate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-003-05.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Breast cancer and bone metastases (BCBM), Outcome 5 SREs: denosumab vs bisphosphonate." data-id="CD003474-fig-0036" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Breast cancer and bone metastases (BCBM), Outcome 5 SREs: denosumab vs bisphosphonate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Breast cancer and bone metastases (BCBM), Outcome 6 SREs: standard vs reduced frequency bone‐targeted agent." data-id="CD003474-fig-0037" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Breast cancer and bone metastases (BCBM), Outcome 6 SREs: standard vs reduced frequency bone‐targeted agent. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Breast cancer and bone metastases (BCBM), Outcome 7 Median time to SRE." data-id="CD003474-fig-0038" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Breast cancer and bone metastases (BCBM), Outcome 7 Median time to SRE.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003474-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/urn:x-wiley:14651858:media:CD003474:CD003474-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_t/tCD003474-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Breast cancer and bone metastases (BCBM), Outcome 8 Overall survival." data-id="CD003474-fig-0039" src="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Breast cancer and bone metastases (BCBM), Outcome 8 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/media/CDSR/CD003474/image_n/nCD003474-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003474-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Bisphosphonates compared to placebo/observation for women with early breast cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Bisphosphonates compared to placebo/observation for women with early breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with early breast cancer<br/> <b>Setting:</b> clinic and at home<br/> <b>Intervention:</b> intravenous bisphosphonates (zoledronate 4 mg every 3 weeks) or oral bisphosphonates (clodronate 1600 mg/day or ibandronate 50 mg/day or pamidronate 300 mg/day)<br/> <b>Comparison:</b> placebo/observation </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo/observation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with bisphosphonates</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Bone metastases</b><br/> Follow‐up: range 1 year to 10 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.86<br/> (0.75 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>15,005<br/> (11 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Additional analysis of iv zoledronate or oral clodronate showed a treatment benefit when compared to placebo/control </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>90 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>77 per 1000<br/> (67 to 89) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b><br/> Follow‐up: range 3 years to 10 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>3‐year risk of death<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.91<br/> (0.83 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13,949<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1000<br/> (67 to 79) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival postmenopausal women</b><br/> Follow‐up: range 7 years to 7.5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000<br/> (33 to 45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.77<br/> (0.66 to 0.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6048<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A sensitivity analysis removing <a href="./references#CD003474-bbs2-0043" title="ColemanR , DeBoerR , EidtmannH , LlombartA , DavidsonN , NevenP , et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO‐FAST study): final 60‐month results. Annals of Oncology2013;24(2):398‐405. ColemanR , DeBoerR , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Influence of delayed zoledronic acid initiation on disease‐free survival in postmenopausal women with endocrine receptor‐positive early breast cancer receiving adjuvant letrozole: exploratory analysis from the ZO‐FAST trial. Cancer Research2011;71(24 Suppl):P2‐17‐01. DeBoerR , BundredN , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Long‐term survival outcomes among postmenopausal women with hormone receptor‐positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5‐year follow‐up of ZO‐FAST. Cancer Research2011;71(24 Suppl):S1‐3. DeBoerR , MartinM , StegerGG , VonMoosR , StopeckA , TonkinK , et al. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMs): a number‐needed‐to‐treat (NNT) analysis. Asia‐Pacific Journal of Clinical Oncology2011;7(3 Suppl):9. EidtmannH , DeBoerR , BundredN , Llombart‐CussacA , DavidsonN , NevenP , et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36‐month results of the ZO‐FAST Study. Annals of Oncology2010;21(11):2188‐94. ">ZO‐FAST 2013</a> (due to the control arm being delayed bisphosphonate) showed equivalent efficacy (HR 0.78, 95% CI 0.66 to 0.92, 3 studies, 4984 women) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival: pre‐ or perimenopausal women</b><br/> Follow‐up: range 5 years to 8 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>51 per 1000<br/> (43 to 60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 1.03<br/> (0.86 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3501<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Disease‐free progression</b><br/> follow‐up: range 3 years to 10 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>3‐year risk of recurrence<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.94<br/> (0.87 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12578<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>113 per 1000<br/> (105 to 122) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐free progression: postmenopausal women</b><br/> Follow‐up: range 3 years to 7.8 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000<sup>e</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000<br/> (83 to 101) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.82<br/> (0.74 to 0.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8314<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A sensitivity analysis removing <a href="./references#CD003474-bbs2-0041" title="BrufskyA ,  BundredN ,  ColemanR ,  Lambert‐FallsR ,  MenaR ,  HadjiP , et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist2008;13(5):503‐14. BrufskyA ,  HarkerWG ,  BeckJT ,  CarrollR ,  Tan‐ChiuE ,  SeidlerC , et al. Zoledronic acid inhibits adjuvant letrozole‐induced bone loss in postmenopausal women with early breast cancer. Journal of Clinical Oncology2007;25(7):829‐36. BrufskyAM , HarkerWG , BeckJT , BossermanL , VogelC , SeidlerC , et al. Final 5‐year results of Z‐FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer2012;118(5):1192‐201. BrufskyAM ,  BossermanLD ,  CaradonnaRR ,  HaleyBB ,  JonesCM ,  MooreHC ,  etal . Zoledronic acid effectively prevents aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z‐FAST study 36‐month follow‐up results. Clinical Breast Cancer2009;9(2):77‐85. ">Z‐FAST 2012</a> and <a href="./references#CD003474-bbs2-0043" title="ColemanR , DeBoerR , EidtmannH , LlombartA , DavidsonN , NevenP , et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO‐FAST study): final 60‐month results. Annals of Oncology2013;24(2):398‐405. ColemanR , DeBoerR , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Influence of delayed zoledronic acid initiation on disease‐free survival in postmenopausal women with endocrine receptor‐positive early breast cancer receiving adjuvant letrozole: exploratory analysis from the ZO‐FAST trial. Cancer Research2011;71(24 Suppl):P2‐17‐01. DeBoerR , BundredN , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Long‐term survival outcomes among postmenopausal women with hormone receptor‐positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5‐year follow‐up of ZO‐FAST. Cancer Research2011;71(24 Suppl):S1‐3. DeBoerR , MartinM , StegerGG , VonMoosR , StopeckA , TonkinK , et al. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMs): a number‐needed‐to‐treat (NNT) analysis. Asia‐Pacific Journal of Clinical Oncology2011;7(3 Suppl):9. EidtmannH , DeBoerR , BundredN , Llombart‐CussacA , DavidsonN , NevenP , et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36‐month results of the ZO‐FAST Study. Annals of Oncology2010;21(11):2188‐94. ">ZO‐FAST 2013</a> (due to the control arm being delayed bisphosphonate), showed equivalent efficacy (HR 0.83, 95% CI 0.74 to 0.93; 5 studies; 6650 women) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐free progression: pre‐ or perimenopausal women</b><br/> Follow‐up: range 3 years to 7.5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000<sup>e</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000<br/> (100 to 124) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 1.01<br/> (0.90 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5493<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fracture incidence</b><br/> Follow‐up: range 5 years to 7.8 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.77<br/> (0.54 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7602<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Three studies used iv bisphosphonate (zoledronate) and three studies used oral bisphosphonate (clodronate or pamidronate) compared to placebo </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000<br/> (31 to 62) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Osteonecrosis of the jaw (ONJ)</b><br/> Follow‐up: range 1 year to 7.5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Bisphosphonates: approximately 35 events of ONJ were recorded in 7047 women</p> <p>Placebo/open: no events of ONJ were recorded in 6195 women</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,242<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Six studies used iv bisphosphonates (zoledronate) and three studies used oral bisphosphonates (ibandronate or clodronate). Most ONJ events came from 2 studies using iv zoledronate (<a href="./references#CD003474-bbs2-0005" title="ColemanR , CameronD , DodwellD , BellR , WilsonC , RathboneE , et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open‐label phase 3 trial. Lancet Oncology2014;15(9):997‐1006. ColemanR , WoodwardE , BrownJ , CameronD , BellR , DodwellD , et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01‐04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment2011;127(2):429‐38. ColemanR , WoodwardE , TurnerL , MarshallH , CollinsonM , DodwellD , et al. Impact of zoledronic acid on fractures, bone mineral density and bone remodeling in the AZURE trial (BIG 01‐04). Cancer Research2011;71(24 Suppl):P2‐19‐01. ColemanRE , MarshallH , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Breast‐cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine2011;365(15):1396‐405. ColemanRE , RathboneEJ , MarshallHC , WilsonC , BrownJE , GossielF , et al. Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study. Cancer Research2012;72(24 Suppl):S6‐4. ColemanRE , ThorpeHC , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Cancer Research2010;70(24 Suppl):S4‐5. ColemanRE , WinterMC , CameronD , BellR , DodwellD , KeaneMM , et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti‐tumour activity in breast cancer. British Journal of Cancer2010;102(7):1099‐105. RathboneEJ , BrownJE , MarshallHC , CollinsonM , LiversedgeV , MurdenGA , et al. Osteonecrosis of the jaw and oral health‐related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). Journal of Clinical Oncology2013;31(21):2685‐91. ">AZURE 2014</a> &amp; <a href="./references#CD003474-bbs2-0026" title="MinckwitzG , RezaiM , TeschH , HuoberJ , GerberB , ZahmDM , et al. Zoledronate for patients with invasive residual disease after anthracyclines‐taxane‐based chemotherapy for early breast cancer ‐ the phase III NeoAdjuvant Trial Add‐oN (NaTaN) study (GBG 36/ABCSG 29). European Journal of Cancer2016;64:12‐21. NCT00512993 . Postoperative use of zoledronic acid in breast cancer patients after neoadjuvant chemotherapy (NATAN). clinicaltrials.gov/ct2/show/NCT00512993 Date first received: 3 August 2007. vonMinckwitzG , RezaiM , EidtmannH , TeschH , HuoberJ , GerberB , et al. Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines‐taxane‐based chemotherapy for primary breast cancer ‐ the phase III NATAN study (GBG 36/ABCSG XX). Cancer Research2013;73(24 Suppl):S5‐05. ">NATAN 2016</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Infusion‐related side effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Seven studies reported 1 or 2 infusion‐related side‐effects (e.g. fever, fatigue, nausea or influenza‐type symptoms). Intravenous bisphosphonate (zoledronate) appeared to slightly increase the incidence of fever (in 3 out of 5 studies), fatigue (in 2 out of 3 studies) and nausea (in 2 out of 3 studies) compared to placebo. However the reporting of the grade toxicity was sometimes unspecified or on different scales. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(7 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>h,i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fever: 6070 women (5 studies), fatigue: 2599 women (3 studies), nausea: 3825 women (3 studies), influenza‐type symptoms: 103 women (1 study) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>HR</b> : hazard ratio; <b>iv</b> : intravenous; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Outcome assessors were either part of an independent adjudication committee or blinded to the treatment allocation in 5 out of 11 studies. We downgraded for risk of bias by 1 point because this outcome measure may be influenced by a lack of blinding in the other 6 studies.<br/> <sup>b</sup>The baseline risk in the control group was based on the average of the 3‐year estimates from nine studies.<br/> <sup>c</sup>The baseline risk in the control group for pre‐ and postmenopausal women were averages of the 3‐year estimates from the contributing studies.<br/> <sup>d</sup>The baseline risk in the control group was based on the average of the 3‐year estimates from seven studies.<br/> <sup>e</sup>The baseline risk in the control group was based on the average of 3‐year estimates from the contributing studies.<br/> <sup>f</sup>The confidence intervals are wide and we downgraded by 1 point for imprecision.<br/> <sup>g</sup>There was a very low event rate so we decided not to downgrade for imprecision.<br/> <sup>h</sup>Differences in reporting of grades of toxicity with some reporting grade 3/4 toxicity and other toxicity scales unspecified. Given this variability, we did not meta‐analyse the data. However the results appeared to be fairly consistent and we did not view this as a serious concern (therefore did not downgrade the quality of evidence).<br/> <sup>i</sup>Three out of the seven studies were open‐label studies and lack of blinding may impact on the patient‐reported subjective outcomes. We downgraded for risk of bias by 1 point. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Bisphosphonates compared to placebo/observation for women with early breast cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003474-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Bisphosphonates compared to placebo/observation for women with advanced breast cancer without bone metastases</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Bisphosphonates compared to placebo/observation for women with advanced breast cancer without bone metastases</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with advanced breast cancer without bone metastases<br/> <b>Settings:</b> clinic and at home<br/> <b>Intervention:</b> oral bisphosphonates (clodronate 1600 mg/day or pamidronate 300 mg/day)<br/> <b>Comparison:</b> placebo or observation </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo/observation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with bisphosphonates</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Bone metastases</b><br/> Follow‐up: range 16 months to 84 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/> (0.65 to 1.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>330<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>235 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>225 per 1000<br/> (152 to 335) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median time to a skeletal‐related event (SRE)</b><br/> Follow‐up: median 84 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>We did not observe any statistically significant benefit using the bisphosphonate, oral clodronate. The median time to an SRE with clodronate was 28.4 months compared to 13.4 months with placebo (P = 0.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b><br/> Follow‐up: range 16 months to 84 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Risk of death</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/> (0.73 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>330<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>556 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>494 per 1000<br/> (406 to 606) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life<br/> assessed with 4‐point scale</b><br/> Follow‐up: range 16 months to 20 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Similar quality‐of‐life scores with bisphosphonates (pamidronate) or no bisphosphonates</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for imprecision because the confidence intervals included no effect and appreciable benefit and harm.<br/> <sup>b</sup>12 out of the 73 participants did not receive treatment for at least 2 months and were not followed‐up. We judged this study to be at high risk of bias for incomplete outcome data and we downgraded risk of bias by 1 point.<br/> <sup>c</sup>Only one study that had a small sample size reported this outcome and the estimates of effect appear to have wide confidence intervals. We downgraded for imprecision by 1 point.<br/> <sup>d</sup>We did not downgrade for imprecision as the confidence intervals were considered sufficiently narrow enough for an all‐encompassing outcome such as overall survival. <br/> <sup>e</sup>Quality‐of‐life measures were patient‐reported; the study was an open‐label trial and deemed to be at high risk of bias for not blinding participants to their treatment allocation. We downgraded risk of bias by 1 point. We did not downgrade the quality of evidence on other domains due to only one study contributing to this outcome (as permitted by GRADE guidance). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Bisphosphonates compared to placebo/observation for women with advanced breast cancer without bone metastases</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003474-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Bisphosphonates compared to placebo/observation for women with metastatic breast cancer and bone metastases</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Bisphosphonates compared to placebo/observation for women with metastatic breast cancer with bone metastases</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with metastatic breast cancer with bone metastases<br/> <b>Setting:</b> clinic and at home<br/> <b>Intervention:</b> intravenous bisphosphonates (pamidronate (45 to 90 mg/day) or ibandronate (6 mg) or zoledronate (4 mg)) or oral bisphosphonates (clodronate (1600 mg/day) or ibandronate (50 mg) or pamidronate (300 mg))<br/> <b>Comparison:</b> placebo or observation </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo/observation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with bisphosphonates</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Skeletal‐related event (SRE)</b><br/> Follow‐up: range 12 months to 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/> (0.78 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2810<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Additional analyses of iv or oral bisphosphonates vs placebo showed equivalent efficacy</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>640 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>550 per 1000<br/> (499 to 608) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median time to a skeletal‐related event</b><br/> Follow‐up: range 12 months to 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Bisphosphonates significantly delayed the median time to an SRE compared to placebo/observation (in 11 out of 12 studies that reported results but not sufficiently to be included in a meta‐analysis). The median time to an SRE in the bisphosphonates group ranged from 8.7 to 20.8 months while the placebo group ranged from 4.9 to 14.9 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median ratio 1.43 (1.29 to 1.58)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2891<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant benefits were observed using iv bisphosphonates (7 studies) and oral bisphosphonates (4 studies) vs placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b><br/> Follow‐up: range 12 months to 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Risk of death</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/> (0.91 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1935<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Analyses of iv or oral bisphosphonates vs placebo showed similar results</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>575 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>581 per 1000<br/> (523 to 638) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bone pain</b><br/> assessed with: Brief Pain Inventory, visual analog/pain scales and other validated or unvalidated scales<br/> Follow‐up: range 12 months to 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Bisphosphonates significantly reduced bone pain compared to placebo (in 6 out of 11 studies). Bone pain was reduced with bisphosphonates in another 3 studies but the effect was not statistically significant or P value not reported </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3297<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone pain was assessed using a wide range of scales across studies and only 6 studies used a validated scale (e.g. Brief Pain Inventory). Significant benefits observed using iv bisphosphonates (3 studies) and oral bisphosphonates (3 studies) when compared to placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><br/> assessed with: EORTC Quality of Life Scale ‐ Core 30 questionnaire (QLQ‐C30), trial‐specific questionnaires, Spitzer quality of life, FACT‐G<br/> Follow‐up: range 12 months to 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Quality‐of‐life scores were better with bisphosphonates than placebo at comparable time‐points (in 3 out of 5 studies). Quality‐of‐life scores decreased during the studies as disease progressed </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1888<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies used validated questionnaires (in one study a trial‐specific but validated one) and unvalidated scales </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>iv</b> : intravenous; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We did not downgrade for heterogeneity. This is because when two studies that used relatively low doses of pamidronate (45 mg or 60 mg) and contributed largely to the heterogeneity were removed from the meta‐analysis, the beneficial effect of bisphosphonates compared to placebo persisted.<br/> <sup>b</sup>Not all confidence intervals overlapped and the point estimate varied widely across studies. We downgraded inconsistency by 1 point.<br/> <sup>c</sup>Measures were self‐reported; 8 out of the 17 studies that reported bone pain scores were at high risk of bias for non‐blinding of participants to their treatment allocation. We downgraded risk of bias by 1 point.<br/> <sup>d</sup>Given that bone pain was assessed on various scales, we did not meta‐analyse the data. However the results appeared to be fairly consistent and we did not view this as a serious concern (therefore did not downgrade the quality of evidence).<br/> <sup>e</sup>Measures were patient‐reported; 3 out of the 8 studies that reported on quality of life were at high risk of bias for non‐blinding participants to their treatment allocation. We downgraded risk of bias by 1 point.<br/> <sup>f</sup>Given the variability in reporting quality‐of‐life results across studies, we were unable to meta‐analyse the data. We did not judge inconsistency across the studies as a serious concern and therefore did not downgrade the quality of the evidence. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Bisphosphonates compared to placebo/observation for women with metastatic breast cancer and bone metastases</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003474-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Early breast cancer: baseline characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment vs comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age: mean &amp; SD<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Menopausal status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ER status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Chemotherapy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Endocrine therapy</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0001" title="GnantM , MlineritschB , Luschin‐EbengreuthG , StoegerH , DubskyP , JakeszR , et al. Long‐term follow‐up in ABCSG‐12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine‐receptor‐positive early breast cancer. Cancer Research2011;71:S1‐2. GnantM , MlineritschB , SchippingerW , Luschin‐EbengreuthG , PöstlbergerS , MenzelC , et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New England Journal of Medicine2009;360(7):679‐91. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , HeckD , MenzelC , et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early‐stage breast cancer: 62‐month follow‐up from the ABCSG‐12 randomised trial. Lancet Oncology2011;12(7):631‐41. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , KnauerM , MoikM , et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Annals of Oncology2015; Vol. 26, issue 2:313‐20. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , PoestlbergerS , DubskyPC , et al. Mature results from ABCSG‐12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine‐responsive early breast cancer. Journal of Clinical Oncology2010;28(15 Suppl):533. ">ABCSG‐12 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate:<br/> &lt; 40 years: 18%<br/> &gt; 40 years: 82%<br/> Observation: </p> <p>&lt; 40 years: 19%<br/> &gt; 40 years: 81% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Premenopausal when recruited</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive:</p> <p>Bisphosphonate: 93%<br/> Control: 94% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Preoperative chemotherapy</b> </p> <p>Bisphosphonate: 6%<br/> Control: 5% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0002" title="GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer (ABCSG‐18): a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet2015;386(9992):433–43. [NCT00556374] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer: results from 3,425 post‐menopausal patients of the ABCSG18 trial. Journal of Clinical Oncology2015;33(15 Suppl):504. [0732‐183X] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. The impact of adjuvant denosumab on disease‐free survival: results from 3,425 postmenopausal patients of the ABCSG‐18 trial. Cancer Research2016;76(4 Suppl):S2‐02. [0008‐5472] ">ABCSG‐18 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab:</p> <p>&lt; 60 years: 30%<br/> &gt; 60 years: 70%<br/> Placebo: </p> <p>&lt; 60 years: 28%<br/> &gt; 60 years: 72% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Postmenopausal only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive:</p> <p>Bisphosphonate: 99%<br/> Control: 100% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Neo/adjuvant therapy:</b><br/> Bisphosphonate: 25% </p> <p>Control: 25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Endocrine therapy before randomisation:</b> </p> <p>Bisphosphonate: 84%</p> <p>Control: 85%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0003" title="AftR , NaughtonM , TrinkausK , WatsonM , YlaganL , Chavez‐MacGregorM , et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncology2010;11(5):421‐8. AftRL , NaughtonM , TrinkausK , WeilbaecherK . Effect of (neo)adjuvant zoledronic acid on disease‐free and overall survival in clinical stage II/III breast cancer. British Journal of Cancer2012;107(1):7‐11. ">Aft 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate: mean 50 (range 30‐68) years</p> <p>Observation: mean 49.1 (range 32‐69) years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Premenopausal</b> </p> <p>Bisphosphonate: 52%</p> <p>Control: 56%</p> <p><b>Postmenopausal:</b> </p> <p>Bisphosphonate: 48%</p> <p>Control: 44%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive:</p> <p>Bisphosphonate: 53%</p> <p>Control: 58%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0005" title="ColemanR , CameronD , DodwellD , BellR , WilsonC , RathboneE , et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open‐label phase 3 trial. Lancet Oncology2014;15(9):997‐1006. ColemanR , WoodwardE , BrownJ , CameronD , BellR , DodwellD , et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01‐04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment2011;127(2):429‐38. ColemanR , WoodwardE , TurnerL , MarshallH , CollinsonM , DodwellD , et al. Impact of zoledronic acid on fractures, bone mineral density and bone remodeling in the AZURE trial (BIG 01‐04). Cancer Research2011;71(24 Suppl):P2‐19‐01. ColemanRE , MarshallH , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Breast‐cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine2011;365(15):1396‐405. ColemanRE , RathboneEJ , MarshallHC , WilsonC , BrownJE , GossielF , et al. Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study. Cancer Research2012;72(24 Suppl):S6‐4. ColemanRE , ThorpeHC , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Cancer Research2010;70(24 Suppl):S4‐5. ColemanRE , WinterMC , CameronD , BellR , DodwellD , KeaneMM , et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti‐tumour activity in breast cancer. British Journal of Cancer2010;102(7):1099‐105. RathboneEJ , BrownJE , MarshallHC , CollinsonM , LiversedgeV , MurdenGA , et al. Osteonecrosis of the jaw and oral health‐related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). Journal of Clinical Oncology2013;31(21):2685‐91. ">AZURE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate: 51.6 ± 9.9 years<br/> Observation: 51.3 ± 10 years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Premenopausal:</b><br/> Bisphosphonate: 45% </p> <p>Control: 45%</p> <p><b>Postmenopausal:</b> </p> <p>Bisphosphonate: 45%</p> <p>Control: 46%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive:</p> <p>Bisphosphonate: 78%<br/> Control: 78% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intended treatment chemotherapy plan:</b> </p> <p>Bisphosphonate: 22%</p> <p>Control: 21%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intended treatment endocrine therapy plan:</b> </p> <p>Bisphosphonate: 5%<br/> Control: 5% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0010" title="DielIJ , SolomayerEF , CostaSD , GollanC , GoernerR , WallweinerD , et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New England Journal of Medicine1998;339(6):357‐63. DielIJ ,  JaschkeA ,  SolomayerEF ,  GollanC ,  BastertG ,  SohnC , et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long‐term follow‐up. Annals of Oncology2008;19(12):2007‐201. JaschkeA , BastertG , SolomayerEF , CostaS , ScheutzF , DielJJ . Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow: a long‐term follow‐up. Journal of Clinical Oncology2004;22(14 Suppl):529. ">Diel 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Across both groups:</p> <p>Median 51 (range: 24‐78) years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Postmenopausal:</b><br/> Bisphosphonate: 64% </p> <p>Control: 61%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive:</p> <p>Bisphosphonate: 66%</p> <p>Control: 58%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adjuvant chemotherapy:</b><br/> Bisphosphonate: 25%<br/> Control: 28% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adjuvant endocrine therapy:</b><br/> Bisphosphonate: 31% </p> <p>Control: 30%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0015" title="MoebusVJ , VonMinckwitzG , JackischC , LueckH‐J , SchneeweissA , TeschH , et al. German Adjuvant Intergroup Node Positive (GAIN) study: a phase III trial to compare IDD‐ETC versus EC‐TX in patients with node‐positive primary breast cancer‐final efficacy analysis. Journal of Clinical Oncology2014;32(5 Suppl):1009. MöbusV , DielI J , HarbeckN , EllingD , JackischC , ThomssenC , et al. GAIN study: a phase III trial to compare ETC vs. EC‐TX and ibandronate vs. observation in patients with node‐positive primary breast cancer ‐ 1st interim efficacy analysis. Cancer Research2011;71(24):S2‐4. NCT00196872 . A study to compare ETC vs EC‐TX and ibandronate vs observation in patients with node‐positive primary breast cancer. clinicaltrials.gov/ct2/show/NCT00196872 Date first received: 12 September 2005. vonMinckwitzG , MobusV , SchneeweissA , HuoberJ , ThomssenC , UntchM , et al. German Adjuvant Intergroup Node‐positive study: a phase III trial to compare oral ibandronate versus observation in patients with high‐risk early breast cancer. Journal of Clinical Oncology2013;31(28):3531‐9. ">GAIN 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate:<br/> &lt; 60 years: 83%<br/> &gt; 60 years: 17%<br/> Observation: </p> <p>&lt; 60 years: 81%<br/> &gt; 60 years: 19% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Premenopausal:</b> </p> <p>Bisphosphonate: 48%<br/> Control: 47% </p> <p><b>Postmenopausal:</b> </p> <p>Bisphosphonate: 51%<br/> Control: 53% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hormone receptor‐positive:</p> <p>Bisphosphonate: 77%</p> <p>Control: 78%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adjuvant therapy:</b><br/> Bisphosphonate: 66%<br/> Control: 65% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0017" title="HershmanDL , McMahonDJ , CrewKD , CremersS , IraniD , CucchiaraG , et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. Journal of Clinical Endocrinology and Metabolism2010;95(2):559‐66. HershmanDL , McMahonDJ , CrewKD , CremersS , IraniD , CucchiaraG , et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early‐stage breast cancer. Journal of Clinical Oncology2008;26(29):4739‐45. ">Hershman 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate: 43 ± 6 years<br/> Placebo: 42 ± 6 years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Premenopausal only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hormone receptor‐positive:</p> <p>Bisphosphonate: 74%<br/> Control: 70% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonates:<br/> 4 cycles: 18%; 6 to 8 cycles: 78% </p> <p>Control:<br/> 4 cycles: 19%; 6 to 8 cycles: 81% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Endocrine therapy after treatment:</b><br/> Bisphosphonates: 70%<br/> Control: 70% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0022" title="KristensenB ,  EjlertsenB ,  MouridsenHT ,  JensenMB ,  AndersenJ ,  BjerregaardB , et al. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncologica2008;47(4):740‐6. ">Kristensen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate:</p> <p>&lt; 39 years: 16%<br/> 40‐49 years: 45% </p> <p>50‐59 years: 23%</p> <p>60‐69 years: 15%</p> <p>Observation:</p> <p>&lt; 39 years: 15%<br/> 40‐49 years: 48% </p> <p>50‐59 years: 23%</p> <p>60‐69 years: 14%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Premenopausal:</b> </p> <p>Bisphosphonate: 67%</p> <p>Control: 66%</p> <p><b>Postmenopausal:</b> </p> <p>Bisphosphonate: 33%</p> <p>Control: 34%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive:</p> <p>Bisphosphonate: 14%</p> <p>Control: 17%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0026" title="MinckwitzG , RezaiM , TeschH , HuoberJ , GerberB , ZahmDM , et al. Zoledronate for patients with invasive residual disease after anthracyclines‐taxane‐based chemotherapy for early breast cancer ‐ the phase III NeoAdjuvant Trial Add‐oN (NaTaN) study (GBG 36/ABCSG 29). European Journal of Cancer2016;64:12‐21. NCT00512993 . Postoperative use of zoledronic acid in breast cancer patients after neoadjuvant chemotherapy (NATAN). clinicaltrials.gov/ct2/show/NCT00512993 Date first received: 3 August 2007. vonMinckwitzG , RezaiM , EidtmannH , TeschH , HuoberJ , GerberB , et al. Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines‐taxane‐based chemotherapy for primary breast cancer ‐ the phase III NATAN study (GBG 36/ABCSG XX). Cancer Research2013;73(24 Suppl):S5‐05. ">NATAN 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate:</p> <p>&lt; 55 years: 67%</p> <p>&gt; 55 years: 33%</p> <p>Observation:</p> <p>&lt; 55 years: 66%<br/> &gt; 55 years: 34% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Premenopausal:</b> </p> <p>Bisphosphonate: 22%<br/> Control: 25% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive and/or PR‐positive:</p> <p>Bisphosphonate: 78%<br/> Control: 78% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0027" title="PatersonAH , AndersonSJ , LemberskyBC , FehrenbacherL , FalksonCI , KingKM , et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B‐34): a multicentre, placebo‐controlled, randomised trial. Lancet Oncology2012; Vol. 13, issue 7:734‐42. PatersonAHG , AndersonSJ , LemberskyBC , FehrenbacherL , FalksonCI , KingKM , et al. NSABP protocol B‐34: a clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy ‐ final analysis. Cancer Research2011;71(24 Suppl):S2‐3. ">NSABP‐34 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate:<br/> &lt; 49 years: 36% </p> <p>&gt; 50 years: 64%</p> <p>Placebo:</p> <p>&lt; 49 years: 36%</p> <p>&gt; 50 years: 65%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive and/or PR‐positive:</p> <p>Bisphosphonate: 78%<br/> Control: 78% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate: 21%</p> <p>Control: 21%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate: 31%<br/> Control: 31% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0030" title="AtulaST , PatersonAHG , PowlesTJ , McLoskeyEV , NevalainenJI , KanisJA . Extended safety profile of oral clodronate after long‐term use in primary breast cancer patients. Drug Safety2003;26(9):661‐71. McCloskeyE , PatersonA , KanisJ , TahtelaR , PowlesT . Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. European Journal of Cancer2009;46(3):558‐65. PowlesT , McCloskeyE , KurkilahtiM , KurkilahtiM , KanisJ . Oral clodronate for the adjuvant treatment of operable breast cancer: results of a randomised, double‐blind, placebo‐controlled multicenter trial. Journal of Clinical Oncology2004;22(14 Suppl):528. PowlesT ,  PatersonA ,  McCloskeyE ,  ScheinP ,  SchefflerB ,  TidyA , et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Research2006;8(2):13. PowlesT ,  PatersonS ,  KanisJA ,  McCloskeyE ,  AshleyS ,  TidyA , et al. Randomized, placebo‐controlled trial of clodronate in patients with primary operable breast cancer. Journal of Clinical Oncology2002;20(15):3219‐24. ">Powles 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate:</p> <p>52.8 ± 6 years<br/> Placebo: </p> <p>52.7 ± 10.5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Premenopausal:</b> </p> <p>Bisphosphonate: 50%</p> <p>Control: 49%</p> <p><b>Postmenopausal:</b> </p> <p>Bisphosphonate: 50%</p> <p>Control: 51%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive:</p> <p>Bisphosphonate: 46%</p> <p>Control: 45%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate: 16%<br/> Control: 15% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tamoxifen:</p> <p>Bisphosphonate: 32%<br/> Control: 29% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0032" title="SaartoT , BlomqvistC , VirkkunenP , ElomaaI . Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node‐positive breast cancer patients: 5 year results of a randomised controlled study. Journal of Clinical Oncology2001;19(1):10‐17. SaartoT , VehmanenL , VirkkunenP , BlomqvistC . Ten‐year follow‐up of a randomized controlled trial of adjuvant clodronate treatment in node‐positive breast cancer patients. Acta Oncologica2004;43(7):650‐6. ">Saarto 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate:</p> <p>52 years (no SD provided)</p> <p>Observation:<br/> 52 years (no SD provided) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Premenopausal:</b> </p> <p>Bisphosphonate: 48%<br/> Control: 57% </p> <p><b>Postmenopausal:</b> </p> <p>Bisphosphonate: 52%<br/> Control: 43% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive:</p> <p>Bisphosphonate: 61%<br/> Control: 68% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate: 50%</p> <p>Control: 58%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pretreatment antioestrogen:</b> </p> <p>Bisphosphonate: 50%</p> <p>Control: 58%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0034" title="GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG‐ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. Journal of Clinical Oncology2015;33(15 Suppl):503. [0732‐183X] GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: comparison of toxicities and patient‐stated preference for oral versus intravenous delivery. Journal of Clinical Oncoloy2014;32(15 Suppl):558. NCT00127205 . Zoledronate, clodronate, or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer. clinicaltrials.gov/ct2/show/NCT00127205 (accessed 30 April 2011); Vol. Date first received: 3 August 2005. ">SWOG‐S0307 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs clodronate vs ibandronate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 53 years (range not provided)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Postmenopausal or aged 50 plus: 58%<br/> (not reported by group) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive:<br/> 77% of tumours<br/> (not reported by group) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Planned adjuvant chemotherapy:</p> <p>80%</p> <p>(not reported by group)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Planned endocrine therapy:<br/> 76%<br/> (not reported by group) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0035" title="LealT ,  TevaarwerkA ,  LoveR ,  StewartJ ,  BinkleyN ,  EickhoffJ , et al. Randomized trial of adjuvant zoledronic acid in postmenopausal women with high‐risk breast cancer. Clinical Breast Cancer2010;10(6):471‐6. TevaarwerkA , StewartJA , LoveR , BinkleyNC , BlackS , EickhoffS , et al. Randomized trial to assess bone mineral density (BMD) effects of zoledronic acid (ZA) in postmenopausal women (PmW) with breast cancer. Journal of Clinical Oncology2007;25(18 Suppl):19558. ">Tevaarwerk 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Across both groups:<br/> All women older than 60 years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Postmenopausal only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ER‐positive:</p> <p>Bisphosphonate: 81%<br/> Control: 91% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adjuvant chemotherapy:</b> </p> <p>Bisphosphonate: 92%<br/> Control: 97% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tamoxifen, other SERM or AI:</b> </p> <p>Bisphosphonate: 75%</p> <p>Control: 72%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0013" title="LlombartA , FrassoldatiA , PaijaO , SleeboomHP , JerusalemG , MebisJ , et al. Immediate administration of zoledronic acid reduces aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer: 12‐month analysis of the E‐ZO‐FAST trial. Clinical Breast Cancer2012;12(1):40‐8. LlombartoA , FrassoldatiA , PaijaO , SleeboomHP , JerusalemG , MebisJ , et al. Effect of zoledronic acid on aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E‐ZO‐FAST 36‐month follow‐up. ASCO Breast Cancer Symposium; 2009; Chicago. Chicago: American Society of Clinical Oncology, 2009. ">E‐ZO‐FAST 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate vs delayed zoledronate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate: median 58 (range 40‐81) years<br/> Delayed: median 58 (range 44‐81) years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Postmenopausal only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prior chemotherapy</b> </p> <p>Immediate: 52%<br/> Delayed: 53% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0041" title="BrufskyA ,  BundredN ,  ColemanR ,  Lambert‐FallsR ,  MenaR ,  HadjiP , et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist2008;13(5):503‐14. BrufskyA ,  HarkerWG ,  BeckJT ,  CarrollR ,  Tan‐ChiuE ,  SeidlerC , et al. Zoledronic acid inhibits adjuvant letrozole‐induced bone loss in postmenopausal women with early breast cancer. Journal of Clinical Oncology2007;25(7):829‐36. BrufskyAM , HarkerWG , BeckJT , BossermanL , VogelC , SeidlerC , et al. Final 5‐year results of Z‐FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer2012;118(5):1192‐201. BrufskyAM ,  BossermanLD ,  CaradonnaRR ,  HaleyBB ,  JonesCM ,  MooreHC ,  etal . Zoledronic acid effectively prevents aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z‐FAST study 36‐month follow‐up results. Clinical Breast Cancer2009;9(2):77‐85. ">Z‐FAST 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate vs delayed zoledronate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate: 61.4 ± 9.28 years<br/> Delayed: 61.0 ± 8.92 years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Postmenopausal only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0043" title="ColemanR , DeBoerR , EidtmannH , LlombartA , DavidsonN , NevenP , et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO‐FAST study): final 60‐month results. Annals of Oncology2013;24(2):398‐405. ColemanR , DeBoerR , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Influence of delayed zoledronic acid initiation on disease‐free survival in postmenopausal women with endocrine receptor‐positive early breast cancer receiving adjuvant letrozole: exploratory analysis from the ZO‐FAST trial. Cancer Research2011;71(24 Suppl):P2‐17‐01. DeBoerR , BundredN , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Long‐term survival outcomes among postmenopausal women with hormone receptor‐positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5‐year follow‐up of ZO‐FAST. Cancer Research2011;71(24 Suppl):S1‐3. DeBoerR , MartinM , StegerGG , VonMoosR , StopeckA , TonkinK , et al. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMs): a number‐needed‐to‐treat (NNT) analysis. Asia‐Pacific Journal of Clinical Oncology2011;7(3 Suppl):9. EidtmannH , DeBoerR , BundredN , Llombart‐CussacA , DavidsonN , NevenP , et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36‐month results of the ZO‐FAST Study. Annals of Oncology2010;21(11):2188‐94. ">ZO‐FAST 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate vs delayed zoledronate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate: median 57 (range 36‐87) years<br/> Delayed: median 58 (range 37‐81) years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Postmenopausal only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prior adjuvant therapy</b><br/> Immediate: 54%<br/> Delayed: 53% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>AI:</b> aromatase inhibitor; <b>ER</b> : oestrogen receptor; <b>NR</b> : not reported; <b>PR</b> : progesterone receptor; <b>SD</b> : standard deviation; <b>SERM</b>: selective estrogen receptor modulator<br/> <sup>a</sup>Unless otherwise stated. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Early breast cancer: baseline characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003474-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Early breast cancer: toxicity ‐ osteonecrosis of the jaw, hypocalcaemia, renal dysfunction &amp; drug‐related death</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Treatment vs comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>ONJ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Hypocalcaemia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Renal dysfunction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Drug‐related death</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0001" title="GnantM , MlineritschB , Luschin‐EbengreuthG , StoegerH , DubskyP , JakeszR , et al. Long‐term follow‐up in ABCSG‐12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine‐receptor‐positive early breast cancer. Cancer Research2011;71:S1‐2. GnantM , MlineritschB , SchippingerW , Luschin‐EbengreuthG , PöstlbergerS , MenzelC , et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New England Journal of Medicine2009;360(7):679‐91. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , HeckD , MenzelC , et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early‐stage breast cancer: 62‐month follow‐up from the ABCSG‐12 randomised trial. Lancet Oncology2011;12(7):631‐41. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , KnauerM , MoikM , et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Annals of Oncology2015; Vol. 26, issue 2:313‐20. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , PoestlbergerS , DubskyPC , et al. Mature results from ABCSG‐12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine‐responsive early breast cancer. Journal of Clinical Oncology2010;28(15 Suppl):533. ">ABCSG‐12 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/904</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0002" title="GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer (ABCSG‐18): a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet2015;386(9992):433–43. [NCT00556374] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer: results from 3,425 post‐menopausal patients of the ABCSG18 trial. Journal of Clinical Oncology2015;33(15 Suppl):504. [0732‐183X] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. The impact of adjuvant denosumab on disease‐free survival: results from 3,425 postmenopausal patients of the ABCSG‐18 trial. Cancer Research2016;76(4 Suppl):S2‐02. [0008‐5472] ">ABCSG‐18 2015</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/1709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/1690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/1709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/1690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2<sup>a</sup>/1709 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3<sup>a</sup>/1690 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/1709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/1690</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0003" title="AftR , NaughtonM , TrinkausK , WatsonM , YlaganL , Chavez‐MacGregorM , et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncology2010;11(5):421‐8. AftRL , NaughtonM , TrinkausK , WeilbaecherK . Effect of (neo)adjuvant zoledronic acid on disease‐free and overall survival in clinical stage II/III breast cancer. British Journal of Cancer2012;107(1):7‐11. ">Aft 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0005" title="ColemanR , CameronD , DodwellD , BellR , WilsonC , RathboneE , et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open‐label phase 3 trial. Lancet Oncology2014;15(9):997‐1006. ColemanR , WoodwardE , BrownJ , CameronD , BellR , DodwellD , et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01‐04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment2011;127(2):429‐38. ColemanR , WoodwardE , TurnerL , MarshallH , CollinsonM , DodwellD , et al. Impact of zoledronic acid on fractures, bone mineral density and bone remodeling in the AZURE trial (BIG 01‐04). Cancer Research2011;71(24 Suppl):P2‐19‐01. ColemanRE , MarshallH , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Breast‐cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine2011;365(15):1396‐405. ColemanRE , RathboneEJ , MarshallHC , WilsonC , BrownJE , GossielF , et al. Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study. Cancer Research2012;72(24 Suppl):S6‐4. ColemanRE , ThorpeHC , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Cancer Research2010;70(24 Suppl):S4‐5. ColemanRE , WinterMC , CameronD , BellR , DodwellD , KeaneMM , et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti‐tumour activity in breast cancer. British Journal of Cancer2010;102(7):1099‐105. RathboneEJ , BrownJE , MarshallHC , CollinsonM , LiversedgeV , MurdenGA , et al. Osteonecrosis of the jaw and oral health‐related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). Journal of Clinical Oncology2013;31(21):2685‐91. ">AZURE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/1685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/1667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>188/1685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>158/1667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/1685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/1667</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0010" title="DielIJ , SolomayerEF , CostaSD , GollanC , GoernerR , WallweinerD , et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New England Journal of Medicine1998;339(6):357‐63. DielIJ ,  JaschkeA ,  SolomayerEF ,  GollanC ,  BastertG ,  SohnC , et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long‐term follow‐up. Annals of Oncology2008;19(12):2007‐201. JaschkeA , BastertG , SolomayerEF , CostaS , ScheutzF , DielJJ . Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow: a long‐term follow‐up. Journal of Clinical Oncology2004;22(14 Suppl):529. ">Diel 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0015" title="MoebusVJ , VonMinckwitzG , JackischC , LueckH‐J , SchneeweissA , TeschH , et al. German Adjuvant Intergroup Node Positive (GAIN) study: a phase III trial to compare IDD‐ETC versus EC‐TX in patients with node‐positive primary breast cancer‐final efficacy analysis. Journal of Clinical Oncology2014;32(5 Suppl):1009. MöbusV , DielI J , HarbeckN , EllingD , JackischC , ThomssenC , et al. GAIN study: a phase III trial to compare ETC vs. EC‐TX and ibandronate vs. observation in patients with node‐positive primary breast cancer ‐ 1st interim efficacy analysis. Cancer Research2011;71(24):S2‐4. NCT00196872 . A study to compare ETC vs EC‐TX and ibandronate vs observation in patients with node‐positive primary breast cancer. clinicaltrials.gov/ct2/show/NCT00196872 Date first received: 12 September 2005. vonMinckwitzG , MobusV , SchneeweissA , HuoberJ , ThomssenC , UntchM , et al. German Adjuvant Intergroup Node‐positive study: a phase III trial to compare oral ibandronate versus observation in patients with high‐risk early breast cancer. Journal of Clinical Oncology2013;31(28):3531‐9. ">GAIN 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/1832</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/1832</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/968</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0017" title="HershmanDL , McMahonDJ , CrewKD , CremersS , IraniD , CucchiaraG , et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. Journal of Clinical Endocrinology and Metabolism2010;95(2):559‐66. HershmanDL , McMahonDJ , CrewKD , CremersS , IraniD , CucchiaraG , et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early‐stage breast cancer. Journal of Clinical Oncology2008;26(29):4739‐45. ">Hershman 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0022" title="KristensenB ,  EjlertsenB ,  MouridsenHT ,  JensenMB ,  AndersenJ ,  BjerregaardB , et al. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncologica2008;47(4):740‐6. ">Kristensen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0026" title="MinckwitzG , RezaiM , TeschH , HuoberJ , GerberB , ZahmDM , et al. Zoledronate for patients with invasive residual disease after anthracyclines‐taxane‐based chemotherapy for early breast cancer ‐ the phase III NeoAdjuvant Trial Add‐oN (NaTaN) study (GBG 36/ABCSG 29). European Journal of Cancer2016;64:12‐21. NCT00512993 . Postoperative use of zoledronic acid in breast cancer patients after neoadjuvant chemotherapy (NATAN). clinicaltrials.gov/ct2/show/NCT00512993 Date first received: 3 August 2007. vonMinckwitzG , RezaiM , EidtmannH , TeschH , HuoberJ , GerberB , et al. Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines‐taxane‐based chemotherapy for primary breast cancer ‐ the phase III NATAN study (GBG 36/ABCSG XX). Cancer Research2013;73(24 Suppl):S5‐05. ">NATAN 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7<sup>b</sup>/343 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4<sup>b</sup>/350 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/350</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0027" title="PatersonAH , AndersonSJ , LemberskyBC , FehrenbacherL , FalksonCI , KingKM , et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B‐34): a multicentre, placebo‐controlled, randomised trial. Lancet Oncology2012; Vol. 13, issue 7:734‐42. PatersonAHG , AndersonSJ , LemberskyBC , FehrenbacherL , FalksonCI , KingKM , et al. NSABP protocol B‐34: a clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy ‐ final analysis. Cancer Research2011;71(24 Suppl):S2‐3. ">NSABP‐34 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/1612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/1623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/1612 (G3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/1523 (G3/4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/1612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/1623</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0030" title="AtulaST , PatersonAHG , PowlesTJ , McLoskeyEV , NevalainenJI , KanisJA . Extended safety profile of oral clodronate after long‐term use in primary breast cancer patients. Drug Safety2003;26(9):661‐71. McCloskeyE , PatersonA , KanisJ , TahtelaR , PowlesT . Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. European Journal of Cancer2009;46(3):558‐65. PowlesT , McCloskeyE , KurkilahtiM , KurkilahtiM , KanisJ . Oral clodronate for the adjuvant treatment of operable breast cancer: results of a randomised, double‐blind, placebo‐controlled multicenter trial. Journal of Clinical Oncology2004;22(14 Suppl):528. PowlesT ,  PatersonA ,  McCloskeyE ,  ScheinP ,  SchefflerB ,  TidyA , et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Research2006;8(2):13. PowlesT ,  PatersonS ,  KanisJA ,  McCloskeyE ,  AshleyS ,  TidyA , et al. Randomized, placebo‐controlled trial of clodronate in patients with primary operable breast cancer. Journal of Clinical Oncology2002;20(15):3219‐24. ">Powles 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/539</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/539</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/539</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0032" title="SaartoT , BlomqvistC , VirkkunenP , ElomaaI . Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node‐positive breast cancer patients: 5 year results of a randomised controlled study. Journal of Clinical Oncology2001;19(1):10‐17. SaartoT , VehmanenL , VirkkunenP , BlomqvistC . Ten‐year follow‐up of a randomized controlled trial of adjuvant clodronate treatment in node‐positive breast cancer patients. Acta Oncologica2004;43(7):650‐6. ">Saarto 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0034" title="GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG‐ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. Journal of Clinical Oncology2015;33(15 Suppl):503. [0732‐183X] GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: comparison of toxicities and patient‐stated preference for oral versus intravenous delivery. Journal of Clinical Oncoloy2014;32(15 Suppl):558. NCT00127205 . Zoledronate, clodronate, or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer. clinicaltrials.gov/ct2/show/NCT00127205 (accessed 30 April 2011); Vol. Date first received: 3 August 2005. ">SWOG‐S0307 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs clodronate<br/> vs ibandronate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate:</p> <p>24/2094</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate: 6/2151<br/> Ibandronate: 10/1507 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0035" title="LealT ,  TevaarwerkA ,  LoveR ,  StewartJ ,  BinkleyN ,  EickhoffJ , et al. Randomized trial of adjuvant zoledronic acid in postmenopausal women with high‐risk breast cancer. Clinical Breast Cancer2010;10(6):471‐6. TevaarwerkA , StewartJA , LoveR , BinkleyNC , BlackS , EickhoffS , et al. Randomized trial to assess bone mineral density (BMD) effects of zoledronic acid (ZA) in postmenopausal women (PmW) with breast cancer. Journal of Clinical Oncology2007;25(18 Suppl):19558. ">Tevaarwerk 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<sup>c</sup>/36 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<sup>c</sup>/32 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0013" title="LlombartA , FrassoldatiA , PaijaO , SleeboomHP , JerusalemG , MebisJ , et al. Immediate administration of zoledronic acid reduces aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer: 12‐month analysis of the E‐ZO‐FAST trial. Clinical Breast Cancer2012;12(1):40‐8. LlombartoA , FrassoldatiA , PaijaO , SleeboomHP , JerusalemG , MebisJ , et al. Effect of zoledronic acid on aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E‐ZO‐FAST 36‐month follow‐up. ASCO Breast Cancer Symposium; 2009; Chicago. Chicago: American Society of Clinical Oncology, 2009. ">E‐ZO‐FAST 2012</a><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate vs delayed zoledronate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/270</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0041" title="BrufskyA ,  BundredN ,  ColemanR ,  Lambert‐FallsR ,  MenaR ,  HadjiP , et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist2008;13(5):503‐14. BrufskyA ,  HarkerWG ,  BeckJT ,  CarrollR ,  Tan‐ChiuE ,  SeidlerC , et al. Zoledronic acid inhibits adjuvant letrozole‐induced bone loss in postmenopausal women with early breast cancer. Journal of Clinical Oncology2007;25(7):829‐36. BrufskyAM , HarkerWG , BeckJT , BossermanL , VogelC , SeidlerC , et al. Final 5‐year results of Z‐FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer2012;118(5):1192‐201. BrufskyAM ,  BossermanLD ,  CaradonnaRR ,  HaleyBB ,  JonesCM ,  MooreHC ,  etal . Zoledronic acid effectively prevents aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z‐FAST study 36‐month follow‐up results. Clinical Breast Cancer2009;9(2):77‐85. ">Z‐FAST 2012</a><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate vs delayed zoledronate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/300 (G1 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/300 (G1 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/300</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0043" title="ColemanR , DeBoerR , EidtmannH , LlombartA , DavidsonN , NevenP , et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO‐FAST study): final 60‐month results. Annals of Oncology2013;24(2):398‐405. ColemanR , DeBoerR , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Influence of delayed zoledronic acid initiation on disease‐free survival in postmenopausal women with endocrine receptor‐positive early breast cancer receiving adjuvant letrozole: exploratory analysis from the ZO‐FAST trial. Cancer Research2011;71(24 Suppl):P2‐17‐01. DeBoerR , BundredN , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Long‐term survival outcomes among postmenopausal women with hormone receptor‐positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5‐year follow‐up of ZO‐FAST. Cancer Research2011;71(24 Suppl):S1‐3. DeBoerR , MartinM , StegerGG , VonMoosR , StopeckA , TonkinK , et al. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMs): a number‐needed‐to‐treat (NNT) analysis. Asia‐Pacific Journal of Clinical Oncology2011;7(3 Suppl):9. EidtmannH , DeBoerR , BundredN , Llombart‐CussacA , DavidsonN , NevenP , et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36‐month results of the ZO‐FAST Study. Annals of Oncology2010;21(11):2188‐94. ">ZO‐FAST 2013</a><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate vs delayed zoledronate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/524 (G1/2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/536 (G1/2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/536</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><b>G</b> : grade; <b>n</b> : number of events; <b>N</b> : number of women studied in each group; <b>NR</b> : not reported; <b>ONJ</b>: osteonecrosis of the jaw<br/> <sup>a</sup>Number of events for renal dysfunction refers to renal failure.<br/> <sup>b</sup>Any grade.<br/> <sup>c</sup>"No clinically significant changes in calcium" (<a href="./references#CD003474-bbs2-0035" title="LealT ,  TevaarwerkA ,  LoveR ,  StewartJ ,  BinkleyN ,  EickhoffJ , et al. Randomized trial of adjuvant zoledronic acid in postmenopausal women with high‐risk breast cancer. Clinical Breast Cancer2010;10(6):471‐6. TevaarwerkA , StewartJA , LoveR , BinkleyNC , BlackS , EickhoffS , et al. Randomized trial to assess bone mineral density (BMD) effects of zoledronic acid (ZA) in postmenopausal women (PmW) with breast cancer. Journal of Clinical Oncology2007;25(18 Suppl):19558. ">Tevaarwerk 2007</a>).<br/> <sup>d</sup>Control arm was delayed zoledronate. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Early breast cancer: toxicity ‐ osteonecrosis of the jaw, hypocalcaemia, renal dysfunction &amp; drug‐related death</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003474-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Early breast cancer: toxicity ‐ nausea, fatigue, fever &amp; influenza symptoms</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Treatment vs comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Nausea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fatigue</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fever</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Influenza‐type symptoms</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0001" title="GnantM , MlineritschB , Luschin‐EbengreuthG , StoegerH , DubskyP , JakeszR , et al. Long‐term follow‐up in ABCSG‐12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine‐receptor‐positive early breast cancer. Cancer Research2011;71:S1‐2. GnantM , MlineritschB , SchippingerW , Luschin‐EbengreuthG , PöstlbergerS , MenzelC , et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New England Journal of Medicine2009;360(7):679‐91. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , HeckD , MenzelC , et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early‐stage breast cancer: 62‐month follow‐up from the ABCSG‐12 randomised trial. Lancet Oncology2011;12(7):631‐41. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , KnauerM , MoikM , et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Annals of Oncology2015; Vol. 26, issue 2:313‐20. GnantM , MlineritschB , StoegerH , Luschin‐EbengreuthG , PoestlbergerS , DubskyPC , et al. Mature results from ABCSG‐12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine‐responsive early breast cancer. Journal of Clinical Oncology2010;28(15 Suppl):533. ">ABCSG‐12 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79/899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55/904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>192/899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>169/904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85/899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0002" title="GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer (ABCSG‐18): a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet2015;386(9992):433–43. [NCT00556374] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. Adjuvant denosumab in breast cancer: results from 3,425 post‐menopausal patients of the ABCSG18 trial. Journal of Clinical Oncology2015;33(15 Suppl):504. [0732‐183X] GnantM , PfeilerG , DubskyPC , HubalekM , GreilR , JakeszR , et al. The impact of adjuvant denosumab on disease‐free survival: results from 3,425 postmenopausal patients of the ABCSG‐18 trial. Cancer Research2016;76(4 Suppl):S2‐02. [0008‐5472] ">ABCSG‐18 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49/1709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42/1690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108/1709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98/1690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/1709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/1690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/1709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/1690</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0003" title="AftR , NaughtonM , TrinkausK , WatsonM , YlaganL , Chavez‐MacGregorM , et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncology2010;11(5):421‐8. AftRL , NaughtonM , TrinkausK , WeilbaecherK . Effect of (neo)adjuvant zoledronic acid on disease‐free and overall survival in clinical stage II/III breast cancer. British Journal of Cancer2012;107(1):7‐11. ">Aft 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0005" title="ColemanR , CameronD , DodwellD , BellR , WilsonC , RathboneE , et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open‐label phase 3 trial. Lancet Oncology2014;15(9):997‐1006. ColemanR , WoodwardE , BrownJ , CameronD , BellR , DodwellD , et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01‐04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment2011;127(2):429‐38. ColemanR , WoodwardE , TurnerL , MarshallH , CollinsonM , DodwellD , et al. Impact of zoledronic acid on fractures, bone mineral density and bone remodeling in the AZURE trial (BIG 01‐04). Cancer Research2011;71(24 Suppl):P2‐19‐01. ColemanRE , MarshallH , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Breast‐cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine2011;365(15):1396‐405. ColemanRE , RathboneEJ , MarshallHC , WilsonC , BrownJE , GossielF , et al. Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study. Cancer Research2012;72(24 Suppl):S6‐4. ColemanRE , ThorpeHC , CameronD , DodwellD , BurkinshawR , KeaneM , et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Cancer Research2010;70(24 Suppl):S4‐5. ColemanRE , WinterMC , CameronD , BellR , DodwellD , KeaneMM , et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti‐tumour activity in breast cancer. British Journal of Cancer2010;102(7):1099‐105. RathboneEJ , BrownJE , MarshallHC , CollinsonM , LiversedgeV , MurdenGA , et al. Osteonecrosis of the jaw and oral health‐related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). Journal of Clinical Oncology2013;31(21):2685‐91. ">AZURE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37/1685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24/1667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0010" title="DielIJ , SolomayerEF , CostaSD , GollanC , GoernerR , WallweinerD , et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New England Journal of Medicine1998;339(6):357‐63. DielIJ ,  JaschkeA ,  SolomayerEF ,  GollanC ,  BastertG ,  SohnC , et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long‐term follow‐up. Annals of Oncology2008;19(12):2007‐201. JaschkeA , BastertG , SolomayerEF , CostaS , ScheutzF , DielJJ . Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow: a long‐term follow‐up. Journal of Clinical Oncology2004;22(14 Suppl):529. ">Diel 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0015" title="MoebusVJ , VonMinckwitzG , JackischC , LueckH‐J , SchneeweissA , TeschH , et al. German Adjuvant Intergroup Node Positive (GAIN) study: a phase III trial to compare IDD‐ETC versus EC‐TX in patients with node‐positive primary breast cancer‐final efficacy analysis. Journal of Clinical Oncology2014;32(5 Suppl):1009. MöbusV , DielI J , HarbeckN , EllingD , JackischC , ThomssenC , et al. GAIN study: a phase III trial to compare ETC vs. EC‐TX and ibandronate vs. observation in patients with node‐positive primary breast cancer ‐ 1st interim efficacy analysis. Cancer Research2011;71(24):S2‐4. NCT00196872 . A study to compare ETC vs EC‐TX and ibandronate vs observation in patients with node‐positive primary breast cancer. clinicaltrials.gov/ct2/show/NCT00196872 Date first received: 12 September 2005. vonMinckwitzG , MobusV , SchneeweissA , HuoberJ , ThomssenC , UntchM , et al. German Adjuvant Intergroup Node‐positive study: a phase III trial to compare oral ibandronate versus observation in patients with high‐risk early breast cancer. Journal of Clinical Oncology2013;31(28):3531‐9. ">GAIN 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0017" title="HershmanDL , McMahonDJ , CrewKD , CremersS , IraniD , CucchiaraG , et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. Journal of Clinical Endocrinology and Metabolism2010;95(2):559‐66. HershmanDL , McMahonDJ , CrewKD , CremersS , IraniD , CucchiaraG , et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early‐stage breast cancer. Journal of Clinical Oncology2008;26(29):4739‐45. ">Hershman 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24/50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0022" title="KristensenB ,  EjlertsenB ,  MouridsenHT ,  JensenMB ,  AndersenJ ,  BjerregaardB , et al. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncologica2008;47(4):740‐6. ">Kristensen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>324<sup>a</sup>/460 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>337<sup>a</sup>/493 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0026" title="MinckwitzG , RezaiM , TeschH , HuoberJ , GerberB , ZahmDM , et al. Zoledronate for patients with invasive residual disease after anthracyclines‐taxane‐based chemotherapy for early breast cancer ‐ the phase III NeoAdjuvant Trial Add‐oN (NaTaN) study (GBG 36/ABCSG 29). European Journal of Cancer2016;64:12‐21. NCT00512993 . Postoperative use of zoledronic acid in breast cancer patients after neoadjuvant chemotherapy (NATAN). clinicaltrials.gov/ct2/show/NCT00512993 Date first received: 3 August 2007. vonMinckwitzG , RezaiM , EidtmannH , TeschH , HuoberJ , GerberB , et al. Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines‐taxane‐based chemotherapy for primary breast cancer ‐ the phase III NATAN study (GBG 36/ABCSG XX). Cancer Research2013;73(24 Suppl):S5‐05. ">NATAN 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65<sup>b</sup>/343 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36<sup>b</sup>/350 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28<sup>b</sup>/343 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1<sup>b</sup>/350 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0027" title="PatersonAH , AndersonSJ , LemberskyBC , FehrenbacherL , FalksonCI , KingKM , et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B‐34): a multicentre, placebo‐controlled, randomised trial. Lancet Oncology2012; Vol. 13, issue 7:734‐42. PatersonAHG , AndersonSJ , LemberskyBC , FehrenbacherL , FalksonCI , KingKM , et al. NSABP protocol B‐34: a clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy ‐ final analysis. Cancer Research2011;71(24 Suppl):S2‐3. ">NSABP‐34 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0030" title="AtulaST , PatersonAHG , PowlesTJ , McLoskeyEV , NevalainenJI , KanisJA . Extended safety profile of oral clodronate after long‐term use in primary breast cancer patients. Drug Safety2003;26(9):661‐71. McCloskeyE , PatersonA , KanisJ , TahtelaR , PowlesT . Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. European Journal of Cancer2009;46(3):558‐65. PowlesT , McCloskeyE , KurkilahtiM , KurkilahtiM , KanisJ . Oral clodronate for the adjuvant treatment of operable breast cancer: results of a randomised, double‐blind, placebo‐controlled multicenter trial. Journal of Clinical Oncology2004;22(14 Suppl):528. PowlesT ,  PatersonA ,  McCloskeyE ,  ScheinP ,  SchefflerB ,  TidyA , et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Research2006;8(2):13. PowlesT ,  PatersonS ,  KanisJA ,  McCloskeyE ,  AshleyS ,  TidyA , et al. Randomized, placebo‐controlled trial of clodronate in patients with primary operable breast cancer. Journal of Clinical Oncology2002;20(15):3219‐24. ">Powles 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>143/530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>161/539</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0032" title="SaartoT , BlomqvistC , VirkkunenP , ElomaaI . Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node‐positive breast cancer patients: 5 year results of a randomised controlled study. Journal of Clinical Oncology2001;19(1):10‐17. SaartoT , VehmanenL , VirkkunenP , BlomqvistC . Ten‐year follow‐up of a randomized controlled trial of adjuvant clodronate treatment in node‐positive breast cancer patients. Acta Oncologica2004;43(7):650‐6. ">Saarto 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0034" title="GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG‐ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. Journal of Clinical Oncology2015;33(15 Suppl):503. [0732‐183X] GralowJ , BarlowWE , PatersonAHG , LewD , StopeckA , HayesDF , et al. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: comparison of toxicities and patient‐stated preference for oral versus intravenous delivery. Journal of Clinical Oncoloy2014;32(15 Suppl):558. NCT00127205 . Zoledronate, clodronate, or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer. clinicaltrials.gov/ct2/show/NCT00127205 (accessed 30 April 2011); Vol. Date first received: 3 August 2005. ">SWOG‐S0307 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs clodronate<br/> vs ibandronate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0035" title="LealT ,  TevaarwerkA ,  LoveR ,  StewartJ ,  BinkleyN ,  EickhoffJ , et al. Randomized trial of adjuvant zoledronic acid in postmenopausal women with high‐risk breast cancer. Clinical Breast Cancer2010;10(6):471‐6. TevaarwerkA , StewartJA , LoveR , BinkleyNC , BlackS , EickhoffS , et al. Randomized trial to assess bone mineral density (BMD) effects of zoledronic acid (ZA) in postmenopausal women (PmW) with breast cancer. Journal of Clinical Oncology2007;25(18 Suppl):19558. ">Tevaarwerk 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate vs observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0013" title="LlombartA , FrassoldatiA , PaijaO , SleeboomHP , JerusalemG , MebisJ , et al. Immediate administration of zoledronic acid reduces aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer: 12‐month analysis of the E‐ZO‐FAST trial. Clinical Breast Cancer2012;12(1):40‐8. LlombartoA , FrassoldatiA , PaijaO , SleeboomHP , JerusalemG , MebisJ , et al. Effect of zoledronic acid on aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E‐ZO‐FAST 36‐month follow‐up. ASCO Breast Cancer Symposium; 2009; Chicago. Chicago: American Society of Clinical Oncology, 2009. ">E‐ZO‐FAST 2012</a><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate vs delated zoledronate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38/252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50/270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/270</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0041" title="BrufskyA ,  BundredN ,  ColemanR ,  Lambert‐FallsR ,  MenaR ,  HadjiP , et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist2008;13(5):503‐14. BrufskyA ,  HarkerWG ,  BeckJT ,  CarrollR ,  Tan‐ChiuE ,  SeidlerC , et al. Zoledronic acid inhibits adjuvant letrozole‐induced bone loss in postmenopausal women with early breast cancer. Journal of Clinical Oncology2007;25(7):829‐36. BrufskyAM , HarkerWG , BeckJT , BossermanL , VogelC , SeidlerC , et al. Final 5‐year results of Z‐FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer2012;118(5):1192‐201. BrufskyAM ,  BossermanLD ,  CaradonnaRR ,  HaleyBB ,  JonesCM ,  MooreHC ,  etal . Zoledronic acid effectively prevents aromatase inhibitor‐associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z‐FAST study 36‐month follow‐up results. Clinical Breast Cancer2009;9(2):77‐85. ">Z‐FAST 2012</a><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate vs delated zoledronate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41/300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40/300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101/300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88/300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0043" title="ColemanR , DeBoerR , EidtmannH , LlombartA , DavidsonN , NevenP , et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO‐FAST study): final 60‐month results. Annals of Oncology2013;24(2):398‐405. ColemanR , DeBoerR , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Influence of delayed zoledronic acid initiation on disease‐free survival in postmenopausal women with endocrine receptor‐positive early breast cancer receiving adjuvant letrozole: exploratory analysis from the ZO‐FAST trial. Cancer Research2011;71(24 Suppl):P2‐17‐01. DeBoerR , BundredN , EidtmannH , NevenP , vonMinckwitzG , MartinN , et al. Long‐term survival outcomes among postmenopausal women with hormone receptor‐positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5‐year follow‐up of ZO‐FAST. Cancer Research2011;71(24 Suppl):S1‐3. DeBoerR , MartinM , StegerGG , VonMoosR , StopeckA , TonkinK , et al. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMs): a number‐needed‐to‐treat (NNT) analysis. Asia‐Pacific Journal of Clinical Oncology2011;7(3 Suppl):9. EidtmannH , DeBoerR , BundredN , Llombart‐CussacA , DavidsonN , NevenP , et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36‐month results of the ZO‐FAST Study. Annals of Oncology2010;21(11):2188‐94. ">ZO‐FAST 2013</a><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immediate vs delated zoledronate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46/524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42/536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84/524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81/536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78/524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45/524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/536</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><b>n</b> : number of events; <b>N</b> : number of women studied in each group; <b>NR</b>: not reported<br/> <sup>a</sup>Nausea and vomited reported together.<br/> <sup>b</sup>Any grade.<br/> <sup>c</sup>Control arm was delayed zoledronate. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Early breast cancer: toxicity ‐ nausea, fatigue, fever &amp; influenza symptoms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003474-tbl-0007"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Advanced breast cancer: skeletal‐related event expressed as a risk ratio</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Number of skeletal‐related events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Ratio: Bisphosphonate/comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0019" title="KanisJA , PowlesT , PatersonAH , McCloskeyEV , AshleyS . Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone1996;19(6):663‐7. ">Kanis 1996</a><br/> (N = 133) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> <p>Event rate = event/100 patient years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0024" title="MardiakJ , BohunickyL , ChovanecJ , SalekT , KozaI . Adjuvant clodronate therapy in patients with locally advanced breast cancer ‐ long term results of a double blind randomised trial. Neoplasma2000;47(3):177‐80. ">Mardiak 2000</a><br/> (N = 73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0039" title="VanHolten‐VerzantvoortAT , HermansJ , BeexLVAM , BlijhamG , CletonFJ , VanEck‐SmitBCF , et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients?. European Journal of Cancer1996;32A(3):450‐4. ">Van‐Holten 1996</a> </p> <p>(N = 124)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 300 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>N</b> : total number of women in the study; <b>NR</b>: not reported </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Advanced breast cancer: skeletal‐related event expressed as a risk ratio</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003474-tbl-0008"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Advanced breast cancer: median time to skeletal‐related event</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Median time to event (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Ratio ‐ Bisphosphonate/Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0019" title="KanisJA , PowlesT , PatersonAH , McCloskeyEV , AshleyS . Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone1996;19(6):663‐7. ">Kanis 1996</a><br/> (N = 133) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<br/> Reported no. of people "event free" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0024" title="MardiakJ , BohunickyL , ChovanecJ , SalekT , KozaI . Adjuvant clodronate therapy in patients with locally advanced breast cancer ‐ long term results of a double blind randomised trial. Neoplasma2000;47(3):177‐80. ">Mardiak 2000</a><br/> (N = 73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0039" title="VanHolten‐VerzantvoortAT , HermansJ , BeexLVAM , BlijhamG , CletonFJ , VanEck‐SmitBCF , et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients?. European Journal of Cancer1996;32A(3):450‐4. ">Van‐Holten 1996</a> </p> <p>(N = 124)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 300 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reached.</p> <p>First bone event was not within the first 36 months of the analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reached</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>N</b> : total number of women in the study; <b>NR</b>: not reported </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Advanced breast cancer: median time to skeletal‐related event</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003474-tbl-0009"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Advanced breast cancer: median survival time</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Median survival time (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Ratio ‐ Bisphosphonate/comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0019" title="KanisJA , PowlesT , PatersonAH , McCloskeyEV , AshleyS . Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone1996;19(6):663‐7. ">Kanis 1996</a><br/> (N = 133) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<br/> Reported no. of events in each group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not significantly different</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0024" title="MardiakJ , BohunickyL , ChovanecJ , SalekT , KozaI . Adjuvant clodronate therapy in patients with locally advanced breast cancer ‐ long term results of a double blind randomised trial. Neoplasma2000;47(3):177‐80. ">Mardiak 2000</a><br/> (N = 73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0039" title="VanHolten‐VerzantvoortAT , HermansJ , BeexLVAM , BlijhamG , CletonFJ , VanEck‐SmitBCF , et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients?. European Journal of Cancer1996;32A(3):450‐4. ">Van‐Holten 1996</a> </p> <p>(N = 124)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 300 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.30</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>N</b> : total number of women in the study; <b>NR</b>: not reported </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Advanced breast cancer: median survival time</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003474-tbl-0010"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Advanced breast cancer: quality of life</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Questionnaires used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Summary of findings</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0019" title="KanisJA , PowlesT , PatersonAH , McCloskeyEV , AshleyS . Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone1996;19(6):663‐7. ">Kanis 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0024" title="MardiakJ , BohunickyL , ChovanecJ , SalekT , KozaI . Adjuvant clodronate therapy in patients with locally advanced breast cancer ‐ long term results of a double blind randomised trial. Neoplasma2000;47(3):177‐80. ">Mardiak 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0039" title="VanHolten‐VerzantvoortAT , HermansJ , BeexLVAM , BlijhamG , CletonFJ , VanEck‐SmitBCF , et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients?. European Journal of Cancer1996;32A(3):450‐4. ">Van‐Holten 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants scored questionnaire items on a 4‐point scale (0 = none, 3 = very severe)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At baseline, mean scores were similar across the 2 groups however pamidronate had a worse score for fatigue compared to control. At follow‐up, the mean scores were similar in the 2 groups with similar worsening over time in mobility and gastrointestinal toxicity. There was no change in bone pain and fatigue over time or between the 2 groups </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><b>NR</b>: not reported </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Advanced breast cancer: quality of life</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003474-tbl-0011"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Advanced breast cancer: toxicity ‐ osteonecrosis of the jaw, renal dysfunction, bone pain, drug‐related death</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Treatment vs comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Osteonecrosis of the jaw</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Renal dysfunction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Bone pain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Drug‐related death</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Additional comment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0019" title="KanisJA , PowlesT , PatersonAH , McCloskeyEV , AshleyS . Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone1996;19(6):663‐7. ">Kanis 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13<sup>a</sup>/66 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17<sup>a</sup>/67 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No hypocalcaemia observed in either group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0024" title="MardiakJ , BohunickyL , ChovanecJ , SalekT , KozaI . Adjuvant clodronate therapy in patients with locally advanced breast cancer ‐ long term results of a double blind randomised trial. Neoplasma2000;47(3):177‐80. ">Mardiak 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 participant with rash (clodronate); 2 participants with gastrointestinal toxicity (1 clodronate, 1 placebo); 1 participant with abdominal pain (placebo) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0039" title="VanHolten‐VerzantvoortAT , HermansJ , BeexLVAM , BlijhamG , CletonFJ , VanEck‐SmitBCF , et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients?. European Journal of Cancer1996;32A(3):450‐4. ">Van‐Holten 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 300 mg oral vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>"...did not change over time and there was no effect of pamidronate treatment"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 participants with gastrointestinal intolerance in pamidronate group</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p><b>n</b> : number of events; <b>N</b> : number of women studied in each group; <b>NR</b>: not reported<br/> <sup>a</sup>Received radiotherapy for bone pain. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Advanced breast cancer: toxicity ‐ osteonecrosis of the jaw, renal dysfunction, bone pain, drug‐related death</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003474-tbl-0012"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Advanced breast cancer: toxicity ‐ nausea, fatigue, fever &amp; influenza symptoms</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Treatment vs comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Nausea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fatigue</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fever</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Influenza‐type symptoms</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0019" title="KanisJA , PowlesT , PatersonAH , McCloskeyEV , AshleyS . Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone1996;19(6):663‐7. ">Kanis 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0024" title="MardiakJ , BohunickyL , ChovanecJ , SalekT , KozaI . Adjuvant clodronate therapy in patients with locally advanced breast cancer ‐ long term results of a double blind randomised trial. Neoplasma2000;47(3):177‐80. ">Mardiak 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0039" title="VanHolten‐VerzantvoortAT , HermansJ , BeexLVAM , BlijhamG , CletonFJ , VanEck‐SmitBCF , et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients?. European Journal of Cancer1996;32A(3):450‐4. ">Van‐Holten 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 300 mg oral vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scored 0.6 (worse than control arm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scored 0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><b>n</b> : number of events; <b>N</b> : number of women studied in each group; <b>NR</b>: not reported </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Advanced breast cancer: toxicity ‐ nausea, fatigue, fever &amp; influenza symptoms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003474-tbl-0013"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Breast cancer with bone metastases: skeletal‐related event rate</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>No. of skeletal‐related events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Ratio: Bisphosphonate/comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bisphosphonate vs placebo/open</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a><br/> (N = 751) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 90 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4<br/> Event rate = mean no. of events/year </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0006" title="BodyJJ , DielIJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology2003;14(9):1399‐405. BodyJJ , LichinitserMR , DiehlI , SchlosserK , PfarrE , CavalliF , et al. Double‐blind placebo‐controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. DielIJ , BodyJJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Improved quality of life after long‐term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer2004;40(11):1704‐12. LyubimovaN , KushlinkskyNE , LichinitserMR . Long‐term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease. 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003. New York: Supportive Care in Cancer, 2003. ">Body 2003</a> </p> <p>(N = 312)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56<br/> Event rate = events/patient year </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0007" title="BodyJJ , DielI , BellR , PecherstorferM , LichinitserM , LazarevA , et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111(3):306‐12. BodyJJ , DielIJ , LichinitzerM , LazarevA , PecherstorferM , BellR , et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo‐controlled phase III studies. British Journal of Cancer2004;90(6):1133‐7. ">Body 2004</a><br/> (N = 564) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99<br/> Rate assessed using SMPR; pooled results of 50 mg ibandronate versus placebo from studies MF4434 and MF4414 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.041</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0009" title="ContePF , GiannessiPG , LatreilleJ , MauriacL , KolirenL , CabresiF , et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology1994;5(Suppl 7):41‐4. ContePF , LatrielleJ , MauriacL , CalbresiF , SantosR , CamposD , et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology1996;14(9):2552‐9. ">Conte 1996</a><br/> (N = 224) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 45 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135<br/> Event rate = total events per arm </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0012" title="ElomaaI , BlomqvistC , GrohnP , PorkkaL , KairentoA‐L , SelanderK , et al. Long‐term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet1983;1(8317):146‐9. ElomaaI , BlomqvistC , Porkka , HoltstromT , TaubeT , Lamberg‐AllardtC , et al. Clodronate for osteolytic metastases due to breast cancer. Biomedicine and Pharmacotherapy1988;42(2):111‐6. ElommaI , BlomqvistL , PorkkaL , Lamberg‐AllardtC , BorgstromGH . Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone1987;8(Suppl 1):53‐6. ">Elomaa 1983</a><br/> (N = 34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0016" title="HerasP , HatzopoulosA , MitsibounasD . Efficacy of ibandronate for the prevention of skeletal‐related events in breast cancer patients with metastatic bone disease. European Journal of Cancer2005;3(2):121. HerasP , KritikosK , HatzopoulosA , GeorgopoulouAP . Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. European Journal of Cancer Care2009;18(6):653‐6. ">Heras 2009</a><br/> (N = 150) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0018" title="HultbornR , GundersenS , RydenS , HolmbergE , CarstensenJ , WallgrenUB , et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double‐blind placebo‐controlled multicenter study. Anticancer Research1999;19(4C):3383‐92. ">Hultborn 1999</a><br/> (N = 404) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98</p> <p>Event rate = cumulative events/follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0020" title="KohnoN , AogiK , MinamiH , NakamuraS , AsagaT , IinoY , et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo‐controlled trial. Journal of Clinical Oncology2005;23(15):3314‐21. ">Kohno 2005</a><br/> (N = 227) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63<br/> Event rate = events per year </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.016</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0021" title="KristensenB , EjlertsenB , GroenvoldM , HeinS , LoftH , MouridsenHT . Oral clodronate in breast cancer patients with bone metastases: a randomised study. Journal of Internal Medicine1999;246(1):67‐74. ">Kristensen 1999</a><br/> (N = 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral, 2/d for 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4<br/> Event rate = cumulative proportion of skeletal events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0025" title="MartoniA , GuaraldiM , CameraP , BiagiR , MarriS , BegheF , et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology1991;48(2):97‐101. ">Martoni 1991</a><br/> (N = 38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 300 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0029" title="PatersonAHG , KanisJA , PowlesTJ , McCloskeyEV , ArchabaultWT , KurmanMR , et al. A re‐analysis of a trial of clodronate in patients with breast cancer and bone metastases. Anthra Pharmaceuticals. PatersonAHG , PowlesTJ , KanisJA , McCloskeyE , HansonJ , AshleyS . Double‐blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(1):59‐65. ">Paterson 1993</a><br/> (N = 173) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral, 2/d for up to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>218.6<br/> Event rate = cumulative proportion of skeletal events per 100 patient‐years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>304.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0036" title="TripathyD , LichinitzerM , LazarevA , MacLachianA , ApffelstaedtJ , BuddeM , et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomised, double‐blind, placebo‐controlled trial. Annals of Oncology2004;15(5):743‐50. ">Tripathy 2004</a><br/> (N = 287) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98<br/> Rate assessed using SMPR; refers only to the results of the 50 mg ibandronate arm versus placebo within study MF4434 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.037</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0037" title="Tubiana‐HulinM , BeuzebocP , MauriacL , BarbetN , FrenayM , MonnierA , et al. Double‐blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bulletin du Cancer2001;88(7):701‐7. ">Tubiana‐Hulin 2001</a><br/> (N = 144) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<br/> "No difference between groups" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0038" title="CletonFJ , VanHolten‐VerzantvoortAT , BijvoetOLM . Effect of long‐term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results in Cancer Research. Vol. 116, Berlin‐Heidelberg: Springer‐Verlag, 1989:73‐8. VanHolten‐VaerzantvoortATM , KroonHM , BijvoetOLM , CletonFJ , BeexLVAM , BlijhamG , et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(3):491‐8. VanHolten‐VerzantvoortAT , BijvoetOLM , CletonFJ , HermansJ , KroonHM , HarinckHIJ , et al. Reduced morbidity from skeletal metastases in breast cancer patients during long‐term bisphosphonate (APD) treatment. Lancet1987;330(8566):983‐5. VanHolten‐VerzantvoortATM , ZwindermanAH , AaronsonNK , HermansJ , VanEmmerikB , VanDamFSAM , et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. European Journal of Cancer1991;27(5):544‐9. ">Van‐Holten 1987</a><br/> (N = 161) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 150 mg oral, 2/d indefinitely</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90<br/> Event rate = total number of events. Events = "complications" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.003</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Direct comparisons of different bisphosphonate regimens</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a> </p> <p>(N = 318)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 2400 mg oral or 900 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> <p>Event = number of people with fractures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate oral = 11</p> <p>Clodronate iv = 19</p> <p>Event = number of people with fractures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a><br/> (N = 1130) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 90 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.037</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0040" title="vonAuA , MillothE , DielI , StefanovicS , HennigsA , WallwienerM , et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open‐label, non‐inferiority phase III trial. OncoTargets and Therapy2016; Vol. 2016, issue 9:4173‐80. ">von Au 2016</a><br/> (N = 375) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 900 mg iv every 3 weeks or 2400 mg/d oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3%<br/> Event rate = fracture rate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.3% or 17.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.07 (pamidronate versus clodronate oral)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a><br/> (N = 1404) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.507<br/> Event rate = annual rate of SRE </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.035</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bone‐targeted agents vs bisphosphonate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a><br/> (N = 44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate iv (clinician choice)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0023" title="LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clinical Cancer Research2008;14(20):6690‐6. LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Randomized active‐controlled phase II study of denosumab efficacy and safety in patients with breast cancer‐related bone metastases. Journal of Clinical Oncology2007;25(28):4431‐7. ">Lipton 2008</a><br/> (N = 255) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab sc every 4 weeks (30 mg, 120 mg or 180 mg) or every 12 weeks (60 mg or 180 mg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate iv (either zoledronate, pamidronate or ibandronate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a> </p> <p>(N = 2046)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 120 mg sc (iv placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv (sc placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58<br/> Event rate assessed using SMPR, defined as the ratio of the number of SREs per participant divided by the participant’s time at risk. An exploratory endpoint </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.004</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Standard vs reduced bisphosphonate/bone agent</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0008" title="HimelsteinAL , QinR , NovotnyPJ , SeislerDK , KhatcheressianJL , RobertsJD , et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of Clinical Oncology2015; Vol. 33, issue 15 Suppl:9501. [0732‐183X] NCT00869206 . Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. clinicaltrials.gov/ct2/show/NCT00869206 Date first received: 24 March 2009. ">CALGB‐70604 2015</a><br/> (N = 820) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a><br/> (N = 73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a> </p> <p>(N = 403)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46<br/> Event rate assessed using SMR, defined as the number of events per year </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a><br/> (N = 425) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22</p> <p>Event rate = skeletal morbidity rate (SRE/patient/year)</p> <p>Non‐inferiority not demonstrated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>iv</b> : intravenous; <b>N</b> : total number of women in each study; <b>NR</b> : not reported; <b>sc</b> : subcutaneous; <b>SMPR</b> : skeletal morbidity period rate; <b>SRE</b>: skeletal related event </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Breast cancer with bone metastases: skeletal‐related event rate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003474-tbl-0014"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Breast cancer with bone metastases: median time to skeletal‐related event</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Median time to event (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Ratio: bisphosphonate/comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bisphosphonate vs placebo/open</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a><br/> (N = 751) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 90 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0006" title="BodyJJ , DielIJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology2003;14(9):1399‐405. BodyJJ , LichinitserMR , DiehlI , SchlosserK , PfarrE , CavalliF , et al. Double‐blind placebo‐controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. DielIJ , BodyJJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Improved quality of life after long‐term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer2004;40(11):1704‐12. LyubimovaN , KushlinkskyNE , LichinitserMR . Long‐term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease. 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003. New York: Supportive Care in Cancer, 2003. ">Body 2003</a> </p> <p>(N = 312)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.018</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0007" title="BodyJJ , DielI , BellR , PecherstorferM , LichinitserM , LazarevA , et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111(3):306‐12. BodyJJ , DielIJ , LichinitzerM , LazarevA , PecherstorferM , BellR , et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo‐controlled phase III studies. British Journal of Cancer2004;90(6):1133‐7. ">Body 2004</a><br/> (N = 564) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.8<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.9<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.089</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0009" title="ContePF , GiannessiPG , LatreilleJ , MauriacL , KolirenL , CabresiF , et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology1994;5(Suppl 7):41‐4. ContePF , LatrielleJ , MauriacL , CalbresiF , SantosR , CamposD , et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology1996;14(9):2552‐9. ">Conte 1996</a><br/> (N = 224) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 45 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0012" title="ElomaaI , BlomqvistC , GrohnP , PorkkaL , KairentoA‐L , SelanderK , et al. Long‐term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet1983;1(8317):146‐9. ElomaaI , BlomqvistC , Porkka , HoltstromT , TaubeT , Lamberg‐AllardtC , et al. Clodronate for osteolytic metastases due to breast cancer. Biomedicine and Pharmacotherapy1988;42(2):111‐6. ElommaI , BlomqvistL , PorkkaL , Lamberg‐AllardtC , BorgstromGH . Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone1987;8(Suppl 1):53‐6. ">Elomaa 1983</a><br/> (N = 34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0016" title="HerasP , HatzopoulosA , MitsibounasD . Efficacy of ibandronate for the prevention of skeletal‐related events in breast cancer patients with metastatic bone disease. European Journal of Cancer2005;3(2):121. HerasP , KritikosK , HatzopoulosA , GeorgopoulouAP . Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. European Journal of Cancer Care2009;18(6):653‐6. ">Heras 2009</a><br/> (N = 150) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.2<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.1<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.007</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0018" title="HultbornR , GundersenS , RydenS , HolmbergE , CarstensenJ , WallgrenUB , et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double‐blind placebo‐controlled multicenter study. Anticancer Research1999;19(4C):3383‐92. ">Hultborn 1999</a><br/> (N = 404) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.006</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0020" title="KohnoN , AogiK , MinamiH , NakamuraS , AsagaT , IinoY , et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo‐controlled trial. Journal of Clinical Oncology2005;23(15):3314‐21. ">Kohno 2005</a><br/> (N = 228) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12^</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<br/> The median time to first SRE was not reached in the zoledronic acid arm, versus 364 days in the placebo arm </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.007</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0021" title="KristensenB , EjlertsenB , GroenvoldM , HeinS , LoftH , MouridsenHT . Oral clodronate in breast cancer patients with bone metastases: a randomised study. Journal of Internal Medicine1999;246(1):67‐74. ">Kristensen 1999</a><br/> (N = 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral, 2/d for 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<br/> Time to skeletal event delayed with clodronate according to Kaplan‐Meier curves </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.015</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0025" title="MartoniA , GuaraldiM , CameraP , BiagiR , MarriS , BegheF , et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology1991;48(2):97‐101. ">Martoni 1991</a><br/> (N = 38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 300 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0029" title="PatersonAHG , KanisJA , PowlesTJ , McCloskeyEV , ArchabaultWT , KurmanMR , et al. A re‐analysis of a trial of clodronate in patients with breast cancer and bone metastases. Anthra Pharmaceuticals. PatersonAHG , PowlesTJ , KanisJA , McCloskeyE , HansonJ , AshleyS . Double‐blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(1):59‐65. ">Paterson 1993</a><br/> (N = 173) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral, 2/d for up to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.022</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0036" title="TripathyD , LichinitzerM , LazarevA , MacLachianA , ApffelstaedtJ , BuddeM , et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomised, double‐blind, placebo‐controlled trial. Annals of Oncology2004;15(5):743‐50. ">Tripathy 2004</a><br/> (N = 287) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.5<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.1<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0037" title="Tubiana‐HulinM , BeuzebocP , MauriacL , BarbetN , FrenayM , MonnierA , et al. Double‐blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bulletin du Cancer2001;88(7):701‐7. ">Tubiana‐Hulin 2001</a><br/> (N = 144) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0038" title="CletonFJ , VanHolten‐VerzantvoortAT , BijvoetOLM . Effect of long‐term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results in Cancer Research. Vol. 116, Berlin‐Heidelberg: Springer‐Verlag, 1989:73‐8. VanHolten‐VaerzantvoortATM , KroonHM , BijvoetOLM , CletonFJ , BeexLVAM , BlijhamG , et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(3):491‐8. VanHolten‐VerzantvoortAT , BijvoetOLM , CletonFJ , HermansJ , KroonHM , HarinckHIJ , et al. Reduced morbidity from skeletal metastases in breast cancer patients during long‐term bisphosphonate (APD) treatment. Lancet1987;330(8566):983‐5. VanHolten‐VerzantvoortATM , ZwindermanAH , AaronsonNK , HermansJ , VanEmmerikB , VanDamFSAM , et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. European Journal of Cancer1991;27(5):544‐9. ">Van‐Holten 1987</a><br/> (N = 161) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 150 mg oral, 2/d indefinitely</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Direct comparisons of different bisphosphonate regimens</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a> </p> <p>(N = 318)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 2400 mg oral or 900 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a><br/> (N = 1130) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 90 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.013</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0040" title="vonAuA , MillothE , DielI , StefanovicS , HennigsA , WallwienerM , et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open‐label, non‐inferiority phase III trial. OncoTargets and Therapy2016; Vol. 2016, issue 9:4173‐80. ">von Au 2016</a><br/> (N = 375) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 900 mg iv every 3 weeks or 2400 mg/d oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a><br/> (N = 1404) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.4<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.9<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.034</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bone‐targeted agents vs bisphosphonate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a><br/> (N = 44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate iv (clinician choice)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0023" title="LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clinical Cancer Research2008;14(20):6690‐6. LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Randomized active‐controlled phase II study of denosumab efficacy and safety in patients with breast cancer‐related bone metastases. Journal of Clinical Oncology2007;25(28):4431‐7. ">Lipton 2008</a><br/> (N = 255) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab sc every 4 weeks (30 mg, 120 mg or 180 mg) or every 12 weeks (60 mg or 180 mg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate iv (either zoledronate, pamidronate or ibandronate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a> </p> <p>(N = 2046)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 120 mg sc (iv placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv (sc placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not yet reached</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Standard vs reduced bisphosphonate/bone agent</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0008" title="HimelsteinAL , QinR , NovotnyPJ , SeislerDK , KhatcheressianJL , RobertsJD , et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of Clinical Oncology2015; Vol. 33, issue 15 Suppl:9501. [0732‐183X] NCT00869206 . Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. clinicaltrials.gov/ct2/show/NCT00869206 Date first received: 24 March 2009. ">CALGB‐70604 2015</a><br/> (N = 820) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a><br/> (N = 73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a> </p> <p>(N = 403)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<br/> "Median time to first SRE was not estimable because there were too few events to calculate the median" (clinical trials registry record) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a><br/> (N = 425) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<br/> "Median time to first on‐study skeletal‐related event could not be calculated because of the very low event rate." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>iv</b> : intravenous; <b>N</b> : total number of women in each study; <b>NR</b> : not reported; <b>NS</b> : not significant; <b>sc</b> : subcutaneous; <b>SMPR</b> : skeletal morbidity period rate; <b>SRE</b>: skeletal‐related event.<br/> <sup>a</sup>We converted data from weeks or days into months.<br/> <sup>b</sup>Trial authors did not provided numerical value for median TSE of control and treatment groups. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Breast cancer with bone metastases: median time to skeletal‐related event</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003474-tbl-0015"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Breast cancer with bone metastases: median survival time</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Median survival (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Ratio: bisphosphonate/comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bisphosphonate vs placebo/open</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a><br/> (N = 751) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 90 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0006" title="BodyJJ , DielIJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology2003;14(9):1399‐405. BodyJJ , LichinitserMR , DiehlI , SchlosserK , PfarrE , CavalliF , et al. Double‐blind placebo‐controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. DielIJ , BodyJJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Improved quality of life after long‐term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer2004;40(11):1704‐12. LyubimovaN , KushlinkskyNE , LichinitserMR . Long‐term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease. 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003. New York: Supportive Care in Cancer, 2003. ">Body 2003</a> </p> <p>(N = 312)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.3<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.7<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0007" title="BodyJJ , DielI , BellR , PecherstorferM , LichinitserM , LazarevA , et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111(3):306‐12. BodyJJ , DielIJ , LichinitzerM , LazarevA , PecherstorferM , BellR , et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo‐controlled phase III studies. British Journal of Cancer2004;90(6):1133‐7. ">Body 2004</a><br/> (N = 564) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0009" title="ContePF , GiannessiPG , LatreilleJ , MauriacL , KolirenL , CabresiF , et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology1994;5(Suppl 7):41‐4. ContePF , LatrielleJ , MauriacL , CalbresiF , SantosR , CamposD , et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology1996;14(9):2552‐9. ">Conte 1996</a><br/> (N = 295) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 45 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0012" title="ElomaaI , BlomqvistC , GrohnP , PorkkaL , KairentoA‐L , SelanderK , et al. Long‐term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet1983;1(8317):146‐9. ElomaaI , BlomqvistC , Porkka , HoltstromT , TaubeT , Lamberg‐AllardtC , et al. Clodronate for osteolytic metastases due to breast cancer. Biomedicine and Pharmacotherapy1988;42(2):111‐6. ElommaI , BlomqvistL , PorkkaL , Lamberg‐AllardtC , BorgstromGH . Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone1987;8(Suppl 1):53‐6. ">Elomaa 1983</a><br/> (N = 34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.004</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0016" title="HerasP , HatzopoulosA , MitsibounasD . Efficacy of ibandronate for the prevention of skeletal‐related events in breast cancer patients with metastatic bone disease. European Journal of Cancer2005;3(2):121. HerasP , KritikosK , HatzopoulosA , GeorgopoulouAP . Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. European Journal of Cancer Care2009;18(6):653‐6. ">Heras 2009</a><br/> (N = 150) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0018" title="HultbornR , GundersenS , RydenS , HolmbergE , CarstensenJ , WallgrenUB , et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double‐blind placebo‐controlled multicenter study. Anticancer Research1999;19(4C):3383‐92. ">Hultborn 1999</a><br/> (N = 404) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0020" title="KohnoN , AogiK , MinamiH , NakamuraS , AsagaT , IinoY , et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo‐controlled trial. Journal of Clinical Oncology2005;23(15):3314‐21. ">Kohno 2005</a><br/> (N = 228) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0021" title="KristensenB , EjlertsenB , GroenvoldM , HeinS , LoftH , MouridsenHT . Oral clodronate in breast cancer patients with bone metastases: a randomised study. Journal of Internal Medicine1999;246(1):67‐74. ">Kristensen 1999</a><br/> (N = 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral, 2/d for 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0025" title="MartoniA , GuaraldiM , CameraP , BiagiR , MarriS , BegheF , et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology1991;48(2):97‐101. ">Martoni 1991</a><br/> (N = 38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 300 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0029" title="PatersonAHG , KanisJA , PowlesTJ , McCloskeyEV , ArchabaultWT , KurmanMR , et al. A re‐analysis of a trial of clodronate in patients with breast cancer and bone metastases. Anthra Pharmaceuticals. PatersonAHG , PowlesTJ , KanisJA , McCloskeyE , HansonJ , AshleyS . Double‐blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(1):59‐65. ">Paterson 1993</a><br/> (N = 173) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral, 2/d for up to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.198</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0036" title="TripathyD , LichinitzerM , LazarevA , MacLachianA , ApffelstaedtJ , BuddeM , et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomised, double‐blind, placebo‐controlled trial. Annals of Oncology2004;15(5):743‐50. ">Tripathy 2004</a><br/> (N = 287) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0037" title="Tubiana‐HulinM , BeuzebocP , MauriacL , BarbetN , FrenayM , MonnierA , et al. Double‐blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bulletin du Cancer2001;88(7):701‐7. ">Tubiana‐Hulin 2001</a><br/> (N = 144) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0038" title="CletonFJ , VanHolten‐VerzantvoortAT , BijvoetOLM . Effect of long‐term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results in Cancer Research. Vol. 116, Berlin‐Heidelberg: Springer‐Verlag, 1989:73‐8. VanHolten‐VaerzantvoortATM , KroonHM , BijvoetOLM , CletonFJ , BeexLVAM , BlijhamG , et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(3):491‐8. VanHolten‐VerzantvoortAT , BijvoetOLM , CletonFJ , HermansJ , KroonHM , HarinckHIJ , et al. Reduced morbidity from skeletal metastases in breast cancer patients during long‐term bisphosphonate (APD) treatment. Lancet1987;330(8566):983‐5. VanHolten‐VerzantvoortATM , ZwindermanAH , AaronsonNK , HermansJ , VanEmmerikB , VanDamFSAM , et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. European Journal of Cancer1991;27(5):544‐9. ">Van‐Holten 1987</a><br/> (N = 161) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 150 mg oral, 2/d indefinitely</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Direct comparisons of different bisphosphonate regimens</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a> </p> <p>(N = 318)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 2400 mg oral or 900 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a><br/> (N = 1130) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 90 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0040" title="vonAuA , MillothE , DielI , StefanovicS , HennigsA , WallwienerM , et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open‐label, non‐inferiority phase III trial. OncoTargets and Therapy2016; Vol. 2016, issue 9:4173‐80. ">von Au 2016</a><br/> (N = 375) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 900 mg iv every 3 weeks or 2400 mg/d oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a><br/> (N = 1404) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02<br/> Hazard ratio = 1.086 (95% confidence interval 0.948 to 1.245) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bone‐targeted agents vs bisphosphonate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a><br/> (N = 44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate iv (clinician choice)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0023" title="LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clinical Cancer Research2008;14(20):6690‐6. LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Randomized active‐controlled phase II study of denosumab efficacy and safety in patients with breast cancer‐related bone metastases. Journal of Clinical Oncology2007;25(28):4431‐7. ">Lipton 2008</a><br/> (N = 255) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab sc every 4 weeks (30 mg, 120 mg or 180 mg) or every 12 weeks (60 mg or 180 mg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate iv (either zoledronate, pamidronate or ibandronate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a> </p> <p>(N = 2046)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 120 mg sc (iv placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv (sc placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95<br/> Actual median overall survival values are not reported, but about 60% of participants alive at 27 months in both arms according to Kaplan‐Meier curve </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Standard vs reduced bisphosphonate/bone agent</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0008" title="HimelsteinAL , QinR , NovotnyPJ , SeislerDK , KhatcheressianJL , RobertsJD , et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of Clinical Oncology2015; Vol. 33, issue 15 Suppl:9501. [0732‐183X] NCT00869206 . Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. clinicaltrials.gov/ct2/show/NCT00869206 Date first received: 24 March 2009. ">CALGB‐70604 2015</a><br/> (N = 820) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a><br/> (N = 73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a> </p> <p>(N = 403)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a><br/> (N = 425) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>iv</b> : intravenous; <b>N</b> : total number of women in each study; <b>NR</b> : not reported; <b>NS</b> : not significant; <b>sc</b>: subcutaneous<br/> <sup>a</sup>We converted data from weeks into months. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Breast cancer with bone metastases: median survival time</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003474-tbl-0016"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Breast cancer with bone metastases: bone pain</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Bone pain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Pain tool used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bisphosphonate vs placebo/open</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a><br/> (N = 751) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 90 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>A significant difference in mean change from baseline pain score favouring pamidronate was first noted at 24 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reference to validation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.015</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0006" title="BodyJJ , DielIJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology2003;14(9):1399‐405. BodyJJ , LichinitserMR , DiehlI , SchlosserK , PfarrE , CavalliF , et al. Double‐blind placebo‐controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. DielIJ , BodyJJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Improved quality of life after long‐term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer2004;40(11):1704‐12. LyubimovaN , KushlinkskyNE , LichinitserMR . Long‐term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease. 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003. New York: Supportive Care in Cancer, 2003. ">Body 2003</a> </p> <p>(N = 312)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Significantly improved bone pain score over time favouring the ibandronate 6 mg group compared to placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐point scale. No reference to validation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0007" title="BodyJJ , DielI , BellR , PecherstorferM , LichinitserM , LazarevA , et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111(3):306‐12. BodyJJ , DielIJ , LichinitzerM , LazarevA , PecherstorferM , BellR , et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo‐controlled phase III studies. British Journal of Cancer2004;90(6):1133‐7. ">Body 2004</a><br/> (N = 564) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>At week 96, mean bone pain scores were significantly reduced from baseline with ibandronate compared to placebo (‐0.10, 95% CI ‐0.32 to 0.02 vs 0.20, 95% CI 0.07 to 0.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant‐rated scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0009" title="ContePF , GiannessiPG , LatreilleJ , MauriacL , KolirenL , CabresiF , et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology1994;5(Suppl 7):41‐4. ContePF , LatrielleJ , MauriacL , CalbresiF , SantosR , CamposD , et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology1996;14(9):2552‐9. ">Conte 1996</a><br/> (N = 268) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 45 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>No significant difference between the groups at the predefined time points; most symptomatic variables showed a greater degree of improvement in the pamidronate group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6‐point self‐assessment scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0012" title="ElomaaI , BlomqvistC , GrohnP , PorkkaL , KairentoA‐L , SelanderK , et al. Long‐term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet1983;1(8317):146‐9. ElomaaI , BlomqvistC , Porkka , HoltstromT , TaubeT , Lamberg‐AllardtC , et al. Clodronate for osteolytic metastases due to breast cancer. Biomedicine and Pharmacotherapy1988;42(2):111‐6. ElommaI , BlomqvistL , PorkkaL , Lamberg‐AllardtC , BorgstromGH . Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone1987;8(Suppl 1):53‐6. ">Elomaa 1983</a><br/> (N = 34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0016" title="HerasP , HatzopoulosA , MitsibounasD . Efficacy of ibandronate for the prevention of skeletal‐related events in breast cancer patients with metastatic bone disease. European Journal of Cancer2005;3(2):121. HerasP , KritikosK , HatzopoulosA , GeorgopoulouAP . Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. European Journal of Cancer Care2009;18(6):653‐6. ">Heras 2009</a><br/> (N = 150) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0018" title="HultbornR , GundersenS , RydenS , HolmbergE , CarstensenJ , WallgrenUB , et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double‐blind placebo‐controlled multicenter study. Anticancer Research1999;19(4C):3383‐92. ">Hultborn 1999</a><br/> (N = 404) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>"...results favoured pamidronate however insignificant when corrected for the prestudy values" (page 3387) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Questionnaire &amp; VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0020" title="KohnoN , AogiK , MinamiH , NakamuraS , AsagaT , IinoY , et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo‐controlled trial. Journal of Clinical Oncology2005;23(15):3314‐21. ">Kohno 2005</a><br/> (N = 268) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>From weeks 4‐52, a chart of mean change in the BPI was statistically significant in favour of a reduction by zoledronic acid </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0021" title="KristensenB , EjlertsenB , GroenvoldM , HeinS , LoftH , MouridsenHT . Oral clodronate in breast cancer patients with bone metastases: a randomised study. Journal of Internal Medicine1999;246(1):67‐74. ">Kristensen 1999</a><br/> (N = 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral, 2/d for 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>No difference between groups using a physician‐rated scale (no reference to validation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physician‐rated scale. No reference to validation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0025" title="MartoniA , GuaraldiM , CameraP , BiagiR , MarriS , BegheF , et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology1991;48(2):97‐101. ">Martoni 1991</a><br/> (N = 38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 300 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>No significant difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scott‐Huskinsson Visual Analog method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0029" title="PatersonAHG , KanisJA , PowlesTJ , McCloskeyEV , ArchabaultWT , KurmanMR , et al. A re‐analysis of a trial of clodronate in patients with breast cancer and bone metastases. Anthra Pharmaceuticals. PatersonAHG , PowlesTJ , KanisJA , McCloskeyE , HansonJ , AshleyS . Double‐blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(1):59‐65. ">Paterson 1993</a><br/> (N = 173) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral, 2/d for up to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0036" title="TripathyD , LichinitzerM , LazarevA , MacLachianA , ApffelstaedtJ , BuddeM , et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomised, double‐blind, placebo‐controlled trial. Annals of Oncology2004;15(5):743‐50. ">Tripathy 2004</a><br/> (N = 287) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>From baseline to study end point, bone pain scores increased by +0.21 in the placebo group and a slight increase of +0.03 in the ibandronate 50 mg group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.201</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0037" title="Tubiana‐HulinM , BeuzebocP , MauriacL , BarbetN , FrenayM , MonnierA , et al. Double‐blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bulletin du Cancer2001;88(7):701‐7. ">Tubiana‐Hulin 2001</a><br/> (N = 144) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Significant reduction in pain in clodronate group compared to control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Visual pain scale. No reference to validation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0038" title="CletonFJ , VanHolten‐VerzantvoortAT , BijvoetOLM . Effect of long‐term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results in Cancer Research. Vol. 116, Berlin‐Heidelberg: Springer‐Verlag, 1989:73‐8. VanHolten‐VaerzantvoortATM , KroonHM , BijvoetOLM , CletonFJ , BeexLVAM , BlijhamG , et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(3):491‐8. VanHolten‐VerzantvoortAT , BijvoetOLM , CletonFJ , HermansJ , KroonHM , HarinckHIJ , et al. Reduced morbidity from skeletal metastases in breast cancer patients during long‐term bisphosphonate (APD) treatment. Lancet1987;330(8566):983‐5. VanHolten‐VerzantvoortATM , ZwindermanAH , AaronsonNK , HermansJ , VanEmmerikB , VanDamFSAM , et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. European Journal of Cancer1991;27(5):544‐9. ">Van‐Holten 1987</a><br/> (N = 161) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 150 mg oral, 2/d indefinitely</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Bone scores were significantly higher in the control group with an early reduction in bone pain within the first 3 months of pamidronate. However, bone pain then increased significantly over time (P = 0.005) in both groups although more rapidly in the control than pamidronate group (P = 0.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 items on bone pain within a quality‐of‐life questionnaire designed specifically for this trial. Reliability of the questionnaire tested at first observation point of participants </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.007 (pamidronate vs control at 3 months)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Direct comparisons of different bisphosphonate regimens</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a> </p> <p>(N = 318)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 2400 mg oral or 900 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Trend to improvement with iv bisphosphonates (30% reduction with pamidronate iv, 25% reduction with clodronate iv) compared with oral clodronate (15%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain tool not reported in abstract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a><br/> (N = 766) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 90 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0040" title="vonAuA , MillothE , DielI , StefanovicS , HennigsA , WallwienerM , et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open‐label, non‐inferiority phase III trial. OncoTargets and Therapy2016; Vol. 2016, issue 9:4173‐80. ">von Au 2016</a><br/> (N = 375) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 900 mg iv every 3 weeks or 2400 mg/d oral</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Pain scores at baseline and final examinations were not significantly different among the groups. Overall, a slight increase in pain scores over time with no significant differences among the groups (P = 0.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a><br/> (N = 1404) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Pain scores reduced from baseline at 12 weeks and were maintained over 96 weeks. There was no difference between the groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bone‐targeted agents vs bisphosphonate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a><br/> (N = 44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate iv (clinician choice)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0023" title="LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clinical Cancer Research2008;14(20):6690‐6. LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Randomized active‐controlled phase II study of denosumab efficacy and safety in patients with breast cancer‐related bone metastases. Journal of Clinical Oncology2007;25(28):4431‐7. ">Lipton 2008</a><br/> (N = 255) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab sc every 4 weeks (30 mg, 120 mg or 180 mg) or every 12 weeks (60 mg or 180 mg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bisphosphonate iv (either zoledronate, pamidronate or ibandronate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a> </p> <p>(N = 2046)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 120 mg sc (iv placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv (sc placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Prolonged median time to develop moderate/severe pain from no pain on baseline (denosumab: zoledronate hazard ratio 0.78). Lower proportion of participants with moderate/severe pain from no pain on baseline (denosumab 14.8% vs zoledronate 26.7% at week 73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Standard vs reduced bisphosphonate/bone agent</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0008" title="HimelsteinAL , QinR , NovotnyPJ , SeislerDK , KhatcheressianJL , RobertsJD , et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of Clinical Oncology2015; Vol. 33, issue 15 Suppl:9501. [0732‐183X] NCT00869206 . Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. clinicaltrials.gov/ct2/show/NCT00869206 Date first received: 24 March 2009. ">CALGB‐70604 2015</a><br/> (N = 820) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a><br/> (N = 73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a> </p> <p>(N = 189)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Change from baseline in mean BPI score was 0.24 (standard deviation 1.976) in zoledronate every 4 weeks while the change from baseline score was 0.31 (standard deviation 2.099) in zoledronate every 12 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a><br/> (N = 425) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Most people had a score &lt; 4; median pain at rest and pain on movement scores were &lt; 4 at all points in both groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Validated 6‐point Verbal Rating Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>BPI</b> : Brief Pain Inventory; <b>CI</b> : confidence interval; <b>iv</b> : intravenous; <b>N</b> : total number of women in each study; <b>NR</b> : not reported; <b>NS</b> : not significantly different; <b>sc</b> : subcutaneous; <b>VAS</b>: visual analogue scale </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Breast cancer with bone metastases: bone pain</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003474-tbl-0017"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Breast cancer with bone metastases: quality of life</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Questionnaires used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Summary of findings</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Bisphosphonate vs placebo/open</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spitzer Quality‐of‐Life Index scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"...quality of life scores worsened from baseline to the last visit in both groups, although less so in the pamidronate group (P = 0.057 and 0.088, respectively)" (page 1087) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0006" title="BodyJJ , DielIJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology2003;14(9):1399‐405. BodyJJ , LichinitserMR , DiehlI , SchlosserK , PfarrE , CavalliF , et al. Double‐blind placebo‐controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. DielIJ , BodyJJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Improved quality of life after long‐term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer2004;40(11):1704‐12. LyubimovaN , KushlinkskyNE , LichinitserMR . Long‐term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease. 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003. New York: Supportive Care in Cancer, 2003. ">Body 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EORTC Quality of Life Scale ‐ Core 30 questionnaire (QLQ‐C30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"...overall quality of life scores decreased to a lesser extent between baseline and last assessment for patients receiving 2 mg ibandronate (‐18.1) and 6 mg ibandronate (‐10.3) compared with patients receiving placebo (‐45.4)" (page 1709) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0007" title="BodyJJ , DielI , BellR , PecherstorferM , LichinitserM , LazarevA , et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111(3):306‐12. BodyJJ , DielIJ , LichinitzerM , LazarevA , PecherstorferM , BellR , et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo‐controlled phase III studies. British Journal of Cancer2004;90(6):1133‐7. ">Body 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EORTC QLQ‐C30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global quality of life scores decreased significantly during the study, though significantly less with ibandronate than with placebo (‐8.3, 95% CI ‐20.6 to 4.1 vs ‐26.8, 95% CI ‐39.4 to 14.3, P = 0.03) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0009" title="ContePF , GiannessiPG , LatreilleJ , MauriacL , KolirenL , CabresiF , et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology1994;5(Suppl 7):41‐4. ContePF , LatrielleJ , MauriacL , CalbresiF , SantosR , CamposD , et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology1996;14(9):2552‐9. ">Conte 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0012" title="ElomaaI , BlomqvistC , GrohnP , PorkkaL , KairentoA‐L , SelanderK , et al. Long‐term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet1983;1(8317):146‐9. ElomaaI , BlomqvistC , Porkka , HoltstromT , TaubeT , Lamberg‐AllardtC , et al. Clodronate for osteolytic metastases due to breast cancer. Biomedicine and Pharmacotherapy1988;42(2):111‐6. ElommaI , BlomqvistL , PorkkaL , Lamberg‐AllardtC , BorgstromGH . Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone1987;8(Suppl 1):53‐6. ">Elomaa 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0016" title="HerasP , HatzopoulosA , MitsibounasD . Efficacy of ibandronate for the prevention of skeletal‐related events in breast cancer patients with metastatic bone disease. European Journal of Cancer2005;3(2):121. HerasP , KritikosK , HatzopoulosA , GeorgopoulouAP . Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. European Journal of Cancer Care2009;18(6):653‐6. ">Heras 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0018" title="HultbornR , GundersenS , RydenS , HolmbergE , CarstensenJ , WallgrenUB , et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double‐blind placebo‐controlled multicenter study. Anticancer Research1999;19(4C):3383‐92. ">Hultborn 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0020" title="KohnoN , AogiK , MinamiH , NakamuraS , AsagaT , IinoY , et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo‐controlled trial. Journal of Clinical Oncology2005;23(15):3314‐21. ">Kohno 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0021" title="KristensenB , EjlertsenB , GroenvoldM , HeinS , LoftH , MouridsenHT . Oral clodronate in breast cancer patients with bone metastases: a randomised study. Journal of Internal Medicine1999;246(1):67‐74. ">Kristensen 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EORTC QLQ‐C30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"There was no significant difference between patients receiving clodronate and controls in the change from baseline to 3 or 6 months in any of the 17 quality‐of‐life variables" (page 71) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0025" title="MartoniA , GuaraldiM , CameraP , BiagiR , MarriS , BegheF , et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology1991;48(2):97‐101. ">Martoni 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0029" title="PatersonAHG , KanisJA , PowlesTJ , McCloskeyEV , ArchabaultWT , KurmanMR , et al. A re‐analysis of a trial of clodronate in patients with breast cancer and bone metastases. Anthra Pharmaceuticals. PatersonAHG , PowlesTJ , KanisJA , McCloskeyE , HansonJ , AshleyS . Double‐blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(1):59‐65. ">Paterson 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0036" title="TripathyD , LichinitzerM , LazarevA , MacLachianA , ApffelstaedtJ , BuddeM , et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomised, double‐blind, placebo‐controlled trial. Annals of Oncology2004;15(5):743‐50. ">Tripathy 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0037" title="Tubiana‐HulinM , BeuzebocP , MauriacL , BarbetN , FrenayM , MonnierA , et al. Double‐blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bulletin du Cancer2001;88(7):701‐7. ">Tubiana‐Hulin 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0038" title="CletonFJ , VanHolten‐VerzantvoortAT , BijvoetOLM . Effect of long‐term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results in Cancer Research. Vol. 116, Berlin‐Heidelberg: Springer‐Verlag, 1989:73‐8. VanHolten‐VaerzantvoortATM , KroonHM , BijvoetOLM , CletonFJ , BeexLVAM , BlijhamG , et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(3):491‐8. VanHolten‐VerzantvoortAT , BijvoetOLM , CletonFJ , HermansJ , KroonHM , HarinckHIJ , et al. Reduced morbidity from skeletal metastases in breast cancer patients during long‐term bisphosphonate (APD) treatment. Lancet1987;330(8566):983‐5. VanHolten‐VerzantvoortATM , ZwindermanAH , AaronsonNK , HermansJ , VanEmmerikB , VanDamFSAM , et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. European Journal of Cancer1991;27(5):544‐9. ">Van‐Holten 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A questionnaire was developed specifically for the trial (validated 4‐point ordinal scale). The 4 items were related to mobility impairment, gastrointestinal toxicity, bone pain and fatigue </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The mean mobility impairment score was higher in the control group than the pamidronate group (P = 0.03). Similarly, bone pain scores were higher in the control group compared to pamidronate (P = 0.007). No differences were noted in fatigue or gastrointestinal toxicity between the two groups </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Direct comparisons of different bisphosphonate regimens</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FACT‐G</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference between groups. Quality‐of‐life data reported in conference presentation only </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0040" title="vonAuA , MillothE , DielI , StefanovicS , HennigsA , WallwienerM , et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open‐label, non‐inferiority phase III trial. OncoTargets and Therapy2016; Vol. 2016, issue 9:4173‐80. ">von Au 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EORTC QLQ‐C30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Bone‐targeted agents vs bisphosphonate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0023" title="LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clinical Cancer Research2008;14(20):6690‐6. LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Randomized active‐controlled phase II study of denosumab efficacy and safety in patients with breast cancer‐related bone metastases. Journal of Clinical Oncology2007;25(28):4431‐7. ">Lipton 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FACT‐G</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"...over monthly time points during an 18‐month period, an average of 10% more patients in the denosumab group compared with the zoledronic acid group had a clinically meaningful improvement in HRQoL ( &gt; 5‐point increase in FACT‐G total score) over the course of the study. An average of 7% fewer patients in the denosumab group than in the zoledronic acid group had worsening of HRQoL on study" (page 7, Clinical Cancer Research) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Standard vs reduced bisphosphonate/bone agent</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0008" title="HimelsteinAL , QinR , NovotnyPJ , SeislerDK , KhatcheressianJL , RobertsJD , et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of Clinical Oncology2015; Vol. 33, issue 15 Suppl:9501. [0732‐183X] NCT00869206 . Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. clinicaltrials.gov/ct2/show/NCT00869206 Date first received: 24 March 2009. ">CALGB‐70604 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><b>CI</b> : confidence interval; <b>EORTC</b> : European Organisation for the Research and Treatment of Cancer; <b>NR</b>: not reported </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Breast cancer with bone metastases: quality of life</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003474-tbl-0018"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Breast cancer with bone metastases: toxicity ‐ osteonecrosis of the jaw, hypocalcaemia, renal dysfunction &amp; drug‐related death</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Treatment vs comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Osteonecrosis of the jaw</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Hypocalcaemia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Renal dysfunction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Drug‐related death</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Bisphosphonate vs placebo/open</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 90 mg iv vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One participant had a "symptomatic hypocalcemia episode" (page 1088): 1/367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/189</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0006" title="BodyJJ , DielIJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology2003;14(9):1399‐405. BodyJJ , LichinitserMR , DiehlI , SchlosserK , PfarrE , CavalliF , et al. Double‐blind placebo‐controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. DielIJ , BodyJJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Improved quality of life after long‐term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer2004;40(11):1704‐12. LyubimovaN , KushlinkskyNE , LichinitserMR . Long‐term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease. 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003. New York: Supportive Care in Cancer, 2003. ">Body 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>No difference between ibandronate and control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/158</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0007" title="BodyJJ , DielI , BellR , PecherstorferM , LichinitserM , LazarevA , et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111(3):306‐12. BodyJJ , DielIJ , LichinitzerM , LazarevA , PecherstorferM , BellR , et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo‐controlled phase III studies. British Journal of Cancer2004;90(6):1133‐7. ">Body 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/286 "renal AEs".</p> <p>"No reports of serious AEs (renal failure) in the active treatment group" (page 1136)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/277 "renal AEs"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/277</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0009" title="ContePF , GiannessiPG , LatreilleJ , MauriacL , KolirenL , CabresiF , et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology1994;5(Suppl 7):41‐4. ContePF , LatrielleJ , MauriacL , CalbresiF , SantosR , CamposD , et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology1996;14(9):2552‐9. ">Conte 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 45 mg iv vs open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transient asymptomatic hypocalcemia: 24/143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transient asymptomatic hypocalcaemia: 9/152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0012" title="ElomaaI , BlomqvistC , GrohnP , PorkkaL , KairentoA‐L , SelanderK , et al. Long‐term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet1983;1(8317):146‐9. ElomaaI , BlomqvistC , Porkka , HoltstromT , TaubeT , Lamberg‐AllardtC , et al. Clodronate for osteolytic metastases due to breast cancer. Biomedicine and Pharmacotherapy1988;42(2):111‐6. ElommaI , BlomqvistL , PorkkaL , Lamberg‐AllardtC , BorgstromGH . Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone1987;8(Suppl 1):53‐6. ">Elomaa 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0016" title="HerasP , HatzopoulosA , MitsibounasD . Efficacy of ibandronate for the prevention of skeletal‐related events in breast cancer patients with metastatic bone disease. European Journal of Cancer2005;3(2):121. HerasP , KritikosK , HatzopoulosA , GeorgopoulouAP . Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. European Journal of Cancer Care2009;18(6):653‐6. ">Heras 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>No comparable differences between ibandronate and control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0018" title="HultbornR , GundersenS , RydenS , HolmbergE , CarstensenJ , WallgrenUB , et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double‐blind placebo‐controlled multicenter study. Anticancer Research1999;19(4C):3383‐92. ">Hultborn 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0020" title="KohnoN , AogiK , MinamiH , NakamuraS , AsagaT , IinoY , et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo‐controlled trial. Journal of Clinical Oncology2005;23(15):3314‐21. ">Kohno 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G1: 44/114, G2&amp;3: 0/114;</p> <p>G4: 1/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G1: 8/113; G2&amp;3: 0/113; G4: 1/113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0021" title="KristensenB , EjlertsenB , GroenvoldM , HeinS , LoftH , MouridsenHT . Oral clodronate in breast cancer patients with bone metastases: a randomised study. Journal of Internal Medicine1999;246(1):67‐74. ">Kristensen 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral, 2/d for 2 years</p> <p>vs open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0025" title="MartoniA , GuaraldiM , CameraP , BiagiR , MarriS , BegheF , et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology1991;48(2):97‐101. ">Martoni 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 300 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0029" title="PatersonAHG , KanisJA , PowlesTJ , McCloskeyEV , ArchabaultWT , KurmanMR , et al. A re‐analysis of a trial of clodronate in patients with breast cancer and bone metastases. Anthra Pharmaceuticals. PatersonAHG , PowlesTJ , KanisJA , McCloskeyE , HansonJ , AshleyS . Double‐blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(1):59‐65. ">Paterson 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral bid for up to 3 years vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0036" title="TripathyD , LichinitzerM , LazarevA , MacLachianA , ApffelstaedtJ , BuddeM , et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomised, double‐blind, placebo‐controlled trial. Annals of Oncology2004;15(5):743‐50. ">Tripathy 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/143</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0037" title="Tubiana‐HulinM , BeuzebocP , MauriacL , BarbetN , FrenayM , MonnierA , et al. Double‐blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bulletin du Cancer2001;88(7):701‐7. ">Tubiana‐Hulin 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0038" title="CletonFJ , VanHolten‐VerzantvoortAT , BijvoetOLM . Effect of long‐term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results in Cancer Research. Vol. 116, Berlin‐Heidelberg: Springer‐Verlag, 1989:73‐8. VanHolten‐VaerzantvoortATM , KroonHM , BijvoetOLM , CletonFJ , BeexLVAM , BlijhamG , et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(3):491‐8. VanHolten‐VerzantvoortAT , BijvoetOLM , CletonFJ , HermansJ , KroonHM , HarinckHIJ , et al. Reduced morbidity from skeletal metastases in breast cancer patients during long‐term bisphosphonate (APD) treatment. Lancet1987;330(8566):983‐5. VanHolten‐VerzantvoortATM , ZwindermanAH , AaronsonNK , HermansJ , VanEmmerikB , VanDamFSAM , et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. European Journal of Cancer1991;27(5):544‐9. ">Van‐Holten 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 150 mg oral, 2/d indefinitely</p> <p>vs open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/81 "gradual deterioration in kidney function during 40 months of study"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Direct comparisons of different bisphosphonate regimens</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv vs</p> <p>Clodronate 2400 mg oral or</p> <p>900 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv vs</p> <p>Pamidronate 90 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Renal toxicity was greater in the zoledronate arm and was dependent on the dose and infusion time, compared to the pamidronate arm </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0040" title="vonAuA , MillothE , DielI , StefanovicS , HennigsA , WallwienerM , et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open‐label, non‐inferiority phase III trial. OncoTargets and Therapy2016; Vol. 2016, issue 9:4173‐80. ">von Au 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv vs</p> <p>Clodronate 900 mg iv</p> <p>every 3 weeks</p> <p>or</p> <p>2400 mg/d oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral vs</p> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/697</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 4/704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 4/697</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>172/704 "renal toxic effects"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>226/697 "renal toxic effects"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/697</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Bone‐targeted agents vs bisphosphonate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks</p> <p>or every 12 weeks vs</p> <p>Bisphosphonate iv (clinician choice)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 7/73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G/3/4: 1/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0023" title="LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clinical Cancer Research2008;14(20):6690‐6. LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Randomized active‐controlled phase II study of denosumab efficacy and safety in patients with breast cancer‐related bone metastases. Journal of Clinical Oncology2007;25(28):4431‐7. ">Lipton 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab sc every 4 weeks (30 mg, 120 mg or 180 mg) or every 12 weeks (60 mg or 180 mg) vs </p> <p>Bisphosphonate iv (either zoledronate, pamidronate or ibandronate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>No significant renal impairment in either arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 120 mg sc (iv placebo)</p> <p>vs</p> <p>Zoledronate 4 mg iv (sc placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/1020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/1013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62/1020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37/1013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50/1020. Renal failure: 2/1020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86/1013. Renal failure: 25/1013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Standard vs reduced bisphosphonate/bone agent</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0008" title="HimelsteinAL , QinR , NovotnyPJ , SeislerDK , KhatcheressianJL , RobertsJD , et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of Clinical Oncology2015; Vol. 33, issue 15 Suppl:9501. [0732‐183X] NCT00869206 . Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. clinicaltrials.gov/ct2/show/NCT00869206 Date first received: 24 March 2009. ">CALGB‐70604 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> <p>vs</p> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR (reported for breast, prostate and multiple myeloma patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks</p> <p>vs</p> <p>Denosumab 180 mg sc every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>"denosumab did not affect renal function" (page 1569). Data were not reported separately for denosumab every 4 weeks and every 12 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> <p>vs</p> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2<sup>a</sup>/198 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2<sup>a</sup>/202 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1<sup>a</sup>/198 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2<sup>a</sup>/202 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Renal failure: 0<sup>a</sup>/198 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Renal failure: 2<sup>a</sup>/202 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> <p>vs</p> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/209 "renal adverse event"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/216 "renal adverse event"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/216</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><b>AE</b> : adverse event; <b>G</b> : grade; <b>iv</b> : intravenous; <b>n</b> : number of events; <b>N</b> : number of women studies in each group; <b>NR</b> : not reported; <b>sc</b>: subcutaneous<br/> <sup>a</sup>Reported as serious adverse events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Breast cancer with bone metastases: toxicity ‐ osteonecrosis of the jaw, hypocalcaemia, renal dysfunction &amp; drug‐related death</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003474-tbl-0019"> <div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Breast cancer with bone metastases: toxicity ‐ nausea, gastrointestinal events, fatigue &amp; fever</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Treatment vs comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Nausea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>GI events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fatigue</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fever</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone agent (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Bisphosphonate vs placebo/open</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0004" title="HortobagyiGN , TheriaultRL , LiptonA , PorterL , BlayneyD , SinoffC , et al. Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology1998;16(6):2038‐44. HortobagyiGN , TheriaultRL , PorterL , BlayneyD , LiptonA , SinoffC , et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine1996;335(24):1785‐91. LiptonA , TheriaultRL , HortobagyiGN , SimeoneJ , KnightRD , MellarsK , et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer2000;88(5):1082‐90. TheriaultRL , LiptonA , HortobagyiGN , LeffR , GluckS , StewartJF , et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo‐controlled trial. Journal of Clinical Oncology1999;17(3):846‐54. ">AREDIA 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 90 mg iv vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>147/367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112/386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51/367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/386</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0006" title="BodyJJ , DielIJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology2003;14(9):1399‐405. BodyJJ , LichinitserMR , DiehlI , SchlosserK , PfarrE , CavalliF , et al. Double‐blind placebo‐controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. DielIJ , BodyJJ , LichinitserMR , KreuserED , DornoffW , GorbunovaVA , et al. Improved quality of life after long‐term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer2004;40(11):1704‐12. LyubimovaN , KushlinkskyNE , LichinitserMR . Long‐term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease. 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003. New York: Supportive Care in Cancer, 2003. ">Body 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0007" title="BodyJJ , DielI , BellR , PecherstorferM , LichinitserM , LazarevA , et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111(3):306‐12. BodyJJ , DielIJ , LichinitzerM , LazarevA , PecherstorferM , BellR , et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo‐controlled phase III studies. British Journal of Cancer2004;90(6):1133‐7. ">Body 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0009" title="ContePF , GiannessiPG , LatreilleJ , MauriacL , KolirenL , CabresiF , et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology1994;5(Suppl 7):41‐4. ContePF , LatrielleJ , MauriacL , CalbresiF , SantosR , CamposD , et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology1996;14(9):2552‐9. ">Conte 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 45 mg iv vs open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/152</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0012" title="ElomaaI , BlomqvistC , GrohnP , PorkkaL , KairentoA‐L , SelanderK , et al. Long‐term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet1983;1(8317):146‐9. ElomaaI , BlomqvistC , Porkka , HoltstromT , TaubeT , Lamberg‐AllardtC , et al. Clodronate for osteolytic metastases due to breast cancer. Biomedicine and Pharmacotherapy1988;42(2):111‐6. ElommaI , BlomqvistL , PorkkaL , Lamberg‐AllardtC , BorgstromGH . Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone1987;8(Suppl 1):53‐6. ">Elomaa 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0016" title="HerasP , HatzopoulosA , MitsibounasD . Efficacy of ibandronate for the prevention of skeletal‐related events in breast cancer patients with metastatic bone disease. European Journal of Cancer2005;3(2):121. HerasP , KritikosK , HatzopoulosA , GeorgopoulouAP . Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. European Journal of Cancer Care2009;18(6):653‐6. ">Heras 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 6 mg iv vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0018" title="HultbornR , GundersenS , RydenS , HolmbergE , CarstensenJ , WallgrenUB , et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double‐blind placebo‐controlled multicenter study. Anticancer Research1999;19(4C):3383‐92. ">Hultborn 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0020" title="KohnoN , AogiK , MinamiH , NakamuraS , AsagaT , IinoY , et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo‐controlled trial. Journal of Clinical Oncology2005;23(15):3314‐21. ">Kohno 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60/113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36/113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37/113</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0021" title="KristensenB , EjlertsenB , GroenvoldM , HeinS , LoftH , MouridsenHT . Oral clodronate in breast cancer patients with bone metastases: a randomised study. Journal of Internal Medicine1999;246(1):67‐74. ">Kristensen 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral, 2/d for 2 years</p> <p>vs open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0025" title="MartoniA , GuaraldiM , CameraP , BiagiR , MarriS , BegheF , et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology1991;48(2):97‐101. ">Martoni 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 300 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0029" title="PatersonAHG , KanisJA , PowlesTJ , McCloskeyEV , ArchabaultWT , KurmanMR , et al. A re‐analysis of a trial of clodronate in patients with breast cancer and bone metastases. Anthra Pharmaceuticals. PatersonAHG , PowlesTJ , KanisJA , McCloskeyE , HansonJ , AshleyS . Double‐blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(1):59‐65. ">Paterson 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 800 mg oral, 2/d for up to 3 years<br/> vs placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐specific GI symptoms: 2/85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐specific GI symptoms: 1/88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0036" title="TripathyD , LichinitzerM , LazarevA , MacLachianA , ApffelstaedtJ , BuddeM , et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomised, double‐blind, placebo‐controlled trial. Annals of Oncology2004;15(5):743‐50. ">Tripathy 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/143</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Upper GIT events: 10% and similar to placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0037" title="Tubiana‐HulinM , BeuzebocP , MauriacL , BarbetN , FrenayM , MonnierA , et al. Double‐blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bulletin du Cancer2001;88(7):701‐7. ">Tubiana‐Hulin 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate 1600 mg oral vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0038" title="CletonFJ , VanHolten‐VerzantvoortAT , BijvoetOLM . Effect of long‐term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results in Cancer Research. Vol. 116, Berlin‐Heidelberg: Springer‐Verlag, 1989:73‐8. VanHolten‐VaerzantvoortATM , KroonHM , BijvoetOLM , CletonFJ , BeexLVAM , BlijhamG , et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology1993;11(3):491‐8. VanHolten‐VerzantvoortAT , BijvoetOLM , CletonFJ , HermansJ , KroonHM , HarinckHIJ , et al. Reduced morbidity from skeletal metastases in breast cancer patients during long‐term bisphosphonate (APD) treatment. Lancet1987;330(8566):983‐5. VanHolten‐VerzantvoortATM , ZwindermanAH , AaronsonNK , HermansJ , VanEmmerikB , VanDamFSAM , et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. European Journal of Cancer1991;27(5):544‐9. ">Van‐Holten 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 150 mg oral, 2/d indefinitely</p> <p>vs open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Direct comparisons of different bisphosphonate regimens</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0011" title="DielIJ , MarschnerN , KindlerM , LangeO , UntachM , HurtzHJ , et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. ">Diel 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv vs</p> <p>Clodronate 2400 mg oral or 900 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0031" title="RosenL , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer2003;98(8):1735‐44. RosenLS , GordonD , DuganW , MajorP , EisenbergPD , ProvencherL , et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer2004;100(1):36‐43. RosenLS , GordonD , KaminskiM , HowellA , BelchA , MackeyJ , et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial. Cancer2001;7(5):377‐87. ">Rosen 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv vs</p> <p>Pamidronate 90 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>355/742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>179/388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>294/742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>159/388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>231/742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103/388</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0040" title="vonAuA , MillothE , DielI , StefanovicS , HennigsA , WallwienerM , et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open‐label, non‐inferiority phase III trial. OncoTargets and Therapy2016; Vol. 2016, issue 9:4173‐80. ">von Au 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate 60 mg iv vs</p> <p>Clodronate 900 mg iv every 3 weeks</p> <p>or 2400 mg/d oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>900 mg iv every 3 weeks: 11/105;</p> <p>2400 mg oral daily: 24/107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0042" title="Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial]. Lancet Oncology2014;15(2):e52‐3. Barrett‐LeeP , CasbardA , AbrahamJ , HoodK , ColemanR , SimmondsP , et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non‐inferiority phase 3 trial. Lancet Oncology2014;15(1):114‐22. Barrett‐LeePJ , CasbardA , AbrahamJ , GrieveR , WheatleyD , SimmonsP , et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial‐first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research2012;72(24 Suppl):PD07‐09. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. NelsonA , FenlonD , MorrisJ , SampsonC , HarropE , MurrayN , et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials2013;14:325. ">ZICE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate 50 mg oral vs</p> <p>Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 41/704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4:38/697</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 8/704 "dyspepsia"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 2/697 "dyspepsia"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 98/704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 97/697</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4:12/704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 18/697</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Bone‐targeted agents vs bisphosphonate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks or every 12 weeks vs</p> <p>Bisphosphonate iv (clinician choice)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0023" title="LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clinical Cancer Research2008;14(20):6690‐6. LiptonA ,  StegerGG ,  FigueroaJ ,  AlvaradoC ,  Solal‐CelignyP ,  BodyJJ , et al. Randomized active‐controlled phase II study of denosumab efficacy and safety in patients with breast cancer‐related bone metastases. Journal of Clinical Oncology2007;25(28):4431‐7. ">Lipton 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab sc every 4 weeks (30 mg, 120 mg or 180 mg)</p> <p>or every 12 weeks (60 mg or 180 mg)</p> <p>vs</p> <p>Bisphosphonate iv</p> <p>(either zoledronate, pamidronate or ibandronate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36/211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0033" title="BodyJJ , VonMoosR , StopeckA , QianY , BraunA , ChungK . Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health2010;13:A279. CleelandCS , BodyJJ , StopeckA , VonMoosR , FallowfieldL , MathiasSD , et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer2013;119(4):832‐8. DeBoerR , StegerG , VonMoosR , MartinM , StopeckA , TonkinK , et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice2012;18:22. DeBoerRH , StopeckA , FallowfieldL , PatrickD , CleelandCS , StegerGG , et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia‐Pacific Journal of Clinical Oncology2012;8:40. DeBoerRH , StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre‐specified two year open‐label extension treatment phase of a pivotal phase iii study. Asia‐Pacific Journal of Clinical Oncology2012;8:44. DielIJ , BodyJJ , StopeckAT , Vadhan‐RajS , SpencerA , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer2011;47:S237. FallowfieldL , CleelandCS , BodyJJ , StopeckA , VonMoosR , PatrickDL , et al. Pain severity and analgesic use associated with skeletal‐related events in patients with advanced breast cancer and bone metastases. Cancer Research2011;71(24 Suppl):P4‐13‐01. FallowfieldL , PatrickD , BodyJ J , LiptonA , TonkinK S , QianY , et al. Health‐related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer2012;20:S37. FallowfieldL , PatrickD , BodyJ , LiptonA , TonkinK S , QianY , et al. Effect of denosumab versus zoledronic acid on health‐related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology2011;29(27 Suppl):272. FallowfieldL , PatrickD , BodyJJ , LiptonA , TonkinKS , QianY , et al. Abstract P1‐13‐05: The effect of treatment with denosumab or zoledronic acid on health‐related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research2010;70:1‐13. LiptonA , FizaziK , StopeckA , HenryDH , SmithMR , ShoreND , et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal‐related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology2014;32(15 Suppl):9501. MartinM , BellR , BourgeoisH , BrufskyA , DielI , EniuA , et al. Bone‐related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research2012;18:4841‐9. SpencerA , DielI , BodyJ J , StopeckA , Vadhan‐RajS , StegerG , et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice2012;18:22‐3. SpencerA , DielIJ , BodyJJ , StopeckA , Vadhan‐RajS , StegerGG , et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post‐hoc analysis of the effect of denosumab treatment. Asia‐Pacific Journal of Clinical Oncology2012;8:45‐6. StopeckA , DeBoerR , FujiwaraY , LichinitserM , TonkinK , YardleyD , et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal‐related events in breast cancer patients with bone metastases. Cancer Research2009;69(24 Suppl):09‐22. StopeckA , FallowfieldL , PatrickD , CleelandCS , DeBoerRH , StegerGG , et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology2010;28(15 Suppl):1024. StopeckA , MartinM , RitchieD , BodyJJ , PatersonA , ViniegraM , et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research2010;70(24 Suppl):P6‐14‐01. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study. Cancer Research2011;71(24 Suppl):P3‐16‐07. StopeckAT , LiptonA , MartinM , BodyJJ , PatersonA , StegerGG , et al. Results from the 2‐year open‐label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer2012;48(4 Suppl):S3. StopeckAT , LiptonAA , Campbell‐BairdC , vonMoosR , FanM , HaddockB , et al. Abstract P6‐14‐09: Acute‐phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research2010;70(24 Suppl):P6‐14‐09. StopeckAT ,  LiptonA ,  BodyJJ ,  StegerGG ,  TonkinK ,  De BoerRH , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double‐blind study. Journal of Clinical Oncology2010;28(35):5132‐9. ">Stopeck 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 120 mg sc (iv placebo) vs</p> <p>Zoledronate 4 mg iv (sc placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>356/1020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>384/1013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>301/1020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>324/1013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>170/1020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>247/1013</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Standard vs reduced bisphosphonate/bone agent</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0008" title="HimelsteinAL , QinR , NovotnyPJ , SeislerDK , KhatcheressianJL , RobertsJD , et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of Clinical Oncology2015; Vol. 33, issue 15 Suppl:9501. [0732‐183X] NCT00869206 . Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. clinicaltrials.gov/ct2/show/NCT00869206 Date first received: 24 March 2009. ">CALGB‐70604 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> <p>vs</p> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0014" title="FizaziK ,  LiptonA ,  MarietteX ,  BodyJJ ,  RahimY ,  GralowJR , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology2009;27(10):1564‐71. SuarezT , FizaziK , RahimY , WilsonJ , FanM , JunS , et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology2006;24(18 Suppl):8562. ">Fizazi 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denosumab 180 mg sc every 4 weeks</p> <p>vs</p> <p>Denosumab 180 mg sc every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0028" title="HortobagyiGN , LiptonA , ChewHK , GradisharWJ , SauterNP , MohanlalRW , et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE‐2 trial. Journal of Clinical Oncology2014;32(5 Suppl):LBA9500. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. ">OPTIMIZE‐2 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> <p>vs</p> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/198<br/> "abdominal pain" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/202<br/> "abdominal pain" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/202</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003474-bbs2-0044" title="AmadoriD , AgliettaM , AlessiB , GianniL , IbrahimT , FarinaG , et al. Efficacy and safety of 12‐weekly versus 4‐weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open‐label, randomised, non‐inferiority trial. Lancet Oncology2013;14(7):663‐70. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. ">ZOOM 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoledronate 4 mg iv every 4 weeks</p> <p>vs</p> <p>Zoledronate 4 mg iv every 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 24/209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 33/216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65/209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91/216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4:18/209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 19/216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 22/209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G3/4: 28/216</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><b>G</b> : grade; <b>iv</b> : intravenous; <b>n</b> : number of events; <b>N</b> : number of women studies in each group; <b>NR</b> : not reported; <b>sc</b>: subcutaneous </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Breast cancer with bone metastases: toxicity ‐ nausea, gastrointestinal events, fatigue &amp; fever</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/full#CD003474-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003474-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Early Breast Cancer (EBC)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Bone metastases <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Bisphosphonate vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.75, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Immediate vs delayed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.38, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Bone metastases by bisphosphonate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.74, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.60, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Clodronate 1600 mg oral daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.70, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Pamidronate 150 mg oral twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>953</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.88, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Ibandronate 50 mg oral daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.56, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Visceral recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17092</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.91, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Bisphosphonate vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14902</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.92, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Immediate vs delayed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.46, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Locoregional recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15721</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.83, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Bisphosphonate vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.85, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Immediate vs delayed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.26, 4.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Overall recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.88, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Bisphosphonate vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.89, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Immediate vs delayed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.52, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Overall recurrence by bisphosphonate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.88, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.76, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Clodronate 1600 mg oral daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.84, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Pamidronate 150 mg oral twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>953</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.94, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Ibandronate 50 mg oral daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.82, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Overall survival: time‐to‐event outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.82, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Bisphosphonate vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13949</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.83, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Immediate vs delayed bisphosphonate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1064</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.42, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Overall survival: dichotomous outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.81, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Bisphosphonate vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14902</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.80, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Immediate vs delayed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.14 [0.69, 6.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Overall survival by bisphosphonate: time‐to‐event outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.82, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.81, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Clodronate 1600 mg oral daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.74, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Ibandronate 50 mg oral daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.76, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Overall survival by bisphosphonate: dichotomous outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.81, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.80, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Clodronate 1600 mg oral daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.60, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Pamidronate 150 mg oral twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>953</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.94, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Ibandronate 50 mg oral daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.82, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Overall survival by menopausal status: time‐to‐event outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14906</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.82, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Pre‐ or perimenopausal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.86, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Postmenopausal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6048</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.66, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Pre‐ or postmenopausal, or both, or status not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.81, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Overall survival by menopausal status: dichotomous outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.84, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Pre‐ or perimenopausal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.96, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Postmenopausal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.78, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Pre‐ or postmenopausal or status not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1670</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.50, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Disease‐free survival: time‐to‐event outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.86, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Bisphosphonate vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.87, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Immediate vs delayed bisphosphonate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.52, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Disease‐free survival: dichotomous outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.87, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Bisphosphonate vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.89, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Immediate vs delayed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.55, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Disease‐free survival by bisphosphonate: time‐to‐event outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.86, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7638</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.80, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Clodronate 1600 mg oral daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.87, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 Ibandronate 50 mg oral daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.77, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Disease‐free survival by bisphosphonate: dichotomous outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.87, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Zoledronate 4 mg iv every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7638</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.79, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Clodronate 1600 mg oral daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3617</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.79, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Pamidronate 150 mg oral twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>953</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.98, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 Ibandronate 50 mg oral daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.83, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Disease‐free survival by menopausal status: time‐to‐event outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.86, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Pre‐ or perimenopausal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5493</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.90, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Postmenopausal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.74, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 Pre‐ or postmenopausal or status not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.11, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Disease‐free survival by menopausal status: dichotomous outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Pre‐ or perimenopausal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.96, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Postmenopausal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.77, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 Pre‐ or postmenopausal or both, or status not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3617</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.79, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Fracture incidence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.57, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Bisphosphonate vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.54, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Denosumab vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.41, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 Immediate vs delayed bisphosphonate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.57, 1.13]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Early Breast Cancer (EBC)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003474-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Advanced Breast Cancer (ABC)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Bone metastases <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.65, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.73, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Advanced Breast Cancer (ABC)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003474-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Breast cancer and bone metastases (BCBM)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 SREs: bisphosphonate vs placebo/observation (including hypercalcaemia) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.77, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 SREs: bisphosphonate vs placebo/observation (excluding hypercalcaemia) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2810</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.78, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 SREs: by route of administration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.78, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Intravenous bisphosphonates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.73, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Oral bisphosphonates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.76, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 SREs: by bisphosphonate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Zoledronate 4 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.43, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Pamidronate 90 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>754</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.69, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Ibandronate 6 mg iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.67, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Clodronate 1600 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.71, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Ibandronate 50 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.73, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Pamidronate 300 mg oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.70, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 SREs: denosumab vs bisphosphonate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.72, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 SREs: standard vs reduced frequency bone‐targeted agent <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.72, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Median time to SRE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2891</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Median Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [1.29, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Bisphosphosphonate vs placebo/observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2891</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Median Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [1.29, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1935</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.91, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Intravenous bisphosphonate vs placebo/observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.90, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Oral bisphosphonate vs placebo/observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.71, 1.33]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Breast cancer and bone metastases (BCBM)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003474.pub4/references#CD003474-tbl-0022">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003474.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD003474-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD003474-note-0007">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003474-note-0030">فارسی</a> </li> <li class="section-language"> <a class="" href="ja#CD003474-note-0005">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD003474-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD003474-note-0006">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003474-note-0002">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD003474-note-0003">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003474\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003474\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003474\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003474\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003474\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003474\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003474\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003474\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003474\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003474\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003474\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003474\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003474\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003474\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003474\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003474\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003474\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003474\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003474.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003474.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003474.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003474.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003474.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714729959"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003474.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714729963"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003474.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d75c60abe937d',t:'MTc0MDcxNDczMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 